{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.23951"}, {"@name": "filename", "#text": "8233_000876978.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "1 \n \n\n \nUNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL \n\nFACULDADE DE MEDICINA \n\nPROGRAMA DE P\u00d3S-GRADUA\u00c7\u00c3O EM MEDICINA: CI\u00caNCIAS M\u00c9DICAS \n\n \n\n \n\n \n\n \n\n \n\nASPECTOS CL\u00cdNICOS E BIOQU\u00cdMICOS DA DOEN\u00c7A DE MACHADO-JOSEPH: \n\nDA DESCRI\u00c7\u00c3O DE NOVOS BIOMARCADORES \u00c0 BUSCA DE UM TRATAMENTO \n\nEFETIVO \n\n \n\n \n\n \n\n \n\nJONAS ALEX MORALES SAUTE \n\n \n\n \n\nOrientador: Profa. Dra. Laura Bannach Jardim \n\nTese apresentada ao Programa de P\u00f3s-Gradua\u00e7\u00e3o \n\nem Medicina: Ci\u00eancias M\u00e9dicas, UFRGS, como \n\nrequisito para obten\u00e7\u00e3o do t\u00edtulo de Doutor  \n\n \n\nPorto Alegre, janeiro de 2013 \n\n \n\n\n\n2 \n \n\nDedicat\u00f3ria \n\n \n\n\u00c0 minha m\u00e3e, Loiva. \n\n  \n\n\n\n3 \n \n\nAgradecimentos \n\n \n\n\u00c0 minha orientadora Dra. Laura Bannach Jardim pelo exemplo como m\u00e9dica, \n\nprofessora e pesquisadora, e pelo apoio dado em todas as etapas deste trabalho \n\nbem como em minha forma\u00e7\u00e3o em Neurogen\u00e9tica.  \n\nAos meus mestres do Departamento de Bioqu\u00edmica da UFRGS, Prof. Luis Valmor \n\nCruz Portela e Prof. Diogo Souza por me abrirem as portas do mundo cient\u00edfico. \n\n\u00c0 professora M\u00e1rcia Chaves, chefe do Servi\u00e7o de Neurologia do HCPA, por ter \n\npermitido a simultaneidade da realiza\u00e7\u00e3o da resid\u00eancia m\u00e9dica em Neurologia e do \n\ndoutorado em Ci\u00eancias M\u00e9dicas. \n\nA todos os meus colegas de resid\u00eancia m\u00e9dica em Neurologia e Gen\u00e9tica M\u00e9dica, \n\nem especial para Carlos, Lenise e Antonette que me acompanharam em boa parte \n\ndeste percurso e o tornaram ainda mais agrad\u00e1vel. \n\n\u00c0 equipe de pesquisa em Neurogen\u00e9tica, em especial para Artur Schuh, Thais \n\nMonte, Carlos Rieder, Raphael Castilhos, Gabriele Souza, Aline Russo, Karina, \n\nDonis, Rui D\u2018\u00c1vila, Gabriel Furtado, Tailise Gheno, Maria Luiza Saraiva-Pereira e \n\nAndrew Chaves pela inestim\u00e1vel colabora\u00e7\u00e3o. \n\n\u00c0 Vanessa Torman e Suzi Camey pelo aux\u00edlio estat\u00edstico, literalmente express. \n\nAos professores, contratados, funcion\u00e1rios e bolsistas dos servi\u00e7os de Neurologia e \n\nGen\u00e9tica M\u00e9dica do HCPA por todo apoio e aprendizado. \n\nAos colaboradores e colegas do Departamento de Bioqu\u00edmica da UFRGS, \n\nespecialmente para Alexandre Muller, J\u00falia Moreira, Marcelo Ganzella e Prof. Diogo \n\nLara, pela inestim\u00e1vel coopera\u00e7\u00e3o e incentivo.  \n\n\u00c0 Janine, que me acompanhou durante toda esta jornada, pelo amor e compreens\u00e3o \n\ne por me mostrar um olhar mais cr\u00edtico e mais bonito sobre v\u00e1rios aspectos da vida, \n\ninclusive da ci\u00eancia. \n\nAos meus pais, Newton e Loiva e ao meu irm\u00e3o, Edson pelo imensur\u00e1vel apoio, \n\nincentivo, carinho e compreens\u00e3o em mais este percurso que se encerra. \n\n\n\n4 \n \n\nAos pacientes e seus familiares. \n\n \n\n \n\n   \n\n  \n\n\n\n5 \n \n\nResumo  \n\nIntrodu\u00e7\u00e3o: A doen\u00e7a de Machado-Joseph (DMJ) ou ataxia espinocerebelar tipo 3 \n\n(SCA3) \u00e9 causada por uma expans\u00e3o de trinucleot\u00eddeos CAG no gene ATXN3,  que \n\nleva \u00e0 degenera\u00e7\u00e3o de m\u00faltiplos sistemas neurol\u00f3gicos. Seu curso \u00e9 invariavelmente \n\nprogressivo, n\u00e3o havendo tratamento espec\u00edfico.  \n\nObjetivos: Descrever novos biomarcadores, aspectos n\u00e3o motores e definir quais \n\nescalas cl\u00ednicas devem ser utilizadas como desfechos principais nos futuros ensaios \n\ncl\u00ednicos randomizados (ECR) para a DMJ/SCA3. Al\u00e9m de avaliar se o tratamento \n\ncom carbonato de l\u00edtio \u00e9 seguro e efetivo em reduzir a progress\u00e3o desta condi\u00e7\u00e3o. \n\n M\u00e9todos: Em estudo caso-controle avaliamos: 1) a rela\u00e7\u00e3o dos sintomas \n\ndepressivos na DMJ/SCA3, pelo invent\u00e1rio de Beck (BDI), com aspectos de \n\ngravidade cl\u00ednica e molecular; 2) altera\u00e7\u00f5es no \u00edndice de massa corporal (IMC) e sua \n\ncorrela\u00e7\u00e3o com aspectos cl\u00ednico-moleculares e de neuroimagem; e 3) o Sistema \n\nInsulina/ IGF-1 (IIS) e o potencial de seus componentes como biomarcadores. \n\nFizemos uma revis\u00e3o sistem\u00e1tica sobre os aspectos psicom\u00e9tricos das escalas \n\ncl\u00ednicas de SCAs j\u00e1 descritas, para em seguida iniciarmos um ECR, duplo-cego, \n\nparalelo, placebo-controlado de fase 2/3. Para este estudo foram randomizados 62 \n\npacientes com diagn\u00f3stico molecular pr\u00e9vio de DMJ/SCA3 com marcha \n\nindependente e ? 10 anos de doen\u00e7a (1:1) para tratamento com carbonato de l\u00edtio \n\n(0.5-0.8mEq/L) ou placebo.  \n\nResultados: Os escores do BDI foram mais elevados na DMJ/SCA3 (p= 0.012) e \n\ncorrelacionaram-se significativamente apenas com as escalas SARA (R=0.359, \n\np=0.01) e NESSCA (R=0.412, p=0.003). Os pacientes com DMJ/SCA3 (N=46) \n\napresentaram IMC menor (24.4 \u00b1 4.1) do que os indiv\u00edduos controle (N=42, 27.1\u00b1 \n\n4.5, p=0.01), havendo correla\u00e7\u00e3o inversa (R=?0.396, p=0.015) entre o IMC e o \n\ntamanho da sequencia repetitiva CAG (CAGn). Encontramos uma maior \n\nsensibilidade perif\u00e9rica \u00e0 insulina (HOMA2-%S, p=0.003, corrigido pelo IMC) e n\u00edveis \n\ns\u00e9ricos mais elevados da prote\u00edna ligante do IGF-1, IGFBP-1 (p=0.001) na \n\n\n\n6 \n \n\nDMJ/SCA3. A IGFBP1 correlacionou-se diretamente \u00e0 CAGn (R=0.452; p = 0.006) e \n\na sensibilidade \u00e0 insulina inversamente \u00e0 idade de in\u00edcio dos sintomas (R=-0.444; P \n\n= 0.003). Conclu\u00edmos, na revis\u00e3o sistem\u00e1tica, que as escalas semi-quantitativas \n\nSARA e NESSCA, e as quantitativas SCAFI e CCFS seriam os melhores desfechos \n\npara um ECR.  O uso de l\u00edtio foi seguro ap\u00f3s 24 semanas de tratamento, n\u00e3o \n\nhavendo diferen\u00e7as no n\u00famero total de eventos adversos entre os grupos l\u00edtio \n\n(50,3%) e placebo (49,7%, p=1.00). O grupo placebo apresentou maior progress\u00e3o \n\n(que n\u00e3o foi significativa) nos escores NESSCA (0.35 pontos, 95% IC -1.0 a 1.7, \n\np=0.222, desfecho prim\u00e1rio de efetividade) e SARA (0.96 pontos, 95% IC -0.46 a \n\n2.38, p=0.329), ap\u00f3s 48 semanas de tratamento. A gravidade da ataxia de marcha \n\n(p=0.008), as provas funcionais quantitativas: PATA rate (p=0.002) e Click Test ND \n\n(p=0.023), e os escores compostos SCAFI (p=0.015) e CCFS (p=0.029) \n\napresentaram menor progress\u00e3o no grupo tratado com l\u00edtio durante as 48 semanas. \n\nConclus\u00e3o: Os resultados destes estudos ajudam no entendimento da depress\u00e3o e \n\naltera\u00e7\u00f5es nutricionais da DMJ/SCA3 e apontam a IGFBP-1 como biomarcador e a \n\nsensibilidade perif\u00e9rica insul\u00ednica como modificador do fen\u00f3tipo. Houve efetividade \n\ndo tratamento com carbonato de l\u00edtio nos desfechos secund\u00e1rios do ECR, sendo \n\nnecess\u00e1ria confirma\u00e7\u00e3o por ensaios cl\u00ednicos multic\u00eantricos.  \n\n \n\nPALAVRAS-CHAVE  \n\nDoen\u00e7a de Machado Joseph; Ataxia Espinocerebelar tipo 3; poliglutaminopatias; \n\ndepress\u00e3o; aspectos nutricionais; \u00edndice de massa corporal; biomarcador; fator \n\nmodificador; escalas de ataxia; escores de ataxia; tratamento; ensaio cl\u00ednico; \n\ncarbonato de l\u00edtio. \n\n  \n\n\n\n7 \n \n\nAbstract  \n\nBackground: Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3 \n\n(SCA3) is caused by a CAG repeat expansion at ATXN3 gene, leading to \n\nprogressive degeneration of multiple neurological systems. MJD/SCA3 is an \n\ninvariably progressive disorder, with no current treatment. \n\nObjectives: To describe new disease biomarkers, non-motor aspects and to define \n\nthe clinical SCA scales to be utilized as main outcomes in future randomized \n\ncontrolled trials (RCT) on MJD/SCA3. And further assess safety and effectiveness of \n\nlithium carbonate in reducing the progression of this condition. \n\nMethods: We performed a case-control study to evaluate: 1) the relation of \n\nMJD/SCA3 depressive symptoms, through Beck depression Inventory (BDI), with \n\nother clinical and molecular findings; 2) the Body Mass Index (BMI) of MJD/SCA3 \n\npatients and the correlation with other clinical, molecular and neuroimaging findings; \n\nand 3) the Insulin/IGF-1 system (IIS) in MJD/SCA3 and the possible biomarker \n\nproperties of its components. We further performed a systematic review on the \n\npsychometric properties of the described SCAs scales in order to initiate the double-\n\nblind, parallel, placebo-controlled phase 2/3 clinical trial. 62 independently \n\nambulatory MJD/SCA3 patients with ? 10 years of disease duration were randomly \n\nassigned in the RCT (1:1) to lithium (0.5-0.8mEq/L) or placebo. \n\nResults: BDI scores were higher in MJD/SCA3 patients (p= 0.012), with significant \n\ncorrelations only with the scales SARA (R=0.359, p=0.01) and NESSCA (R=0.412, \n\np=0.003). MJD/SCA3 patients (N=46) presented lower BMI (24.4 \u00b1 4.1) than control \n\nindividuals (N=42, 27.1\u00b1 4.5, p=0.01). BMI correlated inversely with the length of the \n\nexpanded CAG repeat (CAGn). We found higher peripheral sensitivity to insulin \n\n(HOMA2-%S, p=0.003, corrected for BMI) and serum levels of the IGF-1 binding \n\nprotein, IGFBP-1 (p=0.001) in MJD/SCA3. IGFBP-1 correlated with CAGn (R=0.452; \n\np = 0.006) and insulin sensitivity with the age of disease onset (R=-0.444; P = 0.003). \n\nIn the systematic review we concluded that the semiquantitative SCA scales SARA \n\nand NESSCA and the quantitative instruments SCAFI and CCFS would be the most \n\nappropriate outcomes for the RCT.  After 24 weeks, there were no differences in the \n\nnumber of adverse events in lithium (50.3%) and placebo (40.7%) groups (p=1.00) in \n\nthe RCT. The placebo group presented a non-significant faster progression on \n\nNESSCA (0.35 points, 95% CI -1.0 to 1.7, p=0.612, primary effectiveness outcome) \n\n\n\n8 \n \n\nand SARA (0.96 points, 95% CI -0.46 to 2.38, p=0.186), after 48 weeks of treatment. \n\nGait ataxia severity (p=0.008), the quantitative performance tasks: PATA rate \n\n(p=0.002) and Click Test ND (p=0.023), and the composite scores SCAFI (p=0.015) \n\nand CCFS (p=0.029) presented a slower progression under lithium therapy in the \n\noverall 48 weeks period.  \n\n  \n\nConclusion: These studies added to the understanding of depressive and nutritional \n\nmanifestations of MJD/SCA3 and points IGFBP-1 as a biomarker and peripheral \n\ninsulin sensitivity as a disease phenotype modifier. The effectiveness of lithium \n\ncarbonate treatment shown in secondary outcomes of the RCT opened a perspective \n\nfor an effective therapy for this untreatable disorder that must be confirmed by large \n\nmulticentric clinical trials.   \n\n \n\nKEYWORDS  \n\nMachado-Joseph Disease, Spinocerebellar ataxia type 3, polyglutamine disorders; \n\ndepression; nutrition; body mass index; biomarker; disease modifier; ataxia scales; \n\nataxia scores; treatment; clinical trial; lithium carbonate.   \n\n  \n\n\n\n9 \n \n\nLista de Figuras \n \n\nFigura n\u00ba 1 \u2013 Mapa de frequ\u00eancia da DMJ/SCA3 no RS ..........................................20 \n\nFigura n\u00ba 2 - Agregados intranucleares neuronais ....................................................23 \n\nFigura n\u00ba 3 - Dom\u00ednios funcionais da Ataxina-3.........................................................24 \n\n  \n\n\n\n10 \n \n\nLista de Abreviaturas  \n\n \n\n \nSIGLA Significado \n\n8MW 8m Walking-time \n\n9HPT 9-Hole Pegboard Test \n\nARN \u00e1cido ribonucleico \n\nATXN1 gene associado \u00e0 SCA1 \n\nATXN2 gene associado \u00e0 SCA2 \n\nATXN3 gene associado \u00e0 DMJ/SCA3 \n\nATXN3 prote\u00edna ataxina-3 \n\nCAG glutamina \n\nCCFS Composite Cerebellar Functional Score \n\nDH doen\u00e7a de Huntington \n\nDHL2 doen\u00e7a de Huntington-like tipo 2 \n\nDMJ doen\u00e7a de Machado-Joseph \n\nDRPLA atrofia dentato-rubro-palido-luisiana \n\nECR ensaio cl\u00ednico randomizado \n\nELA esclerose lateral amiotr\u00f3fica \n\nHAT acetiltransferases de histonas \n\nHDAC desacetilases de histonas \n\nHSP prote\u00ednas heat shock \n\nICARS International Cooperative Ataxia Rating Scale \n\nIGF-1 Fator de Crescimento Semelhante \u00e0 Insulina Tipo 1 \n\n\n\n11 \n \n\nIMC \u00edndice de massa corporal \n\nIIS Sistema Insulina / IGF-1 \n\nNESSCA Neurological Examination Score for the Assessment of \n\nSpinocerebellar Ataxia \n\nNI neuroinclus\u00f5es ou agregados intranucleares neuronais \n\npoliQ poliglutaminopatias \n\nPoliQ poliglutaminas expandidas \n\nREM fase do sono em que ocorrem movimentos oculares r\u00e1pidos \n\nROS esp\u00e9cies reativas de oxig\u00eanio \n\nSARA Scale for the Assessment and Rating of Ataxia \n\nSBMA atrofia muscular espinhal e bulbar \n\nSCA ataxia espinocerebelar \n\nSCAFI SCA Functional Index \n\nSNC sistema nervoso central \n\nSNP sistema nervoso perif\u00e9rico \n\nUIM motivos de intera\u00e7\u00e3o com a ubiquitina \n\nUPS sistema ubiquitina-proteassoma \n\nUMSARS Unified Multiple System Atrophy Rating Scale \n\n \n\n\n\n12 \n \n\nSum\u00e1rio \n\nResumo ..................................................................................................................... 5 \n\nAbstract ..................................................................................................................... 7 \n\n1. Introdu\u00e7\u00e3o ......................................................................................................... 14 \n\n2. Revis\u00e3o da Literatura ......................................................................................... 17 \n\n2.1 Aspectos Hist\u00f3ricos ............................................................................................ 17 \n\n2.2 Aspectos Epidemiol\u00f3gicos .............................................................................. 19 \n\n2.3 Aspectos Gen\u00e9ticos ......................................................................................... 21 \n\n2.4 Fisiopatologia ................................................................................................... 23 \n\n2.4.1 Agregados Intracelulares e proteotoxicidade ................................................... 23 \n\n2.4.2 Fun\u00e7\u00f5es da ATXN3 ......................................................................................... 24 \n\n2.4.3. Haploinsufici\u00eancia como principal mecanismo de doen\u00e7a? ............................ 26 \n\n2.4.4 Efeitos diretos da PoliQ e da sua tend\u00eancia \u00e0 agrega\u00e7\u00e3o ............................... 27 \n\n2.5 Aspectos Cl\u00ednicos e Patol\u00f3gicos ....................................................................... 27 \n\n2.5.1 Manifesta\u00e7\u00f5es Cl\u00ednicas Motoras ...................................................................... 28 \n\n2.5.1.1 Manifesta\u00e7\u00f5es Cerebelares .......................................................................... 28 \n\n2.5.1.2 Manifesta\u00e7\u00f5es Oculares ............................................................................... 29 \n\n2.5.1.3 Achados Piramidais ...................................................................................... 29 \n\n2.5.1.4 Achados Extrapiramidais .............................................................................. 29 \n\n2.5.1.5 Achados relacionados ao SNP ..................................................................... 30 \n\n2.5.2 Manifesta\u00e7\u00f5es Cl\u00ednicas N\u00e3o Motoras .............................................................. 30 \n\n2.5.2.1. Dist\u00farbios do Sono e Olfativos..................................................................... 31 \n\n2.5.2.2. Altera\u00e7\u00f5es Cognitivas e Transtornos Psiqui\u00e1tricos ...................................... 31 \n\n2.5.2.3. Outras Manifesta\u00e7\u00f5es N\u00e3o Motoras ............................................................ 32 \n\n2.5.3 Achados Anatomopatol\u00f3gicos ......................................................................... 32 \n\n2.6 Diagn\u00f3stico ......................................................................................................... 33 \n\n2.7 Hist\u00f3ria Natural ................................................................................................... 34 \n\n2.8 Biomarcadores.................................................................................................... 34 \n\n2.9 Tratamento .......................................................................................................... 35 \n\n3 Objetivos................................................................................................................ 37 \n\n3.1 Objetivo principal ............................................................................................... 37 \n\n3.2 Objetivos secund\u00e1rios................................................................................... 37 \n\n4 Refer\u00eancias bibliogr\u00e1ficas da revis\u00e3o ................................................................. 39 \n\n\n\n13 \n \n5 ARTIGOS EM INGL\u00caS ........................................................................................... 54 \n\n5.1 Cap\u00edtulo 1 - Depressive Mood is Associated with Ataxic and Non-Ataxic \n\nNeurological Dysfunction in SCA3 Patients\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..54 \n\n5.2 Cap\u00edtulo 2 - Body Mass Index is Inversely Correlated with the Expanded \n\nCAG Repeat Length in SCA3/MJD Patients\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u202662 \n\n5.3 Cap\u00edtulo 3 - Serum Insulin-Like System Alterations in Patients with \n\nSpinocerebellar Ataxia Type 3\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u202671 \n\n5.4 Cap\u00edtulo 4 - Ataxia Rating Scales\u2014Psychometric Profiles, Natural History \n\nand Their Application in Clinical Trials\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..86 \n\n5.5 Cap\u00edtulo 5 - A randomized, phase 2/3 trial of lithium carbonate in \n\nMachado-Joseph disease..\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026136 \n\n6 CONSIDERA\u00c7\u00d5ES FINAIS ................................................................................ 172 \n\n7 AP\u00caNDICES ......................................................................................................... 175 \n\n7.1 Termos de consentimento livre e esclarecido ................................................... 175 \n\n8 ANEXOS ............................................................................................................... 186 \n\n8.1 Escalas de Ataxias ............................................................................................. 186 \n\n \n\n  \n\n \n\n\n\n14 \n \n\n1. Introdu\u00e7\u00e3o  \n\n \n\nAs ataxias espinocerebelares ou SCAs (do ingl\u00eas, spinocerebellar ataxias), \n\ns\u00e3o um grupo de doen\u00e7as heterog\u00eaneas com heran\u00e7a autoss\u00f4mica dominante e \n\nin\u00edcio na vida adulta, caracterizado por degenera\u00e7\u00e3o progressiva do cerebelo e de \n\nsuas vias aferentes e eferentes. (Sch\u00f6ls et al, 2004; D\u00fcrr, 2010; Bettencourt e Lima, \n\n2012). A doen\u00e7a de Machado-Joseph (DMJ) ou ataxia espinocerebelar do tipo 3 \n\n(SCA3) \u00e9 a SCA mais prevalente no Brasil e em todo mundo (Sch\u00f6ls et al, 2004; \n\nTrott et al., 2006; Sequeiros, Martins e Silveira, 2012). Sua preval\u00eancia m\u00ednima no \n\nEstado do Rio Grande do Sul \u00e9 estimada em 3,5:100.000 habitantes (Prestes et al, \n\n2008) representando 84% das fam\u00edlias com SCAs (Trott et al., 2006). \n\nA DMJ/SCA3 \u00e9 causada por uma expans\u00e3o de sequ\u00eancias repetitivas CAG no \n\nexon 10 do gene ATXN3, localizado no cromossomo 14q32.1 (Takiyama et al, 1993, \n\nKawaguchi et al, 1994). Essa muta\u00e7\u00e3o leva \u00e0 express\u00e3o de uma cadeia \n\nexcessivamente longa de poliglutaminas na prote\u00edna codificada, chamada ataxina-3 \n\n(Costa e Paulson, 2012). Al\u00e9m da DMJ/SCA3, as SCAs 1,2,6,7,17 e DRPLA, a \n\ndoen\u00e7a de Huntington (DH) e Huntington-like tipo 2 (DHL2) e a atrofia muscular \n\nespinhal e bulbar (SBMA) compartilham o mesmo mecanismo de muta\u00e7\u00e3o e muitos \n\ndos processo patog\u00eanicos, fazendo parte do grupo denominado de \n\npoliglutaminopatias (poliQ) (D\u00fcrr, 2010; Costa e Paulson, 2012).  \n\nA DMJ/SCA3 apresenta express\u00e3o cl\u00ednica heterog\u00eanea, com manifesta\u00e7\u00f5es \n\nque abrangem m\u00faltiplos sistemas neurol\u00f3gicos (Soong e Paulson, 2007; Kieling, \n\nSaute e Jardim, 2007). A idade m\u00e9dia de in\u00edcio dos sintomas, entre brasileiros, \u00e9 de \n\n32 anos (Jardim et al, 2001a), sendo a ataxia cerebelar, de predom\u00ednio axial, a \n\nprincipal manifesta\u00e7\u00e3o cl\u00ednica. A ataxia pode ser acompanhada por oftalmoplegia \n\nexterna progressiva, disartria, disfagia, sinais piramidais e extrapiramidais e \n\nneuropatia perif\u00e9rica (D\u00fcrr et al, 1996; Jardim et al, 2001a, 2010; Fran\u00e7a Jr. et al, \n\n2009; Costa e Paulson, 2012). Seu curso \u00e9 progressivo, levando os pacientes \u00e0 \n\ndepend\u00eancia funcional e ao retraimento social (Kieling et al, 2007). Sintomas \n\npsiqui\u00e1tricos tamb\u00e9m s\u00e3o comuns na DMJ/SCA3 e representam um significativo \n\nimpacto negativo na qualidade de vida dos pacientes (Schmitz-H\u00fcbsch et al., 2010).  \n\nA progress\u00e3o cl\u00ednica da DMJ/SCA3 \u00e9 indiscutivelmente lenta (Kieling et al, \n\n2007; Fran\u00e7a et al, 2009; Jardim et al, 2010). Diversos instrumentos de avalia\u00e7\u00e3o de \n\n\n\n15 \n \n\ngravidade das manifesta\u00e7\u00f5es cerebelares (Trouillas et al, 1997; Schmitz-H\u00fcbsch et \n\nal, 2006) e extracerebelares (Kieling et al, 2008; Schmitz-H\u00fcbsch et al, 2008) das \n\nSCAs foram desenvolvidos nos \u00faltimos anos, n\u00e3o havendo consenso sobre quais \n\ndestes instrumentos parecem ser os mais adequados para utiliza\u00e7\u00e3o em ensaios \n\ncl\u00ednicos randomizados (ECR) ou se h\u00e1 uma clara necessidade de desenvolvimento \n\nde novas escalas. A evolu\u00e7\u00e3o lentamente progressiva medida pelas escalas de \n\navalia\u00e7\u00e3o cl\u00ednica (Jardim et al, 2010; Schmitz-H\u00fcbsch et al, 2010) pode impedir ou \n\ndificultar muito a detec\u00e7\u00e3o de efeitos terap\u00eauticos em futuros ECRs, o que torna de \n\ngrande import\u00e2ncia a busca por novos biomarcadores.  \n\nV\u00e1rios f\u00e1rmacos j\u00e1 foram estudados na tentativa de retardar a progress\u00e3o da \n\nSCAs, como buspirona (Assadi et al, 2007), fluoxetina (Monte et al,2003), \n\ntandospirona (Takei et al, 2004), amantadina (Botez et al., 1996), TRH (Waragai et \n\nal,1997), fisostigmina (Wessel et al, 1997), entre outros. Todos apresentaram \n\nresultados negativos ou inconclusivos, o que pode indicar uma aus\u00eancia de efeito \n\npor n\u00e3o atuarem em mecanismos relevantes da doen\u00e7a (ainda pouco conhecidos), \n\ne/ou que o seguimento foi curto para uma doen\u00e7a de progress\u00e3o lenta, e/ou ainda \n\nque o poder dos estudos foi insuficiente. Assim, o manejo da DMJ/SCA3 se resume \n\nao aconselhamento gen\u00e9tico, ao acompanhamento fisioter\u00e1pico e de terapia \n\nocupacional (Silva et al, 2010) e ao manejo sintom\u00e1tico para alguns de seus sinais e \n\nsintomas (D\u2018Abreu et al, 2010). \n\nConsiderando a aus\u00eancia de tratamentos farmacol\u00f3gicos que modifiquem o \n\ncurso letal da DMJ/SCA3, o principal objetivo deste trabalho foi o desenvolvimento e \n\nrealiza\u00e7\u00e3o de um ECR para avaliar a efetividade de um potencial tratamento \n\nneuroprotetor na DMJ/SCA3. Os estudos que ser\u00e3o apresentados nos cap\u00edtulos \n\niniciais da presente tese tornaram poss\u00edvel e definiram diversas das etapas para a \n\nrealiza\u00e7\u00e3o deste ECR.  \n\nA avalia\u00e7\u00e3o dos sintomas depressivos da DMJ/SCA3 e a revis\u00e3o sistem\u00e1tica \n\nsobre as escalas para SCAs possibilitaram a escolha dos desfechos prim\u00e1rios e \n\nsecund\u00e1rios para o ECR. As altera\u00e7\u00f5es nutricionais encontradas e os achados de \n\nmarcadores e fatores modificadores do fen\u00f3tipo da DMJ/SCA3 relacionados ao IIS - \n\nSistema Insulina/ Fator de Crescimento Semelhante \u00e0 Insulina Tipo 1 (IGF-1) - \n\nserviram como base para a escolha dos biomarcadores utilizados como desfechos \n\nsecund\u00e1rios no ECR. \n\n\n\n16 \n \n\nOs relatos de efic\u00e1cia do tratamento com L\u00edtio atrav\u00e9s da inibi\u00e7\u00e3o da enzima \n\nGSK-3? e da indu\u00e7\u00e3o de mecanismos de limpeza celular de prote\u00ednas malformadas \n\nem um modelo celular de DH (Carmichael, 2002); em camundongos transg\u00eanicos \n\ncom SCA1 (Watase et al, 2007) e esclerose lateral amiotr\u00f3fica (ELA) familiar (SOD1) \n\n(Fornai et al, 2008); em pacientes com ELA espor\u00e1dica (Fornai et al, 2008); e em  \n\num relato de caso de paciente com SCA2 (Hering et al, 2009), fizeram com que o \n\nf\u00e1rmaco Carbonato de L\u00edtio, utilizado h\u00e1 v\u00e1rias d\u00e9cadas no tratamento de \n\ntranstornos psiqui\u00e1tricos e amplamente dispon\u00edvel na rede do Sistema \u00danico de \n\nSa\u00fade brasileiro, fosse escolhido como potencial terapia a ser avaliado no maior e \n\nmais longo Ensaio Cl\u00ednico Randomizado realizado nas SCAs at\u00e9 o presente \n\nmomento.  \n\n  \n\n\n\n17 \n \n\n2. Revis\u00e3o da Literatura \n\n \n\nDoen\u00e7a de Machado Joseph / Ataxia espinocerebelar \n\ntipo 3: aspectos hist\u00f3ricos, cl\u00ednicos e moleculares. \n\n \n\n2.1 Aspectos Hist\u00f3ricos \n\nEm 1971, Nakano, Dawson e Spence, neurologistas do Peter Bent Brigham \n\nHospital de Boston, Massachusetts, Estados Unidos (EUA), observaram uma grande \n\nfam\u00edlia de imigrantes a\u00e7orianos (descendentes de William Machado, nativo da Ilha \n\nde S\u00e3o Miguel, nos A\u00e7ores) com quadro cl\u00ednico de ataxia cerebelar e neuropatia \n\nperif\u00e9rica com in\u00edcio ap\u00f3s os 40 anos que era herdada de modo autoss\u00f4mico \n\ndominante. Os autores relataram que os 51 indiv\u00edduos afetados na fam\u00edlia Machado \n\nmanifestavam a mesma doen\u00e7a e que, devido ao comprometimento do cerebelo e \n\ntronco cerebral, apresentavam formas cl\u00ednicas variadas, causando diferentes \n\ns\u00edndromes neurol\u00f3gicas em diferentes momentos da vida dos indiv\u00edduos. Esta \n\ndoen\u00e7a foi nomeada em artigo publicado em 1972 (Nakano, Dawson e Spence, \n\n1972) como Doen\u00e7a de Machado.  \n\nNo mesmo ano da publica\u00e7\u00e3o do artigo da Doen\u00e7a de Machado, Woods e \n\nSchaumburg descreveram a degenera\u00e7\u00e3o nigroespinodenteada com oftalmoplegia \n\nnuclear, presente em outra grande fam\u00edlia que vivia no sudoeste de Massachusetts \n\n(fam\u00edlia Thomas) descendente de um emigrante da ilha de Flores nos A\u00e7ores \n\n(Woods e Schaumburg, 1972). Em 1976, Rosenberg e colaboradores descreveram \n\nmais uma fam\u00edlia, n\u00e3o relacionada \u00e0s anteriores, tamb\u00e9m de origem a\u00e7oriana que \n\nvivia no Estado da Calif\u00f3rnia, EUA, de sobrenome Joseph. A doen\u00e7a, denominada \n\nde degenera\u00e7\u00e3o estriatonigral autoss\u00f4mica dominante, manifestava-se entre os 17 e \n\nos 42 anos por ataxia de marcha, ?rigidez parkinsoniana?, espasticidade, disartria e \n\noftalmoplegia, sem haver altera\u00e7\u00f5es intelectuais (Rosenberg et al, 1976). Em 1978 \n\npassa a ser chamada de Doen\u00e7a de Joseph (Rosenberg et al, 1978) \n\nDevido \u00e0s diferen\u00e7as fenot\u00edpicas relacionadas \u00e0 heterogeneidade dos \n\nsintomas cl\u00ednicos, acreditava-se que estas tr\u00eas fam\u00edlias apresentassem doen\u00e7as \n\ndistintas. As descri\u00e7\u00f5es vindas dos EUA de doen\u00e7as neurol\u00f3gicas heredit\u00e1rias em \n\n\n\n18 \n \n\ndescendentes a\u00e7orianos e o relato da exist\u00eancia nos A\u00e7ores de v\u00e1rias fam\u00edlias com \n\ndoen\u00e7as degenerativas do sistema nervoso central (SNC) levaram os pesquisadores \n\nportugueses Coutinho e Andrade a visitar os A\u00e7ores em 1976. O resultado foi a \n\ndescri\u00e7\u00e3o de 40 doentes, pertencentes a 15 grandes fam\u00edlias, com in\u00edcio dos \n\nsintomas entre 30 e 50 anos de idade, mostrando grande variabilidade de \n\napresenta\u00e7\u00e3o cl\u00ednica (Coutinho e Andrade, 1978). Estes autores sistematizaram os \n\nfen\u00f3tipos da doen\u00e7a em 3 tipos cl\u00ednicos principais. Sinais cerebelares e \n\noftalmoplegia externa progressiva eram achados em quase todos os pacientes, \n\nassociados a sinais piramidais em graus variados. Os tipos cl\u00ednicos poderiam ser \n\ndistinguidos com base na presen\u00e7a/aus\u00eancia de sinais extrapiramidais e \n\nrelacionados ao sistema nervoso perif\u00e9rico (SNP) e idade de in\u00edcio da apresenta\u00e7\u00e3o \n\n(Coutinho e Andrade, 1978).  \n\nA descri\u00e7\u00e3o de outras fam\u00edlias de descend\u00eancia a\u00e7oriana nos EUA com \n\ncaracter\u00edsticas cl\u00ednicas semelhantes e que reuniam a sintomatologia presente nas \n\ntr\u00eas fam\u00edlias anteriores (Romanul et al., 1977) e a descri\u00e7\u00e3o das fam\u00edlias nos A\u00e7ores \n\n(Coutinho e Andrade, 1978) levou a conclus\u00e3o de que se tratava da mesma doen\u00e7a, \n\npor\u00e9m com expressividade cl\u00ednica vari\u00e1vel, sendo denominada de ?doen\u00e7a a\u00e7oriana? \n\n(Romanul et al., 1977). Lima e Coutinho identificaram em 1980 a primeira fam\u00edlia n\u00e3o \n\nrelacionada \u00e0 Ilha dos A\u00e7ores ou \u00e0 Am\u00e9rica do Norte na qual alguns indiv\u00edduos \n\napresentavam os sintomas da ?doen\u00e7a a\u00e7oriana? e propuseram a denomina\u00e7\u00e3o de \n\ndoen\u00e7a de Machado-Joseph (DMJ) (Lima e Coutinho, 1980). Essa denomina\u00e7\u00e3o \n\njustificava-se pelo fato de a fam\u00edlia Machado ter sido a primeira a ser descrita e a \n\nfam\u00edlia Joseph por ser a maior e mais bem conhecida fam\u00edlia com DMJ. \n\nApesar do enfoque dado para as fam\u00edlias de descend\u00eancia a\u00e7oriana como \n\nsendo os primeiros relatos da DMJ, na verdade, a fam\u00edlia Drew, origin\u00e1ria de \n\nWalworth, uma localidade na regi\u00e3o nordeste da Inglaterra, foi a fam\u00edlia mais antiga \n\na ser descrita com DMJ (Fergunson  e Critchley, 1929). A primeira avalia\u00e7\u00e3o de um \n\npaciente da fam\u00edlia Drew ocorreu no ano de 1895, no National Hospital (hoje The \n\nNational Hospital for Neurology and Neurosurgery, Queen Square, Londres, Reino \n\nUnido), e foi realizada pelo eminente neurologista Sir William Gowers. O paciente \n\nera William Drew, com 40 anos de idade na \u00e9poca, apresentava-se com quadro \n\ncl\u00ednico compat\u00edvel com parkinsonismo e recebeu o diagn\u00f3stico final de Paralisia \n\nAgitans, conforme demonstrou a ficha cl\u00ednica assinada por Gowers (Teive e Arruda, \n\n2004). Em 1995, Giunti, Sweeney e Harding publicaram estudo com an\u00e1lise \n\n\n\n19 \n \n\nmolecular para DMJ em uma s\u00e9rie de fam\u00edlias com SCAs, incluindo a fam\u00edlia Drew \n\nde Walworth, concluindo que esta fam\u00edlia segregava a DMJ.  \n\n Em 1993 estudos de liga\u00e7\u00e3o mapearam o gene da DMJ no bra\u00e7o longo do \n\ncromossomo 14 (Takiyama et al, 1993). Em 1994, expans\u00f5es CAG em um novo \n\ngene localizado no cromossomo 14q32.1 foram descritas como associadas \u00e0 DMJ \n\n(Kawaguchi et al, 1994). No mesmo ano, a mesma regi\u00e3o no cromossomo 14q24.3-\n\nq32.2 foi associado a fam\u00edlias com SCA ainda sem diagn\u00f3stico molecular por um \n\ngrupo de pesquisadores franceses, que acreditaram encontrar uma nova condi\u00e7\u00e3o e \n\na denominaram de SCA3 (Stevanin et al, 1994-1). Nos meses seguintes os mesmos \n\nautores conclu\u00edram que as assim chamadas SCA3 e DMJ eram causadas por \n\nanormalidades no mesmo gene (Stevanin et al, 1994-2), sendo finalmente aceitas \n\ncomo a mesma doen\u00e7a tr\u00eas anos depois (Haberhausen et al, 1995). Atualmente \n\nambas a denomina\u00e7\u00f5es, SCA3 ou DMJ, s\u00e3o utilizadas e amplamente aceitas. Na \n\npresente revis\u00e3o esta doen\u00e7a ser\u00e1 referida como DMJ/SCA3.   \n\nCabe ainda ressaltar que a hip\u00f3tese de uma origem portuguesa/a\u00e7oriana \n\nproposta nas descri\u00e7\u00f5es iniciais da DMJ/SCA3 tem sido contestada por estudos \n\nmulticontinentais recentes, que sugerem uma origem Asi\u00e1tica ou abor\u00edgene \n\naustraliana para a linhagem mais prevalente da doen\u00e7a (hapl\u00f3tipo ACA), permitindo \n\ndatar a muta\u00e7\u00e3o original em mais de 7 mil anos (Martins et al 2007, Martins et al, \n\n2012). Uma introdu\u00e7\u00e3o mais recente desta linhagem teria sucessivamente ocorrido \n\nna Am\u00e9rica do Norte, Alemanha, Fran\u00e7a, Portugal e Brasil.  \n\n2.2 Aspectos Epidemiol\u00f3gicos \n\n A preval\u00eancia das SCAs varia significativamente entre as diferentes \n\npopula\u00e7\u00f5es. Nas SCAs causadas por expans\u00e3o de repeti\u00e7\u00f5es de trinucleot\u00eddeos os \n\nfatores que podem estar envolvidos nesta varia\u00e7\u00e3o incluem a frequ\u00eancia de alelos \n\nnormais grandes (inst\u00e1veis) e de hapl\u00f3tipos que tenham maior tend\u00eancia \u00e0 expans\u00e3o \n\nem cada popula\u00e7\u00e3o. Mecanismos de deriva g\u00eanica, como o efeito fundador, podem \n\nser importantes fatores na distribui\u00e7\u00e3o geogr\u00e1fica de alguns subtipos de SCAs \n\n(Sequeiros, Martins e Silveira, 2012). Isso ocorreu, por exemplo, com a SCA2 em \n\nCuba e com a DMJ/SCA3 nas Ilhas dos A\u00e7ores e no sul do Brasil (Jardim et al, \n\n2001b; Schols, et al, 2004; Vel\u00e1zquez-P\u00e9rez et al, 2011, Camargo, 2011). \n\n\n\n20 \n \n\n Em Portugal, em estudo de base populacional conduzido por mais de 12 \n\nanos, a preval\u00eancia geral de ataxias heredit\u00e1rias foi de 7,9:100.000 (Silva et al, \n\n1997). Contudo, h\u00e1 grande varia\u00e7\u00e3o na frequ\u00eancia das SCAs entre os pa\u00edses e estes \n\nfrequentemente tamb\u00e9m apresentam diferen\u00e7as regionais.  Independente desta \n\nvaria\u00e7\u00e3o de frequ\u00eancias, a DMJ/SCA3 \u00e9 considerada a SCA mais comum \n\nmundialmente (Schols, et al., 2004; Sequeiros, Martins e Silveira, 2012), sendo de \n\nlonge a mais frequente no Brasil (Lopes-Cendes et al, 1997; Trott et al, 2006), \n\nPortugal (Silveira et al., 2002), China (Jiang et al., 2005) e Taiwan (Soong,et al., \n\n2001). \n\nNo Brasil, a preval\u00eancia de DMJ/SCA3 \u00e9 especialmente elevada no Estado do \n\nRio Grande do Sul (RS), onde \u00e9 estimada em pelo menos 3,5:100.000 habitantes \n\n(Prestes et al, 2008) e onde representa 84% das fam\u00edlias com SCAs (Trott et al, \n\n2006). Um efeito fundador a\u00e7oriano, ocorrido a partir de 1748 quando foi iniciada a \n\nemigra\u00e7\u00e3o de a\u00e7orianos para o Sul do Brasil, \u00e9 considerado como a principal raz\u00e3o \n\npara o elevado n\u00famero de casos nesta regi\u00e3o. Esta explica\u00e7\u00e3o hist\u00f3rica foi \n\nrecentemente refor\u00e7ada pela descri\u00e7\u00e3o de elevadas frequ\u00eancias regionais, \n\ncompat\u00edveis com um efeito fundador, por Camargo e colaboradores. Neste trabalho \n\na preval\u00eancia de DMJ/SCA3 foi estimada nos diferentes mun\u00edcipios do RS. Algumas \n\nlocalidades apresentaram alta preval\u00eancia de DMJ/SCA3, como as cidades de \n\nGeneral C\u00e2mara (106:100.000), Palmitinho (86,7:100.000), S\u00e3o Jer\u00f4nimo \n\n(49,8:100.000) e S\u00e3o Pedro do Sul (42,7:100.000) (Camargo, 2011). A figura n\u00ba 1 \n\nmostra a distribui\u00e7\u00e3o destas frequ\u00eancias nos munic\u00edpios do RS. As preval\u00eancias \n\ndescritas nestas localidades est\u00e3o bem acima das encontradas em Portugal e ilhas \n\n(3,1:100.000), Ilha de S\u00e3o Miguel nos A\u00e7ores (27,1:100.000) e Portugal continental \n\n(1:100.000) (Camargo, 2011). Somente a Ilha de Flores, com preval\u00eancia de \n\n418:100.000, continua como a regi\u00e3o de maior preval\u00eancia mundial de DMJ/SCA3 \n\n(Bettencourt e Lima, 2011). \n\n \n\n  \n\n\n\n21 \n \nFigura n\u00ba 1 \u2013 Mapa de frequ\u00eancia da DMJ/SCA3 no RS. \n\n \n\nMapa do Rio Grande do Sul com as localidades com maior preval\u00eancia de \n\nDMJ/SCA3 e suas respectivas frequ\u00eancias. FONTE: Camargo, 2011. \n\n2.3 Aspectos Gen\u00e9ticos \n\nA DMJ/SCA3 \u00e9 causada por uma expans\u00e3o de sequ\u00eancias repetitivas CAG na \n\ntermina\u00e7\u00e3o 5\u2018 do exon 10 do gene ATXN3, localizado no cromossomo 14q32.1 \n\n(Takiyama et al, 1993; Kawaguchi et al, 1994). O alelo normal cont\u00e9m entre 12 e 44 \n\nrepeti\u00e7\u00f5es, enquanto o mutante cont\u00e9m entre 61 e 86 repeti\u00e7\u00f5es (Maciel et al, 1995; \n\nSequeiros, Martins e Silveira, 2012) e leva a uma expans\u00e3o de poliglutaminas \n\n(PoliQ) na prote\u00edna correspondente, chamada ataxina-3 ou ATXN3. Nesta tese, \n\ndenominaremos a prote\u00edna de ATXN3, em contraste com a denomina\u00e7\u00e3o do gene, \n\nATXN3 (em it\u00e1lico). Alelos de tamanhos intermedi\u00e1rios (45-56 repeti\u00e7\u00f5es) foram \n\npoucas vezes descritos. O seu exato papel na penetr\u00e2ncia da doen\u00e7a, bem como na \n\ngera\u00e7\u00e3o de expans\u00f5es de novo de penetr\u00e2ncia completa n\u00e3o est\u00e1 claro. Cabe \n\n\n\n22 \n \n\nressaltar que muta\u00e7\u00f5es de novo n\u00e3o foram descritas para a DMJ/SCA3, sendo \n\nsugerido por estudos de hapl\u00f3tipos intrag\u00eanicos a exist\u00eancia de dois eventos \n\nmutag\u00eanicos independentes ocorridos h\u00e1 cerca de mil e quatrocentos e sete mil \n\nanos (Sequeiros, Martins e Silveira, 2012). \n\nA heran\u00e7a \u00e9 autoss\u00f4mica dominante, ou seja, cada filho de um genitor \n\nafetado tem um risco a priori de 50% de ser portador da muta\u00e7\u00e3o, com a \n\nprobabilidade de receber ou transmitir a muta\u00e7\u00e3o igual entre os sexos. A penetr\u00e2ncia \n\nda DMJ/SCA3 \u00e9 pr\u00f3xima de 100%, considerada para fins de aconselhamento \n\ngen\u00e9tico como completa. Existe tamb\u00e9m uma clara tend\u00eancia \u00e0 idade de in\u00edcio ser \n\nmenor em cada gera\u00e7\u00e3o sucessiva (Maciel et al, 1995), no fen\u00f4meno conhecido \n\ncomo antecipa\u00e7\u00e3o \n\nAl\u00e9m da DMJ/SCA3 e SCAs 1,2,6,7,17 e DRPLA; as doen\u00e7as de Huntington \n\n(DH), a atrofia muscular espinhal e bulbar (SBMA) e, mais recentemente, a doen\u00e7a \n\nHuntington-like tipo 2 (DHL2) compartilham o mesmo mecanismo de muta\u00e7\u00e3o e \n\nmuitos dos processo patog\u00eanicos, fazendo parte do grupo denominado de doen\u00e7as \n\ndas PoliQs ou poliglutaminopatias (D\u00fcrr, 2010; Costa e Paulson, 2012). Cabe \n\nressaltar que para a express\u00e3o cl\u00ednica da DMJ/SCA3 s\u00e3o necess\u00e1rios tratos de \n\nrepeti\u00e7\u00f5es CAG mais longos do que nas demais SCAs causadas por este mesmo \n\nmecanismo de muta\u00e7\u00e3o (Riley e Orr, 2006). \n\nH\u00e1 uma tend\u00eancia \u00e0 instabilidade no n\u00famero de repeti\u00e7\u00f5es de glutaminas \n\nquando estas atravessam divis\u00f5es celulares, sejam elas mit\u00f3ticas ou mei\u00f3ticas. \n\nEssa instabilidade, que tende a favorecer as expans\u00f5es especialmente ao \n\natravessar espermatog\u00eaneses, resulta na varia\u00e7\u00e3o do n\u00famero de repeti\u00e7\u00f5es em \n\ncada gera\u00e7\u00e3o dentro das fam\u00edlias afetadas. Isso, por sua vez, explica em grande \n\nparte o fen\u00f4meno da antecipa\u00e7\u00e3o (Maciel et al, 1995). Existe uma forte rela\u00e7\u00e3o \n\ninversa entre n\u00famero de repeti\u00e7\u00f5es CAG e a idade de in\u00edcio dos sintomas (Maciel et \n\nal, 1995), que explica de 50 a 75% da varia\u00e7\u00e3o na idade de aparecimento dos \n\nprimeiros achados cl\u00ednicos (Bettencourt e Lima, 2011).  \n\nAl\u00e9m da antecipa\u00e7\u00e3o per se, a instabilidade do tamanho da repeti\u00e7\u00e3o \n\nexpandida explica uma boa parte da variabilidade nas manifesta\u00e7\u00f5es cl\u00ednicas da \n\nDMJ/SCA3 (ver abaixo). \n\n\n\n23 \n \n\n2.4 Fisiopatologia \n\n2.4.1 Agregados Intracelulares e proteotoxicidade \n\nUm dos marcos patol\u00f3gicos na DMJ/SCA3 \u00e9 a forma\u00e7\u00e3o de neuroinclus\u00f5es \n\n(NI) ou agregados intranucleares (Figura n\u00ba 2), em que um poss\u00edvel efeito t\u00f3xico \n\ndireto tem sido intensamente debatido (Costa e Paulson, 2012). As \n\npoliglutaminopatias s\u00e3o causadas por prote\u00ednas com estrutura terci\u00e1ria an\u00f4mala e \n\ncom propens\u00e3o \u00e0 agrega\u00e7\u00e3o (Paulson, 1999). Essas prote\u00ednas misfolded, \n\ndenominadas de ataxinas por estarem relacionadas \u00e0s ataxias espinocerebelares, \n\nacumulam-se nas NIs junto com ubiquitinas e com chaperonas. Al\u00e9m de terem em \n\ncomum uma PoliQ, h\u00e1 tamb\u00e9m marcante sobreposi\u00e7\u00e3o de sintomas entre essas \n\nafec\u00e7\u00f5es, com neurodegenera\u00e7\u00e3o predominante do cerebelo e de n\u00facleos do tronco \n\ncerebral (Paulson, 1999). \n\nH\u00e1 NI em todas as regi\u00f5es afetadas pela doen\u00e7a (descritas adiante) e \n\ntamb\u00e9m em estruturas nas quais n\u00e3o h\u00e1 clara perda neuronal. A presen\u00e7a de NI \n\nantecede os sintomas cl\u00ednicos, havendo um maior n\u00famero nos pacientes com \n\nexpans\u00f5es CAG mais longas. A composi\u00e7\u00e3o das NI da DMJ/SCA3 inclui ubiquitina, \n\nATXN3, tratos de PoliQ e v\u00e1rios fatores de transcri\u00e7\u00e3o (Paulson, 1999). Al\u00e9m das NI, \n\nos neur\u00f4nios afetados possuem gr\u00e2nulos citoplasm\u00e1ticos imunomarcados com 1C2 \n\n(um anticorpo monoclonal contra PoliQ) que correspondem a um subgrupo de \n\nlisossomos, sugerindo que as vias de autofagocitose para a degrada\u00e7\u00e3o proteica \n\ntamb\u00e9m t\u00eam rela\u00e7\u00e3o com a ATXN3 mutada (Yamada, Tsuji e Takahashi, 2002; \n\nYamada et al, 2008).  \n\nComo as NI n\u00e3o se correlacionam diretamente com a neurodegenera\u00e7\u00e3o elas \n\nt\u00eam sido consideradas atualmente como biomarcadores da fal\u00eancia celular no \n\nprocesso de limpeza da ATXN3 mutada (Costa e Paulson, 2012). \n\n \n\n\n\n24 \n \n\nFigura n\u00ba 2 - Agregados intranucleares neuronais \n\n \n\nInclus\u00e3o intranuclear com imunorreatividade para ATXN3 em um neur\u00f4nio do n\u00facleo \n\nintersticial de Cajal de uma paciente com DMJ/SCA3. FONTE: Riess et al, 2008 \n\nSemelhante \u00e0s demais condi\u00e7\u00f5es relacionadas \u00e0 PoliQ, a ATXN3 selvagem \n\nse colocaliza com a expandida, nas NIs  (Uchihara et al, 2001; Haacke et al, 2006). \n\nDesta forma, a patog\u00eanese da DMJ/SCA3 al\u00e9m de ser devida \u00e0s caracter\u00edsticas da \n\nprote\u00edna mutante (ganho de fun\u00e7\u00e3o t\u00f3xica), tamb\u00e9m pode ter rela\u00e7\u00e3o com algum \n\ngrau de perda de fun\u00e7\u00e3o da prote\u00edna selvagem, ?sequestrada? nas NI. Assim, o \n\nconhecimento sobre a fun\u00e7\u00e3o da ATXN3 passou a ser de grande relev\u00e2ncia \n\n2.4.2 Fun\u00e7\u00f5es da ATXN3 \n\nA ATXN3 (Figura n\u00ba 3) \u00e9 um pept\u00eddeo que se localiza tanto no citoplasma \n\ncomo no n\u00facleo de todas as c\u00e9lulas dos animais superiores. Sua principal fun\u00e7\u00e3o \n\nparece ser no controle de qualidade proteica celular e ocorre fora do n\u00facleo, \n\nparticipando do sistema ubiquitina-proteassoma (UPS). A ATXN3 cont\u00e9m motivos de \n\nintera\u00e7\u00e3o com a ubiquitina (UIMs) em sua estrutura (Burnett e Pittman, 2003; Costa \n\ne Paulson, 2012), age como uma protease ubiquitina-espec\u00edfica (Nicastro et al, \n\n2005), est\u00e1 envolvida no reconhecimento de substratos proteol\u00edticos pelo \n\nproteassoma (Doss-Pepe et al, 2003), regula a forma\u00e7\u00e3o de agressomas (Burnett \n\nand Pittman, 2005) e tamb\u00e9m, por via relacionada ao UPS, suprime a toxicidade \n\ninduzida por PoliQ (Warrick et al, 2005).  \n\n \n\n\n\n25 \n \nFigura n\u00ba 3 - Dom\u00ednios funcionais da Ataxina-3 \n\n \n\nDom\u00ednios funcionais da ATXN3: A regi\u00e3o N-terminal cont\u00e9m um dom\u00ednio DUB \n\ncatal\u00edtico (Dom\u00ednio Joseph, JD), dois s\u00edtios ligantes de ubiquitina e dois sinais de \n\nexporta\u00e7\u00e3o nuclear (NES). A regi\u00e3o C-terminal da ATXN3 cont\u00e9m 2 ou 3 UIMs, \n\nsinais de localiza\u00e7\u00e3o nuclear (NLS) e o trato de PoliQ. A figura tamb\u00e9m mostra os \n\ns\u00edtios de fosforila\u00e7\u00e3o da prote\u00edna.  FONTE: Costa e Paulson, 2012.  \n\nA ATXN3 tamb\u00e9m se localiza no n\u00facleo (Tait et al, 1998) onde tem papel na \n\nregula\u00e7\u00e3o da transcri\u00e7\u00e3o de outros genes (Li et al, 2002). A ATXN3 interage com \n\nfatores de transcri\u00e7\u00e3o geralmente resultando em a\u00e7\u00e3o repressora sobre a \n\ntranscri\u00e7\u00e3o. A repress\u00e3o da transcri\u00e7\u00e3o relacionada \u00e0 ATXN3 se d\u00e1 via inibi\u00e7\u00e3o de \n\nacetiltransferases de histonas (HAT) (Li et al, 2002) e via recrutamento de \n\ndesacetilases de histonas (HDAC) (Evert et al, 2006). Coativadores transcricionais \n\ncom atividade HAT o fazem ao promover a acetila\u00e7\u00e3o das histonas (Torchia et al, \n\n1997). Ao contr\u00e1rio, a desacetila\u00e7\u00e3o das histonas via HDAC torna os promotores \n\ng\u00eanicos inacess\u00edveis aos seus fatores reguladores (Nagy et al., 1997). O equil\u00edbrio \n\nentre acetila\u00e7\u00e3o e desacetila\u00e7\u00e3o de histonas pode ser um processo chave na \n\npatog\u00eanese das poliglutaminopatias em geral.  \n\nEstudos mais recentes mostram que a ATXN3 mutada leva tanto a infra \n\nquanto a supra-regula\u00e7\u00e3o de alguns genes (Costa e Paulson, 2012). De modo geral \n\nh\u00e1 supress\u00e3o de transcri\u00e7\u00e3o de genes envolvidos na neurotransmiss\u00e3o \n\nglutamat\u00e9rgica, sinaliza\u00e7\u00e3o do c\u00e1lcio intracelular, prote\u00ednas heat shock (HSP), e \n\nfatores reguladores da sobreviv\u00eancia e diferencia\u00e7\u00e3o neuronal (Chou et al, 2008) e \n\nsupra-regula\u00e7\u00e3o de genes relacionados com morte celular e inflama\u00e7\u00e3o (Chou et al., \n\n2008; Evert et al., 2001, 2003). \n\n\n\n26 \n \n\nH\u00e1 v\u00e1rios exemplos de altera\u00e7\u00f5es de transcri\u00e7\u00e3o de outros genes nas demais \n\npoliglutaminopatias. Na DH a prote\u00edna envolvida, chamada huntingtina, interage com \n\ncomplexos nucleares envolvidos com repress\u00e3o da transcri\u00e7\u00e3o e no processamento \n\ndos \u00e1cidos ribonucleicos (ARN) (Steffan et al, 2000; Kegel et al, 2002); na SCA7,  a \n\nataxina-7 pode atuar tamb\u00e9m como repressora da transcri\u00e7\u00e3o ao inibir a atividade de \n\nacetila\u00e7\u00e3o de complexos reguladoras da transcri\u00e7\u00e3o (Strom et al, 2005); e na SCA1,   \n\na ataxina-1 inibe a  transcri\u00e7\u00e3o geral, tamb\u00e9m atrav\u00e9s da intera\u00e7\u00e3o com o co-\n\nrepressores da transcri\u00e7\u00e3o (Tsai et al., 2004).  \n\n\u00c9 poss\u00edvel que alguns dos eventos relacionados \u00e0 fun\u00e7\u00e3o da ATXN3 sejam \n\nprotagonistas na fisiopatologia da condi\u00e7\u00e3o. Fen\u00f4menos t\u00e3o comuns \u00e0 DMJ/SCA3 \n\ncomo \u00e0s demais poliglutaminopatias, como antecipa\u00e7\u00e3o e a importante associa\u00e7\u00e3o \n\nentre gravidade e idade de in\u00edcio, s\u00e3o mais logicamente relacionados ao trato PoliQ, \n\nindependente das prote\u00ednas selvagens. Eles, no entanto, n\u00e3o excluem um potencial \n\nimpacto direto da perda de fun\u00e7\u00e3o da ATXN3 nos mecanismos celulares da doen\u00e7a, \n\nCabe destacar que o conceito de ?perda de fun\u00e7\u00e3o? a ser utilizado deve estar \n\nvinculado \u00e0 presen\u00e7a de uma PoliQ na prote\u00edna. Uma vez que a perda de fun\u00e7\u00e3o \n\n?literal?, demonstrada pelos estudos knock-out, n\u00e3o se associou a fen\u00f3tipos \n\nrelevantes (Schmitt et al, 2007; Huynh et al, 2009) \u2013 como veremos a seguir.  \n\n2.4.3. Haploinsufici\u00eancia como principal mecanismo de doen\u00e7a? \n\nPerdas de fun\u00e7\u00e3o s\u00e3o tamb\u00e9m chamadas de haploinsufici\u00eancia; e \n\nhaploinsufici\u00eancias t\u00eam sido descritas algumas vezes em condi\u00e7\u00f5es dominantes, \n\nespecialmente quando o gene transcreve prote\u00ednas estruturais. Nos casos de perda \n\nde fun\u00e7\u00e3o, entretanto, costuma-se registrar efeitos relacionados \u00e0 dosagem g\u00eanica. \n\nPor exemplo, nos indiv\u00edduos com perda dos dois alelos, a condi\u00e7\u00e3o cl\u00ednica \u00e9 ainda \n\nmais grave do que a dos heterozigotos. Infelizmente, o n\u00famero de homozigotos \n\ndescritos para expans\u00f5es CAG no gene ATXN3 \u00e9 bastante pequeno. H\u00e1 pelo menos \n\n8 casos de homozigotos que iniciaram ap\u00f3s os 25 anos de idade, em que n\u00e3o houve \n\nassocia\u00e7\u00e3o clara com uma piora da gravidade das manifesta\u00e7\u00f5es (Lysenko et al, \n\n2010). Embora em uma crian\u00e7a com DMJ/SCA3 homozigota (67/72 repeti\u00e7\u00f5es) a \n\ndoen\u00e7a tenha iniciado aos 4 anos (Carvalho et al, 2008). \n\nModelos de camundongos knockout foram desenvolvidos para os genes \n\nATXN1, ATXN2 e ATXN3. Todos surpreendentemente geraram animais vi\u00e1veis, \n\n\n\n27 \n \n\nf\u00e9rteis e sem doen\u00e7a histol\u00f3gica ou comportamental. Portanto, a supress\u00e3o das \n\nprote\u00ednas envolvidas nas doen\u00e7as de PoliQ n\u00e3o traz consequ\u00eancias maiores \u00e0s \n\nfun\u00e7\u00f5es neurol\u00f3gicas, o que \u00e9 um forte argumento contra a hip\u00f3tese da perda de \n\nfun\u00e7\u00e3o como causa destas condi\u00e7\u00f5es (Matilla et al, 1998; Kiehl et al, 2006; Schmitt \n\net al, 2007; Huynh et al, 2009). \n\n2.4.4 Efeitos diretos da PoliQ e da sua tend\u00eancia \u00e0 agrega\u00e7\u00e3o \n\nA expans\u00e3o de sequ\u00eancias CAG codifica repeti\u00e7\u00f5es puras do amino\u00e1cido \n\nglutamina. Sup\u00f5e-se que esta expans\u00e3o leve a uma altera\u00e7\u00e3o na conforma\u00e7\u00e3o do \n\npept\u00eddeo produzido e que isso traga uma maior tend\u00eancia \u00e0 agrega\u00e7\u00e3o. N\u00e3o se sabe \n\nao certo qual o papel t\u00f3xico da agrega\u00e7\u00e3o das PoliQ, por\u00e9m existem evid\u00eancias de \n\nque ocorra altera\u00e7\u00e3o dos mecanismos de controle de qualidade proteica intracelular \n\n(Soong e Paulson, 2007).  \n\nV\u00e1rios mecanismos de controle celular devem regular os n\u00edveis de prote\u00ednas \n\npropensas \u00e0 agrega\u00e7\u00e3o. Chaperonas moleculares est\u00e3o entre esses mecanismos, \n\nincluindo as chaperonas da fam\u00edlia das prote\u00ednas heat shock HSP40/HSP70. A \n\nsuperexpress\u00e3o da HSP70 e da HSP40 reduziu a agrega\u00e7\u00e3o e a morte celular em \n\nmodelos celulares da doen\u00e7a de Huntington (Carmichael et al, 2002). A HSP27, \n\ntamb\u00e9m suprimiu a morte celular relacionada \u00e0s PoliQ ao reduzir os n\u00edveis de \n\nesp\u00e9cies reativas de oxig\u00eanio (ROS), mas neste caso sem suprimir a agrega\u00e7\u00e3o \n\n(Wyttenbach et al, 2002). A fam\u00edlia de chaperonas HSP40, tamb\u00e9m chamada de \n\nDNAJB, tem a\u00e7\u00e3o supressora sobre a agrega\u00e7\u00e3o de poliglutaminas expandidas que \n\n\u00e9 superior a das demais chaperonas (Hageman et al, 2010). A express\u00e3o de \n\nDNAJB1 em fibroblastos de pacientes com DMJ/SCA3 foi menor do que nos \n\nindiv\u00edduos controles, havendo correla\u00e7\u00e3o inversa de sua express\u00e3o com a idade de \n\nin\u00edcio dos sintomas, independente do tamanho da expans\u00e3o CAG (Zijlstra et al, \n\n2010). Em verdade, o rearranjo e a limpeza da ATXN3 mutada parece ser realizado \n\ntanto pelas chaperonas moleculares, quanto pelo UPS e autofagia (Costa e Paulson, \n\n2012).  \n\n2.5 Aspectos Cl\u00ednicos e Patol\u00f3gicos \n\nA DMJ/SCA3 apresenta express\u00e3o cl\u00ednica heterog\u00eanea, com manifesta\u00e7\u00f5es \n\nque abrangem m\u00faltiplos sistemas neurol\u00f3gicos, sendo a ataxia cerebelar, de \n\n\n\n28 \n \n\npredom\u00ednio axial, a principal manifesta\u00e7\u00e3o cl\u00ednica (Soong e Paulson, 2007; Kieling, \n\nSaute e Jardim, 2007). Seu curso \u00e9 invariavelmente progressivo, levando os \n\npacientes \u00e0 depend\u00eancia funcional e ao retraimento social (Kieling et al, 2007).  \n\nA idade de in\u00edcio dos sintomas em brasileiros \u00e9 em m\u00e9dia de 32-36 anos \n\n(Jardim et al, 2001a; Trott et al, 2006) e o tempo de sobrevida ap\u00f3s o inicio dos \n\nsintomas, de 21 anos em m\u00e9dia (Kieling et al, 2007). Idades de in\u00edcio precoce e \n\nexpans\u00f5es CAG mais longas s\u00e3o preditores de menor sobrevida (Kieling et al, \n\n2007). \n\nAtualmente h\u00e1 descri\u00e7\u00e3o de 5 tipos cl\u00ednicos distintos, sendo os mais \n\nfrequentes o tipo cl\u00ednico 1 (?tipo Joseph?), caracterizado por in\u00edcio precoce (m\u00e9dia de \n\n24.3 anos) e progress\u00e3o r\u00e1pida dos sintomas, com sinais piramidais e \n\nextrapiramidais (principalmente distonia) marcados; o tipo 2 (?tipo Thomas?), com \n\nidade de in\u00edcio intermedi\u00e1ria, pr\u00f3ximo dos 40 anos, ataxia cerebelar e oftalmoplegia \n\nexterna progressiva com ou sem sinais piramidais; e o tipo 3 (?tipo Machado?), de \n\nin\u00edcio mais tardio (m\u00e9dia de 46.8 anos) e associado a altera\u00e7\u00f5es proeminentes do \n\nSNP (Bettencourt e Lima, 2011). Como j\u00e1 mencionamos, existe uma importante \n\ncorrela\u00e7\u00e3o gen\u00f3tipo-fen\u00f3tipo, envolvendo a rela\u00e7\u00e3o inversa entre n\u00famero de \n\nrepeti\u00e7\u00f5es CAG e a idade de in\u00edcio dos sintomas (Maciel et al, 1995, Jardim et al, \n\n2001).  Da\u00ed tamb\u00e9m haver associa\u00e7\u00e3o entre o n\u00famero das repeti\u00e7\u00f5es CAG e os tr\u00eas \n\nsubtipos cl\u00ednicos mais cl\u00e1ssicos. \n\n2.5.1 Manifesta\u00e7\u00f5es Cl\u00ednicas Motoras \n\n2.5.1.1 Manifesta\u00e7\u00f5es Cerebelares \n\n A maior parte dos pacientes nota os primeiros sinais de altera\u00e7\u00f5es no \n\nmovimento na quarta d\u00e9cada de vida com o surgimento de ataxia cerebelar, a qual \n\nter\u00e1 um curso inexoravelmente progressivo a partir deste momento. A ataxia de \n\nmarcha geralmente predomina como manifesta\u00e7\u00e3o cl\u00ednica, mas os sinais de \n\nincoordena\u00e7\u00e3o dos movimentos apendiculares tamb\u00e9m s\u00e3o vistos comumente no \n\nexame neurol\u00f3gico destes indiv\u00edduos (Jardim et al, 2001a). Fala escandida, disfagia \n\ne ataxia de tronco tamb\u00e9m s\u00e3o achados t\u00edpicos da DMJ/SCA3, mas n\u00e3o costumam \n\nestar presentes no in\u00edcio do quadro cl\u00ednico.   \n\n\n\n29 \n \n\n2.5.1.2 Manifesta\u00e7\u00f5es Oculares \n\n Anormalidades oculomotoras, como a oftalmoplegia externa progressiva, s\u00e3o \n\nos segundos achados mais frequentes na DMJ/SCA3 (Jardim et al, 2001a; \n\nBettencourt e Lima, 2011). Alguns raros pacientes t\u00eam na diplopia sua primeira \n\nmanifesta\u00e7\u00e3o. As anormalidades oculomotoras podem ser muito sugestivas de \n\nDMJ/SCA3 em contraste com as demais SCAs. As queixas mais comuns s\u00e3o de \n\ndiplopia e em alguns casos de oscilopsia (D\u00fcrr et al, 1996). No exame destes \n\npacientes pode ser observado nistagmo horizontal na mirada lateral, anormalidades \n\nno movimento sac\u00e1dico e no acompanhamento visual e paralisia supranuclear \n\nvertical. O movimento sac\u00e1dico vertical para cima e a converg\u00eancia s\u00e3o os primeiros \n\na serem acometidos, seguidos pelos movimentos laterais e por \u00faltimo pelos \n\nmovimentos sac\u00e1dicos verticais para baixo (Gordon et al, 2003). Outro achado \n\nrelativamente comum e caracter\u00edstico da DMJ/SCA3 \u00e9 o chamado ?bulging eyes \n\nappearance? que ocorre pela combina\u00e7\u00e3o de retra\u00e7\u00e3o palpebral e redu\u00e7\u00e3o no \n\npiscamento (Jardim et al, 2001; Gordon et al, 2003), ambos aparentemente de \n\nnatureza extrapiramidal.   \n\n2.5.1.3 Achados Piramidais \n\n Altera\u00e7\u00f5es piramidais como hiperreflexia generalizada, espasticidade e a \n\npresen\u00e7a do sinal de Babinski podem estar presentes na DMJ/SCA3, sendo os \n\nindiv\u00edduos com in\u00edcio precoce e expans\u00f5es de repeti\u00e7\u00f5es CAG mais longas os mais \n\nafetados (Coutinho e Andrade, 1978; Jardim et al, 2001a). Os membros inferiores \n\ns\u00e3o muito mais acometidos do que os superiores, onde a espasticidade, sem \n\nfraqueza muscular evidente, predomina (Teive et al, 2001). H\u00e1 inclusive relatos de \n\ncaso de indiv\u00edduos com paraparesia esp\u00e1stica como manifesta\u00e7\u00e3o inicial ou isolada \n\n(Sakai e Kawakami, 1996; Teive et al, 2001), sendo este considerado um tipo cl\u00ednico \n\ndistinto dos 3 anteriores, denominado de tipo cl\u00ednico 5.  \n\n2.5.1.4 Achados Extrapiramidais \n\nDois outros dist\u00farbios do movimento s\u00e3o caracter\u00edsticos da DMJ/SCA3: a \n\ndistonia e o parkinsonismo (Rosenberg et al, 1976; Jardim et al, 2001a). A distonia \n\nest\u00e1 geralmente presente em indiv\u00edduos com in\u00edcio precoce dos sintomas e, na \n\nmaioria dos casos, \u00e9 de distribui\u00e7\u00e3o segmentar ou focal, acometendo dedos, p\u00e9s e \n\n\n\n30 \n \n\nocasionalmente a regi\u00e3o cervical. Entretanto, pacientes com distonia generalizada \n\ngrave e formas responsivas a levodopa t\u00eam sido descritos (M\u00fcnchau et al, 1999; \n\nWilder-Smith et al, 2003). O parkinsonismo sim\u00e9trico, manifestado por rigidez, \n\nbradicinesia e geralmente com resposta a levodopa, tamb\u00e9m pode ocorrer (Gwinn-\n\nHardy et al, 2001; Jardim et al, 2001a). Quando a manifesta\u00e7\u00e3o cl\u00ednica predominante \n\n\u00e9 parkinsoniana, este fen\u00f3tipo tem sido denominado de tipo cl\u00ednico 4 (Bettencourt e \n\nLima, 2011). Recentemente muta\u00e7\u00f5es no gene da glicocerebrosidase (GBA), que \n\nem heterozigose t\u00eam sido associadas com o desenvolvimento de Doen\u00e7a de \n\nParkinson (Sidransky et al, 2009), foram estudas na DMJ/SCA3. Muta\u00e7\u00f5es neste \n\ngene foram encontradas em 33% dos pacientes com fen\u00f3tipo parkinsoniano e em \n\n0% dos pacientes sem parkinsonismo, sendo consideradas como um fator \n\nmodificador do fen\u00f3tipo da DMJ/SCA3 (Siebert et al, 2012).  \n\n2.5.1.5 Achados relacionados ao SNP \n\n Os nervos perif\u00e9ricos est\u00e3o acometidos em cerca de 60% dos pacientes com \n\nDMJ/SCA3 (Klockgether et al, 1999; Jardim et al, 2001a). Diferentemente da distonia \n\ne espasticidade, a neuropatia perif\u00e9rica \u00e9 determinada principalmente pela idade do \n\nindiv\u00edduo, n\u00e3o dependendo do tamanho da expans\u00e3o CAG, da idade de in\u00edcio ou da \n\ndura\u00e7\u00e3o dos sintomas da doen\u00e7a (Klockgether et al, 1999). As fibras sensitivas s\u00e3o \n\nmais comumente afetadas; ocorrendo \u00e1reas disseminadas de hipoestesia t\u00e1til e \n\nproprioceptiva. O dano causado \u00e0s fibras motoras pode ocasionar atrofia muscular e \n\nfraqueza de padr\u00e3o distal (Klockgether et al, 1999). Anormalidades da excitabilidade \n\nmuscular como a presen\u00e7a de c\u00e3ibras e fascicula\u00e7\u00f5es s\u00e3o encontradas em mais de \n\n50% dos pacientes (Fran\u00e7a Jr. et al, 2008). Manifesta\u00e7\u00f5es auton\u00f4micas tamb\u00e9m s\u00e3o \n\ncomuns; especialmente as relacionadas ao sistema genitourin\u00e1rio e sudomotor, \n\nsendo mais frequentes em pacientes com fen\u00f3tipo predominante de polineuropatia \n\nou parkinsonismo (Fran\u00e7a Jr. et al, 2010).  \n\n2.5.2 Manifesta\u00e7\u00f5es Cl\u00ednicas N\u00e3o Motoras \n\n Os achados motores da DMJ/SCA3 s\u00e3o amplamente discutidos e relatados \n\nna literatura desde as primeiras descri\u00e7\u00f5es da doen\u00e7a, entretanto estudos mais \n\nrecentes tamb\u00e9m t\u00eam destacado a relev\u00e2ncia de seus aspectos n\u00e3o motores. Estes \n\nachados s\u00e3o frequentemente pouco reconhecidos e valorizados, apesar de seu \n\ngrande impacto negativo na qualidade de vida.  As principais manifesta\u00e7\u00f5es n\u00e3o \n\n\n\n31 \n \n\nmotoras relatadas e que ser\u00e3o discutidas brevemente a seguir s\u00e3o: dist\u00farbios do \n\nsono, anormalidades olfativas e transtornos cognitivos e psiqui\u00e1tricos.   \n\n2.5.2.1. Dist\u00farbios do Sono e Olfativos \n\n Dist\u00farbios do sono como sonol\u00eancia diurna excessiva, ins\u00f4nia, s\u00edndrome das \n\npernas inquietas e dist\u00farbio comportamental do sono REM s\u00e3o achados frequentes \n\nna DMJ/SCA3 (D\u2018Abreu et al, 2009; Pedroso et al, 2011). A disfun\u00e7\u00e3o olfat\u00f3ria \n\n(hiposmia), um achado comum e precoce de diferentes doen\u00e7as \n\nneurodegenerativas, tamb\u00e9m foi descrita em pacientes com DMJ/SCA3 (Braga-Neto \n\net al,2012a).  \n\n2.5.2.2. Altera\u00e7\u00f5es Cognitivas e Transtornos Psiqui\u00e1tricos  \n\nApesar de as fun\u00e7\u00f5es intelectuais dos indiv\u00edduos com DMJ/SCA3 terem sido \n\nconsideradas preservadas nas suas primeiras descri\u00e7\u00f5es (Rosenberg et al, 1976), \n\nestudos mais recentes t\u00eam demonstrado que de fato ocorre preju\u00edzo cognitivo, mas \n\nsem haver um quadro francamente demencial. Os pacientes podem apresentar \n\ndisfun\u00e7\u00e3o executiva, altera\u00e7\u00e3o no processamento de informa\u00e7\u00f5es visuais e d\u00e9ficits \n\nem mem\u00f3ria verbal e visual (Braga-Neto et al, 2012b).  \n\nOs sintomas psiqui\u00e1tricos s\u00e3o comuns na DMJ/SCA3 e representam um \n\nimpacto negativo significativo na qualidade de vida dos pacientes que \u00e9 compar\u00e1vel \n\nou superior ao que \u00e9 causado pelos sintomas motores desta doen\u00e7a (Schmitz-\n\nH\u00fcbsch et al, 2010). Os sintomas depressivos s\u00e3o os mais estudados, seguidos \n\npelos transtornos de ansiedade que tamb\u00e9m s\u00e3o frequentes (Kawai et al, 2004; \n\nBraga-Neto et al, 2012c). Os sintomas psiqui\u00e1tricos n\u00e3o parecem ser manifesta\u00e7\u00f5es \n\nprodr\u00f4micas da doen\u00e7a, j\u00e1 que indiv\u00edduos portadores da muta\u00e7\u00e3o no gene ATXN3 \n\npr\u00e9-sintom\u00e1ticos apresentam escores em escalas de depress\u00e3o e ansiedades \n\nsimilares aos de seus familiares n\u00e3o portadores da muta\u00e7\u00e3o (Cecchin et al, 2007; \n\nRodrigues et al, 2012).  \n\nO cerebelo tem conex\u00f5es com \u00e1reas corticais e subcorticais n\u00e3o motoras \n\nassociadas com processamento emocional, sendo sugerido um papel na \n\npersonalidade e afeto (Wolf, Rapoport e Schweizer, 2009). A disfun\u00e7\u00e3o cognitiva na \n\nDMJ/SCA3 foi sugerida como associada \u00e0 neurodegenera\u00e7\u00e3o induzida pela doen\u00e7a, \n\nonde, em uma s\u00edndrome afetiva cognitiva cerebelar, o componente afetivo seria \n\n\n\n32 \n \n\nrelacionado a dano neural (Wolf, Rapoport e Schweizer, 2009; Braga-Neto et al, \n\n2012b). Contudo at\u00e9 o momento os estudos que avaliaram a rela\u00e7\u00e3o entre a \n\ndisfun\u00e7\u00e3o cognitiva e transtornos do humor na DMJ/SCA3 tiveram resultados \n\nnegativos (Kawai et al, 2004; Schmitz-H\u00fcbsch et al 2011).  \n\n2.5.2.3. Outras Manifesta\u00e7\u00f5es N\u00e3o Motoras \n\n Dor cr\u00f4nica (Fran\u00e7a Jr. et al, 2007) e fadiga (Friedman e Amick, 2008) \n\ntamb\u00e9m s\u00e3o achados frequentes na DMJ/SCA3 e que levam a preju\u00edzo na qualidade \n\nde vida. Altera\u00e7\u00f5es nutricionais s\u00e3o descritas em algumas poliglutaminopatias, como \n\nna DH, em que h\u00e1 perda de peso em est\u00e1gios inicias e mesmo em indiv\u00edduos pr\u00e9-\n\nsintom\u00e1ticos (Marder et al, 2009). Em camundongos transg\u00eanicos para DMJ/SCA3 \n\nh\u00e1 perda de peso progressiva durante o curso da doen\u00e7a que \u00e9 prevenida com o \n\nbloqueio da express\u00e3o do transgene da ataxina-3 mutada (Boy et al, 2009). Apesar \n\ndisso, as altera\u00e7\u00f5es nutricionais, assim como outras altera\u00e7\u00f5es perif\u00e9ricas, sem \n\nrela\u00e7\u00e3o direta com o SNC ou SNP, n\u00e3o foram ainda avaliadas de forma sistem\u00e1tica \n\nna DMJ/SCA3.   \n\n2.5.3 Achados Anatomopatol\u00f3gicos \n\n A avalia\u00e7\u00e3o macrosc\u00f3pica de c\u00e9rebros de pacientes com DMJ/SCA3 em \n\nest\u00e1gios avan\u00e7ados demonstra despigmenta\u00e7\u00e3o da substantia nigra, atrofia \n\nsignificativa do cerebelo, ponte e bulbo cerebral, assim como atrofia dos nervos \n\ncranianos III ao XII (Riess et al, 2008). Contudo, diversos estudos recentes com \n\nt\u00e9cnicas n\u00e3o convencionais t\u00eam demonstrado que a degenera\u00e7\u00e3o \u00e9 muito mais \n\nampla, com dano disseminado em cerebelo, t\u00e1lamo, mesenc\u00e9falo, ponte, bulbo e \n\nmedula espinhal (Riess et al, 2008; R\u00fcb et 2008). Estes achados excedem o \n\nchamado padr\u00e3o olivopontocerebelar de neurodegenera\u00e7\u00e3o e d\u00e3o suporte a uma \n\ns\u00e9rie de achados cl\u00ednicos que eram menos compreendidos.  \n\nAs seguintes vias e n\u00facleos de subst\u00e2ncia cinzenta podem estar entre os \n\nalvos do processo degenerativo: n\u00facleos das vias cerebelo-t\u00e1lamo-cortical e \n\ng\u00e2nglios da base-t\u00e1lamo-cortical, substantia nigra, n\u00facleos n\u00e3o motores tal\u00e2micos, \n\ncomponentes subcorticais do sistema somato-sensitivo, n\u00facleos vestibulares e \n\noculomotores, e n\u00facleos do tronco cerebral relacionados \u00e0 ingest\u00e3o alimentar (Riess \n\net al, 2008; R\u00fcb et 2008). Cabe ressaltar a preserva\u00e7\u00e3o dos componentes corticais e \n\n\n\n33 \n \n\nsubcorticais do sistema l\u00edmbico na DMJ/SCA3, diferentemente do que \u00e9 visto em \n\noutras SCAs (Riess et al, 2008). H\u00e1 tamb\u00e9m degenera\u00e7\u00e3o da subst\u00e2ncia branca \n\ncentral e perif\u00e9rica na DMJ/SCA3, incluindo: nervos perif\u00e9ricos, ped\u00fanculos \n\ncerebelares, tratos vestibuloespinhal e espinocerebelar, assim como os fasc\u00edculos \n\nlongitudinal medial, gr\u00e1cil e cuneiforme (Riess et al, 2008).  \n\nA progress\u00e3o temporal dos achados patol\u00f3gicos na DMJ/SCA3 n\u00e3o \u00e9 bem \n\nconhecida, sendo sugerido que o n\u00facleo denteado cerebelar, n\u00facleos vestibulares e \n\noculomotores, e substantia nigra seriam as estruturas encef\u00e1licas primeiramente \n\nenvolvidas, enquanto t\u00e1lamo, n\u00facleos do tronco cerebral relacionados \u00e0 ingest\u00e3o \n\nalimentar e os demais nervos cranianos seriam afetados mais tardiamente (Riess et \n\nal, 2008). \n\n2.6 Diagn\u00f3stico \n\n O diagnostico \u00e9 suspeito com base em sinais e sintomas cl\u00ednicos e hist\u00f3ria \n\nfamiliar detalhada, e \u00e9 realizado pelo exame molecular. Cabe ressaltar que nem \n\nsempre a hist\u00f3ria familiar \u00e9 aparente, como nos casos de morte prematura do \n\ngenitor afetado (antes do in\u00edcio dos sintomas), de marcado fen\u00f4meno de \n\nantecipa\u00e7\u00e3o, ou de ilegitimidade (Subramony, 2012). Apesar de algumas \n\nmanifesta\u00e7\u00f5es cl\u00ednicas serem altamente sugestivas do diagn\u00f3stico de DMJ/SCA3, \n\nn\u00e3o h\u00e1 achado cl\u00ednico ou neurorradiol\u00f3gico patognom\u00f4nico. Naqueles indiv\u00edduos em \n\nque a ataxia cerebelar n\u00e3o \u00e9 acompanhada de heran\u00e7a familiar definida, outros \n\nexames ser\u00e3o mandat\u00f3rios para descartar causas trat\u00e1veis sist\u00eamicas ou \n\nneurol\u00f3gicas. \n\nEm indiv\u00edduos com s\u00edndrome at\u00e1xica progressiva e diagn\u00f3stico molecular \n\nconfirmado de DMJ/SCA3 em sua fam\u00edlia, a testagem espec\u00edfica para muta\u00e7\u00e3o no \n\ngene ATXN3 \u00e9 apropriada e deve confirmar o diagn\u00f3stico. O teste molecular para \n\nDMJ/SCA3 \u00e9 dispon\u00edvel na pr\u00e1tica cl\u00ednica com sensibilidade e especificidade \n\npr\u00f3ximas a 100%. A abordagem diagn\u00f3stica para os indiv\u00edduos com SCA sem \n\ndiagn\u00f3stico molecular definido na fam\u00edlia \u00e9 geralmente realizada atrav\u00e9s de pain\u00e9is \n\ndiagn\u00f3sticos constru\u00eddos com base epidemiol\u00f3gica (Saute e Jardim, 2008). \n\nProgramas baseados em diretrizes internacionais de testes pr\u00e9-sintom\u00e1ticos est\u00e3o \n\ndispon\u00edveis em alguns centros, podendo ser oferecido aos familiares em risco \n\n(Rodrigues et al, 2012; Rolim et al, 2006). \n\n\n\n34 \n \n\n2.7 Hist\u00f3ria Natural \n\nA progress\u00e3o cl\u00ednica da DMJ/SCA3 \u00e9 bastante lenta (Kieling et al, 2007; \n\nFran\u00e7a et al, 2009; Jardim et al, 2010). Diversos instrumentos de avalia\u00e7\u00e3o da \n\ngravidade das manifesta\u00e7\u00f5es cerebelares (Trouillas et al, 1997; Schmitz-H\u00fcbsch et \n\nal, 2006) e extracerebelares (Kieling et al, 2008; Schmitz-H\u00fcbsch et al, 2008-1) das \n\nSCAs foram desenvolvidos nos \u00faltimos anos, assim como escores funcionais com \n\nmedidas quantitativas (Schmitz-H\u00fcbsch et al, 2008-2; du Montcel et al, 2008). Tanto \n\nnos escores de avalia\u00e7\u00e3o de ataxia, ICARS e SARA (D\u2018Abreu et al, 2007; Schmitz-\n\nH\u00fcbsch et al, 2010), quanto nos de disfun\u00e7\u00e3o de m\u00faltiplos sistemas neurol\u00f3gicos, \n\nNESSCA e UMSARS (D\u2018Abreu et al, 2007; Jardim et al, 2010), a progress\u00e3o das \n\nSCAs estudadas foi lenta, mostrando pequena sensibilidade \u00e0 mudan\u00e7a. Fatores \n\ncomo o tamanho da expans\u00e3o CAG mutada e a idade de in\u00edcio parecem influenciar a \n\nvelocidade de progress\u00e3o, sendo maior em pacientes com expans\u00f5es mais longas e \n\nidades mais precoces de in\u00edcio dos sintomas (Jardim et al, 2010, Jacobi et al, 2011). \n\nO conhecimento da hist\u00f3ria natural da DMJ/SCA3 e demais SCAs \u00e9 de \n\nfundamental import\u00e2ncia para o desenvolvimento de futuros ensaios cl\u00ednicos. \n\nContudo, a evolu\u00e7\u00e3o lentamente progressiva medida pelas escalas de avalia\u00e7\u00e3o \n\ncl\u00ednica at\u00e9 o momento mostra a dificuldade da detec\u00e7\u00e3o de efeitos terap\u00eauticos, o \n\nque torna de grande import\u00e2ncia a busca por outros biomarcadores que possam ser \n\nutilizados como desfechos substitutos. \n\n2.8 Biomarcadores  \n\nA descri\u00e7\u00e3o de biomarcadores pode auxiliar no entendimento fisiopatol\u00f3gico \n\nda DMJ/SCA3, dar informa\u00e7\u00f5es de relev\u00e2ncia cl\u00ednica que possam auxiliar na decis\u00e3o \n\nde f\u00e1rmacos com potencial terap\u00eautico a serem testados em ECR ou mesmo \n\nencurtar o tempo de seguimento e aumentar o poder estat\u00edstico dos estudos quando \n\nutilizados como desfechos substitutos. Os diversos candidatos a biomarcadores j\u00e1 \n\nrelatados para a DMJ/SCA3 ser\u00e3o descritos a seguir. \n\nOs achados de neuroimagem parecem ter sido os mais estudados at\u00e9 o \n\nmomento. O grau de atrofia cerebelar e do tronco cerebral por resson\u00e2ncia \n\nmagn\u00e9tica nuclear (RMN) apresenta correla\u00e7\u00e3o com a idade do paciente e com o \n\ntamanho da expans\u00e3o CAG (Abe et al 1998; Onodera et al 1998, Schulz et al, 2009). \n\nA atrofia do tronco cerebral tamb\u00e9m se correlaciona com a escala de ataxia SARA \n\n\n\n35 \n \n\n(Schulz et al, 2009). A t\u00e9cnica de avalia\u00e7\u00e3o da morfometria encef\u00e1lica por RMN foi \n\nmuito aprimorada nos \u00faltimos anos (D\u2018Abreu et al, 2012), contudo sua aplicabilidade \n\ne utilidade nos ECRs ainda parece ser complicada. Os achados de neuroimagem \n\nn\u00e3o s\u00e3o precoces na doen\u00e7a e provavelmente ter\u00e3o uma baixa sensibilidade a \n\nmudan\u00e7as, tanto terap\u00eauticas como de hist\u00f3ria natural. \n\nAchados neurofisiol\u00f3gicos tamb\u00e9m foram estudados como potenciais \n\nbiomarcadores da DMJ/SCA3. Entre eles, recordamos os achados relacionados ao \n\nSNP como a redu\u00e7\u00e3o da amplitude do potencial de a\u00e7\u00e3o sensitivo do nervo sural \n\n(Fran\u00e7a Jr. et al, 2009). Ocorre progress\u00e3o significativa desta altera\u00e7\u00e3o em 12 \n\nmeses, a qual \u00e9 maior em indiv\u00edduos com expans\u00f5es mais longas. Al\u00e9m disso, \n\ntamb\u00e9m parece haver disfun\u00e7\u00e3o em filtros sensoriais, como o filtro sensorial auditivo \n\nP50 (Guisolfi et al, 2004). No entanto, a d\u00favida sobre a aplicabilidade do uso da \n\nneurofisiologia no acompanhamento de um ECR reside novamente na suspeita de \n\nque as altera\u00e7\u00f5es ter\u00e3o baixa sensibilidade a mudan\u00e7as, tanto terap\u00eauticas como de \n\nhist\u00f3ria natural. \n\nMarcadores bioqu\u00edmicos de rotas relacionadas ao processo patog\u00eanico, \n\navaliados em sangue perif\u00e9rico ou l\u00edquido c\u00e9rebro espinhal, apresentam um \n\npotencial de biomarcador com maior responsividade a mudan\u00e7a. Entre eles, \n\nencontramos na literatura apenas a enolase neur\u00f4nio-espec\u00edfica (NSE) s\u00e9rica, que \n\nfoi inicialmente associada \u00e0 DMJ/SCA3 pelo nosso grupo (Tort et al, 2005). Este \n\nresultado foi confirmado recentemente por um estudo realizado na China (Zhou et al, \n\n2011). Contudo, sua aplicabilidade e utilidade em estudos de hist\u00f3ria natural e em \n\nECRs, assim como para os demais biomarcadores citados n\u00e3o est\u00e1 estabelecida.  \n\n2.9 Tratamento \n\nV\u00e1rios f\u00e1rmacos j\u00e1 foram estudados como tratamentos sintom\u00e1ticos para \n\nataxia ou na tentativa de retardar a progress\u00e3o da SCAs, como foi o caso de \n\namantadina (Botez et al., 1996), TRH (Waragai et al.,1997), fisostigmina (Wessel et \n\nal., 1997), fluoxetina (Monte et al.,2003), tandospirona (Takei et al., 2004), buspirona \n\n(Assadi et al., 2007) e IGF-1 (Arpa et al, 2012). Dois estudos recentes merecem \n\nmaior detalhamento. Um deles foi um ECR com objetivo de avaliar o efeito do \n\nriluzole como tratamento sintom\u00e1tico para ataxias. O grupo tratado com riluzole \n\napresentou com maior frequ\u00eancia melhora de 5 pontos na escala de ataxia ICARS \n\n\n\n36 \n \n\nap\u00f3s 4 e 8 semanas de tratamento. Este estudo avaliou 40 pacientes com diferentes \n\ntipos de ataxias heredit\u00e1rias e espor\u00e1dicas, nenhum deles com DMJ/SCA3 (Ristoria \n\net al, 2010). Outro ECR recente com o agonista parcial do receptor nicot\u00ednico de \n\nacetilcolina ?4?2, vareniclina, tratou por 8 semanas 20 pacientes (10 vareniclina, 10 \n\nplacebo) com DMJ/SCA3 (Zesiewicz et al, 2012). Os resultados foram controversos \n\ne apresentaram efic\u00e1cia em alguns desfechos de an\u00e1lises explorat\u00f3rias da escala \n\nSARA. O n\u00famero pequeno de pacientes avaliados, as diferen\u00e7as nas caracter\u00edsticas \n\nbasais entre os grupos e os resultados controversos n\u00e3o d\u00e3o suporte ao uso da \n\nvareniclina como uma op\u00e7\u00e3o terap\u00eautica estabelecida.  \n\nDesta forma, continuamos sem dispor de tratamentos farmacol\u00f3gicos que \n\nmodifiquem a evolu\u00e7\u00e3o da DMJ/SCA3 e demais SCAs. O atendimento desses \n\npacientes baseia-se no aconselhamento gen\u00e9tico, acompanhamento fisioter\u00e1pico e \n\nde terapia ocupacional (Silva et al, 2010), bem como manejo sintom\u00e1tico para alguns \n\nde seus sinais e sintomas (D\u2018Abreu et al, 2010). \n\nO uso de inibidores de HDAC (Chou et al, 2011), de f\u00e1rmacos que atuem \n\nmelhorando os sistemas de controle celular de qualidade proteica (Fornai et al, \n\n2008; Yamamoto, Cremona Rothman, 2006) e em outros mecanismos de \n\nmodifica\u00e7\u00e3o p\u00f3s transcricionais das ataxinas expandidas (Paulson, 2003; Vig et al, \n\n2006); e as t\u00e9cnicas de silenciamento e degrada\u00e7\u00e3o do ARN que levaria a \n\nexpress\u00e3o da prote\u00edna mutada atrav\u00e9s de ARNs de interfer\u00eancia (Alves et al, 2008) e \n\nolinucleot\u00eddeos antisense (Kordasiewicz  et al, 2012) s\u00e3o algumas das estrat\u00e9gias \n\nterap\u00eauticas a serem melhor estudadas, especialmente \u00e0 luz do atual entendimento \n\nda fisiopatologia da DMJ/SCA3. Essas abordagens provavelmente trabalhariam com \n\nterap\u00eauticas candidatas a se tornarem espec\u00edficas da DMJ/SCA3.  \n\nUm ECR sobre seguran\u00e7a e efic\u00e1cia de um inibidor da HDAC foi planejado \n\npelo nosso grupo. No entanto, raz\u00f5es regulat\u00f3rias impediram a realiza\u00e7\u00e3o do ensaio \n\nno Brasil. As demais abordagens, embora pare\u00e7am muito promissoras por atuarem \n\nproximalmente na cadeia de eventos causais da doen\u00e7a, ainda dependem de v\u00e1rios \n\nestudos de seguran\u00e7a pr\u00e9-cl\u00ednicos. Por isso, torna-se imperioso o estudo de \n\nsubst\u00e2ncias neuroprotetoras, embora talvez menos espec\u00edficas e possivelmente \n\nmais distais na cadeia de causalidade celular.  Evid\u00eancias qualificadas, similares \u00e0s \n\ndemonstrados nos modelos pr\u00e9-cl\u00ednicos, s\u00e3o necess\u00e1rias, para que neuroprotetores \n\npossam ser aplic\u00e1veis aos pacientes contempor\u00e2neos.  \n\n\n\n37 \n \n\n3 Objetivos \n\n3.1 Objetivos Gerais  \n\n1) Descrever as seguintes manifesta\u00e7\u00f5es cl\u00ednicas n\u00e3o motoras da DMJ/SCA3: \n\nsintomas depressivos  e altera\u00e7\u00f5es nutricionais; \n\n2) Caracterizar novos biomarcadores e fatores modificadores do fen\u00f3tipo da \n\nDMJ/SCA3. \n\n3) Revisar os instrumentos de avalia\u00e7\u00e3o cl\u00ednica de SCAs j\u00e1 descritos na literatura, na \n\ntentativa de identificar quais s\u00e3o os mais indicados como desfechos principais nos \n\nfuturos ECR. \n\n4) Avaliar a seguran\u00e7a e efetividade do tratamento com Carbonato de L\u00edtio sobre os \n\nsintomas motores at\u00e1xicos e n\u00e3o-at\u00e1xicos da DMJ/SCA3;  \n\n3.2 Objetivos Espec\u00edficos \n\n1) Sintomas n\u00e3o motores: \n\n- sintomas depressivos e sua rela\u00e7\u00e3o com os aspectos at\u00e1xicos e n\u00e3o-at\u00e1xicos \n\navaliado pelas escalas SARA e NESSCA, bem como sua correla\u00e7\u00e3o com outros \n\naspectos cl\u00ednicos e moleculares; \n\n- achados nutricionais: atrav\u00e9s da compara\u00e7\u00e3o do \u00edndice de massa corporal (IMC) de \n\npacientes com DMJ/SCA3 com indiv\u00edduos controles de caracter\u00edsticas s\u00f3cio-\n\ndemogr\u00e1ficas semelhantes e da correla\u00e7\u00e3o destes achados com os demais aspectos \n\ncl\u00ednicos, moleculares e de neuroimagem.  \n\n2) Novos biomarcadores na DMJ/SCA3: \n\n- caracteriza\u00e7\u00e3o do Sistema Insulina/ IGF-1 na DMJ/SCA3 e o potencial de \n\nbiomarcador e modificador da doen\u00e7a de seus componentes.  \n\n3) Analisar os instrumentos cl\u00ednicos de avalia\u00e7\u00e3o das SCAs descritos at\u00e9 o momento \n\nem seus aspectos de valida\u00e7\u00e3o, estudos de hist\u00f3ria natural e aplica\u00e7\u00e3o em ECRs. \n\nSer\u00e1 realizada revis\u00e3o sistem\u00e1tica da literatura, na tentativa de identificar quais \n\n\n\n38 \n \n\ndesfechos s\u00e3o os mais indicados para utiliza\u00e7\u00e3o nos futuros ECRs e se h\u00e1 uma clara \n\nnecessidade de desenvolvimento de novos escores cl\u00ednicos.  \n\n4) Avaliar a seguran\u00e7a e efetividade do tratamento com Carbonato de L\u00edtio sobre os \n\nsintomas motores at\u00e1xicos e n\u00e3o-at\u00e1xicos da DMJ/SCA3 em um ensaio cl\u00ednico \n\nrandomizado, duplo-cego, paralelo, placebo controlado de fase 2/3. \n\n\n\n39 \n \n\n4 Refer\u00eancias bibliogr\u00e1ficas da revis\u00e3o  \n\n \n\n1.  Abe Y, Tanaka F, Matsumoto M, Doyu M, Hirayama M, Kachi T, et al. CAG \n\nrepeat number correlates with the rate of brainstem and cerebellar atrophy in \n\nMachado-Joseph disease. Neurology. 1998 Sep;51(3):882\u20134.  \n\n2. Alves S, Nascimento-Ferreira I, Auregan G, Hassig R, Dufour N, Brouillet E, et \n\nal. Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in \n\na rat model of Machado-Joseph disease. PLoS ONE. 2008;3(10):e3341.  \n\n3. Arpa J, Sanz-Gallego I, Medina-B\u00e1ez J, Portela LV, Jardim LB, Torres-Aleman \n\nI, Saute JA. Subcutaneous Insulin-Like Growth Factor-1 Treatment in \n\nSpinocerebellar Ataxias: An Open Label Clinical Trial. Mov Disord. 2011; 26 \n\n(2):358 59.  \n\n \n4.  Assadi M, Campellone JV, Janson CG, Veloski JJ, Schwartzman RJ, Leone P. \n\nTreatment of spinocerebellar ataxia with buspirone. J. Neurol. Sci. 2007 Sep \n\n15;260(1-2):143\u20136.  \n\n5.  Bettencourt C, Lima M. Machado-Joseph Disease: from first descriptions to \n\nnew perspectives. Orphanet J Rare Dis. 2011;6:35.  \n\n6.  Botez MI, Botez-Marquard T, Elie R, Pedraza OL, Goyette K, Lalonde R. \n\nAmantadine hydrochloride treatment in heredodegenerative ataxias: a double \n\nblind study. J. Neurol. Neurosurg. Psychiatr. 1996 Sep;61(3):259\u201364.  \n\n7.  Boy J, Schmidt T, Wolburg H, Mack A, Nuber S, B\u00f6ttcher M, et al. Reversibility \n\nof symptoms in a conditional mouse model of spinocerebellar ataxia type 3. \n\nHum. Mol. Genet. 2009 Nov 15;18(22):4282\u201395.  \n\n8.  Braga-Neto P, Dutra LA, Pedroso JL, Fel\u00edcio AC, Alessi H, Santos-Galduroz \n\nRF, et al. Cognitive deficits in machado-joseph disease correlate with \n\nhypoperfusion of visual system areas. Cerebellum. 2012a Dec;11(4):1037\u201344.  \n\n9.  Braga-Neto P, Felicio AC, Hoexter MQ, Pedroso JL, Dutra LA, Alessi H, et al. \n\nCognitive and olfactory deficits in Machado-Joseph disease: a dopamine \n\ntransporter study. Parkinsonism Relat. Disord. 2012b Aug;18(7):854\u20138.  \n\n\n\n40 \n \n\n10.  Braga-Neto P, Pedroso JL, Alessi H, Dutra LA, Fel\u00edcio AC, Minett T, et al. \n\nCerebellar cognitive affective syndrome in Machado Joseph disease: core \n\nclinical features. Cerebellum. 2012c Jun;11(2):549\u201356.  \n\n11.  Burnett B, Li F, Pittman RN. The polyglutamine neurodegenerative protein \n\nataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. \n\nHum. Mol. Genet. 2003 Dec 1;12(23):3195\u2013205.  \n\n12.  Burnett BG, Pittman RN. The polyglutamine neurodegenerative protein ataxin 3 \n\nregulates aggresome formation. Proc. Natl. Acad. Sci. U.S.A. 2005 Mar \n\n22;102(12):4330\u20135.  \n\n13. Camargo, G. Muta\u00e7\u00e3o do gene ATNX3 da Doen\u00e7a de Machado-Joseph no Rio \n\nGrande do Sul: aspectos epidemiol\u00f3gicos e de comportamento mei\u00f3tico. 2011. \n\n60f. Disserta\u00e7\u00e3o de Mestrado. Programa de P\u00f3s-Gradua\u00e7\u00e3o em Gen\u00e9tica e \n\nBiologia Molecular, Universidade Federal do Rio Grande do Sul, Porto Alegre. \n\n2011.  \n\n14.  Carmichael J, Sugars KL, Bao YP, Rubinsztein DC. Glycogen synthase kinase-\n\n3beta inhibitors prevent cellular polyglutamine toxicity caused by the \n\nHuntington\u2018s disease mutation. J. Biol. Chem. 2002 Sep 13;277(37):33791\u20138.  \n\n15.  Carvalho DR, La Rocque-Ferreira A, Rizzo IM, Imamura EU, Speck-Martins \n\nCE. Homozygosity enhances severity in spinocerebellar ataxia type 3. Pediatr. \n\nNeurol. 2008 Apr;38(4):296\u20139.  \n\n16.  Cecchin CR, Pires AP, Rieder CR, Monte TL, Silveira I, Carvalho T, et al. \n\nDepressive symptoms in Machado-Joseph disease (SCA3) patients and their \n\nrelatives. Community Genet. 2007;10(1):19\u201326.  \n\n17.  Chou A-H, Chen S-Y, Yeh T-H, Weng Y-H, Wang H-L. HDAC inhibitor sodium \n\nbutyrate reverses transcriptional downregulation and ameliorates ataxic \n\nsymptoms in a transgenic mouse model of SCA3. Neurobiol. Dis. 2011 \n\nFeb;41(2):481\u20138.  \n\n18.  Chou A-H, Yeh T-H, Ouyang P, Chen Y-L, Chen S-Y, Wang H-L. \n\nPolyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 \n\ntransgenic mice by inducing transcriptional dysregulation. Neurobiol. Dis. 2008 \n\n\n\n41 \n \n\nJul;31(1):89\u2013101.  \n\n19.  Costa M do C, Paulson HL. Toward understanding Machado-Joseph disease. \n\nProg. Neurobiol. 2012 May;97(2):239\u201357.  \n\n20.  Coutinho P, Andrade C. Autosomal dominant system degeneration in \n\nPortuguese families of the Azores Islands. A new genetic disorder involving \n\ncerebellar, pyramidal, extrapyramidal and spinal cord motor functions. \n\nNeurology. 1978 Jul;28(7):703\u20139.  \n\n21.  D\u2018Abreu A, Fran\u00e7a M Jr, Conz L, Friedman JH, Nucci AM, Cendes F, et al. \n\nSleep symptoms and their clinical correlates in Machado-Joseph disease. Acta \n\nNeurol. Scand. 2009 Apr;119(4):277\u201380.  \n\n22.  D\u2018Abreu A, Franca M Jr, Lopes-Cendes I, Cendes F. The international \n\ncooperative ataxia rating scale in Machado-Joseph disease. Comparison with \n\nthe unified multiple system atrophy rating scale. Mov. Disord. 2007 Oct \n\n15;22(13):1976\u20139.  \n\n23.  D\u2018Abreu A, Fran\u00e7a MC Jr, Paulson HL, Lopes-Cendes I. Caring for Machado-\n\nJoseph disease: current understanding and how to help patients. Parkinsonism \n\nRelat. Disord. 2010 Jan;16(1):2\u20137.  \n\n24.  D\u2018Abreu A, Fran\u00e7a MC Jr, Yasuda CL, Campos BAG, Lopes-Cendes I, Cendes \n\nF. Neocortical atrophy in Machado-Joseph disease: a longitudinal \n\nneuroimaging study. J Neuroimaging. 2012 Jul;22(3):285\u201391.  \n\n25.  Doss-Pepe EW, Stenroos ES, Johnson WG, Madura K. Ataxin-3 interactions \n\nwith rad23 and valosin-containing protein and its associations with ubiquitin \n\nchains and the proteasome are consistent with a role in ubiquitin-mediated \n\nproteolysis. Mol. Cell. Biol. 2003 Sep;23(18):6469\u201383.  \n\n26.  Du Montcel ST, Charles P, Ribai P, Goizet C, Le Bayon A, Labauge P, et al. \n\nComposite cerebellar functional severity score: validation of a quantitative \n\nscore of cerebellar impairment. Brain. 2008 May;131(Pt 5):1352\u201361.  \n\n27.  Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and \n\nbeyond. Lancet Neurol. 2010 Sep;9(9):885\u201394.  \n\n\n\n42 \n \n\n28.  D\u00fcrr A, Stevanin G, Cancel G, Duyckaerts C, Abbas N, Didierjean O, et al. \n\nSpinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and \n\nneuropathological features. Ann. Neurol. 1996 Apr;39(4):490\u20139.  \n\n29.  Evert BO, Vogt IR, Kindermann C, Ozimek L, De Vos RA, Brunt ER, et al. \n\nInflammatory genes are upregulated in expanded ataxin-3-expressing cell lines \n\nand spinocerebellar ataxia type 3 brains. J. Neurosci. 2001 Aug 1;21(15):5389\u2013\n\n96.  \n\n30.  Evert BO, Araujo J, Vieira-Saecker AM, De Vos RAI, Harendza S, Klockgether \n\nT, et al. Ataxin-3 represses transcription via chromatin binding, interaction with \n\nhistone deacetylase 3, and histone deacetylation. J. Neurosci. 2006 Nov \n\n1;26(44):11474\u201386.  \n\n31.  Evert BO, Vogt IR, Vieira-Saecker AM, Ozimek L, De Vos RAI, Brunt ERP, et \n\nal. Gene expression profiling in ataxin-3 expressing cell lines reveals distinct \n\neffects of normal and mutant ataxin-3. J. Neuropathol. Exp. Neurol. 2003 \n\nOct;62(10):1006\u201318.  \n\n32. Fergunson FR, Critchley M. A clinical study of an heredo-familial disease \n\nresembling disseminated sclerosis. Brain 1929 Jul;52:203-225. \n\n33.  Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca ML, et al. \n\nLithium delays progression of amyotrophic lateral sclerosis. Proc. Natl. Acad. \n\nSci. U.S.A. 2008 Feb 12;105(6):2052\u20137.  \n\n34. Fran\u00e7a M Jr, D\u2018abreu A, Nucci A, Cendes F, Lopes-Cendes I. Prospective \n\nstudy of peripheral neuropathy in Machado-Joseph disease. Muscle Nerve. \n\n2009 Dec;40(6):1012\u20138. \n\n35.  Fran\u00e7a MC Jr, D\u2018Abreu A, Nucci A, Lopes-Cendes I. Clinical correlates of \n\nautonomic dysfunction in patients with Machado-Joseph disease. Acta Neurol. \n\nScand. 2010 Jun;121(6):422\u20135.  \n\n36.  Fran\u00e7a MC Jr, D\u2018Abreu A, Friedman JH, Nucci A, Lopes-Cendes I. Chronic \n\npain in Machado-Joseph disease: a frequent and disabling symptom. Arch. \n\nNeurol. 2007 Dec;64(12):1767\u201370.  \n\n37.  Fran\u00e7a MC Jr, D\u2018Abreu A, Nucci A, Cendes F, Lopes-Cendes I. Progression of \n\n\n\n43 \n \n\nataxia in patients with Machado-Joseph disease. Mov. Disord. 2009 Jul \n\n15;24(9):1387\u201390.  \n\n38.  Fran\u00e7a MC Jr, D\u2018Abreu A, Nucci A, Lopes-Cendes I. Muscle excitability \n\nabnormalities in Machado-Joseph disease. Arch. Neurol. 2008 Apr;65(4):525\u2013\n\n9.  \n\n39.  Friedman JH, Amick MM. Fatigue and daytime somnolence in Machado Joseph \n\nDisease (spinocerebellar ataxia type 3). Mov. Disord. 2008 Jul 15;23(9):1323\u2013\n\n4.  \n\n40.  Gaspar C, Lopes-Cendes I, Hayes S, Goto J, Arvidsson K, Dias A, et al. \n\nAncestral origins of the Machado-Joseph disease mutation: a worldwide \n\nhaplotype study. Am. J. Hum. Genet. 2001 Feb;68(2):523\u20138.  \n\n41.  Giunti P, Sweeney MG, Harding AE. Detection of the Machado-Joseph \n\ndisease/spinocerebellar ataxia three trinucleotide repeat expansion in families \n\nwith autosomal dominant motor disorders, including the Drew family of \n\nWalworth. Brain. 1995 Oct;118 ( Pt 5):1077\u201385.  \n\n42.  Gordon CR, Joffe V, Vainstein G, Gadoth N. Vestibulo-ocular arreflexia in \n\nfamilies with spinocerebellar ataxia type 3 (Machado-Joseph disease). J. \n\nNeurol. Neurosurg. Psychiatr. 2003 Oct;74(10):1403\u20136.  \n\n43.  Gwinn-Hardy K, Singleton A, O\u2018Suilleabhain P, Boss M, Nicholl D, Adam A, et \n\nal. Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease \n\nin a black family. Arch. Neurol. 2001 Feb;58(2):296\u20139.  \n\n44.  Haacke A, Broadley SA, Boteva R, Tzvetkov N, Hartl FU, Breuer P. Proteolytic \n\ncleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and \n\nsequestration of non-expanded ataxin-3. Hum. Mol. Genet. 2006 Feb \n\n15;15(4):555\u201368.  \n\n45.  Haberhausen G, Damian MS, Leweke F, M\u00fcller U. Spinocerebellar ataxia, type \n\n3 (SCA3) is genetically identical to Machado-Joseph disease (MJD). J. Neurol. \n\nSci. 1995 Sep;132(1):71\u20135.  \n\n46.  Hageman J, Rujano MA, Van Waarde MAWH, Kakkar V, Dirks RP, \n\nGovorukhina N, et al. A DNAJB chaperone subfamily with HDAC-dependent \n\n\n\n44 \n \n\nactivities suppresses toxic protein aggregation. Mol. Cell. 2010 Feb \n\n12;37(3):355\u201369.  \n\n47.  Hering S, Achm\u00fcller C, K\u00f6hler A, Poewe W, Schneider R, Boesch SM. \n\nPhenotype variability in spinocerebellar ataxia type 2: a longitudinal family \n\nsurvey and a case featuring an unusual benign course of disease. Mov. Disord. \n\n2009 Apr 15;24(5):774\u20137.  \n\n48.  Huynh DP, Maalouf M, Silva AJ, Schweizer FE, Pulst SM. Dissociated fear and \n\nspatial learning in mice with deficiency of ataxin-2. PLoS ONE. \n\n2009;4(7):e6235.  \n\n49  Jacobi H, Bauer P, Giunti P, Labrum R, Sweeney MG, Charles P, et al. The \n\nnatural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up \n\nstudy. Neurology. 2011 Sep 13;77(11):1035\u201341.  \n\n50.  Jardim LB, Pereira ML, Silveira I, Ferro A, Sequeiros J, Giugliani R. Neurologic \n\nfindings in Machado-Joseph disease: relation with disease duration, subtypes, \n\nand (CAG)n. Arch. Neurol. 2001 Jun;58(6):899\u2013904.  \n\n51 Jardim LB, Silveira I, Pereira ML, Ferro A, Alonso I, Do C\u00e9u Moreira M, et al. A \n\nsurvey of spinocerebellar ataxia in South Brazil - 66 new cases with Machado-\n\nJoseph disease, SCA7, SCA8, or unidentified disease-causing mutations. J. \n\nNeurol. 2001 Oct;248(10):870\u20136. \n\n52.  Jardim LB, Hauser L, Kieling C, Saute JAM, Xavier R, Rieder CRM, et al. \n\nProgression rate of neurological deficits in a 10-year cohort of SCA3 patients. \n\nCerebellum. 2010 Sep;9(3):419\u201328.  \n\n53.  Jiang H, Tang B, Xu B, Zhao G, Shen L, Tang J, et al. Frequency analysis of \n\nautosomal dominant spinocerebellar ataxias in mainland Chinese patients and \n\nclinical and molecular characterization of spinocerebellar ataxia type 6. Chin. \n\nMed. J. 2005 May 20;118(10):837\u201343.  \n\n54.  Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, et al. \n\nCAG expansions in a novel gene for Machado-Joseph disease at chromosome \n\n14q32.1. Nat. Genet. 1994 Nov;8(3):221\u20138.  \n\n55.  Kawai Y, Takeda A, Abe Y, Washimi Y, Tanaka F, Sobue G. Cognitive \n\n\n\n45 \n \n\nimpairments in Machado-Joseph disease. Arch. Neurol. 2004 \n\nNov;61(11):1757\u201360.  \n\n56.  Kegel KB, Meloni AR, Yi Y, Kim YJ, Doyle E, Cuiffo BG, et al. Huntingtin is \n\npresent in the nucleus, interacts with the transcriptional corepressor C-terminal \n\nbinding protein, and represses transcription. J. Biol. Chem. 2002 Mar \n\n1;277(9):7466\u201376.  \n\n57.  Kiehl T-R, Nechiporuk A, Figueroa KP, Keating MT, Huynh DP, Pulst S-M. \n\nGeneration and characterization of Sca2 (ataxin-2) knockout mice. Biochem. \n\nBiophys. Res. Commun. 2006 Jan 6;339(1):17\u201324.  \n\n58.  Kieling C, Prestes PR, Saraiva-Pereira ML, Jardim LB. Survival estimates for \n\npatients with Machado-Joseph disease (SCA3). Clin. Genet. 2007 \n\nDec;72(6):543\u20135.  \n\n59.  Kieling C, Rieder CRM, Silva ACF, Saute JAM, Cecchin CR, Monte TL, et al. A \n\nneurological examination score for the assessment of spinocerebellar ataxia 3 \n\n(SCA3). Eur. J. Neurol. 2008 Apr;15(4):371\u20136.  \n\n60.  Kieling C, Morales Saute JA, Jardim LB. When ataxia is not just ataxia. Nat Clin \n\nPract Neurol. 2007 May;3(5):E2.  \n\n61.  Klockgether T, Sch\u00f6ls L, Abele M, B\u00fcrk K, Topka H, Andres F, et al. Age \n\nrelated axonal neuropathy in spinocerebellar ataxia type 3/Machado-Joseph \n\ndisease (SCA3/MJD). J. Neurol. Neurosurg. Psychiatr. 1999 Feb;66(2):222\u20134.  \n\n62.  Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel \n\nKA, et al. Sustained therapeutic reversal of Huntington\u2018s disease by transient \n\nrepression of huntingtin synthesis. Neuron. 2012 Jun 21;74(6):1031\u201344.  \n\n63.  Li F, Macfarlan T, Pittman RN, Chakravarti D. Ataxin-3 is a histone-binding \n\nprotein with two independent transcriptional corepressor activities. J. Biol. \n\nChem. 2002 Nov 22;277(47):45004\u201312.  \n\n64.  Lima L, Coutinho P. Clinical criteria for diagnosis of Machado-Joseph disease: \n\nreport of a non-Azorena Portuguese family. Neurology. 1980 Mar;30(3):319\u2013\n\n22.  \n\n\n\n46 \n \n\n65.  Lopes-Cendes I, Teive HG, Calcagnotto ME, Da Costa JC, Cardoso F, Viana \n\nE, et al. Frequency of the different mutations causing spinocerebellar ataxia \n\n(SCA1, SCA2, MJD/SCA3 and DRPLA) in a large group of Brazilian patients. \n\nArq Neuropsiquiatr. 1997 Sep;55(3B):519\u201329.  \n\n66.  Lysenko L, Grewal RP, Ma W, Peddareddygari LR. Homozygous Machado \n\nJoseph Disease: a case report and review of literature. Can J Neurol Sci. 2010 \n\nJul;37(4):521\u20133.  \n\n67.  Maciel P, Gaspar C, DeStefano AL, Silveira I, Coutinho P, Radvany J, et al. \n\nCorrelation between CAG repeat length and clinical features in Machado-\n\nJoseph disease. Am. J. Hum. Genet. 1995 Jul;57(1):54\u201361.  \n\n68.  Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I. Dietary intake \n\nin adults at risk for Huntington disease: analysis of PHAROS research \n\nparticipants. Neurology. 2009 Aug 4;73(5):385\u201392.  \n\n69.  Martins S, Calafell F, Gaspar C, Wong VCN, Silveira I, Nicholson GA, et al. \n\nAsian origin for the worldwide-spread mutational event in Machado-Joseph \n\ndisease. Arch. Neurol. 2007 Oct;64(10):1502\u20138.  \n\n70.  Martins S, Soong B-W, Wong VCN, Giunti P, Stevanin G, Ranum LPW, et al. \n\nMutational origin of Machado-Joseph disease in the Australian Aboriginal \n\ncommunities of Groote Eylandt and Yirrkala. Arch. Neurol. 2012 Jun;69(6):746\u2013\n\n51.  \n\n71.  Matilla A, Roberson ED, Banfi S, Morales J, Armstrong DL, Burright EN, et al. \n\nMice lacking ataxin-1 display learning deficits and decreased hippocampal \n\npaired-pulse facilitation. J. Neurosci. 1998 Jul 15;18(14):5508\u201316.  \n\n72.  Monte TL, Rieder CRM, Tort AB, Rockenback I, Pereira ML, Silveira I, et al. \n\nUse of fluoxetine for treatment of Machado-Joseph disease: an open-label \n\nstudy. Acta Neurol. Scand. 2003 Mar;107(3):207\u201310.  \n\n73.  M\u00fcnchau A, Dressler D, Bhatia KP, Vogel P, Z\u00fchlke C. Machado-Joseph \n\ndisease presenting as severe generalised dystonia in a German patient. J. \n\nNeurol. 1999 Sep;246(9):840\u20132.  \n\n74.  Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, et al. Nuclear \n\n\n\n47 \n \n\nreceptor repression mediated by a complex containing SMRT, mSin3A, and \n\nhistone deacetylase. Cell. 1997 May 2;89(3):373\u201380.  \n\n75.  Nakano KK, Dawson DM, Spence A. Machado disease. A hereditary ataxia in \n\nPortuguese emigrants to Massachusetts. Neurology. 1972 Jan;22(1):49\u201355.  \n\n76.  Nicastro G, Menon RP, Masino L, Knowles PP, McDonald NQ, Pastore A. The \n\nsolution structure of the Josephin domain of ataxin-3: structural determinants \n\nfor molecular recognition. Proc. Natl. Acad. Sci. U.S.A. 2005 Jul \n\n26;102(30):10493\u20138.  \n\n77.  Paulson HL. Protein fate in neurodegenerative proteinopathies: polyglutamine \n\ndiseases join the (mis)fold. Am. J. Hum. Genet. 1999 Feb;64(2):339\u201345.  \n\n78.  Paulson H. Polyglutamine neurodegeneration: minding your Ps and Qs. Nat. \n\nMed. 2003 Jul;9(7):825\u20136.  \n\n79.  Paulson H. Machado-Joseph disease/spinocerebellar ataxia type 3. Handb Clin \n\nNeurol. 2012;103:437\u201349.  \n\n80.  Paulson HL. Dominantly inherited ataxias: lessons learned from Machado-\n\nJoseph disease/spinocerebellar ataxia type 3. Semin Neurol. 2007 \n\nApr;27(2):133\u201342.  \n\n81.  Pedroso JL, Braga-Neto P, Fel\u00edcio AC, Dutra LA, Santos WAC, Do Prado GF, \n\net al. Sleep disorders in machado-joseph disease: frequency, discriminative \n\nthresholds, predictive values, and correlation with ataxia-related motor and \n\nnon-motor features. Cerebellum. 2011 Jun;10(2):291\u20135.  \n\n82.  Prestes PR, Saraiva-Pereira ML, Silveira I, Sequeiros J, Jardim LB. Machado-\n\nJoseph disease enhances genetic fitness: a comparison between affected and \n\nunaffected women and between MJD and the general population. Ann. Hum. \n\nGenet. 2008 Jan;72(Pt 1):57\u201364.  \n\n83.  Riess O, R\u00fcb U, Pastore A, Bauer P, Sch\u00f6ls L. SCA3: neurological features, \n\npathogenesis and animal models. Cerebellum. 2008;7(2):125\u201337.  \n\n84.  Riley BE, Orr HT. Polyglutamine neurodegenerative diseases and regulation of \n\ntranscription: assembling the puzzle. Genes Dev. 2006 Aug 15;20(16):2183\u2013\n\n\n\n48 \n \n\n92.  \n\n85.  Ristori G, Romano S, Visconti A, Cannoni S, Spadaro M, Frontali M, et al. \n\nRiluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled \n\npilot trial. Neurology. 2010 Mar 9;74(10):839\u201345.  \n\n86.  Rodrigues CSM, De Oliveira VZ, Camargo G, Os\u00f3rio CM da S, De Castilhos \n\nRM, Saraiva-Pereira ML, et al. Presymptomatic testing for neurogenetic \n\ndiseases in Brazil: assessing who seeks and who follows through with testing. J \n\nGenet Couns. 2012 Feb;21(1):101\u201312.  \n\n87.  Rolim L, Leite A, L\u00eado S, Paneque M, Sequeiros J, Fleming M. Psychological \n\naspects of pre-symptomatic testing for Machado-Joseph disease and familial \n\namyloid polyneuropathy type I. Clin. Genet. 2006 Apr;69(4):297\u2013305.  \n\n88.  Romanul FC, Fowler HL, Radvany J, Feldman RG, Feingold M. Azorean \n\ndisease of the nervous system. N. Engl. J. Med. 1977 Jun 30;296(26):1505\u20138.  \n\n89.  Rosenberg RN, Nyhan WL, Bay C, Shore P. Autosomal dominant striatonigral \n\ndegeneration. A clinical, pathologic, and biochemical study of a new genetic \n\ndisorder. Neurology. 1976 Aug;26(8):703\u201314.  \n\n90.  Rosenberg RN, Nyhan WL, Coutinho P, Bay C. Joseph\u2018s disease: an \n\nautosomal dominant neurological disease in the Portuguese of the United \n\nStates and the Azores Islands. Adv Neurol. 1978;21:33\u201357.  \n\n91.  R\u00fcb U, Brunt ER, Deller T. New insights into the pathoanatomy of \n\nspinocerebellar ataxia type 3 (Machado-Joseph disease). Curr. Opin. Neurol. \n\n2008 Apr;21(2):111\u20136.  \n\n92.  Sakai T, Kawakami H. Machado-Joseph disease: A proposal of spastic \n\nparaplegic subtype. Neurology. 1996 Mar;46(3):846\u20137.  \n\n93. Saute JA, Jardim LB. Ataxias heredit\u00e1rias. In: M\u00e1rcia L. F. Chaves; Alessandro \n\nFinkelsztejn; Marco Antonio Stefani. (Org.). Rotinas em Neurologia e \n\nNeurocirurgia. 1ed.Porto Alegre: ARTMED, 2008, v. 1, p. 363-380. \n\n94.  Schmitt I, Linden M, Khazneh H, Evert BO, Breuer P, Klockgether T, et al. \n\nInactivation of the mouse Atxn3 (ataxin-3) gene increases protein \n\n\n\n49 \n \n\nubiquitination. Biochem. Biophys. Res. Commun. 2007 Oct 26;362(3):734\u20139.  \n\n95.  Schmitz-H\u00fcbsch T, Coudert M, Bauer P, Giunti P, Globas C, Baliko L, et al. \n\nSpinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia \n\nsymptoms. Neurology. 2008 Sep 23;71(13):982\u20139.  \n\n96.  Schmitz-H\u00fcbsch T, Du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, \n\net al. Scale for the assessment and rating of ataxia: development of a new \n\nclinical scale. Neurology. 2006 Jun 13;66(11):1717\u201320.  \n\n97.  Schmitz-H\u00fcbsch T, Fimmers R, Rakowicz M, Rola R, Zdzienicka E, Fancellu R, \n\net al. Responsiveness of different rating instruments in spinocerebellar ataxia \n\npatients. Neurology. 2010 Feb 23;74(8):678\u201384.  \n\n98.  Schmitz-H\u00fcbsch T, Giunti P, Stephenson DA, Globas C, Baliko L, Sacc\u00e0 F, et \n\nal. SCA Functional Index: a useful compound performance measure for \n\nspinocerebellar ataxia. Neurology. 2008 Aug 12;71(7):486\u201392.  \n\n99 Schulz JB, Borkert J, Wolf S, Schmitz-H\u00fcbsch T, Rakowicz M, Mariotti C, et al. \n\nVisualization, quantification and correlation of brain atrophy with clinical \n\nsymptoms in spinocerebellar ataxia types 1, 3 and 6. Neuroimage. 2010 Jan \n\n1;49(1):158\u201368.  \n\n100.  Sequeiros J, Martins S, Silveira I. Epidemiology and population genetics of \n\ndegenerative ataxias. Handb Clin Neurol. 2012;103:227\u201351.  \n\n101.  Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et \n\nal. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2018s \n\ndisease. N. Engl. J. Med. 2009 Oct 22;361(17):1651\u201361.  \n\n102.  Siebert M, Donis KC, Socal M, Rieder CRM, Emmel VE, Vairo F, et al. \n\nGlucocerebrosidase gene variants in parkinsonian patients with Machado \n\nJoseph/spinocerebellar ataxia 3. Parkinsonism Relat. Disord. 2012 \n\nFeb;18(2):185\u201390.  \n\n103.  Silva MC, Coutinho P, Pinheiro CD, Neves JM, Serrano P. Hereditary ataxias \n\nand spastic paraplegias: methodological aspects of a prevalence study in \n\nPortugal. J Clin Epidemiol. 1997 Dec;50(12):1377\u201384.  \n\n\n\n50 \n \n\n104  Silva RCR, Saute JAM, Silva ACF, Coutinho ACO, Saraiva-Pereira ML, Jardim \n\nLB. Occupational therapy in spinocerebellar ataxia type 3: an open-label trial. \n\nBraz. J. Med. Biol. Res. 2010 Jun;43(6):537\u201342.  \n\n105.  Silveira I, Lopes-Cendes I, Kish S, Maciel P, Gaspar C, Coutinho P, et al. \n\nFrequency of spinocerebellar ataxia type 1, dentatorubropallidoluysian atrophy, \n\nand Machado-Joseph disease mutations in a large group of spinocerebellar \n\nataxia patients. Neurology. 1996 Jan;46(1):214\u20138.  \n\n106.  Soong B, Paulson HL. Spinocerebellar ataxias: an update. Curr. Opin. Neurol. \n\n2007 Aug;20(4):438\u201346.  \n\n107.  Soong B W, Lu Y C, Choo K B, Lee H Y. Frequency analysis of autosomal \n\ndominant cerebellar ataxias in Taiwanese patients and clinical and molecular \n\ncharacterization of spinocerebellar ataxia type 6. Arch. Neurol. 2001 \n\nJul;58(7):1105\u20139.  \n\n108.  Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, \n\net al. The Huntington\u2018s disease protein interacts with p53 and CREB-binding \n\nprotein and represses transcription. Proc. Natl. Acad. Sci. U.S.A. 2000 Jun \n\n6;97(12):6763\u20138.  \n\n109.  Stevanin G, Le Guern E, Ravis\u00e9 N, Chneiweiss H, D\u00fcrr A, Cancel G, et al. A \n\nthird locus for autosomal dominant cerebellar ataxia type I maps to \n\nchromosome 14q24.3-qter: evidence for the existence of a fourth locus. Am. J. \n\nHum. Genet. 1994 Jan;54(1):11\u201320.  \n\n110.  Stevanin G, Sousa PS, Cancel G, D\u00fcrr A, Dubourg O, Nicholson GA, et al. The \n\ngene for Machado-Joseph disease maps to the same 3-cM interval as the \n\nspinal cerebellar ataxia 3 gene on chromosome 14q. Neurobiol. Dis. 1994 \n\nNov;1(1-2):79\u201382.  \n\n111.  Str\u00f6m A-L, Forsgren L, Holmberg M. A role for both wild-type and expanded \n\nataxin-7 in transcriptional regulation. Neurobiol. Dis. 2005 Dec;20(3):646\u201355.  \n\n112. Subramony SH. Overview of autosomal dominant ataxias. Handb Clin Neurol. \n\n2012;103:389\u201398. \n\n113.  Tait D, Riccio M, Sittler A, Scherzinger E, Santi S, Ognibene A, et al. Ataxin-3 \n\n\n\n51 \n \n\nis transported into the nucleus and associates with the nuclear matrix. Hum. \n\nMol. Genet. 1998 Jun;7(6):991\u20137.  \n\n114.  Takei A, Fukazawa T, Hamada T, Sohma H, Yabe I, Sasaki H, et al. Effects of \n\ntandospirone on ?5-HT1A receptor-associated symptoms? in patients with \n\nMachado-Josephe disease: an open-label study. Clin Neuropharmacol. 2004 \n\nFeb;27(1):9\u201313.  \n\n115.  Takiyama Y, Nishizawa M, Tanaka H, Kawashima S, Sakamoto H, Karube Y, \n\net al. The gene for Machado-Joseph disease maps to human chromosome \n\n14q. Nat. Genet. 1993 Jul;4(3):300\u20134.  \n\n116.  Teive HA, Iwamoto FM, Camargo CH, Lopes-Cendes I, Werneck LC. \n\nMachado-Joseph disease versus hereditary spastic paraplegia: case report. \n\nArq Neuropsiquiatr. 2001 Sep;59(3-B):809\u201311.  \n\n117.  Teive HAG, Arruda WO. [The Drew family of Walworth: one century from the \n\nfirst evaluation until the final diagnosis, Machado-Joseph disease]. Arq \n\nNeuropsiquiatr. 2004 Mar;62(1):177\u201380.  \n\n118.  Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, et al. The \n\ntranscriptional co-activator p/CIP binds CBP and mediates nuclear-receptor \n\nfunction. Nature. 1997 Jun 12;387(6634):677\u201384.  \n\n119.  Tort ABL, Portela LVC, Rockenbach IC, Monte TL, Pereira ML, Souza DO, et \n\nal. S100B and NSE serum concentrations in Machado Joseph disease. Clin. \n\nChim. Acta. 2005 Jan;351(1-2):143\u20138.  \n\n120.  Trott A, Jardim LB, Ludwig HT, Saute JAM, Artigal\u00e1s O, Kieling C, et al. \n\nSpinocerebellar ataxias in 114 Brazilian families: clinical and molecular \n\nfindings. Clin. Genet. 2006 Aug;70(2):173\u20136.  \n\n121.  Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, et \n\nal. International Cooperative Ataxia Rating Scale for pharmacological \n\nassessment of the cerebellar syndrome. The Ataxia Neuropharmacology \n\nCommittee of the World Federation of Neurology. J. Neurol. Sci. 1997 Feb \n\n12;145(2):205\u201311.  \n\n122.  Tsai C-C, Kao H-Y, Mitzutani A, Banayo E, Rajan H, McKeown M, et al. Ataxin \n\n\n\n52 \n \n\n1, a SCA1 neurodegenerative disorder protein, is functionally linked to the \n\nsilencing mediator of retinoid and thyroid hormone receptors. Proc. Natl. Acad. \n\nSci. U.S.A. 2004 Mar 23;101(12):4047\u201352.  \n\n123.  Uchihara T, Fujigasaki H, Koyano S, Nakamura A, Yagishita S, Iwabuchi K. \n\nNon-expanded polyglutamine proteins in intranuclear inclusions of hereditary \n\nataxias--triple-labeling immunofluorescence study. Acta Neuropathol. 2001 \n\nAug;102(2):149\u201352.  \n\n124.  Vel\u00e1zquez-P\u00e9rez L, Rodr\u00edguez-Labrada R, Garc\u00eda-Rodr\u00edguez JC, Almaguer-\n\nMederos LE, Cruz-Mari\u00f1o T, Laffita-Mesa JM. A comprehensive review of \n\nspinocerebellar ataxia type 2 in Cuba. Cerebellum. 2011 Jun;10(2):184\u201398.  \n\n125.  Vig PJS, Subramony SH, D\u2018Souza DR, Wei J, Lopez ME. Intranasal \n\nadministration of IGF-I improves behavior and Purkinje cell pathology in SCA1 \n\nmice. Brain Res. Bull. 2006 May 15;69(5):573\u20139.  \n\n126.  Waragai M, Ogawara K, Takaya Y, Hayashi M. [Efficacy of TRH-T for \n\nspinocerebellar degeneration--the relation between clinical features and effect \n\nof TRH therapy]. Rinsho Shinkeigaku. 1997 Jul;37(7):587\u201394.  \n\n127.  Warrick JM, Morabito LM, Bilen J, Gordesky-Gold B, Faust LZ, Paulson HL, et \n\nal. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a \n\nubiquitin-associated mechanism. Mol. Cell. 2005 Apr 1;18(1):37\u201348.  \n\n128.  Watase K, Gatchel JR, Sun Y, Emamian E, Atkinson R, Richman R, et al. \n\nLithium therapy improves neurological function and hippocampal dendritic \n\narborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med. 2007 \n\nMay;4(5):e182.  \n\n129.  Wessel K, Langenberger K, Nitschke MF, K\u00f6mpf D. Double-blind crossover \n\nstudy with physostigmine in patients with degenerative cerebellar diseases. \n\nArch. Neurol. 1997 Apr;54(4):397\u2013400.  \n\n130.  Wilder-Smith E, Tan EK, Law HY, Zhao Y, Ng I, Wong MC. Spinocerebellar \n\nataxia type 3 presenting as an L-DOPA responsive dystonia phenotype in a \n\nChinese family. J. Neurol. Sci. 2003 Sep 15;213(1-2):25\u20138.  \n\n131.  Wolf U, Rapoport MJ, Schweizer TA. Evaluating the affective component of the \n\n\n\n53 \n \n\ncerebellar cognitive affective syndrome. J Neuropsychiatry Clin Neurosci. \n\n2009;21(3):245\u201353.  \n\n132.  Woods BT, Schaumburg HH. Nigro-spino-dentatal degeneration with nuclear \n\nophthalmoplegia. A unique and partially treatable clinico-pathological entity. J. \n\nNeurol. Sci. 1972 Oct;17(2):149\u201366.  \n\n133.  Wyttenbach A, Sauvageot O, Carmichael J, Diaz-Latoud C, Arrigo A-P, \n\nRubinsztein DC. Heat shock protein 27 prevents cellular polyglutamine toxicity \n\nand suppresses the increase of reactive oxygen species caused by huntingtin. \n\nHum. Mol. Genet. 2002 May 1;11(9):1137\u201351.  \n\n134.  Yamada M, Sato T, Tsuji S, Takahashi H. CAG repeat disorder models and \n\nhuman neuropathology: similarities and differences. Acta Neuropathol. 2008 \n\nJan;115(1):71\u201386.  \n\n135.  Yamada M, Tsuji S, Takahashi H. Involvement of lysosomes in the \n\npathogenesis of CAG repeat diseases. Ann. Neurol. 2002 Oct;52(4):498\u2013503.  \n\n136.  Yamamoto A, Cremona ML, Rothman JE. Autophagy-mediated clearance of \n\nhuntingtin aggregates triggered by the insulin-signaling pathway. J. Cell Biol. \n\n2006 Feb 27;172(5):719\u201331.  \n\n137.  Zesiewicz TA, Greenstein PE, Sullivan KL, Wecker L, Miller A, Jahan I, et al. A \n\nrandomized trial of varenicline (Chantix) for the treatment of spinocerebellar \n\nataxia type 3. Neurology. 2012 Feb 21;78(8):545\u201350.  \n\n138 Zhou J, Lei L, Shi Y, Wang J, Jiang H, Shen L, et al. Serum concentrations of \n\nNSE and S100B in spinocerebellar ataxia type 3/Machado-Joseph disease. \n\nZhong Nan Da Xue Xue Bao Yi Xue Ban. 2011 Jun;36(6):504\u201310. \n\n139.  Zijlstra MP, Rujano MA, Van Waarde MA, Vis E, Brunt ER, Kampinga HH. \n\nLevels of DNAJB family members (HSP40) correlate with disease onset in \n\npatients with spinocerebellar ataxia type 3. Eur. J. Neurosci. 2010 \n\nSep;32(5):760\u201370.  \n\n\n\n54 \n \n\nCap\u00edtulo 1 - Depressive Mood is Associated with Ataxic and \n\nNon-Ataxic Neurological Dysfunction in SCA3 Patients \n\n5 ARTIGOS EM INGL\u00caS \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n   \n\n\n\n55 \n \n\nDepressive mood is associated with ataxic and non-ataxic neurological \n\ndysfunction in SCA3 patients. \n\n \n\nJonas Alex Morales Saute,\n1,3\n\n Andrew Chaves Feitosa da Silva,\n4\n Karina \n\nCarvalho Donis,\n4\n Leonardo Vedolin,\n\n5\n Maria Luiza Saraiva-Pereira,\n\n4\n Laura Bannach \n\nJardim. \n1,2,4 \n\n \n\n1\n Postgraduate Program in Medical Sciences and Department of \n\n2\nInternal \n\nMedicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; \n3\n \n\nNeurology and \n4\nMedical Genetics Services, Hospital de Cl\u00ednicas de Porto Alegre \n\n(HCPA), Porto Alegre, RS, Brazil; \n5\nNeuroradiology Service, Hospital Moinhos de \n\nVento, Porto Alegre, Brazil \n\n \n\n* Corresponding author: \n\n \n\nJonas Alex Morales Saute \n\nPostgraduate Program in Medical Sciences \n\nNeurology Service, Hospital de Cl\u00ednicas de Porto Alegre (HCPA) \n\nUniversidade Federal do Rio Grande do Sul. \n\nRua Ramiro Barcelos, 2.350 \n\nZip Code 90035-903, Porto Alegre, Rio Grande do Sul, Brazil  \n\ne-mail: j4ws@yahoo.com \n\ntel/Fax: +55 51 3359 8520/ 55 51 3359.8001 \n\n \n\nFinancial Disclosure: None of the authors declared a conflict of interest.  \n\n\n\n56 \n \n\n \n\nLetter to the Editor \n\nWe read with interest the article recently published in Cerebellum by Klinke, et al., \n\nentitled Neuropsychological Features of Patients with Spinocerebellar Ataxia (SCA) \n\nTypes 1, 2, 3, and 6., especially as it pertains to the depressive mood scores \n\nobtained in those patients [1].  SCAs are a group of autosomal dominant ataxic \n\ndisorders affecting mainly the cerebellum and its afferent and efferent connections; \n\nhowever in most SCAs the consecutive degenerative process also involves \n\nextracerebellar structures [2].  \n\nA recent survey of subjective health status performed in 526 SCA patients from the \n\nEUROSCA clinical group, found that 46% of those patients reported \n\ndepression/anxiety problems, which was one of the three independent predictors of \n\nsubjective health status together with ataxia severity and extent of noncerebellar \n\ninvolvement [3]. We previously reported that SCA3 symptomatic patients have higher \n\ndepressive mood scores on the Beck Depression Inventory (BDI) than controls \n\n(caregivers), whereas their children at risk have BDI scores lower than the same \n\ncontrol group. Depressive mood scores on the BDI correlated with the neurological \n\ndisability measured by the Barthel Index of Physical Incapacitation in our study [4], \n\nand correlated with the dominant motor hand dysfunction in the study by Klinke et al. \n\n[1]. \n\nIn order to further evaluate depressive symptoms in SCA3 patients and their \n\nrelationship with the recently obtained ataxia scores, we performed a case control-\n\nstudy in 49 molecularly confirmed SCA3 patients from the neurogenetics clinic of \n\nHCPA and 41 healthy, non-related individuals with similar age, gender, and \n\nenvironmental characteristics\u2013 such as spouses or neighbors of the affected \n\nindividuals (mainly caregivers) \u2013 as the control group. The ATXN3 expanded regions \n\nwere analyzed as previously described [5].\n \n \n\nThe Beck Depression Inventory (BDI), in its Brazilian version [6],\n \nwas applied to \n\nquantify the depressive symptoms of subjects. BDI is usually interpreted as follows: \n\n0\u201310 (absence or subtle depression), 11\u201318 (mild depression), 19\u2013 29 (moderate \n\ndepression), and 30\u201363 (severe depression). \n\n\n\n57 \n \n\nTwo clinical ataxia scales were applied: the SARA [7],\n \nwhich evaluates ataxic signals \n\nand the NESSCA [8], which is a global neurological evaluation encompassing ataxic \n\nand non-ataxic signals. Both scores vary from 0 to 40 points, increasing with disease \n\nseverity. Disease duration and age of onset were informed by patients and their \n\nrelatives.  \n\nFor detailed patient characteristics see Table 1. SCA3 patients presented higher \n\ndepressive scores on BDI (p=0.012) when compared to controls (Fig.1A). \n\nConsidering the severity of depressive symptoms, 61% of controls versus 36.7% of \n\nSCA3 patients had absence of or subtle depression, 17% versus 28.5% had mild, \n\n22% versus 34.6% had moderate or severe scores on BDI (Fig. 1B). BDI correlated \n\nmoderately with SARA (R= 0.359, p=0.01 - Fig 1C) and NESSCA (R= 0.412, p=0.003 \n\n\u2013 Fig. 1D). When dividing NESSCA into two sub-scores, the first related to ataxic \n\nsignals (maximum of 16 points) and the second to non-ataxic signals (maximum of \n\n24 points), both scores correlated significantly with BDI (R=0.411, p=0.003; R=0.348 \n\np=0.01, respectively). BDI was also correlated with disease duration, though did not \n\nachieve statistical significance (R=0.273 p=0.057). BDI was not associated with other \n\nclinical or molecular parameters of SCA3 (data not shown).   \n\nWe also performed MRI (1.5 T system) randomly in 30 (16 females) of these SCA3 \n\npatients - whose demographic characteristics were similar to those found in the \n\noverall group of patients - in order to correlate the measures of normalized volumes \n\nof the brainstem, mesencephalus, pontine tegmentum, basis of pons, medulla \n\noblongata, and cerebellum with BDI. More detailed procedures of the utilized \n\ntechnique were described elsewhere [9]. We found no significant correlations of MRI \n\nvolumetries with BDI (data not shown). \n\nOur data shows a direct correlation of disease severity (measured by SARA and \n\nNESSCA) with depressive symptoms, and is in accordance with the results \n\npresented by Klinke et al [1], though perhaps with slightly stronger evidence, since \n\nthose authors reported only a trend towards correlation of BDI with SARA [1]. Our \n\nsignificance probably relied on a larger and more homogeneous sample of patients \n\n(only with SCA3), with worse SARA and BDI scores.  \n\nConsidering SCA3 only, it is evident that our patients had longer disease duration \n\nand CAG repeat lengths than those described in that paper [1]. One could argue that \n\n\n\n58 \n \n\nthe higher depression scores could be related to the longer CAG expansions we saw, \n\nbut we did not find any evidence of that. We found a correlation of BDI with disease \n\nduration; however this was likely to be a confounding factor relating larger disease \n\ndurations with more severe ataxic scores. Lastly, sociocultural differences between \n\nBrazilians and Europeans should be borne in mind, though it is impossible to test for \n\nthese. \n\nAlthough these factors \u2013 mutation severity, disease duration, and cultural \n\ncharacteristics - are not mutually exclusive, the absence of any association between \n\nBDI and molecular findings or MRI normalized volumes, in our study, suggest that \n\ndepression in SCA3 is not primarily related to brain involvement, but rather related to \n\nphysical incapacity [1,10].  \n\nDepressive symptoms are very common and significantly impair the quality of life of \n\nataxic patients [3,4]. At least in SCA3, patients may respond well to treatments aimed \n\nat improving the ways in which they deal with their disability, such as Occupational \n\nTherapy [11]. That our data support the view that depressive symptoms in SCA3 are \n\nnot primarily related to the underlying pathological process could be a matter of \n\ndebate. However \u2013 whether organic or reactive \u2013 depressive symptoms are an \n\nintegral part of SCA3 deserving attention from the physicians who treat this disease. \n\nReferences: \n\n1 - Klinke I, Minnerop M, Schmitz-H\u00fcbsch T, Hendriks M, Klockgether T, W\u00fcllner U, \n\net al. Neuropsychological Features of Patients with Spinocerebellar Ataxia (SCA) \n\nTypes 1, 2, 3, and 6. Cerebellum. 2010. [Epub ahead of print] \n\n2 - Sch\u00f6ls L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar \n\nataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 2004;3:291\u2013\n\n304. \n\n3 - Schmitz-H\u00fcbsch T, Coudert M, Giunti P, Globas C, Baliko L, Fancellu R, et al. \n\nSelf-Rated Health Status in Spinocerebellar Ataxia\u2014Results from a European \n\nMulticenter Study. Mov Disord. 2010;5: 587-95. \n\n4 - Cecchin CR, Pires AP, Rieder CR, Monte TL, Silveira I, Carvalho T, et al. \n\nDepressive Symptoms in Machado-Joseph Disease (SCA-3): Patients and Their \n\nRelatives. Community Genet. 2007;10:19-26. \n\n\n\n59 \n \n\n5 - Bauer PO, Kotliarova SE, Matoska V, Musova Z, Hedvicakova P, Boday A, et al. \n\nFluorescent multiplex PCR--fast method for autosomal dominant spinocerebellar \n\nataxias screening. Genetika. 2005;41:830-7. \n\n6 - Gorenstein C, Andrade L. Validation of a portuguese version of the beck \n\ndepression inventory and the state -trait anxiety inventory in Brazilian subjects. Braz \n\nJ Med Biol Res.1996; 29: 453-7. \n\n7 - Schmitz-H\u00fcbsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et \n\nal. Scale for the assessment and rating of ataxia: development of a new clinical \n\nscale. Neurology. 2006; 66:1717\u201320. \n\n8 - Kieling C, Rieder CR, Silva AC, Saute JA, Cecchin CR, Monte TL, Jardim LB. A \n\nneurological examination score for the assessment of spinocerebellar ataxia 3 \n\n(SCA3). Eur J Neurol. 2008;15:371-6. \n\n9 - Vedolin L, Schwartz IV, Komlos M, Schuch A, Azevedo AC, Vieira T, et al. Brain \n\nMRI in mucopolysaccharidosis: effect of aging and correlation with biochemical \n\nfindings. Neurology. 2007;69:917-24. \n\n10 - R\u00fcb U, Brunt ER, Deller T. New insights into the pathoanatomy of \n\nspinocerebellar ataxia type 3 (Machado-Joseph disease). Curr Opin Neurol. 2008; \n\n21:111-6. \n\n11 \u2013 Silva RCR, Saute JA, Silva ACF, Coutinho ACO,  Saraiva-Pereira ML, Jardim \n\nLB. Occupational therapy in spinocerebellar ataxia type 3: an open-label trial. Braz J \n\nMed Biol Res. 2010 [Epub ahead of print] \n\n  \n\n\n\n60 \n \nTable 1 \n\n \n\n \n\nFigure 1: Depression scores in SCA3 (A) BDI score in SCA3 patients and controls. \n\n(B) Representation (%) of the severity of BDI scores between groups. (C) Correlation \n\n\n\n61 \n \n\nof BDI with SARA and (D) Correlation of BDI with NESSCA. Values are given as \n\nmeans and error bars represent standard error (SEM); * p &lt;0.05;** p &lt;0.01. \n\n \n\n  \n\n\n\n62 \n \n\nCap\u00edtulo 2 - Body Mass Index is Inversely Correlated with \n\nthe Expanded CAG Repeat Length in SCA3/MJD Patients  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  \n\n\n\n63 \n \n\nBody mass index is inversely correlated with the expanded CAG repeat \n\nnumber in SCA3 patients \n\n \n\nJonas Alex Morales Saute\n1,4\n\n, Karina Carvalho Donis\n5\n, Gabriele Nunes Souza\n\n5\n, \n\nAndrew Chaves Feitosa da Silva\n5\n, Leonardo Vedolin\n\n6\n, Maria Luiza Saraiva-Pereira\n\n3,5\n, \n\nLuis Valmor Cruz Portela\n3\n, Laura Bannach Jardim. \n\n1,2,5 \n\n \n\n1\nPostgraduate Program in Medical Sciences and Departments of \n\n2\nInternal Medicine \n\nand \n3\nBiochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, \n\nBrazil; \n4\n Neurology and \n\n5\nMedical Genetics Services, Hospital de Cl\u00ednicas de Porto \n\nAlegre (HCPA), Porto Alegre, RS, Brazil; \n6\nNeuroradiology Service, Hospital Moinhos \n\nde Vento, Porto Alegre, Brazil \n\n \n\n* Corresponding author: \n\nJonas Alex Morales Saute \n\nNeurology Service, Hospital de Cl\u00ednicas de Porto Alegre (HCPA) \n\nUniversidade Federal do Rio Grande do Sul. \n\nRua Ramiro Barcelos, 2.350 \n\nZip Code 90035-903, Porto Alegre, Rio Grande do Sul, Brazil  \n\ne-mail: j4ws@yahoo.com \n\ntel/Fax: +55 51 3359 8520/ 55 51 3359.8001 \n\n \n\n\n\n64 \n \n\n Search Terms: \n\n[ 298 ] Spinocerebellar ataxia, [ 98 ] Trinucleotide repeat diseases, [ 163 ] Gait \n\ndisorders/ataxia, [ 175 ] Neuroendocrinology. \n\nFinancial Disclosure: None of the authors declared a conflict of interest.  \n\nAcknowledgments \n\nThis research was supported by the Brazilian funding agencies FIPE-HCPA, \n\nCNPq, FINEP, INAGEMP and FAPERGS and by the Spanish institute CIBERNED.  \n\n\n\n65 \n \n\nAbstract \n\n \n\nObjectives: We aimed to evaluate the body mass index (BMI) of patients with SCA3 \n\nand to assess the correlations with clinical, molecular, biochemical and neuroimaging \n\nfindings. \n\nMethods: A case-control study with 46 SCA3 patients and 42 healthy, non-related \n\ncontrol individuals with similar age and sex was performed. Clinical evaluation was \n\ndone with the ataxia scales SARA and NESSCA. Serum insulin, insulin like-growth \n\nfactor 1 (IGF-1) and magnetic resonance imaging (MRI) normalized volumetries of \n\ncerebellum and brain stem were also assessed. \n\nResults: BMI was lower in SCA3 patients when compared to controls (p=0.01). BMI \n\nwas associated with NESSCA, expanded CAG repeat number (CAG)n and serum \n\ninsulin levels; however in the linear regression model, (CAG)n was the only variable \n\nindependently associated with BMI, in an inverse manner (R=-0.404, p=0.012).  \n\nConclusions: In this report we present evidence that low BMI is not only present in \n\nSCA3, but is also directly related to the size of the expanded CAG repeats, which is \n\nthe causative mutation of the disease. This association points that weight loss might \n\nbe a primary disturbance of SCA3, although further detailed analyses are necessary \n\nfor a better understanding of the nutritional deficit and its role in the pathophysiology \n\nof SCA3. \n\n \n\n \n\n \n\n\n\n66 \n \n\nIntroduction \n\nSpinocerebellar ataxia type 3 (SCA3) is an autosomal dominant neurodegenerative \n\ndisease with no current treatment caused by a dynamic mutation involving CAG \n\ntrinucleotide repeat expansions, being part of the so-called group of polyglutamine \n\n(polyQ) disorders\n1\n.  \n\nIn spite of clearly present in clinical practice, nutritional alterations in SCA3 patients \n\nwere only covered by anecdotal reports in the literature. We have recently evaluated \n\nthe role of insulin/insulin-like growth factor 1 (IGF-1) system (IIS) in SCA3 patients \n\nfinding that SCA3 patients presented lower Body Mass Index (BMI) than controls\n2\n. In \n\nthe present report, we aimed to deepen the understanding about weight loss in this \n\ndisease, looking for correlations with clinical, molecular, biochemical and \n\nneuroimaging findings, in a case-control study. \n\nMethods \n\nWe recruited 46 SCA3 patients from the neurogenetics clinic of HCPA and 42 \n\nhealthy, non-related individuals, with similar age, gender, and environmental \n\ncharacteristics \u2013 mainly caregivers \u2013 as the control group. The clinical evaluation was \n\nperformed with the Scale for the Assessment and Rating of Ataxia (SARA)\n3\n and the \n\nNeurological Examination Score for Spinocerebellar Ataxia (NESSCA)\n4\n. Both scores \n\nvary from 0\u201340 points, increasing with disease severity. Weight and height were \n\nmeasured always in the same devices and BMI was calculated with the formula \n\n[weight / (height)\u00b2]. Disease duration and age of onset were informed by patients and \n\ntheir relatives.  \n\nWe also performed brain magnetic resonance imaging (MRI - 1.5 T system) \n\nrandomly in 26 (14 females) of these SCA3 patients - whose demographic \n\ncharacteristics were similar to those found in the overall group of patients - in order to \n\ncorrelate the measures of normalized volumes of the brainstem, mesencephalus, \n\npontine tegmentum, basis of pons, medulla oblongata, and cerebellum with BMI. \n\nMore detailed procedures of the utilized technique were described elsewhere\n5\n.  \n\nA blood sample was collected in the same day of the clinical evaluation in order to \n\nmeasure serum lipid profile, glucose, insulin (Electrochemiluminescence - Roche \n\nDiagnostics, Germany) and IGF-1 levels (ELISA - DuoSet R&amp;D System, USA). All \n\n\n\n67 \n \n\nsamples were obtained between 10 AM and 4 PM and all subjects were under fasting \n\nconditions. The study was approved by the local Ethics Committee and all subjects \n\ngave their informed written consent. \n\nAll variables in the study showed a normal distribution on Kolmogorov-Smirnov test. \n\nContinuous variables comparison between cases and controls were performed with \n\ntwo-tailed unpaired Student\u2018s t-test. One-Way ANOVA was performed to compare \n\nthe BMI within the different degrees of dysphagia. Gender was analyzed with ?\n2\n test \n\nand all correlations with Pearson correlation test followed by multiple linear \n\nregression model. Statistical significance was defined as p &lt;0.05.  \n\nResults \n\nFor detailed clinical characteristics of enrolled subjects see Table 1.  \n\nBMI was found to be lower in SCA3 patients when compared to controls (p=0.01 \u2013 \n\ncorrected for age \u2013 Fig 1A), correlating inversely with CAG expanded repeats \u2013 \n\nCAG(n) - (R=-0.484, R\n2\n=0.234, p=0.001 \u2013 Fig 1B) and NESSCA (R=-0.351, \n\nR\n2\n=0.123, p=0.02); and directly with age at onset (R=-0.496, R\n\n2\n=0.246, p=0.001) and \n\nage (R=0.396, R\n2\n=0.157, p=0.008).   \n\nFormer results from this case control study showed that SCA3 patients presented \n\nlower serum insulin and normal IGF-1 levels\n2\n. In the present study, we found that \n\nserum insulin levels were directly associated with BMI (R=0.428, R\n2\n=0.183 p=0.006), \n\nwhile IGF-1 levels were not (R=-0.088, p=0.473). However, in the multiple linear \n\nregression model constructed with insulin levels, NESSCA, age and CAG(n) or age \n\nat onset, the only studied factor that was independently associated with BMI was the \n\nnumber of expanded CAG repeats (R=-0.404, p=0.012), with only a trend for insulin \n\nlevels (R=0.293, p=0.074). \n\nDysphagia might also be an important cause of weight loss, and since one item of \n\nNESSCA evaluates dysphagia, we divided SCA3 patients in accordance to it \u2013 as \n\nhaving no, mild or severe dysphagia. No significant differences in BMI were found \n\namong these subgroups (p=0.228).  \n\nFinally, we found no significant correlation between BMI and brainstem MRI \n\nvolumetries after correction for age (data not shown). \n\n\n\n68 \n \n\n \n\nDiscussion \n\nIn this report we present evidence that low BMI is not only present in SCA3, but is \n\nalso directly related to the severity of SCA3 causal mutation \u2013 the expanded CAG \n\nrepeats size. \n\nA few previous studies evaluated weight loss in polyQ disorders. In a SCA3 \n\ntransgenic model, mice presented a progressive loss of body weight during disease \n\ncourse that was prevented by blocking ataxin-3 transgene expression\n6\n.  In transgenic \n\nHuntington Disease (HD) mice, higher CAG repeats were related to a faster rate of \n\nweight loss\n7\n. Similar results were found in clinical studies of HD, where a significant \n\nunderweight state was found in early stages and even in asymptomatic carriers,\n8\n HD \n\npatients with higher CAG repeats also showed a faster rate of weight loss\n7\n, which is \n\nin agreement with our present findings in SCA3. \n\nWe were not able to relate BMI to the degree of dysphagia, in the present study, \n\nalthough this association needs to be better evaluated. It is also worth to remind that \n\nwe did not find an association between BMI and disease duration and that BMI \n\ninverse correlation with NESSCA was not independent from the CAG expanded \n\nrepeat size. In other words, there was no clear association between clinically severe \n\ndisease depicted by specific ataxia scores or longer disease duration with lower BMI. \n\nAlterations in the insulin/IGF-1 system have been involved in weight loss of \n\ntransgenic animal models and of patients with HD\n9\n. We have formerly described that \n\nSCA3 patients present reduced insulin levels, and that insulin levels were related to \n\nage at onset of symptoms\n2\n. Now, we found that, although insulin levels were directly \n\nassociated with BMI, the CAG expanded repeat length was the only variable \n\nindependently related to weight loss.  \n\nSince the most important determinant of the BMI seems to be the CAG expanded \n\nrepeat, weight loss may be a primary disturbance of SCA3 and therefore further \n\ndetailed analyses are necessary for a better understanding of the nutritional deficit \n\nand its role in the pathophysiology of SCA3. \n\n \n\n\n\n69 \n \n\nReferences \n\n1 - Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and \n\nbeyond. Lancet Neurol. 2010;9:885-894. \n\n2 \u2013 Saute JA, da Silva ACF, Muller AP, et al. Serum Insulin-Like System Alterations \n\nin Patients with Spinocerebellar Ataxia Type 3. Mov Disord. 2010; In Press. \n\n3 - Schmitz-Hubsch T, du Montcel ST, Baliko L, et al. Scale for the assessment and \n\nrating of ataxia: development of a new clinical scale. Neurology 2006;66:1717\u20131720. \n\n4 - Kieling C, Rieder CR, Silva AC, et al. A neurological examination score for the \n\nassessment of spinocerebellar ataxia 3 (SCA3). Eur J Neurol 2008;15:371\u2013376. \n\n5 - Vedolin L, Schwartz IV, Komlos M, et al. Brain MRI in mucopolysaccharidosis: \n\neffect of aging and correlation with biochemical findings. Neurology 2007;69:917-24. \n\n6 - Boy J, Schmidt T, Wolburg H, et al. Reversibility of symptoms in a condicional \n\nmouse model of spinocerebellar ataxia type 3. Hum Mol Genetics 2009; 18:4282-\n\n4295. \n\n7 - Aziz N A, van der Burg M M, Landwehrmeyer GB, et al. Weight loss in Huntington \n\ndisease increases with higher CAG repeat number. Neurology 2008;71:1506-1513. \n\n8 - Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I; Huntington Study \n\nGroup. Dietary intake in adults at risk for Huntington disease: analysis of PHAROS \n\nresearch participants. Neurology 2009;73:385-392. \n\n9 - Andreassen O A, Dedeoglu A, Stanojevic V et al. Huntington\u2018s Disease of the \n\nEndocrine Pancreas: Insulin Deficiency and Diabetes Mellitus due to Impaired Insulin \n\nGene Expression. Neurobiology of Disease 2002;11:410\u2013424. \n\n\n\n70 \n \n\n \nFigure 1 \u2013 BMI of SCA3 patients and its correlation with (CAG)n.  \n\n(A) BMI comparison of patients with SCA3 and controls corrected for age - values are \n\ngiven as means and error bars represent SEM. (B) CAG expanded repeat (CAG)n \n\nsimple correlation with BMI.** p &lt;0.01; ***p &lt;0.001 \n\nTable 1 \u2013 Demographic characteristics of the enrolled individuals \n\n Controls SCA3 Patients p \n\n Mean (SD) Mean (SD)  \n\nN 42 46 NA \n\nAge (years) 45.5 (12) 44.5(11) 0.683 \n\nGender (M/F) 16/26 22/24 0.357 \n\nBMI (kg/m\n2\n) 27.1 (4.5) 24.4 (4.1) 0.01**\n\n a\n \n\nDisease Duration (years) NA 9.97 (6.6) NA \n\nAge at onset (years) NA 34.5 (10) NA \n\nCAG(n) NA 73.3 (3) NA \n\nNESSCA NA 17.5 (6.3) NA \n\nSARA NA 14.4 (7.6) NA \n\na\n \u2013 Corrected for age \n\nNA \u2013 not applicable \n\n** p<0.01 \n\n \n\n\n\n71 \n \n\nCap\u00edtulo 3 - Serum Insulin-Like System Alterations in \n\nPatients with Spinocerebellar Ataxia Type 3 \n\n \n\n \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  \n\n\n\n72 \n \n\nSerum Insulin-like system alterations in patients with spinocerebellar ataxia \n\ntype 3 (SCA3)  \n\nJonas Alex Morales Saute,\n1,3,5\n\n Andrew Chaves Feitosa da Silva,\n4\n Alexandre Pastoris \n\nMuller,\n1\n Gisele Hansel,\n\n1\n Alexandre Silva de Mello,\n\n4\n F\u00e1bio Maeda,\n\n3,6\n Leonardo \n\nVedolin,\n6\n Maria Luiza Saraiva-Pereira,\n\n1,4\n Diogo Onofre Souza,\n\n1\n Ignacio Torres-\n\nAleman,\n7,8\n\n Luis Valmor Cruz Portela,\n1\n* Laura Bannach Jardim \n\n2,3,4\n \n\n1\nDepartments of Biochemistry and of \n\n2\nInternal Medicine, and \n\n3\nPost-Graduate \n\nProgram in Medical Sciences, Universidade Federal do Rio Grande do Sul, Porto \n\nAlegre, RS, Brazil; \n4\nMedical Genetics and \n\n5\nNeurology Services, Hospital de Cl\u00ednicas \n\nde Porto Alegre (HCPA), Porto Alegre, RS, Brazil; \n6\nNeuroradiology Service, Hospital \n\nMoinhos de Vento, Porto Alegre, Brazil\n 7\n\nLaboratory of Cellular and Molecular \n\nNeuroendocrinology, Instituto Cajal, Consejo Superior de Investigaciones Cientificas \n\n(CSIC) and \n8\nCIBERNED, Madrid, Spain;  \n\n \n\n* Corresponding author: \n\nLuis Valmor Cruz Portela \n\nDepartment of Biochemistry, Instituto de Ci\u00eancias B\u00e1sicas da Sa\u00fade \n\nUniversidade Federal do Rio Grande do Sul \n\nRua Ramiro Barcelos 2600 Anexo  \n\nCEP 90.035-003, Porto Alegre, Rio Grande do Sul, Brazil  \n\ne-mail: roskaportela@gmail.com \n\ntel/Fax: +55 51 3316 5540. \n\n\n\n73 \n \n\nSearch terms:  \n\nSpinocerebellar ataxia, polyglutamine disorders, IGF-1, Insulin, IGFBP, Machado-\n\nJoseph Disease \n\nFinantial Disclosure: None of the authors declared a conflict of interest.  \n\nRunning Title: Insulin-like system in SCA3 \n\n\n\n74 \n \n\nAbstract \n\nBackground: Spinocerebellar ataxias (SCAs) constitute a group of autosomal \n\ndominant neurodegenerative disorders without treatment. The Insulin/IGF-1 system \n\n(IIS) has been shown to play a role in the neurological dysfunction of SCAs and other \n\npolyglutamine disorders. We aimed to study the biomarker profile of serum IIS \n\ncomponents in SCA3. \n\nMethods: We performed a case-control study with 46 SCA3 patients and 42 healthy \n\nindividuals evaluating the peripheral IIS profile (Insulin, IGF-1, IGFBP1 and 3) and \n\nthe correlation with clinical, molecular and neuroimaging findings \n\nResults: SCA3 patients presented lower insulin and IGFBP3 levels and higher insulin \n\nsensitivity (HOMA2), free IGF-I, and IGFBP1 levels when compared to controls. \n\nIGFBP-1 levels were directly associated with CAG expanded repeat length; IGF-1 \n\nwas associated with specific brain-stem regions volumetries on MRI. Insulin levels \n\nand sensitivity were related to age at onset of symptoms.   \n\nConclusions: Our findings indicate an involvement of IIS components in SCA3 \n\nneurobiology and IGFBP-1 as a potential biomarker of the disease. \n\nAbbreviations: SCA=Spinocerebellar ataxia; IGF-1 = insulin-like growth factor I; \n\nIGFBP=  insulin-like growth factor binding protein \n\n\n\n75 \n \n\nIntroduction \n\nSpinocerebellar ataxias (SCAs) constitute a group of autosomal dominant \n\nneurodegenerative disorders with no current treatment.\n1,2\n\n The most prevalent SCAs \n\nare those caused by CAG trinucleotide repeat expansions,\n1\n  being part of the so-\n\ncalled group of polyglutamine (polyQ) disorders.\n2\n  \n\nThe insulin/insulin-like growth factor 1 (IGF-1) system (IIS) \u2013 encompassing Insulin, \n\nIGF-1, and IGFBPs - plays important neuromodulatory functions in the central \n\nnervous system (CNS).\n3,4,5\n\n Abnormalities in the IIS signaling pathway were thought to \n\nplay a part in the physiopathological processes of various neurodegenerative \n\ndisorders, including Alzheimer\u00b4s disease, SCAs and Huntington Disease (HD) \n\nthrough different mechanisms.\n3,4,6,7,8\n\n \n\nChronic treatment with IGF-1 improved neurological deficits in neurotoxic and \n\ntransgenic animal models of ataxia.\n9,10\n\n In transgenic animal models of other polyQ \n\ndisorders, there was also evidence of involvement of signaling components of the IIS \n\nin the modulation of mutant proteins and disease phenotype.\n11,12\n\n On clinical grounds, \n\naltered serum levels of IGF-1 and IGF-1 binding proteins (IGFBPs) have been \n\nreported in patients with late onset cerebellar ataxia (LOCA).\n13 \n\nBearing in mind these evidences pointing that IIS might be altered in PolyQ \n\ndisorders, we aimed to investigate the biomarker profile of serum IIS components in \n\nSCA3, considering their relation with clinical, molecular and neuroimaging findings.   \n\nMethods \n\nDesign and Subjects  \n\nA case-control study was performed between May and October of 2007 with 46 \n\nmolecularly confirmed SCA3 patients from the neurogenetics clinic of HCPA and 42 \n\nhealthy, community, non-related individuals with similar age, gender, and \n\nenvironmental characteristics. Nutritional and mood evaluation were done to control \n\nconfounding factors. The ATXN3 expanded regions were analyzed as previously \n\ndescribed.\n14 \n\nSubjects diagnosed with other neurological, endocrine, renal or hepatic \n\ndisorders were excluded. The study was approved by the local Ethics Committee and \n\nall subjects gave their informed written consent. \n\n\n\n76 \n \n\nClinical Evaluation \n\nTwo clinical ataxia scales were applied: the SARA\n15 \n\nand NESSCA scores.\n16\n\n Disease \n\nduration and age of onset were informed by patients and their relatives. All subjects \n\ncompleted Beck Depression Inventory (BDI).\n17\n\n \n\nMagnetic Resonance Imaging   \n\nMRI was done using 1.5 T system. Sagital T1 weighted images (TR=2000 ms and \n\nTE=3.45 ms) - slice thickness of 1mm, pixel size of 0.49mm - were performed. The \n\nnormalized volumes of the brainstem, mesencephalus, pontine tegmentum, basis of \n\npons, medulla oblongata, and cerebellum of SCA3 patients were measured on fluid-\n\nattenuated inversion recovery (FLAIR), using semi-automated segmentation \n\ntechniques and voxel count volumetry using the software ImageJ. More detailed \n\nprocedures of this technique were described elsewere.\n18 \n\n \n\nSamples and Assays \n\nSerum was obtained by blood centrifugation at 6000 x g for 5 min, frozen \n\nimmediately and stored at -70 \u00baC until analyses. All samples were obtained between \n\n10 a.m. and 4 p.m. and all subjects were under fasting conditions. Serum IGF-1 \n\n(DuoSet R&amp;D System, USA), IGFBP-1 (Medix Biochemica, Finland) and IGFBP-3 \n\n(Mediagnost, Germany) were measured in duplicate by ELISA. Serum Insulin (Roche \n\nDiagnostics, Germany) was determined by electrochemiluminescence. We utilized \n\nthe HOMA Calculator v2.2.2 to determine HOMA2 parameters. \n\nStatistical Analysis \n\nAll variables in the study showed a normal distribution on One-Sample Kolmogorov-\n\nSmirnov test, but HOMA2-%S - which was log transformed. Comparisons of IIS \n\ncomponents levels between cases and controls were done by two-tailed unpaired \n\nStudent\u2018s t-test. Univariate General Linear Model was utilized to control for \n\nconfounding factors that were significantly correlated with the outcomes. Gender was \n\nanalyzed with Chi-Square test and all correlations with Pearson correlation test \n\nfollowed by linear regression model. Statistical significance was defined as p &lt;0.05.  \n\n  \n\n\n\n77 \n \nResults  \n\nDemographic data of cases and controls are shown in Table 1. MRI was obtained \n\nrandomly in 26 (14 females) of these SCA3 patients, whose demographic \n\ncharacteristics were similar to those found in the overall group of patients.  \n\nInsulin/IGF-1 System (IIS) \n\nDifferences regarding serum concentrations of IGF-1, IGFBP-1, IGFBP-3, IGF-\n\n1:IGFBP-3 molar ratio, Insulin and HOMA analysis between cases and controls are \n\nshown in Table 2.  \n\nTotal IGF-1 serum levels did not differ between groups (p=0.550 \u2013 corrected for age) \n\nnor correlated with clinical or molecular variables. IGF-1 was inversely correlated with \n\nmedulla oblongata (R=-0.489 p=0.011) and basis of pons volumetry (R=-0.439 \n\np=0.025) on MRI (Supp. Fig 1 and 2) \n\nIGFBP-1 serum levels were higher in patients with SCA3 than in controls (p=0.001 - \n\ncorrected for BMI). IGFBP-1 levels were correlated significantly with CAG expanded \n\nrepeats (R=0.451 p=0.003 \u2013 Fig 1) \u2013 which was the only factor independently \n\nassociated in the linear regression model (R=0.452 p=0.006). IGFBP-1 did not \n\ncorrelate with MRI volumetries. \n\nIGFBP-3 levels were lower (p=0.001) and the IGF-1:IGFBP-3 molar ratio (an indirect \n\nform of measuring free IGF-1) was higher (p=0.039 \u2013 corrected for age and gender) \n\nin SCA3 patients than in controls. Neither IGFBP-3 nor IGF-1:IGFBP-3 molar ratio \n\nindependently correlated significantly with any clinical, molecular or MRI volumetries \n\nvariables. \n\nInsulin levels were lower in cases than in controls (p=0.027, after correction for BMI). \n\nAge of onset correlated directly with insulin levels (R=0.510 p=0.0001) and was the \n\nonly factor independently associated in the linear regression model with insulin \n\n(R=0.365 p=0.026 \u2013 Fig 2). When we considered age of onset as a dependent factor, \n\nboth Insulin (R=0.404 p=0.012) and CAG expanded repeat (R=-0.738 p=0.0001) \n\ninfluenced the variable independently. Insulin levels did not correlate with MRI \n\nvolumetries. \n\n\n\n78 \n \n\nHOMA analysis was perfomed in order to examine the steady state ?-cell function \n\n(HOMA2-%B), peripheral insulin sensitivity (HOMA2-%S) and resistance (HOMA2-IR \n\nIndex). HOMA2-%B (?-cell function) was similar between groups (p=0.637), whereas \n\nthe Log (HOMA2-%S) (insulin sensitivity) was higher (p=0.003 \u2013 corrected for BMI) \n\nand HOMA2-IR Index (insulin resistance) was lower (p=0.022 \u2013 corrected for BMI) in \n\npatients with SCA3 than in control participants.  Log (HOMA2-%S) and HOMA2-IR \n\nIndex correlated with age of onset (R=-0.444 p=0.003 and R=0.492 p=0.001, \n\nrespectively \u2013 Fig 2), which was the only factor independently associated with these \n\nvariables in the linear regression model. (R=-0.408 p=0.014 and R=0.378 p=0.021, \n\nrespectively). When age of onset was considered as the dependent factor HOMA2-\n\n%S (R=-0.408 p=0.014) or HOMA2-IR Index (R=0.378 p=0.021) and CAG expanded \n\nrepeat (R=-0.703 p=0.0001) influenced the variable independently. None of the \n\nHOMA parameters correlated with MRI volumetries.  \n\nDiscussion \n\nThe present results indicated significant changes in various constituents of the IIS in \n\nSCA3 patients, pointing IGFBP-1 as a disease biomarker and a possible disease \n\nmodifier effect related to insulin sensitivity. \n\nWe found no differences in serum IGF-1 levels in SCA3 patients, however we \n\nobserved that IGF-1 serum levels were inversely correlated with the volume of \n\nmedulla oblongata and basis pontis, two brain structures that are primarily affected in \n\nSCA3.  \n\nIGFBP-3 levels \u2013 which binds more than 80% of peripheral IGF-1 and increases its \n\nhalf-life -\n19 \n\nwere lower, while an indirect measure of free IGF-1 levels, the IGF-\n\n1:IGFBP-3 molar ratio, was higher in SCA3 patients than in controls. Higher levels of \n\nfree IGF-1 may have opposite consequences: the peptide might either be early \n\nmetabolized, being in insufficient levels for an adequate transport to the CNS; or \n\nmight be coupled to the higher expressed IGFBP-1 increasing its transport to target \n\nbrain areas, once this binding protein is known to participate in tissue allocation of \n\ncirculating IGF-1.\n20\n\n \n\nIGFBP-1 levels were higher in SCA3 patients than in controls and were \n\nindependently related only to CAG expanded repeats, with more severe mutations \n\nleading to higher levels of IGFBP-1. These results point IGFBP-1 as a possible \n\n\n\n79 \n \n\nbiomarker of the disease, therefore the actual link between this biomarker and \n\nneuropathology should be put in perspective. Mutated ataxin-3 could interfere with \n\nIGFBP-1 synthesis or metabolism due to its ubiquitin related properties and to its \n\ndisruptive effects on gene transcription.\n2\n Since ataxin-3 is also associated with \n\nendoplasmic reticulum (ER) stress and ER stress is in turn related to increased \n\nIGFBP-1 production in liver,\n21\n\n Thus, higher IGFBP-1 levels may constitute a marker \n\nof ER stress due the mutated ataxin-3.  \n\nWe found lower serum levels of insulin in SCA-3 patients when compared to controls, \n\neven when corrected for BMI. These findings are in agreement with those previously \n\ndescribed in patients with LOCA.\n13 \n\nAccording to our data, insulin levels were \n\nindependently and directly associated with age at onset, but interestingly were not \n\ncorrelated with CAG expanded repeats. Because we found different levels of insulin, \n\nbut no changes in glucose levels, we studied the peripheral insulin sensitivity. SCA3 \n\npatients had higher insulin sensitivity and lower resistance index than the control \n\ngroup, with a normal steady state ?-cell function. This higher sensitivity to insulin \n\nwas, again, inversely associated only with age at onset. According to these data, \n\nSCA3 patients seemed to show an increased peripheral sensitivity to insulin, and in \n\nconsequence, a reduction in serum levels of insulin. Higher sensitivity to insulin and \n\nlower insulin levels were both related to earlier disease onset.   \n\nIn polyQ disorders the strongest determinant of age of onset is the number of CAG \n\nexpanded repeats of the mutated protein.\n22\n\n. As our cross-sectional study was \n\nperformed years after the clinical onset of SCA3, we were not able to determine \n\nwhether insulin sensitivity was indeed influencing age of onset or whether the \n\nopposite occurred.  \n\nConclusions \n\nSince SCAs are rare and slow progressive disorders, the identification of biomarkers \n\nwith clinical relevance could help to shorten trials and reduce the number of patients \n\nneeded. In the present study we found a potential role of IGFBP-1 as a serum \n\nbiomarker and a possible disease modifying mechanism related to insulin sensitivity \n\nin SCA3 which deserves future investigations.  \n\n \n\n\n\n80 \n \n\nAcknowledgments \n\nThis research was supported by the Brazilian funding agencies FIPE-HCPA, CNPq, \n\nFINEP, INAGEMP and FAPERGS and by the Spanish institute CIBERNED.  \n\nAuthor Roles \n\n1.       Research project: A. Conception, B. Organization, C. Execution; \n\n2.       Statistical Analysis: A. Design, B. Execution, C. Review and Critique; \n\n3.       Manuscript: A. Writing of the first draft, B. Review and Critique; \n\nSaute: 1A, 1B, 1C, 2A, 2B, 2C, 3A. da Silva: 1B, 1C. Muller: 1B, 1C, 3B. Hansel: 1B, \n\n1C. de Mello: 1C. Maeda: 1C. Vedolin: 1B, 1C. Saraiva-Pereira: 1C. Souza: 1A,3B. \n\nTorres-Aleman: 1A, 1B, 3B. Portela: 1A, 1B, 2C, 3B. Jardim: 1A,1B, 2C, 3B.  \n\nReferences \n\n1 - Sch\u00f6ls L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar \n\nataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 2004;3:291\u2013\n\n304. \n\n2 \u2013 Williams AJ, Paulson HL. Polyglutamine neurodegeneration: protein misfolding \n\nrevisited. Trends Neurosci 2008;31:521-528. \n\n3 - Schulingkamp R, Pagano T, Hung D, Raffa R. Insulin receptors and insulin action \n\nin the brain: review and clinical implications. Neurosci Biobehav Rev 2000;24:855\u2013\n\n872. \n\n4 \u2013 Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific \n\nmechanisms. Lancet Neurol 2004;3:169-178. \n\n5 - Aberg ND, Brywe KG, Isgaard J. Aspects of Growth Hormone and Insuline-Like \n\nGrowth Factor-I Related to Neuroprotection, Regeneration, and Functional Plasticity \n\nin the Adult Brain. ScientificWorldJournal 2006;6:53-80. \n\n6 - Cohen E, Paulsson JF, Blinder P, et al. Reduced IGF-1 signaling \n\ndelays age-associated proteotoxicity in mice. Cell 2009;139:1157-69. \n\n\n\n81 \n \n\n7 - Cohen E, Dillin A. The insulin paradox: aging, proteotoxicity and \n\nneurodegeneration. Nat Rev Neurosci 2008; 9: 759\u2013767. \n\n8 - Emamian ES, Kaytor MD, Duvick LA, et al. Serine 776 of ataxin-1 is critical for \n\npolyglutamine-induced disease in SCA1 transgenic mice. \n\nNeuron 2003;38:375-387. \n\n9 - Fernandez AM, de la Vega AG, Torres-Aleman I. Insulin-like growth factor I \n\nrestores motor coordination in a rat model of cerebellar ataxia. Proc Natl Acad Sci U \n\nS A 1998; 95:1253-1258. \n\n10 - Vig PJ, Subramony SH, D'Souza DR, Wei J, Lopez ME. Intranasal \n\nadministration of IGF-I improves behavior and Purkinje cell pathology in SCA1 mice. \n\nBrain Res Bull 2006;69:573-9. \n\n11 - Colin E, Regulier E, Perrin V, et al. Akt is altered in an animal model of \n\nHuntington's disease and in patients. Eur J Neurosci 2005;21:1478-1488. \n\n12 - Palazzolo I, Burnett BG, Young JE, et al. Akt blocks ligand binding and protects \n\nagainst expanded polyglutamine androgen receptor toxicity. Hum Mol Genet \n\n2007;16:1593-1603. \n\n13 - Torres-Aleman I, Barrios V, Lledo A, Berciano J. The insulin-like growth factor I \n\nsystem in cerebellar degeneration. Ann Neurol 1996;39:335-342. \n\n14 - Bauer PO, Kotliarova SE, Matoska V et al. Fluorescent multiplex PCR--fast \n\nmethod for autosomal dominant spinocerebellar ataxias screening. Genetika \n\n2005;41:830-837 \n\n15 - Schmitz-Hubsch T, du Montcel ST, Baliko L, et al. Scale for the assessment and \n\nrating of ataxia: development of a new clinical scale. Neurology 2006; 66:1717\u20131720. \n\n16 - Kieling C, Rieder CR, Silva AC, Saute JA, Cecchin CR, Monte TL, Jardim LB. A \n\nneurological examination score for the assessment of spinocerebellar ataxia 3 \n\n(SCA3). Eur J Neurol 2008;15:371-376. \n\n17 - Gorenstein C, Andrade L. Validation of a portuguese version of the beck \n\ndepression inventory and the state -trait anxiety inventory in Brazilian subjects. Braz \n\nJ Med Biol Res 1996; 29: 453-457. \n\n\n\n82 \n \n\n18 - Vedolin L, Schwartz IV, Komlos M, et al. Brain MRI in mucopolysaccharidosis: \n\neffect of aging and correlation with biochemical findings. Neurology 2007;69:917-924. \n\n19 - Vardy ER, Rice PJ, Bowie PC, Holmes JD, Grant PJ, Hooper NM. Increased \n\ncirculating insulin-like growth factor-1 in late-onset Alzheimer's disease. J Alzheimer \n\nDis 2007;12:285-90. \n\n20 - Berg U, Gustafsson T, Sundberg CJ, Kaijser L, Carlsson-Skwirut C, Bang P. \n\nInterstitial IGF-I in exercising skeletal muscle in women. Eur J Endocrinol \n\n2007;157:427-435. \n\n21 - Marchand A, Tomkiewicz C, Magne L, Barouki R, Garlatti M. Endoplasmic \n\nreticulum stress induction of insulin-like growth factor-binding protein-1 involves \n\nATF4. J Biol Chem 2006;281:19124-19133. \n\n22 - Wexler NS, Lorimer J, Porter J, et al. Venezuelan kindreds reveal that genetic \n\nand environmental factors modulate Huntington's disease age of onset. Proc Natl \n\nAcad Sci U S A 2004;101:3498-3503. \n\nTable 1 \n\n \n\n\n\n83 \n \n\nTable 2 \n\n \n\nFigure 1: IGFBP-1 as a biomarker of SCA3 (A) Analysis of IGFBP-1 serum levels in \n\nSCA3 patients and controls corrected for BMI. (B) CAG expanded repeat (CAG)n \n\nsimple correlation with IGFBP-1 serum levels. Values are given as means and error \n\nbars represent standard error (SEM); ** p &lt;0.01; ***p &lt;0.001. \n\n \n\n\n\n84 \n \n\nFigure 2: Correlation between Insulin homeostasis parameters with SCA3 age of \n\nonset. Age of Onset simple correlation with Insulin serum levels (A), sensitivity (B) - \n\nLog (HOMA2-%S) - and resistance (HOMA2-IR) index (C).** p &lt;0.01; ***p &lt;0.001 \n\n \n\n \n\nSupplementary Figure 1: The inverse correlation between IGF-1 serum levels and \n\nBasis Pons and Medulla Oblongata volumetries on MRI. Two patients with similar \n\nages, disease duration and CAG expanded repeats were chosen as an example. (A) \n\nand (C) represent a fifty two year old man, with nine years of disease duration and 72 \n\nCAG repeats on MJD gene. (B) and (D) represent a fifty one year old woman, with \n\nthirteen years of disease duration and 71 CAG repeats on MJD gene. Bars indicate \n\npercent difference between the individual and the mean study population values of \n\nIGF-1 serum levels and MRI brain stem volumes. \n\n\n\n85 \n \n\n \n\n Supplementary Figure 2: Total IGF-1 correlations with brain stem volumetries. IGF-\n\n1 serum levels simple correlation with (A) medulla oblongata and (B) basis of pons \n\nMRI volumetries.* p<0.05 \n\n  \n\n\n\n86 \n \n\nCap\u00edtulo 4 - Ataxia Rating Scales - Psychometric Profiles,  \n\nNatural History and Their Application in Clinical Trials.  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  \n\n  \n\n\n\n87 \n \n\nAtaxia rating scales \u2013 psychometric profiles, natural history and their \n\napplication in clinical trials \n\nJonas Alex Morales Saute\n1,2\n\n, Karina Carvalho Donis\n3\n, Carmen Serrano-Munuera\n\n4\n, \n\nDavid Genis\n5\n, Lu\u00eds Torres Ramirez\n\n6\n, Pilar Mazzetti\n\n6\n,  Luis Vel\u00e1zquez P\u00e9rez\n\n7\n, Pilar \n\nLatorre\n8\n,  Antoni Matilla-Due\u00f1as\n\n8,9\n, Jorge Sequeiros\n\n10\n, Laura Bannach Jardim\n\n1,2,3,11\n*, \n\non behalf of the Iberoamerican multidisciplinary network for the study of movement \n\ndisorders (RIBERMOV) study group. \n\n1 - Neurology Service, Hospital de Cl\u00ednicas de Porto Alegre, Rua Ramiro Barcelos \n\n2350, 90.035-903 Porto Alegre, Brazil; 2 - Postgraduate Program in Medical \n\nSciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil; 3 - \n\nMedical Genetics Service, Hospital de Cl\u00ednicas de Porto Alegre, Rua Ramiro \n\nBarcelos 2350, 90.035-903 Porto Alegre, Brazil; 4 \u2013 Department of Internal Medicine, \n\nHospital Sant Joan de D\u00e9u de Martorell, Barcelona, Spain; 5 - Neurodegenerative \n\nDisease Unit, Dr Josep Trueta University Hospital, Girona, Spain; 6 \u2013 National \n\nInstitute for the Neurological Sciences Julio Oscar Trelles Montes, Lima, Peru; 7 - \n\nCenter for Research and Rehabilitation of Hereditary Ataxias ?Carlos Juan Finlay? \n\n(CIRAH), Holgu\u00edn, Cuba; 8 - Department of Neurosciences and Neurology Service, \n\nHealth Sciences Research Institute and Hospital Germans Trias I Pujol, Universitat \n\nAut\u00f2noma de Barcelona, Badalona, Spain; 9 \u2013 Basic, Translational and Molecular \n\nNeurogenetics Research Unit, Health Sciences Research Institute Germans Trias i \n\nPujol (IGTP), Universitat Aut\u00f2noma de Barcelona, Ctra. de Can Ruti, Cam\u00ed de les \n\nescoles s/n, 08916 Badalona, Barcelona, Spain; 10 - IBMC - Institute for Molecular \n\nand Cell Biology, and ICBAS; Universidade do Porto, Porto, Portugal; 11 - \n\nDepartment of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto \n\nAlegre, Brazil \n\n\n\n88 \n \n\n \n\n* Corresponding author: \n\nLaura Bannach Jardim \n\nMedical Genetics Service, Hospital de Cl\u00ednicas de Porto Alegre, \n\nRua Ramiro Barcelos 2350, \n\n90.035-903 Porto Alegre, Brazil \n\ne-mail: ljardim@hcpa.ufrgs.br  \n\n \n\nConflict of Interest: All authors declare no conflicts of interest.  \n\n\n\n89 \n \n\nAbstract \n\nWe aimed to perform a comprehensive systematic review of the existing ataxia \n\nscales. We described the disorders for which the instruments have been validated \n\nand used, the time spent in its application, its validated psychometric properties, and \n\ntheir use in studies of natural history and clinical trials. Methods: a search from 1997 \n\nonwards was performed in the MEDLINE, LILACS and Cochrane databases. The \n\nwebsites ClinicalTrials.gov and Orpha.net were also used to identify the endpoints \n\nused in ongoing randomized clinical trials. Results: we identified and described the \n\nsemi-quantitative ataxia scales (ICARS, SARA, MICARS, BARS); semi-quantitative \n\nataxia and non-ataxia scales (UMSARS, FARS, NESSCA); a semi-quantitative non-\n\nataxia scale (INAS); quantitative ataxia scales (CATSYS 2000, AFCS, CCFS and \n\nCCFSw, and SCAFI); and the self-performed ataxia scale FAIS. Discussion: SARA \n\nand ICARS were the best studied and validated so far, and their reliability sustain \n\ntheir use. Ataxia and non-ataxia scores will probably provide a better view of the \n\noverall disability in long-term trials and studies of natural history. Up to now, no clear \n\nadvantage has been disclosed for any of them; however, we recommend the use of \n\nspecific measurements of gait, since gait ataxia is the first significant manifestation in \n\nthe majority of ataxia disorders and comment on the best scales to be used in \n\nspecific ataxia forms. Quantitative ataxia scales will be needed to speed up evidence \n\nfrom phase-II clinical trials, from trials focused on the early phase of diseases, and \n\nfor secondary endpoints in phase-III trials. Finally, it is worth remembering that \n\nestimation of the actual minimal clinically relevant difference is still lacking;  this, \n\ntogether with changes in quality of life, will probably be the main endpoints to \n\nmeasure in future therapeutic studies. \n\n \n\n\n\n90 \n \n\nKeywords: ataxia scales, ICARS, SARA, MICARS, BARS, UMSARS, FARS, \n\nNESSCA, INAS, CATSYS, ACFS, CCFS, SCAFI, FAIS, hereditary ataxias.\n\n\n\n91 \n \n\n1. INTRODUCTION \n\nOriginally a Greek word, meaning ?confusion? or ?absence of order?, ataxia signifies \n\nmotor incoordination. Ataxias are a very heterogeneous group of diseases with \n\ndifferent etiology, including genetic and non-genetic forms [1].\n \nSince the 19th century, \n\nwhen Pierre Marie suggested a clinical differentiation between Friedreich and other \n\nforms of hereditary ataxia, it has been clear that they affect multiple neurological \n\nsubsystems, presenting also non-ataxia features such as pyramidal and \n\nextrapyramidal signs and peripheral findings, among others [2].\n \n \n\nThere are many reasons for the lack of treatment for cerebellar ataxia, one of them \n\nbeing its relatively low population frequency; others include: the still recent discovery \n\nof some causal mutations; our incomplete knowledge about its pathogenic \n\nmechanisms; and the relatively new development of standardized, well-validated \n\nscales to understand better its natural history and evaluate properly drug efficacy in \n\nclinical trials. Therefore, most ataxic disorders (sporadic or inherited) still have no \n\ncurrent effective pharmacological treatment, and patients endure the inevitable \n\ndegenerative course of their disease. \n\nWe performed a comprehensive, systematic review of classical and more recently \n\ndeveloped ataxia scales. Topics such as the disorders for which each instrument was \n\nvalidated and used, time spent in its application, and the validated psychometric \n\nproperties are discussed. The use of these scales, in particular for natural history \n\nstudies and clinical trials, is described. This review also aims at standardizing the \n\ntools used in studies of natural history, biomarkers, disease modifiers and clinical \n\ntrials, and will be further developed within the Iberoamerican multidisciplinary network \n\nfor the study of movement disorders (RIBERMOV; www.ribermov.org). \n\n\n\n92 \n \n\n2. METHODS \n\nCriteria for including studies in this review \n\nWe intended to include all studies describing and validating ataxia-rating scales or \n\nscores for inherited or sporadic cerebellar ataxia (excluding multiple sclerosis); \n\nstudies evaluating the natural history of an ataxic disorder with one of these scales; \n\nand randomized, placebo-controlled clinical trials using these ataxia scales to \n\nmeasure its clinical endpoints. \n\nSearch methods \n\nTwo investigators (JAMS, KCD) independently performed a search in the MEDLINE, \n\nLILACS and Cochrane databases, and checked also the list of references in relevant \n\npapers, without restriction to language or publication status. The search terms were \n\n?ataxia score? or ?ataxia scale?. After finding an ataxia scale, we searched again \n\nthose databases with its name. In order to determine which scales were used to \n\nmeasure endpoints in randomized clinical trials for ataxias, we also searched for the \n\nterms ?treatment? and ?spinocerebellar ataxia? (also ?SCA?) or autosomal dominant \n\ncerebellar ataxia? (ADCA) or ?Friedreich ataxia? (?FRDA?), or ?Multiple System \n\nAtrophy? (?MSA?) or ?Fragile X-associated tremor/ataxia syndrome? (?FXTAS?). We \n\nlimited the research to 1997 onwards, as this was the year of publication of the first \n\nscale in use, ICARS. We also searched the website ClinicalTrials.gov \n\n(http://clinicaltrials.gov/) and the clinical trials section of the website Orphanet \n\n(http://www.orpha.net) with the term ?ataxia treatment?, in order to find the scores \n\nbeing utilized in ongoing clinical trials. The most recent search was performed during \n\nJuly 2011. \n\nStudy organization \n\n\n\n93 \n \n\nScales were ordered and organized according to their purpose and characteristics, \n\ninto the following groups: (1) semi-quantitative ataxia scales; (2) semi-quantitative \n\nataxia and non-ataxia scales; (3) semi-quantitative non-ataxia scales; (4) quantitative \n\nataxia scales; and (5) self-performed ataxia scales. For each of these groups, scales \n\nwere described according to the year of publication.   \n\nSensitivity to change \n\nIn order to standardize the indices of sensitivity to change in the scores, when \n\navailable, we provided the Cohen\u2018s Effect Size (ES) or the Standardized Response \n\nMean (SRM). Values of 0.20, 0.50, and 0.80 were considered to represent a small, \n\nmoderate, and large change, respectively, for both indices. When not explicit, but \n\ndata were available, we applied the following formulas: (1) mean score change / \n\nstandard deviation (SD) of score at baseline (for ES); and (2) mean score change / \n\nSD of score change (for SRM). \n\n3. RESULTS \n\nTable 1 summarizes the information regarding validation, time needed for application, \n\nstudies of natural history, sensitivity to change and clinical trials performed with each \n\nataxia scale. If studies of natural history or clinical trials using a given scale are \n\nlacking, this information was also pointed out in Table 1. Details are presented below.  \n\n3.1 Semi-quantitative ataxia scales \n\nICARS \u2013 International Cooperative Ataxia Rating Scale [3] \n\na) Scale description \n\nThe ICARS is a semi-quantitative 100-point scale, consisting of 19 items, divided into \n\nfour unequally weighted sub-scores: posture and gait disturbance (7 items; 34 \n\n\n\n94 \n \n\npoints); limb kinetic function (7 items; 52 points); speech disorder (2 items; 8 points); \n\nand oculomotor disorder (3 items; 6 points). The higher the score, the worse is the \n\npatient\u2018s performance [3]. \n\nb) Validation \n\nInternal consistency of the ICARS\u2018 items was first studied in MSA with a high \n\nCronbach\u2018s ? of 0.93 [4]. In 2004, a study evaluating patients with SCA (SCA1 and \n\nSCA2) and Friedreich ataxia found that the inter-rater correlation for the total ICARS \n\nscore (Kendall\u00b4s ?) was 0.99, being the lowest in the speech subscale 0.79 and the \n\nhighest 0.99 for the posture/gait subscales [5]. \n\nSpinocerebellar ataxias. In a large European multicentric study, 156 SCA patients \n\n(SCA1, SCA2, SCA3/MJD - Machado-Joseph disease, SCA6, SCA7 and SCA14) \n\nwere evaluated with ICARS [6]. High inter-rater reliability with an intraclass \n\ncorrelation coefficient (ICC) of 0.95 and high test-retest reliability (ICC of 0.97) were \n\ndepicted. The authors found that some items of posture and gait disturbances were \n\noverlapping and interdependent. If the patient scores between 4 and 8 points i n item \n\n1(gait), he/she would automatically score the maximum in item 2 (gait speed). Items \n\n3 (standing capacities, ranging 0 to 6), 4 (spread of feet, 0 to 4), 5 (body sway with \n\neyes open, 0 to 4) and 6 (body sway with eyes closed, 0 to 4) were also clearly \n\ninterdependent (e.g., oscillating with eyes open, determined oscillating also with eyes \n\nclosed). Factorial analysis showed that four factors determine 70% of the total \n\nvariance. These factors, however, were not coincident with the ICARS subscales, \n\nexcept for the oculomotor one. Significant correlations of ICARS with the Barthel \n\nindex (r=-0.70) and disease duration (r=0.43) were also identified. In another study, \n\n52 SCA3/MJD patients were evaluated by ICARS. Internal consistency for the total \n\n\n\n95 \n \n\nscore showed a Cronbach\u2018s ? of 0.94. The ICARS correlated with both disease \n\nduration (r=0.54) and the number of CAGs in the expanded allele (r=0.35) [7].  \n\nFriedreich ataxia (FRDA).  For FRDA, 96 patients were assessed with ICARS, FARS \n\nand SARA [8]. The internal consistency of ICARS measured by Cronbach\u2018s ? was \n\n0.69, when considering all four subscales, and 0.95, when considering the scale\u2018s \n\nsingle items. There was a strong direct correlation among all three scales, and all \n\nsignificantly correlated with disease duration (r=0.695, for ICARS) and activities of \n\ndaily living (ADL) (r=0.924, for ICARS). The principal component analysis yielded four \n\nfactors explaining the rates of ICARS. Only one factor loaded for a single subscale \n\n(oculomotor function), whereas all other factors were not correlated with any specific \n\nsubscale. Another study assessed 76 patients with FRDA with both ICARS and \n\nFARS, finding a significant correlation between both scales, as well as with functional \n\nindex and disease duration [9]. \n\nc) Natural history \n\nSpinocerebellar ataxias. Thirty-four SCA3/MJD patients were followed for an average \n\nof 13.3 months, depicting a mean deterioration of 5.1/100 points in ICARS, varying \n\nfrom 37.6 \u00b119.2 to 42.7 \u00b118.6. There was no correlation of variation in ICARS with \n\nage of onset , (CAG)n or disease duration [10]. No index of sensitivity to change was \n\nreported, but an ES of 0.26 could be estimated for the study period with the data \n\npresented. There was no reference for Minimally Important Difference (MID) for \n\nICARS in SCAs. \n\nFriedreich ataxia. A study evaluated 43 FRDA patients with both ICARS and FARS, \n\nin a 12-month period; the mean worsening in ICARS was 5/100 (SD 6.8); ES was \n\n0.26. Using the data reported we could also calculate an SRM of 0.73. There was no \n\n\n\n96 \n \n\nattempt in this study to define MID for ICARS, and the authors stated that ?even a \n\nsmall benefit from a therapeutic intervention is likely to be clinically relevant? [9]. \n\nConsidering the placebo groups of clinical trials, there was either no worsening [11], \n\nor even an improvement of 1.3/100 points [12], after 6 months of observation (both \n\nstudies evaluated idebenone efficacy in FRDA). A change from a baseline of 2.5 and \n\n5 points on ICARS, in 6 and 12 months, respectively, was considered clinically \n\nmeaningful in this trial [12]. \n\nd) Clinical trials \n\nAt least 13 trials used ICARS, as the neurological endpoint. Among them, there were \n\ntwo studies on miscellaneous cerebellar disorders: a double--blinded, randomized \n\nclinical trial, designed to evaluate the efficacy of riluzole in different sporadic (MSA, \n\nmultiple sclerosis, paraneoplastic) and inherited ataxias (SCA1, SCA2, SCA28, \n\nFRDA, FXATS ) [13]; and a trial on ondansetron in patients with cerebellar cortical \n\natrophy, MSA, familial cerebellar degeneration and miscellaneous cerebellar \n\ndisorders [14].  \n\nSpinocerebellar ataxias. Four randomized clinical trials utilized ICARS as the \n\nneurological endpoint in patients with SCAs: a crossover trial for the treatment with \n\nbranched-chain amino acids, including patients with SCA6 and SCA7 [15]; and two \n\ntrials evaluating buspirone, in patients with ?olivopontocerebellar atrophy? [16] and in \n\npatients with other SCAs and FRDA [17]. None of them showed significant \n\ndifferences from placebo. On ClinicalTrials.gov one study evaluating lithium in SCA1 \n\n(NCT00683943) also used ICARS to measure outcome. \n\nFriedreich ataxia. Five randomized clinical trials testing antioxidants used ICARS as \n\nthe neurological endpoint [11,12,18,19,20]. In one, in a pre-specified analysis, there \n\n\n\n97 \n \n\nwas a significant improvement on ICARS, but no difference in FARS, after 6 months \n\nof idebenone [11]. On ClinicalTrials.gov, two trials are using ICARS in FRDA: one \n\ntests epoetin alfa (NCT00631202) and another study evaluates pioglitazone \n\n(NCT00811681).  \n\nSARA \u2013 Scale for the Assessment and Rating of Ataxia [21] \n\na) Scale description \n\nSARA has eight items, yielding a total score of 0 (no ataxia) to 40 (most severe \n\nataxia) [21]:  gait (score 0 to 8), stance (0 to 6), sitting (0 to 4), speech disturbance (0 \n\nto 6), finger chase (0 to 4), nose-finger test (0 to 4), fast alternating hand movements \n\n(0 to 4) and heel-shin slide (0 to 4). Limb kinetic functions (items 5 to 8) are rated \n\nindependently for both body sides, and its arithmetic mean is included in the total \n\nscore. \n\nb) Validation \n\nSpinocerebellar ataxia. SARA internal consistency was first studied in patients with \n\nseveral SCAs, within a European multicentric collaborative study [21]. The inter-rater \n\nreliability was very high, with an ICC of 0.98. All single items had good inter-rater \n\nreliability, with ICC >0.80 with the exception of left hand nose-finger test (ICC=0.76) \n\nand left Heel-shin slide (ICC=0.74) Test-retest reliability had an ICC of 0.90. Internal \n\nconsistency was also high, with a Cronbach\u2018s ? of 0.94. SARA score increased with \n\ndisease stage (p&lt;0.001) and was closely correlated with the Barthel index (r=0.80) \n\nand part IV (functional assessment) of the Unified Huntington\u2018s Disease Rating Scale \n\n(UHDRS-IV) (r=0.89), whereas it had only a weak correlation with disease duration \n\n(r=0.34). Linearity of SARA was assessed through a regression analysis, with a \n\n\n\n98 \n \n\nglobal assessment visual analogue scale (VAS). SARA ratings fitted a linear model \n\n(r\n2\n=0.98, p<0.0001). \n\nFriedreich ataxia. A study of 96 patients with FRDA showed an ICC of 0.99 [8]. The \n\ninternal consistency for the eight items was 0.89. All SARA items showed high \n\nconstruct validity. SARA was correlated with ICARS (r=0.953) and FARS (r=0.938) \n\ntotal scores. SARA\u2018s total score correlated with disease duration (r=0.712) and with \n\nthe activities of daily living (r=0.929). The principal component analysis yielded one \n\nsingle factor for SARA results.  \n\nAs RIBERMOV is an Iberoamerican initiative, it is worth mentioning that SARA was \n\ntranslated and validated into Brazilian Portuguese [22]. It was applied to 30 patients \n\nwith SCA2, SCA3/MJD, SCA6, Friedreich ataxia and ataxia with unknown etiology, \n\nwith a Cronbach\u2018s ? of 0.94. There was no significant correlation between SARA and \n\nICARS score in that sample (r=0.33; p<0.07).  \n\nSporadic ataxias. A study tested SARA reliability and validity in 64 patients with \n\ndifferent sporadic ataxia disorders or non-progressing cerebellar lesions. Inter and \n\nintra-rater reliability had an ICC of 0.98 and 0.99 [23]. Most single items had a good \n\ninter-rater and test-retest reliability, with ICCs above 0.80. Internal consistency was \n\nalso high, with a Cronbach\u2018s ? of 0.97. Score increased with disease stage, and was \n\nclosely correlated with Barthel index (r=0.63) and UHDRS-IV (r=0.62), but only \n\nweakly with disease duration (r=0.44). \n\nc) Natural history  \n\nSpinocerebellar ataxias. For one year, 171 patients with SCAs (SCA1, SCA2, \n\nSCA3/MJD, SCA6), were followed ; the mean annual score change was 1.38/40, with \n\na standard deviation of 2.8 [24]. The authors considered SRM to be more adequate \n\n\n\n99 \n \n\nto their sample than ES, with an overall SRM of 0.5. When progression of the \n\ndisease according to patient\u2018s global impression (PGI) was considered, there was an \n\nannual score change of 1.69/40 \u00b1 2.9 points (1.17 to 2.20), if PGI was worse (n=120), \n\nwith an SRM of 0.59; and 0.43/40 \u00b1 2.1 points (-0.21 to 1.07), if PGI was stable \n\n(n=43), with an SRM of 0.21. SARA was also able to correctly classify cases with \n\nsubjectively relevant worsening, based on PGI, therefore showing responsiveness. \n\nAnother recent study evaluated 133 patients with different SCAs, and found that \n\nSARA worsened 1/40 \u00b1 2.4 points, after 12 months [25]. The authors described an \n\nES of less than 0.2 and a SRM of 0.41. Although discussed, none of the studies tried \n\nto define the MID of SARA in SCAs. \n\nd) Clinical trials \n\nA single-blinded, placebo-controlled, pilot study compared the efficacy of pregabalin \n\non cerebellar signs caused by cortical cerebellar atrophy, evaluating the cerebellar \n\nfunction with the SARA [26]. On Clinicaltrials.gov, eight trials are underway using \n\nSARA, for the evaluation of lithium carbonate in SCA1 (NCT00683943), SCA2 \n\n(NCT00998634) and SCA3/MJD (NCT01096082); sodium phenylbutyrate \n\n(NCT01096095) in SCA3/MJD; varenicline (NCT00992771) in SCA3/MJD; \n\ncarbamylated erythropoietin in FRDA (NCT01016366), riluzole in hereditary ataxias \n\n(NCT01104649) and KPS-0373 (mimetic of TRH action) in spinocerebellar \n\ndegeneration (NCT01384435). \n\nMICARS \u2013 Modified International Cooperative Ataxia Rating Scale [27] \n\na) Scale description \n\n\n\n100 \n \n\nThe 120-point MICARS was developed by adding seven additional tests to the \n\nICARS: in kinetic function (decomposition of leg movement,; decomposition of leg \n\ntapping; rebound of the arms; and overshoot of the arms; each 0 to 2 points, and \n\nscored for both left and right); speech disorders (dysarthria alternating syllable, 0 to 2 \n\npoints); and oculomotor function (abnormal eye movements at rest, 0 or 1 point). The \n\nhigher the score, the worse is the ataxic syndrome [27]. \n\nb) Validation \n\nMICARS was applied to 91 patients with different sporadic and inherited cerebellar \n\ndisorders. There was a strong correlation of MICARS with ICARS; the Cronbach\u00b4s ? \n\nof MICARS varied from 0.80 to 0.86. The inter-rater reliability of MICARS was 0.93 \n\n[27]. \n\nBARS ? Brief Ataxia Rating Scale [27] \n\na) Scale description \n\nBARS is a shorter modified form of ICARS (MICARS) [27], consisting of five subsets \n\nthat evaluate walking capacity (0 to 8 points), heel-to-shin test for decomposition of \n\nmovement (0 to 4, scored left and right), finger-to-nose test for decomposition and \n\ndysmetria (0 to 4 points scored left and right), dysarthria (0 to 4), and anomalies of \n\nocular pursuit (0 to 2), with a total score of 30 points (most severe ataxia).  \n\nb) Validation \n\nThis scale was constructed and applied together with MICARS  [27]. Cronbach\u2018s ? for \n\nBARS was 0.90 and inter-rater reliability (intraclass correlation coefficient) was 0.91. \n\n3.2 Semi-quantitative ataxia and non-ataxia scales \n\n\n\n101 \n \n\nUMSARS ? Unified Multiple System Atrophy Rating Scale [28] \n\na) Scale description \n\nUMSARS is a semi-quantitative multidimensional rating scale developed for patients \n\nwith MSA. It was based on well-established scales utilized in Parkinson disease, the \n\nHoehn and Yahr Scale (H&amp;Y) and the Schwab and England Scales [29], on the \n\nICARS and on the Composite Autonomic Symptom Scale (COMPASS) [28]. \n\nUMSARS comprises four parts, including a historical review of disease-related \n\nimpairments (Part I, 12 items), motor examination (Part II, 14 items), autonomic \n\nexamination (Part III), and global disability scale (Part IV). A single score, from 0 (no \n\nimpairment) to 4 (severe impairment), was generated for each item. The maximum \n\n(worst) scores are 48 for UMSARS-I, 56 for UMSARS-II, and 5 for UMSARS-IV. \n\nUMSARS-III is mainly descriptive. \n\nb) Validation \n\nUMSARS was first validated in patients with cerebellar and Parkinsonian MSA \n\nsubtypes [28]. The Cronbach\u2018s ? coefficient of UMSARS-I and UMSARS- II was 0.84 \n\nand 0.90, respectively. The overall inter-rater reliability (k) was at least substantial \n\n(0.6\u20130.8) or excellent (>0.8) for all UMSARS-I items, except for orthostatic \n\nhypotension. The overall analysis showed substantial or excellent inter-rater \n\nagreement for the majority of UMSARS-II items; however ocular motor dysfunction, \n\nincreased tone, rapid alternating movements of hands and fingertapping showed only \n\nmoderate inter-rater agreement. There was a strong and significant correlation of \n\nUMSARS with H&amp;Y, Schwab and England Scale, and ICARS. UMSARS also \n\ncorrelated moderately with timed-walking tests. Items of UMSARS-III related to \n\n\n\n102 \n \n\nautonomic examination did not correlate with UMSARS I, II and IV, nor with other \n\nmeasures of global disability.  \n\nSpinocerebellar ataxia. UMSARS was evaluated in 52 SCA3/MJD patients showing a \n\nhigh internal consistency (Cronbach\u00b4s ? of 0.91 for UMSARS I and 0.93 for UMSARS \n\nII). There was strong correlation between the ICARS and UMSARS-II [7]. \n\nc) Natural history \n\nMultiple system atrophy. In 2005, the EMSA study group published the first natural \n\nhistory study on MSA, using UMSARS, and showed a significant worsening of 4.2/48, \n\n6.6/56, and 0.4/5 points in UMSARS I, II and IV, respectively, after a mean follow-up \n\nof 6.4 months [30]. The study continuation reported a mean worsening of 6.7/48 \n\n(+35.6%), 9.6/56 (+57.3%) and 0.8/5 points (+33.3% relative to baseline) in UMSARS \n\nI, II and IV, respectively, after a mean of 12.3 months [31]. These values were \n\nconsidered as a parameter of sensitivity to change; however, none of the classical \n\nstandardized parameters were reported. From the data provided we could calculate \n\nan ES of 0.79, 1.12 and 0.72 for UMSARS I, II and IV. Patients without pyramidal \n\nsigns showed a faster progression in UMSARS I and II, while patients with cerebellar \n\nsigns showed a faster progression in UMSARS II. Fast progression of UMSARS II \n\nscores was also associated to mild baseline disability, according to UMSARS II, as \n\nwell as to short disease duration. Another study showed a mean worsening of 3.1/48 \n\n(UMSARS I) and 4.5/56 (UMSARS II), after 1 year [32]. The ES (estimated with the \n\npublished study data) was 0.43 and 0.64 for UMSARS I and II. None of the studies \n\ntried to define the MID of UMSARS for MSA. \n\nSpinocerebellar ataxias. After a mean follow-up of 13.3 months, the mean UMSARS-\n\nII score worsened 2.7/56 points in 32 SCA3/MJD patients, with no significant \n\ndifferences in UMSARS-I and IV during that period [7]. Neither an index of sensitivity \n\n\n\n103 \n \n\nto change nor any attempt to define MID were described; however, with the data \n\nprovided, we calculated an ES of 0.23 for UMSARS-II in SCA3/MJD patients during \n\nthis period. \n\nd) Clinical trials \n\nTwo randomized clinical trials on MSA, one evaluating minocycline [33], and the \n\nother evaluating r-hGH [34], used UMSARS or UMSARS-II scores as neurological \n\nendpoints. \n\nFARS \u2013 Friedreich Ataxia Rating Scale [35] \n\na) Scale description \n\nThe Friedreich Ataxia Rating Score (FARS) was developed in 2005, from a larger \n\nscale devised by the Cooperative Ataxia Group, to evaluate functional and \n\nneurological deficits, with a greater weight given to gait and stance [35]. The scale is \n\nascending in severity (0 meaning normal examination), and has four domains: I - \n\nfunctional staging (0 to 6, overall mobility); II - ADL (0 to 36); III - neurological \n\nassessment of bulbar, upper and lower limbs, peripheral nerve, and upright \n\nstability/gait functions (maximum scores of 11, 36, 16, 26, and 28; total  of 117); and \n\nIV - quantitative timed activities: PATA rate, 9-hole pegboard (9-HPT) and timed 25-\n\nfoot walk (T25FW), which will be detailed in the quantitative scales section.  \n\nb) Validation \n\nThe first study evaluating the psychometric properties of FARS assessed only 14 \n\nFRDA patients. ICC was 0.95 for the total neurological score; ICC was also high for \n\nall partial scores, except for the bulbar (0.29) and the peripheral nerves items (0.74) \n\n\n\n104 \n \n\n[35]. A larger study, published the following year, evaluated 155 FRDA patients and \n\nfound a significant correlation between the functional and ADL component of FARS \n\nwith disease duration; the FARS score was predicted by (GAA)n length [36]. They \n\nalso found a significant correlation of FARS to the Physical Component Summary \n\n(PCS) of the quality of life questionnaire SF-36. In another study, ninety-six FRDA \n\npatients were assessed with FARS (Part III), ICARS and SARA [8]. Cronbach\u2018s ? \n\nwas 0.86 for the five subscales and 0.97 for raw data. There was a strong direct \n\ncorrelation among the three scales, and all significantly correlated with disease \n\nduration (r=0.695) and ADL (r=0.918). Principal component analysis yielded five \n\ndifferent factors, of which only factor 4 loaded for a specific subscale (bulbar \n\nfunction). Another study assessed 76 patients with FRDA with ICARS and FARS and \n\nfound a significant correlation between them, as well as with functional indexes and \n\ndisease duration [9]. \n\nc) Natural history \n\nA study evaluated 43 FRDA patients with ICARS and FARS, during a 12-month \n\nperiod, finding a mean worsening of 9.5/159 points (SD 9.1), with an effect size of \n\n0.34 [9]. Using the data provided, we could calculate an SRM of 1.04. Any significant \n\ndifferences were considered as the MID by the authors. Another group reported \n\nprogression in the scores of 168 patients, after 12 and 24 months [37]. Mean change \n\nin FARS and E-FARS (sum of the FARS I, II and III scores) was 3.55/125 \n\n(SRM=0.53) and 5.5/167 (SRM=0.63), after one year, and 6.16/125 (SRM=0.84) and \n\n8.93/167 (SRM=1.00), after two years. In this study, women (SRM=1.02) progressed \n\nsignificantly faster than men (SRM=0.62), after two years. Finally, in placebo groups \n\nof randomized clinical trials, a non-significant deterioration of about 0.6/117 points \n\n[12], or no change at all [11], were reported after 6 months. \n\nd) Clinical trials \n\n\n\n105 \n \n\nTwo randomized-controlled clinical trials (idebenone) used FARS [11,12]. None \n\nfound a significant change with the intervention. On ClinicalTrials.gov one trial \n\nevaluating varenicline utilized FARS as the primary efficacy outcome but was early \n\nterminated (NCT00803868). A study evaluating carbamylated erythropoietin \n\n(NCT01016366) and another evaluating alpha-tocopherolquinone (A0001) \n\n(NCT01035671) also used FARS to measure the endpoint.  \n\nNESSCA \u2013 Neurological Examination Score for the Assessment of \n\nSpinocerebellar Ataxia [38] \n\na) Scale description \n\nNESSCA was developed in 2001 and published in 2008. It is a semi-quantitative 40-\n\npoint scale, covering 18 different items, higher scores indicating worse performance \n\n[38,39]; 14items correspond to parts of a standard neurological examination (gait \n\nataxia, limb ataxia, presence and characteristics of nystagmus, oculomotor deficit, \n\npyramidal findings, dysarthria, distal amyotrophy, fasciculations, sensory loss, \n\ndystonia, rigidity, bradykinesia, eyelid retraction and blepharospasm); and four items \n\nrely on patient information (dysphagia, sphincter function, cramps and vertigo). \n\nPrincipal components analysis showed the 18 items loaded four distinct factors that \n\naccounted together for 52% of total variance (cerebellar and peripheral 24,56%; \n\nextrapyramidal 11,14%; pyramidal, speech and dysphagia 9,37%; vertigo, cramps \n\nand nystagmus 5,9%). \n\nb) Validation \n\nNESSCA was validated only in SCA3/MJD [38]. Cronbach\u2018s ? was 0.77 and inter-\n\nrater reliability (k) was 0.97. In a multidimensional scale like this one, internal \n\nconsistency is considered adequate when the Cronbach\u2018s ? varies from 0.7 to 0.9 [2]. \n\n\n\n106 \n \n\nThe scale significantly correlated with the following external variables: disease stage, \n\ndisease duration, number of CAGs, SARA and Barthel index. \n\nc) Natural history \n\nThe largest published cohort of SCA patients using a validated ataxia score was \n\nperformed with NESSCA: 105 SCA3/MJD patients were followed during a mean \n\nfollow-up of five years [39]. NESSCA scores produced a general growth curve that \n\ncovered at least 18 years of disease duration, with a mean 12-month deterioration of \n\n1.26/40 points. The number of CAG repeats and the age-at-onset of symptoms both \n\nmodify significantly progression of the disease by this scale. A one-year increase in \n\nthe age-of-onset produced a reduction in the growth curve slope of 0.03 points, \n\nshowing improvement in the prognosis, whereas an increase in one CAG repeat was \n\nrelated to an increase by 0.15 points , indicating a poorer prognosis. In other words, \n\nthe larger the (CAG)n and the earlier the disease onset, the faster the disease \n\nprogressed [39]. We could calculate an ES of 0.22 per 12 months. There was no \n\ndefinition of MID in this study. \n\nd) Clinical trials \n\nNo published trial used this scale. On ClinicalTrials.gov, two trials, evaluating lithium \n\ncarbonate (NCT01096082) and sodium phenylbutyrate (NCT01096095), in \n\nSCA3/MJD patients are underway using NESSCA to measure outcome. \n\n3.3 Semi-quantitative non-ataxia scales \n\nINAS ? Inventory of Non-Ataxia Symptoms [40] \n\na) Scale description \n\n\n\n107 \n \n\nThe Inventory of Non-Ataxia Symptoms (INAS) was developed for the extracerebellar \n\nfeatures of ataxias and consists of 30 items, each related to one of 16 \n\nsymptoms/syndromes: areflexia, hyperreflexia, extensor plantar response, spasticity, \n\nparesis, amyotrophy, fasciculations, myoclonus, rigidity, chorea, dystonia, resting \n\ntremor, sensory symptoms, brainstem oculomotor signs (horizontal and vertical \n\nophthalmoparesis, slowing of saccades), urinary dysfunction, and cognitive \n\nimpairment [40]. INAS count thus ranges 0 to 16.  \n\nb) Validation \n\nA study evaluating 526 patients with SCA1, SCA2, SCA3/MJD and SCA6 found that \n\nINAS count correlated with disease duration in all SCAs, and with SARA in SCA1, \n\nSCA2 and SCA3/MJD [40]. In SCA2 and SCA3/MJD, the INAS count increased with \n\nrepeat length and decreased with age at onset. Retest reliability in a study in patients \n\nwith stable disease found a moderate ICC of 0.79 [24].  \n\nc) Natural history  \n\nThe follow up for one year of 171 patients with SCA showed a mean annual change \n\nof 0.37/16 in INAS (SRM=0.26). Considering only patients who reported worsening, \n\naccording to PGI, the annual score change was 0.46/16 \u00b1 1.4 (SRM=0.33), when PGI \n\nwas worse, and 0.26/16 \u00b1 1.5 (SRM=0.17), when the PGI was stable [24]. \n\n3.4 Quantitative performance ataxia scales \n\nThese scales are intended to reliably detect small clinical changes over short periods \n\nof time. Measures of performance give rise to continuous variables, which will \n\ntheoretically provide better sensitivity and responsiveness o the scale. Another \n\nadvantage is that results of the overall or composite scales have been presented as \n\nZ-scores, what allows an easier comparison across tests. Z-scores are a way of \n\n\n\n108 \n \n\nstandardizing results, indicating how many standard deviations an observation is \n\nabove or below the mean. They result in a dimensionless quantity, which is derived \n\nby subtracting the observed mean from an individual raw score and then dividing the \n\ndifference by the standard deviation.  \n\nCATSYS 2000 ? Coordination Ability and Tremor System [41] \n\na) Scale description \n\nDevelopment of CATSYS started in 1986, when searching for a new method to \n\nassess quickly brain damage caused by exposure to organic solvents. During the \n\nnineties, the CATSYS 7 became available for neurotoxicology and occupational \n\nmedicine, and in 2000 was replaced by Windows-based software, the CATSYS 2000. \n\nIt is a portable device, recording four measures of neuromotor control: tremor, \n\nreaction time, hand coordination and postural sway. Hand coordination is measured \n\nwith pronation-supination and finger-tapping movements, executed at constant and \n\naccelerated rhythms, in a recording drum, with the right and left hand, under standard \n\nconditions: (1) hand pronation-supination at a constant slow (1 Hz) and a constant \n\nfast (2.5 Hz) metronome beat; (2) hand pronation-supination at an accelerating \n\nrhythm (from 1.6 Hz to 7.5 Hz); (3) finger tapping at a constant slow (1 Hz) and a \n\nconstant fast (2.5 Hz) beat; and (4) finger tapping at an accelerating rhythm (from 1.6 \n\nHz to 8.1 Hz). Reaction time is assessed in both hands, using a handheld switch \n\nactivated by the thumb to a sound stimulus. Postural tremor is quantified in both \n\nhands over 24.6 sec., by asking the subjects to hold a light pen (Tremor\u00ae Pen), \n\nwhich contains a biaxial accelerometer, horizontally at 10cm in front of their navel, \n\nand free of body contact or any obstacles. Postural sway is tested by asking the \n\nsubject to stand on a force platform, feet 1cm apart and arms at their sides for 75 \n\nsec. Subjects are instructed to look at a picture placed around 2m in front of them, or \n\n\n\n109 \n \n\nto keep their eyes closed. These tasks were performed with or without a pad of \n\npolystyrene foam (2cm thick) under their feet.  Four conditions are thus measured: \n\n(1) eyes open; (2) eyes closed; (3) eyes open standing on a foam pad; and (4) eyes \n\nclosed standing on a foam pad. \n\nb) Validation \n\nCATSYS was validated in normal individuals free of neurological deficits evaluating \n\nthe effect of age and gender on the different tasks [41]. \n\nFragile X-associated tremor and ataxia syndrome (FXTAS). A study of 16 patients \n\nwith FXTAS, 16 premutation carriers and 14 healthy controls was performed with \n\nCATSYS, together with an adapted intention tremor score performed with the \n\nTremor\u00ae Pen [42]. A 30sec postural sway test with eyes open and closed showed \n\ndifferences between those with FXTAS and both controls and premutation carriers \n\n(p=0.0004 - discriminant validity). Up to six FXTAS subjects could not complete the \n\nvarious sway tasks. The manual coordination measures (pronation-supination, hand-\n\ntapping and index finger-tapping) and the reaction time measure were not different \n\namong groups. Within the intention tremor measure, FXTAS patients exhibited a \n\nsignificant difference in the non-dominant (p=0.02) and dominant hand (p=0.0008) \n\nwhen compared to both controls. The authors established statistical criteria to define \n\nataxia in the postural sway test and postural tremor with the Tremor\u00ae Pen. There \n\nwas 70% concordance of self-reported ataxia and 80% for tremor with CATSYS; \n\nhowever, 30% and 23% who did not report ataxia or tremor, respectively, were \n\n?positive\u2018 with the CATSYS criteria [43]. Another recent study using this scale, to \n\nscreen for FXTAS symptoms, found that almost all subjects had tremor and/or ataxia \n\naccording to CATSYS (45/47), but only about 2/3 were aware of symptoms. The \n\nneurological exam performed by a movement disorders specialist detected tremor \n\n\n\n110 \n \n\nand/or ataxia in all but one of the ?CATSYS-positive\u2018 subjects, thus showing the high \n\nsensitivity of this scale [44]. \n\nNo study evaluated CATSYS 2000 in SCAs, MSA or FRDA. \n\nFARS part IV, Z2 and Z3 ? Friedreich Ataxia Rating Scale [35, 36] \n\na) Scale description \n\nPart IV of FARS is composed by quantitative timed activities: the PATA rate, which is \n\nthe number of repetitions of the word ?PATA? in a 10sec interval, using a tape \n\nrecorder; the 9-hole Pegboard (9HPT), to test motor coordination; and gait \n\nassessment, using a timed walk of 50 - 25ft one way, turn and walk back, with or \n\nwithout a device (T25FW). In FARS, the 9HPT time was measured for completion \n\nand removal of all pegs for each hand separately. \n\nTwo composite scores were derived from FARS-IV: the Z2, which is the sum of Z-\n\nscores of 9HPT\n?1\n\n and the reciprocal of the timed 25 feet walk (T25FW\n?1\n\n); and the Z3, \n\nwhich adds Z2 to the Z-score of the low-contrast letter acuity vision test (LCLA). \n\nLCLA is calculated as the number of correct letters read, using both eyes, for three \n\ncharts: 100% contrast from a distance of 3.2m, and 1.25% and 2.5% contrast from a \n\ndistance of 2m. Each chart had a maximum score of 70 letters, with an overall total of \n\n210 letters [36, 37]. \n\nb) Validation \n\nThe psychometric properties of FARS-IV were first evaluated in 14 FRDA patients. \n\nTimed activities tested had high inter-rater reliability: ICC of 0.92 for PATA, 0.93 for \n\n9-HPT and T25FW. The correlation of individual timed measures with ADLs was \n\nmoderate (r varying from 0.50 to 0.66) [35]. A further study evaluating 155 FRDA \n\n\n\n111 \n \n\npatients found an ICC for the different tasks between trials from 0.93 to 0.99. In this \n\nstudy, 136/154 patients were able to perform the 9HPT and only 73/152 were able to \n\nperform the T25FW [36]. Both Z2 and Z3 scores correlated with ADL (r=-0.83, for \n\nboth), functional disability (r=-0.93 and r=-0.89,) and disease duration (r=-0.55 for \n\nboth), as well as with the Physical Component Summary of SF-36 scores (r=-0.41 \n\nand r=-0.36, respectively). \n\nc) Natural history \n\nA study evaluating disease progression in 168 FRDA patients found that the 9HPT\n?1\n\n \n\nmean- change after one year was of 0.00087\u00b10.002 (SRM=0.43) and \n\n?0.0016\u00b10.0024 (SRM=0.66), after two years; T25FW\n?1 \n\nchange -0.0094\u00b10.036 \n\n(SRM=0.26) after one year and -0.015 \u00b1 0.036 (SRM=0.41), after two years; LCLA \n\nchange 2.29\u00b111.9 (SRM=0.19), after one year; and 5.99\u00b116.2 (SRM=0.37), after two \n\nyears. PATA rate showed no change over time. Z2 change was -0.17\u00b10.45 \n\n(SRM=0.37), after one year and -0.32\u00b10.47 (SRM=0.68) after two years. Z3 change \n\nwas -0.23\u00b10.58 (SRM=0.39), after one year; and -0.48\u00b10.66 (SRM=0.72), after two \n\nyears. Changes in 9HPT\n?1\n\n appeared linear over time, as shown by proportional \n\nalterations in the mean at baseline and at years one and two. The same did not \n\nhappen with T25W\n?1\n\n, LCLA and PATA, suggesting either floor or ceiling effects [37]. \n\nIn the placebo group of a clinical trial there was no significant change of Z2 and Z3, \n\nafter 6 months of treatment [12].  \n\nd) Clinical Trials \n\nA clinical trial evaluating idebenone in FRDA used Z2 and Z3 scores as endpoints \n\n[12] \n\n\n\n112 \n \n\nACFS ? Ataxia Functional Composite Scale [45] \n\na) Scale description \n\nThe Ataxia Functional Composite Scale (ACFS) [45] is very similar to the composite \n\nscore Z3, being the sum of the Z-scores for 9HPT, Low Contrast Visual Acuity \n\n(LCVA) and T25W, divided by 3. LCVA, very similar to LCLA (Figure 2), is the \n\nnumber of correct letters read from four charts, with gray letters of progressively \n\nsmaller size, on a white background; each chart in the set corresponds to a different \n\nlevel of contrast, with a maximum score of 60 for each contrast level (100%, 5%, \n\n1.25% and 0.6%) [45]. \n\nb) Validation \n\nThe ACFS was evaluated in a clinical trial with 20 patients with hereditary ataxias (4 \n\neach with SCA2 and FRDA; 2 with SCA3; and one each with DRPLA, SCA6, and \n\nSCA17; 6 with idiopathic SCA; and one with expanded CAG repeat tracts both for in \n\nthe SCA1 and SCA2 genes), finding a strong correlation with ICARS. \n\nc) Natural history \n\nA clinical trial evaluating buspirone in the same population of the score validation, \n\nover 12 weeks, found no significant difference in ACFS from baseline to the final \n\nscore in the placebo group [17]. \n\nd) Clinical trials \n\nOne clinical trial evaluating buspirone used ACFS [17]. \n\nCCFS and CCFSw \u2013 Composite Cerebellar Functional Score [25, 46] \n\na) Scale description \n\n\n\n113 \n \n\nThe CCFS was intended as an objective quantitative test of general coordination, but \n\nended up to be a scale for upper limb ataxia [46]. Although the first version included \n\na walking distance measurement, the final, established CCSF consists of two tests \n\non the dominant side: the 9HPT and the click test (Figure 1). In CCFS, the 9HPT, \n\nmeasured in seconds, from the time first peg is placed in a hole to when the last peg \n\nis placed. The Click test uses a homemade device composed of two mechanical \n\ncounters fixed on a wooden board, 39 cm apart, where finger-pointing coordination is \n\nmeasured. Patients use their index finger to press the buttons on alternate counters, \n\nfor 10 times. The performance of controls on all tests was measured and a linear \n\nmodel fitted for differences between the dominant and non-dominant hands, and \n\nvalues were adjusted for age [46]. The Z-score was obtained by subtracting the \n\nexpected time (obtained in controls) from the time observed in the patient. Linear \n\nregression analysis showed that these two independent tests, the 9HPT and the click \n\ntest on the dominant side, accounted for the severity of the cerebellar syndrome, as \n\nreflected by the SARA scores. \n\nFinal CCFS is calculated as: \n\n10\n\nZ pegboard dominant hand Z click dominant hand\nCCFS log 7 4\n\n10 10\n\n? ?\n? ? ? ?? ?\n\n? ? , \n\nwhere Zpegboard D  equals Pegboard D - (13.4 - 0.16 x age + 0.002 x age\n2\n) and Zclick D = \n\nclick D \u2013 (8 + 0.05 x age). \n\nAs mentioned above, all values were adjusted for age and expressed as logs of Z-\n\nscores, the differences between the observed time and the expected time due to age. \n\nZ-scores of each test varied around 0 in the control group, and around 16-17 in the \n\nSCA group.  \n\n\n\n114 \n \n\nRecently, in order to improve CCFS responsiveness, the CCFSw score was created, \n\nwhich also includes the dominant hand-writing test. The patient is asked to write a \n\nstandard sentence (?ma\u00eetre corbeau sur un arbre perch\u00e9\u2018) (or Master Crow is perched \n\non a tree), with his dominant hand, as fast as possible, but legibly. CCFSw showed \n\nan estimated lower sample size for trials than CCFS in the standardized response \n\nmean (SRM) of the scores [25]. It is important to emphasize that in the description \n\nstudy of the CCFS score [46], the writing test was excluded from the score, because \n\nthe dominant hand 9HPT and click tests alone, independently accounted for the \n\nseverity of the cerebellar syndrome reflected by the SARA score. \n\nCCFSw is calculated as:  \n\n10\n\nZpegboard D Zclick D writing D\nCCFS log 7 4\n\n10 10 10\n\nZ? ?\n? ? ? ? ?? ?\n\n? ? , \n\nwhere ZwritingD = writing D \u2013 (8.5 + 0.05 x age).  \n\nb) Validation \n\nThe CCFS was studied in 141 patients with SCAs (SCA1, SCA2, SCA3/MJD, SCA6, \n\nSCA7, SCA14, SCA25, SCA28 and unknown SCA) and 53 patients with autosomal \n\ndominant spastic paraplegia (SPG4, SPG3, and unknown SPG) [46]; 31 patients \n\nwere not able to perform all the upper limb tests - 26 could not write, 11 could not use \n\nthe pegboard, seven could not perform the click test. All these were excluded from \n\nthe analysis. The CCFS was higher in SCAs than in dominant spastic paraplegias, \n\nand correlated with a visual analogue scale of the quality of life questionnaire EQ-5D, \n\nwith disease duration and with SARA. CCFS scores were lower in SCA3/MJD \n\npatients than in SCA1 and SCA2. Another study evaluated CCFS test-retest reliability \n\nin 14 healthy individuals, and found an ICC of 0.73 [25]. \n\n\n\n115 \n \n\nc) Natural history  \n\nThe 12-month natural history of CCFS was evaluated in 133 patients with different \n\nSCAs (SCA1, SCA2, SCA3/MJD, SCA5, SCA6, SCA7, SCA14, SCA21, SCA25, \n\nSCA28). During this period the score significantly worsened by 0.0197\u00b10.0614 points \n\n(ES<0.2, SRM=0.32), and the CCFSw score worsened by 0.0236\u00b10.0585 points \n\n(ES<0.2, SRM=0.40). Sample size estimates were best when only SCA1, 2 and 3 \n\npatients were considered [25]. MID was defined taken SARA as the standard, looking \n\nfor the minimal number of Z-scores of CCFS that would account for the severity of \n\nthe disease measured by SARA [46]. \n\nd) Clinical trials \n\nNo published trial used this scale. On ClinicalTrials.gov a study evaluating lithium \n\ncarbonate (NCT01096082) in SCA3/MJD patients is underway using CCFS to \n\nmeasure outcome. \n\nSCAFI ? SCA Functional Index [47] \n\na) Scale description \n\nSCAFI is composed of the 8m walking time (8MW) at maximum speed, the 9HPT \n\nperformed as in FARS IV and the PATA repetition rate [47]. The 8MW was defined \n\nas the time needed to walk 8m with any device, but without assistance by another \n\nperson or the walls; 8MW was measured from a standing start with feet behind the \n\nstart line (although the walking aid, if used, was allowed in front of that line). Stop \n\ncriteria were 180sec for 8MW and 300sec for 9HPT. All tests were perfomed twice \n\nresulting in a mean value   After appropriate transformation of the absolute values \n\ninto Z-scores, a functional composite (FC) is formed as the arithmetic mean of all \n\n\n\n116 \n \n\nthree Z-scores. Values are expressed as the arithmetic mean of all three Z-scores. \n\nSCAFI has no fixed range variation, but rather indicates how many standard \n\ndeviations an observation is above or below the mean. \n\nb) Validation \n\nSCAFI was applied in 412 clinically symptomatic patients with SCA; 63  subjects \n\nwere unable to perform one or more tests [47] and were excluded from the analysis. \n\nInternal consistency was indicated by a Cronbach\u2018s ? of 0.82 for all three tests, and \n\nof 0.72 when compared PATA*8MW and 0.80 to 8MW*9HPT. This showed a strong \n\nnegative linear correlation of SCAFI (r=-0.872) and the individual tests with SARA \n\n(PATA Z-score, r=-0.663; 9HPT Z-score, r=-0.817; and 8MW Z-score, r=-0.783). \n\nCorrelations with UHDRS-IV were similarly high and positive higher functional \n\nindependence was associated with better performance for all three functional \n\nmeasures (PATA Z-score. r=0.607; 9HPT Z-score, r=0.708; 8MW Z-score, r= 0.789; \n\nand SCAFI, r=0.814). \n\nc) Natural history  \n\nA one-year follow-up of 171 patients with SCAs [24] showed a mean change of Z-\n\nscores of -0.159\u00b10.33 in SCAFI (SRM=-0.48), -0.084\u00b10.59 in 8MW (SRM=-0.14), -\n\n0.0232\u00b10.35 in 9HPT (SRM=-0.67), and -0.160\u00b10.68 in PATA (SRM=-0.24). When \n\ncases with deterioration according to PGI were considered, the annual score change \n\nwas -0.172\u00b10.30 (-0.12 to -0.23) in SCAFI (SRM=-0.57), -0.115\u00b10.48 (-0.03 to -0.20) \n\nin 8MW (SRM=-0.24), -0.261\u00b10.35 (-0.20 to -0.32) in 9HPT (SRM=-0.74), and -\n\n0.140\u00b10.73 (-0.02 to -0.26) in PATA (SRM=-0.22), when PGI was towards worsening \n\n(n=120); and -0.193\u00b10.38 (-0.08 to -0.31) in SCAFI (SRM=-0.51), -0.114\u00b10.74 (-0.34 \n\nto 0.11) in 8MW (SRM=-0.15), -0.198\u00b10,35 (-0.09 to -0.30) in 9HPT (SRM=-0.57), \n\n\n\n117 \n \n\nand -0.268\u00b10.79 (-0.03 to -0.51) in PATA (SRM=-0.34), when the PGI was for \n\nstability (n=43). The sample size estimation by the standardized response mean \n\n(SRM) for a clinical trial was the lowest for 9HPT, followed by SARA and SCAFI, with \n\nonly a small SRM for PATA and a non-significant change for the 8MW. Although \n\ndiscussed, MID was not defined for SCAFI.  \n\nd) Clinical trials \n\nNo published trial used this scale. On ClinicalTrials.gov a study evaluating lithium \n\ncarbonate (NCT01096082) in SCA3/MJD patients is underway using SCAFI to \n\nmeasure outcome. \n\n3.5 Self-performed ataxia scales \n\nFAIS \u2013 Friedreich\u00b4s Ataxia Impact Scale [48] \n\na) Scale description \n\nFAIS is a patient-reported questionnaire [48], with eight subscales representing three \n\nclinical areas: symptoms (speech, body movement); physical functioning (upper limb, \n\nlower limb, complex tasks); and psychological and social impact (mood, self-\n\nperception, isolation); with a total of 126 items in its larger version. Three shorter \n\nsubscales were constructed: a 65-item version, for observational studies (??FAIS-\n\nOBS\u2018\u2018); a 63-item version, for studies of more disabled patients (??FAIS-MORE\u2018\u2018); and \n\na 63-item version for persons with less disability (??FAIS-LESS\u2018\u2018). The higher the \n\nscore, the worse the patient\u2018s symptoms [48] \n\nb) Validation \n\nFAIS was validated on a postal survey in 307 patients with FRDA. There is no study \n\ncorrelating FAIS or its subscales with any of the other ataxia rating scales [48]. \n\n\n\n118 \n \n\n4. DISCUSSION \n\nDesirable properties of a clinical scale for the ataxias \n\nAtaxia scales were mainly developed to express the burden of a known disease in a \n\ngiven patient, allowing for comparison with other patients with the same disorder. \n\nLike any other clinical scales, several properties, such as validity, reliability and \n\nsensitivity to change are essential, other desirable properties being linearity and \n\nbrevity. In addition, particularly in the case of multidimensional scales, division into \n\nreasonable sub-scales should be supported by factor analysis [49].  \n\nCategorical versus numerical scales  \n\nOne of the first issues to be discussed is whether any scale should be categorical or \n\nnumerical. The coexistence of both qualitative and quantitative classifications has \n\ngood reasons. Of course, the more finely we can measure something, the better; \n\nrating an attribute on a scale in which each point is equally spaced is vastly superior \n\nto dividing it into rougher categories. Functional ataxia scores do fulfill these \n\ncharacteristics; however, they cover only some signals of cerebellar dysfunction; and, \n\nfrequently, patients are unable to perform some of the tasks. By contrast, many of the \n\nataxia scales are categorical or semi-quantitative: their advantage is that they are \n\nbased on specific tests and maneuvers included in any proper neurological \n\nexamination. One way to overcome inconveniences of such scales is to avoid simple \n\ndichotomization (present/absent), as e.g. in the INAS count, as this will reduce all \n\npositive responses (strong, moderate or mild) to a single value, resulting in a loss of \n\ninformation and reliability, as well as sensitivity to change.  \n\nWeighting items and partial scores (subscales) \n\n\n\n119 \n \n\nSince most ataxia scores are categorical and composed of items of different clinical \n\nand individual relevance, another question is how to weight correctly different items \n\nin the whole scale. For example, should mild dysarthria with preserved intelligibility \n\nbe equated to mild gait ataxia? This has been little discussed. Most scales seemed to \n\nadopt a theoretical approach, based on expert opinion, and none presents empirical \n\ndata to estimate weighting of single items in the final score. As most ataxia scales \n\nshow high internal consistency among their various items, it is probable that an \n\nempirical approach for differential weighting would just add complexity for the scorer, \n\nwhile contributing little to improve scale properties [49]. \n\nFace and content validity \n\nWhereas face and content validity of semi-quantitative scales are generally good and \n\nreliable, for quantitative scales, these criteria are more difficult to prove, since most of \n\nthem are timed tasks. For instance, a delay in the 9HPT or 8MW performance may \n\nalso be explained by bradykinesia or dystonic movements, and do not necessarily \n\nrepresent upper limb or gait ataxia. For theses scores, we may only demonstrate \n\nvalidity of each criterion, when correlating them to classical semi-quantitative ataxia \n\nscales. \n\nBrevity and linearity \n\nAchieving all desirable properties in a single scale may be very difficult and not all of \n\nthese do necessarily need to be present. For instance, brevity may or may not be \n\ndesirable, since length can reduce errors of measurements, improving reliability. \n\nLinearity, i.e., if the trait severity is reliably represented by simple summing of the \n\nscores of individual items, should be demonstrated, in order to allow adequate \n\ninterpretation in future trials. This demands longitudinal observations, or may be \n\n\n\n120 \n \n\ninferred from cross-sectional studies through a strong correlation with a well-known \n\nlinear score, as is the case for SARA with a global assessment visual analogue scale \n\n[21]. In transversal observations performed during the construction of a scale, floor \n\nand ceiling effects, or skewness, are hints of non-linearity. Sometimes, linearity is just \n\na matter of interpretation of the results. For instance, in the application of NESSCA to \n\nthe natural history of SCA3/MJD, when each patient\u2018s follow-up was used to obtain a \n\ngrowth curve, a linear progression was obtained [39]. Different rates of change are \n\nsometimes related to the disease stage and may eliminate linearity from a given \n\nscale; however, if we can identify those individuals destined to have a faster \n\nprogression, we may help decreasing the sample size needed for therapeutic trials. \n\nFor example, FARS and its composite scores are most sensitive to change in FRDA \n\npatients under age 30 years [36]. \n\nReliability, validity, internal consistency and responsiveness \n\nReliability, validity and internal consistency are easier to validate, when constructing \n\na scale, than other properties. But, the biggest challenge is possibly to demonstrate \n\nsensitivity to significant changes.  \n\nAssessing disease progression is a topic of considerable divergence in literature [49]. \n\nIn order to allow comparing changes in different scores over time, we used ES or \n\nSRM. Of course, most scores were intended to have high sensitivity to changes in \n\ndisease status, in order to detect clinical minimally important difference (MID) in trials \n\nand natural history studies. MID is not the same as sensitivity to change, or as true \n\nresponsiveness (clinically important changes) and has seldom been demonstrated \n\n[49], particularly for neurodegenerative disorders [50]. Some authors consider any \n\nsmall significant difference as clinically relevant for ataxias [9]. Ideally, MID should \n\ninclude other, mainly subjective changes, such as psychological well-being and \n\n\n\n121 \n \n\nquality of life, which also have validation properties that may be different for different \n\ndisorders. These dimensions, however, were not covered in this review.  \n\nChoosing the adequate scale for the right ataxia \n\nThe ideal ataxia scale should be simple to apply, requiring little training, not much \n\ntime-consuming, well acceptable to the patient and the rater; and, at the same time, \n\nbe valid, reliable, sensitive to disease progression, while little insensitive to small \n\nfluctuations, and provide results that can be easily analyzed and interpreted. \n\nNevertheless, depending on the type of study and the specific form of ataxia, \n\ncompromises may have to be made.  \n\nWhen designing a study of natural history or a clinical trial, authors should choose \n\nbetween disease-specific versus generic ataxia scales. If disease-specific scales, like \n\nUMSARS (for MSA-C) or NESSCA (for MJD/SCA3) were chosen, a greater \n\nspecificity will probably reduce its capacity of generalization. In a generic scale, like \n\nSARA, the opposite might happen. Comparisons between different diseases may or \n\nmay not be the major aim, and the questions under study will be the main factors for \n\nthat choice. The advantages and disadvantages of including functional measures in a \n\ncomposite scale (e.g., FARS), versus using separate scales for deficits, disability and \n\nhandicap, are mainly related to the statistical analysis. If a composite scale is used, \n\nthe study will have only one clinical variable; if separate scales are used, several \n\nvariables will be included, what will imply multiple-testing corrections. \n\n Measuring the ataxia component: ICARS versus SARA \n\nAmong the scales that intend to measure incoordination only, ICARS was the most \n\nwidely used scale for all ataxias, with good reliability and responsiveness. Although \n\n\n\n122 \n \n\nstill largely used, however, ICARS is being replaced by other tools in more recent \n\nstudies. Its main drawback is the interdependency or redundancy of some of its \n\nitems. Redundancy lessens the validity of a scale, since it may under or overestimate \n\nthe effects of a potential treatment. Redundancy may also raise doubts as to the \n\neffect size of disease duration (the average worsening of 5/100 points per year, in \n\nFRDA [ES=0.26, SRM=0.73] and in SCA3/MJD [ES=0.26]) [9,10]. The use of SARA, \n\na very reliable and less time-consuming tool, has been growing. It is more \n\nparsimonious (with probably no redundancy), easier to apply than ICARS, and has \n\nshown reasonable sensitivity to change. The responsiveness of SARA on disease \n\nduration was similar to that of ICARS (SARA showed a mean worsening of 1.38/40 \n\n[SRM=0.5] points per year in various SCAs [24]). Notwithstanding, its variability is \n\nhigh, and a large sample size is required for small differences. Finally, further \n\nvalidation and natural history studies will probably define if MICARS and BARS may \n\nbecome useful ataxia scales. \n\nThe impact of extra-cerebellar manifestations \n\nOther recent scales for the SCAs include also items on extra-cerebellar \n\nmanifestations, which allow a better assessment of disease impact [2, 51]: this is the \n\ncase with UMSARS, FARS, NESSCA and INAS.  \n\nUMSARS and FARS may be described as disease-severity scoring systems (DS3), \n\nsince they measure both impairment and disability. UMSARS is the most used and \n\nwell-validated for MSA. This might be partly explained by the sensitivity of annual \n\nchange in its motor sub-score (UMSARS II). UMSARS may become a promising \n\nscale for SCAs (at least for SCA3/MJD), with an ES=0.23 for UMSARS-II, which is \n\nsimilar to ICARS [7]. FARS is a validated scale, most utilized for assessing ataxic \n\nand non-ataxic signals in FRDA. FARS not only evaluates neurological impairment \n\n\n\n123 \n \n\nand disability, but it also includes other very interesting domains, such as well-known \n\nquantitative measurements of coordination (PATA and 9HPT), and the T25FW. \n\nFARS response is reasonable, with a moderate ES (0.34) and a moderate to high \n\nSRM (0.53-1.04) in FRDA patients, after 12 months of follow-up. But, FARS has \n\nsome drawbacks: first, it is a complex scale and takes more than 30 minutes to \n\ncomplete; secondly, it has only been validated and used in FRDA, though it may be \n\napplied to other inherited ataxias.  \n\nThe NESSCA scale also appears to be a promising scale to assess ataxia and non-\n\nataxia manifestations. Its sensitivity to annual changes is similar to of SARA and \n\nICARS, in SCAs (1.25/40 points of change and an ES of 0.22 per 12 months). With \n\ngood reliability and validity parameters, NESSCA has only been validated in \n\nSCA3/MJD. Regarding only the non-ataxic features, INAS was validated for different \n\nSCAs, but its responsiveness is not clear, with a mean annual change lower than for \n\nthe former scales (0.37/16 points in one year; SRM=0.26). \n\nQuantitative performance scores \n\nThe quantitative ataxia scores, either individual or composite, are intended to \n\nrepresent more precise measures, easier to perform, and with greater effect sizes. \n\nIndividual scores are the 9HPT, Click test, 8MW, T25FW and PATA test. Composite \n\nscores are CATSYS 2000; CCFS \u2013 including 9HPT and click test; CCFSw \u2013 CCFS \n\nplus the hand writing test; SCAFI \u2013 8MW, 9HPT and PATA; and FARS IV, Z2 and Z3. \n\nThey are all very reliable. Discriminant validity (responsiveness) is not so important \n\nhere, since these tests are intended to detect minimal changes. Quantitative scores, \n\nhowever, have the downside of not being feasible in more severely affected patients: \n\nsome may not be able to walk, write, use the pegboard, perform the click test, or \n\neven talk. The ceiling effects that may be produced are probably unavoidable, and \n\n\n\n124 \n \n\nshould preclude the recruitment of more disabled patients for trials using these \n\nscores.  \n\nThe importance of scales in studies of natural history and in future therapeutic \n\ntrials  \n\nNatural history studies bring knowledge about the progression rate of a disease and \n\nhelp delineating clinical trials. They have confirmed the slow progression of SCAs \n\nand FRDA: clinical trials on these disorders thus need to be longer than in other \n\ndiseases. It seems to be clear that low ES or SRM for SCAs and FRDA are mainly \n\ndue to slow disease progression, and not because of the properties of the scales, \n\nsince this is in agreement with the clinical assessment of these patients. For \n\ninstance, it was very clear that UMSARS-II for MSA, a disease with a faster \n\nprogression, showed a larger 12-month ES (1.12) than for SCA3/DMJ (0.23). Another \n\nissue is that the progression rate of disease in placebo groups will not necessarily be \n\nthe same as that of the natural history, as the placebo effect is quite evident in \n\nvarious trials, as was, e.g., in FARS and FRDA: while the mean worsening was 9.5 \n\npoints/159 per year in the natural history study, it was 0.6 points/117 per six months \n\nin a placebo group from a clinical trial [9,12]. This finding stresses the need for \n\nclinically significant and reliable biomarkers to be used as secondary endpoints, in \n\norder to derive evidence from phase-II clinical trials. \n\nConclusions \n\n(1) We recommend that all three kinds of scales should be employed in future clinical \n\ntrials, according to the phase of the study. Given the efforts to develop new \n\ninstruments, and the validation criteria already obtained with the scales currently \n\navailable, we do not think that new tools are needed, for the moment. \n\n\n\n125 \n \n\n(2) Quantitative performance scores will be very important to develop evidence from \n\nphase-II trials, demonstrating a drug's effect in a selected group of patients. The \n\ncomposite SCAFI and CCFS, as well as individual scoring tests, will probably be \n\nuseful as secondary endpoints in phase III trials in ataxia, though SCAFI might be \n\npreferable, since it includes a walking test. Gait ataxia is usually the presenting sign \n\nand the main disability in SCAs and FRDA. Given its clinical importance, gait \n\nperformance should be measured in phase II trials. The 8MW (or T25FW ) may add \n\nsignificant information, although this has been shown only, up to now, in a FRDA \n\ncohort [37].  \n\n(3) Ataxia scales, such as SARA and ICARS, are the best studied and validated, so \n\nfar: one of them should be used in long-term, multicenter phase III studies, as well as \n\nserve as the instrument to validate sensitivity to change in phase II trials (where \n\nperformance tools should be used). SARA is simpler and less time-consuming than \n\nICARS; moreover, redundant items of ICARS may be a problem. SARA may thus be \n\na better choice.  \n\n(4) Ataxia and non-ataxia scores will provide a better view of overall disability and, \n\ntogether with tools for quality of life, will be necessary to demonstrate MID. For the \n\ntime being, there seems to be is no clear advantage between NESSCA and \n\nUMSARS, though it must be noted that NESSCA has been used in the longest \n\nnatural history study ever published [39]. We recommend either NESSCA or \n\nUMSARS for SCAs, mostly for not giving categorical variables. FARS is quite a \n\ncomplete scale, and is the one recommended for studies in FRDA.  \n\n(5) Finally, it is worth reminding that the real MID (which is not clearly measured by \n\nany of the tools reviewed here), as well as indexes of quality of life, will probably be \n\nthe most important endpoints to measure in future therapeutic trials. \n\n\n\n126 \n \n\n5. ACKNOWLEDGEMENTS \n\nWe are grateful to the Latin-American Science and Technology Development \n\nProgramme (CYTED) (210RT0390) for funding the RIBERMOV network, through \n\nwhich initiative this work took form. We thank the reviewers who provided important \n\nhints and fruitful suggestions that have considerably improved this review. L.B. \n\nJardim was supported by CNPq, Brazil, and by INAGEMP, Brazil. \n\n6.  REFERENCES \n\n1 Klockgether T. Sporadic ataxia with adult onset: classification and diagnostic \n\ncriteria. Lancet Neurol. 2010;9:94-104. \n\n2 Kieling C, Morales Saute JA, Jardim LB. When ataxia is not just ataxia. Nat \n\nClin Pract Neurol. 2007 May;3:E2. \n\n3 Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, \n\net al. International Cooperative Ataxia Rating Scale for pharmacological \n\nassessment of the cerebellar syndrome. The Ataxia Neuropharmacology \n\nCommittee of the World Federation of Neurology. J Neurol Sci. 1997;145:205-\n\n11. \n\n4 Tison F, Yekhlef F, Balestre E, Chrysostome V, Quinn N, Wenning et al. \n\nApplication of the International Cooperative Ataxia Scale rating in multiple \n\nsystem atrophy. Mov Disord 2002;17:1248 \u2013 54. \n\n5 Storey E, Tuck K, Hester R, Hughes A, Churchyard A. Inter-rater reliability of \n\nthe International Cooperative Ataxia Rating Scale (ICARS). Mov Disord. \n\n2004;19:190-2. \n\n\n\n127 \n \n\n6 Schmitz-H\u00fcbsch T, Tezenas du Montcel S, Baliko L, Boesch S, Bonato S, \n\nFancellu R, et al. Reliability and validity of the International Cooperative Ataxia \n\nRating Scale: a study in 156 spinocerebellar ataxia patients. Mov Disord. \n\n2006;21:699-704. \n\n7 D'Abreu A, Franca M Jr, Lopes-Cendes I, Cendes F. The international \n\ncooperative ataxia rating scale in Machado-Joseph disease. Comparison with \n\nthe unified multiple system atrophy rating scale. Mov Disord. 2007;22:1976-9. \n\n8 B\u00fcrk K, M\u00e4lzig U, Wolf S, Heck S, Dimitriadis K, Schmitz-H\u00fcbsch T, et al. \n\nComparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov \n\nDisord. 2009;24:1779-84. \n\n9 Fahey MC, Corben L, Collins V, Churchyard AJ, Delatycki MB. How is disease \n\nprogress in Friedreich's ataxia best measured? A study of four rating scales. J \n\nNeurol Neurosurg Psychiatry. 2007;78:411-.. \n\n10 Fran\u00e7a MC Jr, D'Abreu A, Nucci A, Cendes F, Lopes-Cendes I. Progression of \n\nataxia in patients with Machado-Joseph disease. Mov Disord. 2009; 24:1387-\n\n90. \n\n11 Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of \n\nhigh-dose idebenone in patients with Friedreich's ataxia: a randomised, \n\nplacebo-controlled trial. Lancet Neurol. 2007;6:878-86. \n\n12 Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled \n\ntrial of idebenone in friedreich ataxia. Arch Neurol. 2010;67:941-7. \n\n13 Ristori G, Romano S, Visconti A, Cannoni S, Spadaro M, Frontali M, et al. \n\nRiluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled \n\n\n\n128 \n \n\npilot trial. Neurology. 2010;74:839-45. \n\n14 Bier JC, Dethy S, Hildebrand J, Jacquy J, Manto M, Martin JJ, et al. Effects of \n\nthe oral form of ondansetron on cerebellar dysfunction. A multi-center double-\n\nblind study. J Neurol. 2003;250:693-7. \n\n15 Mori M, Adachi Y, Mori N, Kurihara S, Kashiwaya Y, Kusumi M, et al. Double-\n\nblind crossover study of branched-chain amino acid therapy in patients with \n\nspinocerebellar degeneration. J Neurol Sci. 2002;195:149-52. \n\n16 Heo JH, Lee ST, Chu K, Kim M. The efficacy of combined estrogen and \n\nbuspirone treatment in olivopontocerebellar atrophy. J Neurol Sci. \n\n2008;271:87-90. \n\n17 Assadi M, Campellone JV, Janson CG, Veloski JJ, Schwartzman RJ, Leone \n\nP. Treatment of spinocerebellar ataxia with buspirone. J Neurol Sci. \n\n2007;260:143-6. \n\n18 Cooper JM, Korlipara LV, Hart PE, Bradley JL, Schapira AH. Coenzyme Q10 \n\nand vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin \n\nE and coenzyme Q10 therapy. Eur J Neurol. 2008;15:1371-9. \n\n19 Mariotti C, Solari A, Torta D, Marano L, Fiorentini C, Di Donato S. Idebenone \n\ntreatment in Friedreich patients: one-year-long randomized placebo-controlled \n\ntrial. Neurology. 2003;60:1676-9. \n\n20 Sch\u00f6ls L, Vorgerd M, Schillings M, Skipka G, Zange J. Idebenone in patients \n\nwith Friedreich ataxia. Neurosci Lett. 2001;306:169-72. \n\n21 Schmitz-H\u00fcbsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt \n\n\n\n129 \n \n\nC, et al. Scale for the assessment and rating of ataxia: development of a new \n\nclinical scale. Neurology. 2006;66:1717-20. \n\n22 Braga-Neto P, Godeiro-Junior C, Dutra LA, Pedroso JL, Barsottini OG. \n\nTranslation and validation into Brazilian version of the Scale of the \n\nAssessment and Rating of Ataxia (SARA). Arq Neuropsiquiatr. 2010;68:228-\n\n30. \n\n23 Weyer A, Abele M, Schmitz-H\u00fcbsch T, Schoch B, Frings M, Timmann D, et al. \n\nReliability and validity of the scale for the assessment and rating of ataxia: a \n\nstudy in 64 ataxia patients. Mov Disord. 2007;22:1633-7. \n\n24 Schmitz-H\u00fcbsch T, Fimmers R, Rakowicz M, Rola R, Zdzienicka E, Fancellu \n\nR, et al. Responsiveness of different rating instruments in spinocerebellar \n\nataxia patients. Neurology. 2010;74:678-84. \n\n25 Chan E, Charles P, Ribai P, Goizet C, Marelli C, Vincitorio CM, et al. \n\nQuantitative assessment of the evolution of cerebellar signs in spinocerebellar \n\nataxias. Mov Disord. 2011. doi: 10.1002/mds.23531. \n\n26 Gazulla J, Benavente I. Single-blind, placebo-controlled pilot study of \n\npregabalin for ataxia in cortical cerebellar atrophy. Acta Neurol Scand. \n\n2007;116:235-8. \n\n27 Schmahmann JD, Gardner R, MacMore J, Vangel MG. Development of a brief \n\nataxia rating scale (BARS) based on a modified form of the ICARS. Mov \n\nDisord. 2009;24:1820-8 \n\n28 Wenning GK, Tison F, Seppi K, Sampaio C, Diem A, Yekhlef F, et al. Multiple \n\nSystem Atrophy Study Group. Development and validation of the Unified \n\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Schmahmann%20JD%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Gardner%20R%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22MacMore%20J%22%5BAuthor%5D\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Vangel%20MG%22%5BAuthor%5D\njavascript:AL_get(this,%20'jour',%20'Mov%20Disord.');\njavascript:AL_get(this,%20'jour',%20'Mov%20Disord.');\n\n\n130 \n \n\nMultiple System Atrophy Rating Scale (UMSARS). Mov Disord. 2004;19:1391-\n\n402. \n\n29 Schwab R, England A. Projection technique for evaluating surgery in \n\nParkinson\u2018s disease. In: Gillingham F, Donaldson I, editors. Third symposium \n\non Parkinson\u2018s disease. Edinburgh: Livingstone; 1969. p 152\u201375. \n\n30 Geser F, Seppi K, Stampfer-Kountchev M, K\u00f6llensperger M, Diem A, \n\nNdayisaba JP, et al. The European Multiple System Atrophy-Study Group \n\n(EMSA-SG). J Neural Transm. 2005;112:1677-86. \n\n31 Geser F, Wenning GK, Seppi K, Stampfer-Kountchev M, Scherfler C, Sawires \n\nM, et al. Progression of multiple system atrophy (MSA): a prospective natural \n\nhistory study by the European MSA Study Group (EMSA SG). Mov Disord. \n\n2006;21:179-86. \n\n32 May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, et al. \n\nPotential outcome measures and trial design issues for multiple system \n\natrophy. Mov Disord. 2007;22:2371-7. \n\n33 Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, et al. \n\nMinocycline 1-year therapy in multiple-system-atrophy: effect on clinical \n\nsymptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord. \n\n2010;25:97-107. \n\n34 Holmberg B, Johansson JO, Poewe W, Wenning G, Quinn NP, Mathias C, et \n\nal. Safety and tolerability of growth hormone therapy in multiple system \n\natrophy: a double-blind, placebo-controlled study. Mov Disord. 2007;22:1138-\n\n44. \n\n\n\n131 \n \n\n35 Subramony SH, May W, Lynch D, Gomez C, Fischbeck K, Hallett M, et al. \n\nMeasuring Friedreich ataxia: Interrater reliability of a neurologic rating scale. \n\nNeurology. 2005;64:1261-2. \n\n36 Lynch DR, Farmer JM, Tsou AY, Perlman S, Subramony SH, Gomez CM, et \n\nal. Measuring Friedreich ataxia: complementary features of examination and \n\nperformance measures. Neurology. 2006;66:1711-6. \n\n37 Friedman LS, Farmer JM, Perlman S, Wilmot G, Gomez CM, Bushara KO, et \n\nal. Measuring the rate of progression in Friedreich ataxia: implications for \n\nclinical trial design. Mov Disord. 2010 Mar 15;25(4):426-32. \n\n38 Kieling C, Rieder CR, Silva AC, Saute JA, Cecchin CR, Monte TL, et al. A \n\nneurological examination score for the assessment of spinocerebellar ataxia 3 \n\n(SCA3). Eur J Neurol. 2008;15:371-6. \n\n39 Jardim LB, Hauser L, Kieling C, Saute JA, Xavier R, Rieder CR, et al. \n\nProgression rate of neurological deficits in a 10-year cohort of SCA3 patients. \n\nCerebellum. 2010;9:419-28.  \n\n40 Schmitz-H\u00fcbsch T, Coudert M, Bauer P, Giunti P, Globas C, Baliko L, et al. \n\nSpinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia \n\nsymptoms. Neurology. 2008;71:982-9. \n\n41 Despr\u00e9s C, Lamoureux D, Beuter A. Standardization of a neuromotor test \n\nbattery: the CATSYS system. Neurotoxicology. 2000 Oct;21(5):725-35. \n\n42 Aguilar D, Sigford KE, Soontarapornchai K, Nguyen DV, Adams PE, Yuhas \n\nJM, Tassone F, Hagerman PJ, Hagerman RJ. A quantitative assessment of \n\ntremor and ataxia in FMR1 premutation carriers using CATSYS. Am J Med \n\n\n\n132 \n \n\nGenet A. 2008 Mar 1;146A(5):629-35. \n\n43 Allen EG, Juncos J, Letz R, Rusin M, Hamilton D, Novak G, Shubeck L, \n\nTinker SW, Sherman SL. Detection of early FXTAS motor symptoms using the \n\nCATSYS computerised neuromotor test battery. J Med Genet. 2008 \n\nMay;45(5):290-7. Epub 2008 Jan 30. \n\n44 Juncos JL, Lazarus JT, Graves-Allen E, Shubeck L, Rusin M, Novak G, \n\nHamilton D, Rohr J, Sherman SL. New clinical findings in the fragile X-\n\nassociated tremor ataxia syndrome (FXTAS). Neurogenetics. 2011 \n\nMay;12(2):123-35. Epub 2011 Jan 29. \n\n45 Assadi M, Leone P, Veloski JJ, Schwartzman RJ, Janson CG, Campellone \n\nJV. Validating an Ataxia Functional Composite Scale in spinocerebellar ataxia.  \n\nJ Neurol Sci. 2008 May 15;268(1-2):136-9. Epub 2008 Jan 11. \n\n46 du Montcel ST, Charles P, Ribai P, Goizet C, Le Bayon A, Labauge P, et al. \n\nComposite cerebellar functional severity score: validation of a quantitative \n\nscore of cerebellar impairment. Brain. 2008;131:1352-61. \n\n47 Schmitz-H\u00fcbsch T, Giunti P, Stephenson DA, Globas C, Baliko L, Sacc\u00e0 F, et \n\nal. SCA Functional Index: a useful compound performance measure for \n\nspinocerebellar ataxia. Neurology. 2008 ;71:486-92. \n\n48 Cano SJ, Riazi A, Schapira AH, Cooper JM, Hobart JC. Friedreich's ataxia \n\nimpact scale: a new measure striving to provide the flexibility required by \n\ntoday's studies. Mov Disord. 2009;24:984-92. \n\n49 Streiner DL and Norman GR. Health Measurement Scales: A practical guide \n\n\n\n133 \n \n\nto their development and use. Oxford, Oxford University Press, 2008 \n\n50 Molnar FJ, Man-Son-Hing M, Fergusson D. Systematic review of measures of \n\nclinical significance employed in randomized controlled trials of drugs for \n\ndementia. J Am Geriatr Soc. 2009 Mar;57(3):536-46. Epub 2009 Jan 29. \n\n51 Pulst SM. Ataxia rating scales in the balance. Nat Clin Pract Neurol. \n\n2007;3:119. \n\n \n\nTables: \n\nTable 1. Clinical scales used in ataxias: classification, range, validation, time needed \n\nfor application, and studies of natural history, sensitivity to change and clinical trials \n\nperformed with each scale. \n\n \n\n  \n\n \n\n \n\n\n\n134 \n \n\n\n\n135 \n \n\n \n\n  \n\n\n\n136 \n \n\n. Cap\u00edtulo 5 - A randomized, phase 2/3 trial of lithium carbonate \n\nin Machado-Joseph disease. \n\n \n\n  \n\n\n\n137 \n \n\nTitle: A randomized, phase 2/3 trial of lithium carbonate in Machado-Joseph \n\ndisease. \n\nJonas Alex Morales Saute\n1,7\n\n, MD, PhD,; Raphael Machado de Castilhos\n7,10\n\n, MD, \n\nMsC; Thais Lampert Monte\n8\n, MD, MsC; Artur Francisco Schumacher-Schuh\n\n2,8\n, MD, \n\nMsC; Karina Carvalho Donis\n7\n, MD; Rui D\u2018\u00c1vila\n\n7\n, MD; Gabriele Nunes Souza\n\n7\n; Aline \n\nDutra Russo\n7\n; Gabriel Vasata Furtado\n\n2\n, MsC; Tailise Conte Gheno\n\n2\n, MsC; Diogo \n\nOnofre Gomes de Souza\n4\n, MD, PhD; Luis Valmor Cruz Portela\n\n4\n, PhD; Maria Luiza \n\nSaraiva Pereira\n2,4,7,10\n\n, PhD; Suzi Camey\n3,6\n\n, PhD;  Vanessa Bielefeld Leotti Torman\n6\n, \n\nMsC; Carlos R. M. Rieder\n1,8,9\n\n, MD, PhD; Laura Bannach Jardim\n1,5,7,10*\n\n, MD, PhD.\n \n\n1\nPost-Graduate Programs in Medical Sciences, \n\n2\nGenetics and Molecular Biology and \n\n3\nEpidemiology; and  Departments of \n\n4\nBiochemistry, \n\n5\nInternal Medicine and \n\n6\nStatistics, \n\nUniversidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; \n7\nMedical \n\nGenetics and \n8\nNeurology Services, Hospital de Cl\u00ednicas de Porto Alegre (HCPA), \n\nPorto Alegre, RS, Brazil; \n9\nNeurology Department, Universidade Federal de Ci\u00eancias \n\nda Sa\u00fade de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil; \n10\n\nInstituto Nacional \n\nde Gen\u00e9tica M\u00e9dica Populacional (INAGEMP). \n\n \n\n* Corresponding author: Laura Bannach Jardim \n\nMedical Genetics Service, Hospital de Cl\u00ednicas de Porto Alegre, \n\nRua Ramiro Barcelos 2350, \n\nZip Code 90.035-903, Porto Alegre, Brazil \n\ne-mail: ljardim@hcpa.ufrgs.br  \n\n\n\n138 \n \n\nAbstract \n\nObjective: Based on findings in pre-clinical models of polyglutamine disorders, we \n\nhave assessed safety and effectiveness of lithium carbonate (0.5-0.8mEq/L) in \n\npatients with MJD/SCA3. \n\nMethods: A phase 2/3 single center, double-blind, parallel, placebo-controlled trial \n\nwas conducted (ClinicalTrials.gov,NCT01096082). Patients, caregivers, and all study \n\nstaff, but pharmacists and principal investigators, were masked to treatment \n\nassignment. Between May and September, 2011, independently ambulatory \n\nMJD/SCA3 patients with ? 10 years of disease duration were randomly assigned \n\n(1:1, variable size blocks, stratified by CAGexp) by computer-generated \n\nrandomisation sequence. Primary safety end-point (24 weeks) was the difference in \n\nthe total number of adverse events (AE) and of effectiveness (48 weeks), the \n\ndifference in the variation of NESSCA scale between groups. Analysis was by \n\nintention-to-treat (ITT). \n\nFindings: Sixty-two patients were assigned to treatment groups (31/31 \n\nplacebo/lithium). Sixty patients (31/29 placebo/lithium) were analysed according to \n\nITT. After 24 weeks, 169 AE were reported, 50.3% in lithium group (p=1.00). After 48 \n\nweeks, placebo group had a non-significant larger progression in NESSCA (0.35 \n\npoints, 95% CI -1.0 to 1.7, p=0.222) and SARA scales (0.96 points, 95% CI -0.46 to \n\n2.38, p=0.329). Lithium group had significantly slower progression after 48 weeks in \n\ngait ataxia severity (p=0.008), PATA rate (p=0.002), Click Test ND (p=0.023), SCAFI \n\n(p=0.015) and CCFS (p=0.029). \n\nInterpretation: Lithium is safe, but had no significant effect on NESSCA progression \n\nof MJD/SCA3. In contrast, lithium significantly slowed the progression of several \n\nsecondary outcomes all related to ataxic manifestations. These results open new \n\nperspectives for treatment of MJD/SCA3 and other polyglutamine disorders. \n\n \n\n  \n\n\n\n139 \n \nIntroduction \n\nMachado-Joseph Disease [OMIM#109150], also known as spinocerebellar ataxia \n\ntype 3 (MJD/SCA3), is an autosomal dominant neurodegenerative disease caused by \n\na CAG repeat expansion (CAGexp) at ATXN3 gene.\n1\n CAGexp size, as in other \n\npolyglutamine (polyQ) disorders, inversely correlates with age of disease onset and \n\ndirectly correlates with disease severity.\n2,3,4\n\n  \n\nMJD/SCA3 is the most common SCA worldwide, affecting 3.5:100,000 individuals in \n\nSouth Brazil.\n5,6\n\n The clinical picture is composed of adult-onset cerebellar ataxia \n\ncommonly accompanied by progressive external ophthalmoplegia, dysarthria, \n\ndysphagia, pyramidal signs, dystonia, rigidity, and distal muscles atrophy.\n3,4,7,8\n\n As \n\ndisease progresses, patients become confined to a wheelchair and later bedridden.\n9\n \n\nNo effective treatment for SCAs is currently available. Case series and small trials of \n\npotential symptomatic or disease progression modifier medications, as anxiolytics, \n\nantidepressants, cholinesterase inhibitors, and antiepileptic drugs, have shown \n\nlimited efficacy or conflicting results. A recent double-blind randomized trial with \n\nvarenicline treatment for twenty SCA3 patients also showed non-conclusive results, \n\nwith a short course of treatment and relatively unbalanced randomized groups.\n10 \n\n \n\nTherapeutic strategies for polyQ diseases might focus on single disease specific \n\nmechanisms or in class-wide therapeutic targets as the general toxic mechanism \n\ntriggered by expanded polyQ. PolyQ disease proteins share their propensity to \n\nmisfold, oligomerize, and form intracellular aggregates.\n8\n Lithium has been shown to \n\nexert neuroprotective effects in numerous models of neurodegeneration including at \n\nleast two PolyQ diseases: Huntington Disease (HD)\n11,12,13,14 \n\nand SCA1.\n15\n\n \n\nNeuroprotective effects of lithium were mainly attributed to the inhibition of glycogen \n\nsynthase kinase-3? (GSK-3?).\n14,15,16\n\n GSK-3? inhibition increases the expression of \n\nanti-apoptotic proteins and neurotrophins.\n17,18,19\n\n Lithium also acts on cellular protein \n\nquality control systems increasing expression of chaperones\n20\n\n and promoting \n\nautophagy;\n21\n\n and on epigenetics mechanisms modulating histone methylation\n22\n\n and \n\nacetylation.\n23\n\n In an open label trial, high doses of lithium were reported to be \n\nmoderately tolerated in twelve SCA1 patients\n24\n\n and, in a case report, a SCA2 patient \n\ntreated during thirty years with lithium for mood disorder presented a less severe \n\n\n\n140 \n \n\nphenotype than her affected relatives.\n25\n\n In contrast, there are several reports of \n\nlithium toxicity in non-ataxic patients inducing cerebellar dysfunction.\n26\n\n \n\nConsidering the above neuroprotective actions of lithium, we aimed to assess safety \n\nand effectiveness of lithium carbonate in patients with MJD/SCA3.  \n\nMethods \n\nPatients \n\nA randomised, double-blind, parallel, placebo controlled trial of lithium was done in \n\npatients with MJD/SCA3. From May to September, 2011, patients were enrolled in a \n\nsingle center at Hospital de Cl\u00ednicas de Porto Alegre (HCPA), the only Neurogenetic \n\nDisorders center in the State of Rio Grande do Sul, the southernmost State of Brazil. \n\nPatients were recruited from the MJD/SCA3 database of the Neurogenetic and \n\nMovement Disorders outpatient clinic of HCPA.  \n\nPatients were eligible if they were aged 16 years or more and had a molecular \n\ndiagnosis of MJD/SCA3, as described elsewhere.\n27\n\n Inclusion criteria were the ability \n\nto provide informed consent and comply with study procedures; disease duration of \n\n10 years or less from symptoms onset; and being able to walk independently (the \n\nuse of canes, sticks or stroller was allowed). Exclusion criteria were the  presence of \n\nany of the following: known sensitivity or intolerability to lithium; exposure to any \n\ninvestigational drug within the past 30 days; sodium-free diet; previous history of \n\nthyroid disorder (hyper or hypothyroidism); previous history of other neurologic or \n\nsystemic significant medical disorder (cardiac, pulmonary, renal, hepatic, \n\nhematological, active malignancy, or infectious disease); being pregnant, breast \n\nfeeding or not agreeing with the use of contraception during the study; current or \n\nprevious alcohol or other drug abuse during the last year, except for cigarette \n\nsmoking; use of thiazide diuretics, ACE inhibitors or angiotensin receptor blockers; \n\nchronic use of digoxin, indomethacin and piroxicam; use of  aminophylline, \n\nphenothiazine antipsychotics, haloperidol and sibutramine; plasma levels of thyroid \n\nstimulating hormone more than 20% above the upper limit of normal range; \n\ncreatinine, alanine transaminase (ALT) or aspartate transaminase (AST) levels \n\nabove the upper limit of normal range; significant cardiac conduction abnormality on \n\nscreening electrocardiogram.  \n\n\n\n141 \n \nRandomisation and masking \n\nPatients were assessed for eligibility at the screening visit by the study physicians. \n\nEligibility was confirmed by the principal executor investigator (JAMS) after the result \n\nof laboratory evaluation.  \n\nAn independent pharmacist (MLSP) generated the randomisation list with Random \n\nAllocation Software (Isfahan University of Medical Sciences, Iran).  Patients were \n\nrandomly assigned 1:1, in blocks of variable sizes of 4 or 6, stratified by CAGexp (? 74 \n\nor > 74 CAGs). Two lists of random four-digit number were generated, one for each \n\nstratum. The Principal Investigators (PIs - LBJ and CRMR) and the responsible for \n\nstudy drugs dispensation (GVF and TCG) have access to the randomisation list \n\n(unmasked), and none of them had direct contact with patients during the study. GVF \n\nand TCG assigned the treatment by matching the randomisation number to a \n\ncorresponding treatment from the randomisation code sheet and then dispensed \n\neither lithium carbonate or placebo. Each randomisation code was placed in \n\nsequentially numbered, opaque, sealed envelopes in accordance with the \n\nrandomisation list, that were open by the principal executor investigator or study \n\nnurses after patient was considered eligible.  \n\nPatients, caregivers, physicians, nurses, statisticians, with the exception of site \n\npharmacists and PIs (MLSP, GVF, TCG LBJ and CRMR) were masked to treatment \n\nassignment. \n\nOutcomes \n\nPrimary Outcomes: \n\nSafety - The difference in total number of AEs between study groups 24 weeks after \n\nthe beginning of maintenance phase.  \n\nEffectiveness- The difference in the variation of NESSCA - Neurological Examination \n\nScore for the Assessment of Spinocerebellar Ataxia\n28\n\n from baseline to 48 weeks after \n\nthe beginning of maintenance phase between study groups. \n\nSecondary Outcomes: \n\n\n\n142 \n \n\nSafety \u2013 Difference between groups in the: 1) total number of AEs during the 48 \n\nweeks; 2) number of mild, moderate and severe AEs. \n\nEffectiveness \u2013 Difference between groups in the variation of NESSCA from baseline \n\nto 24 weeks and of the following instruments from baseline to 24 and 48 weeks: 1) \n\nSARA - Scale for the Assessment and Rating of Ataxia;\n29\n\n 2) gait ataxia severity \n\ndefined as 0, absent; 1, minimal: only while walking on toes, heels or in tandem; 2, \n\nmoderate: gait autonomy preserved; 3, inability to walk without help; 4, total inability \n\nto walk: the patient being wheelchair-bound or bedridden;\n28\n\n 3) the z scores of the \n\nquantitative ataxia instruments 9-Hole Pegboard Test (9-HPT), 8m Walking-time \n\n(8MW), Click Test and PATA rate;\n30\n\n 4) the composite quantitative ataxia scores SCA \n\nFunctional Index (SCAFI)\n31 \n\nand Composite Cerebellar Functional Score (CCFS);\n32\n\n 5) \n\nthe functional status Barthel Index;\n33\n\n and 6) the Portuguese versions of the quality of \n\nlife instrument WHOQOL bref\n34\n\n and of (BDI) Beck Depression Inventory.\n35\n\n Difference \n\nbetween groups in the mean Patients\u2018 Clinical Global Impression of change (PGI) \n\nwas assessed after 48 weeks.\n36\n\n The comparison of disease serum biomarkers \n\nbetween groups was also performed during 12, 24 and 48 weeks of treatment and \n\nwill be reported separately. \n\nOther planned analysis \u2013 to analyze the interaction of the number of CAGexp, \n\naccording to randomization strata, and of lithium serum levels with patient response \n\nto treatments in NESSCA, SARA and composite quantitative ataxia scores. \n\nProcedures \n\nEach patient had two responsible physicians during the study. The research assistant \n\nphysician, who evaluated adverse events and reviewed laboratory exams (except for \n\nserum lithium levels), and the evaluating physician, who only performed the \n\neffectiveness outcome instruments evaluations. No changes of physicians were \n\nallowed. Each assistant and evaluating physician were trained on study procedures \n\nand on evaluation instruments before the study start.  \n\nAfter being assigned as eligible, patients returned for the baseline visit when they \n\nreceived randomisation and study numbers. Vital signs, weight, NESSCA, SARA, \n\ngait ataxia severity, 9-HPT, 8MW, Click Test, PATA rate, Barthel Index, WHOQOL \n\nbref and BDI were assessed at the baseline visit. For patients who were unable to \n\nperform 8MW the 10-fold value of the maximal performance time was attributed (i.e., \n\n\n\n143 \n \n\n1,800s).\n31 \n\nAfter baseline, patients entered the titration phase which consisted of every \n\nweek visits with lithium dosage until the patient achieved the target (real or sham). A \n\nmaximum of seven weeks for this phase was established. When completed titration \n\nthe maintenance phase started (Week 0) which consisted of telephone calls by the \n\nassistant physician to assess AEs every 2 weeks until week 12. At week 12, patient \n\ncame for consultation and repeated safety laboratory exams and serum lithium \n\nlevels, which were repeated thereafter every 12 weeks. After week 12 until the end of \n\nweek 48 the assistant physician performed a telephone call monthly. At week 24 and \n\n48 the evaluating physician performed the same protocol assessed at baseline visit. \n\nA maximum variation of \u00b1 4 weeks from the planned evaluation date was allowed. \n\nIntervention \n\nLithium Carbonate (Carbolitium\u00ae) was donated by Eurofarma (S\u00e3o Paulo, Brazil) and \n\ndispensed as 300mg tablets. Identical matching placebo tablets were produced and \n\npurchased from the Central Pharmacy of Hospital das Cl\u00ednicas, Faculty of Medicine, \n\nUniversity of Sao Paulo.   \n\nPatients were initially given one tablet of the study drug at night; when taking more \n\nthan one tablet, the study drug was given twice daily. Drug concentrations were \n\nmeasured weekly in the titration phase to achieve a serum lithium concentration of \n\n0.5\u20130.8mEq/L and afterwards every three months. Lithium concentrations were \n\nrecorded for all patients 11:30-12:30hrs after the last dose. Lithium doses were \n\nadjusted centrally by the unmasked PIs and were not available to other study and \n\nhospital staff. If concentrations were less than 0.5mEq/L, dose was increased by one \n\ntablet per day. For patients taking an odd number of tablets, the extra tablet was \n\ntaken in the evening. If concentrations were between 0.8mEq/L and 1.2mEq/L, the \n\ndose was decreased by half or one tablet.  If concentrations were greater than \n\n1.2mEq/L, treatment would be suspended and lithium concentrations would be tested \n\n3\u20135 days later, at which time treatment was either restarted at half the previous dose. \n\nTo maintain masking of patients and investigators throughout the study, sham dose \n\nmodifications were done by LBJ and CRMR for patients assigned to placebo. When \n\npatient achieved the target (or sham) dosage, lithium serum levels were repeated \n\nafter one week in order to confirm stable levels. Every dosage change was \n\ncommunicated by the PIs to two nurses (GNS e ADR) who were blind to treatment \n\nassignment and communicate the posology change to patients. Patient\u2018s assistant \n\n\n\n144 \n \n\nphysician could also change the dosage of study drug in accordance to adverse \n\nevents (AEs). After any study drug changes during the study, lithium levels were \n\nrepeated after one week.  \n\nDuring titration phase each individual received a recipient with sufficient tablets for a \n\nmonth plus 20% additional tablets. During maintenance phase each individual \n\nreceived a recipient with sufficient tablets for three months plus 20% additional \n\ntablets. For per-protocol analysis the individual was considered adherent if he/she \n\ningested 80 to 120% of the estimated number of tablets for the period.   \n\nSample Size \n\nThe trial was designed to have 80% power to detect a 50% decrease in the rate of \n\ndecline in NESSCA, considering a standardized response mean (SRM) of 0.8 and a \n\nType I error of 5%, if 52 patients were recruited in total. However it should be stated \n\nthat there is no previous data on SRM for NESSCA and that scales showing a similar \n\nrate of progression, as SARA, in subsequent studies showed a SRM of 0.41 after 1 \n\nyear.\n30\n\n Therefore the study power might have been overestimated.  \n\nStatistical Analysis  \n\nDistributions of baseline characteristics, adverse events, and laboratory \n\nabnormalities were compared using chi-square or Fisher\u2018s exact test and t tests. \n\nAnalysis was by intention to treat (ITT) and per-protocol. All randomized patients who \n\nreceived at least one dose of study drug and who came to at least one follow-up \n\nendpoint assessment were eligible for inclusion in the primary effectiveness analysis \n\non ITT. Per protocol analysis was performed with patients who took the study drug \n\nduring the whole study, maintained lithium levels of 0.5 to 0.8mEq/L (only for lithium \n\ngroup) and were considered adherent. Patients who were unable to perform the \n\n8MW task in all evaluations (baseline, 24 weeks and 48 weeks) were excluded from \n\nthe ITT and per-protocol analysis for this end-point as well as for SCAFI.  \n\nAnalysis was made by Generalized Estimation Equation (GEE) analysis treating the \n\nmeasures in 24 and 48 weeks as response and adjusting by baseline measures. To \n\nincorporate correlation between measures of the same patient, the exchangeable \n\nstructure was considered for the working correlation matrix. For subgroup analyses, \n\nthe interactions between the subgroups and groups and time were added to the \n\n\n\n145 \n \n\nmodel. Bonferroni correction was used for multiple comparisons. Correlations of \n\nserum lithium levels with effectiveness outcomes were performed with Pearson \n\ncorrelation test. \n\nAll analysis was made by two statisticians (VBLT, SC) who were blind for treatment \n\nallocation. After the final analysis of the primary end-point at 48 weeks the \n\nstatisticians were unblinded in order to perform the analysis of the interaction of \n\nlithium serum levels and patient response to treatment.  \n\nThe estimated responses in 72 weeks were predicted considering the mean change \n\nfrom baseline to 48 weeks for each group. Then the GEE model was adjusted for the \n\nprimary endpoint to see if statistical significance would be reached, if not, then the \n\nstudy would be stopped for futility related to study design. \n\nSPSS/PASW version 18 was utilized for all analysis. \n\nEthics and Registration \n\nThe study was approved by the institutional (GPPG-HCPA) and the Brazilian \n\nNational Bioethics Commission (CONEP) and all subjects provided written consent \n\nbefore commencement of study procedures. The study is registered at \n\nClinicalTrials.gov, NCT01096082. \n\nRole of funding source \n\nThe financial support for the study came from the Brazilian funding agencies \n\nFAPERGS, CNPq and FIPE-HCPA. The pharmaceutical company Eurofarma only \n\ndonated lithium carbonate tablets, with no further support to the study. Eurofarma \n\nand the public Brazilian agencies had no involvement in the study design and \n\nprotocol, collection, analysis, and interpretation of data, in the writing of the report, or \n\nin the decision to submit the paper for publication. JAMS, CRMR and LBJ had full \n\naccess to all the final data in the study and had final responsibility for the decision to \n\nsubmit for publication.  \n\nResults \n\nBetween May and September, 2011, 92 MJD/SCA3 patients were screened (Fig 1) \n\nand 62 were randomly assigned to receive lithium (n=31) or placebo (n=31). \n\nDemographic characteristics, clinical features and values of primary and secondary \n\n\n\n146 \n \n\noutcome variables were similar in the treatment groups at baseline (Table 1). \n\nConcomitant use of other medical treatments was also similar between groups \n\n(Supplemental Table 1). Patients were followed for at least 48 weeks until the study \n\nwas stopped for futility, in November, 2012. The study would be underpowered with \n\nthe current population and design to detect a significant effect in the primary \n\neffectiveness endpoint if continued until 72 weeks.  \n\nSafety Outcomes:  \n\nPrimary Endpoint  \n\nThe total number of AEs, at 24 weeks after the beginning of maintenance phase was \n\nof 85 (50.3%) in the lithium group and 84 (49.7%) in the placebo group (p=1.00).  As \n\nlithium carbonate was proved to be safe in MJD/SCA3 patients at this point, the study \n\ncontinued, aiming to assess lithium effectiveness after 48 weeks of treatment. \n\nSecondary Endpoints \n\nThe total number of AEs after 48 weeks was of 95 events (50.8 %) in the lithium \n\ngroup and 92 events (49.2 %) in the placebo (p=0.884). There was also no significant \n\ndifference among AEs severity between groups (Table 2). The frequency of most \n\ncommon AEs (present in >5 of patients) were also similar between lithium and \n\nplacebo treated patients (p=0.427), with the exception of thyroid and erectile \n\ndysfunction and falls, that seemed to occur more frequently in the lithium group \n\n(Supplemental Table 2).   \n\nFour serious AE were reported. Two of them were related to the increase of \n\ndepressive symptoms. One patient presented worsening of BDI and suicidal ideation \n\n(placebo group) with significant risk and another an unsuccessful suicide attempt \n\n(lithium group) with a major intake of benzodiazepines. Both patients were offered \n\npsychiatric consultation and management with symptom improvement. As depression \n\nis one of the commonest non-motor MJD/SCA3 manifestations\n37\n\n and both events had \n\nno clear temporal association with the study drugs, they were considered unrelated \n\nAEs. Two falls with significant injuries were also reported. The first one happened \n\nduring enrollment and prior to drug start, resulting in shoulder dislocation (lithium \n\ngroup). The other was in the first week of the titration phase, and resulted in coccyx \n\nfracture (lithium group). Titration was suspended until the patient was discharged \n\n\n\n147 \n \n\nfrom hospital, and then restarted, with no further related falls. Both AE were also \n\nconsidered unrelated to the study drug. \n\nProtocol adhesion \n\nSix patients discontinued the allocated drug. Two withdrew informed consent soon \n\nafter baseline assessment for reasons unrelated to AE and were excluded from all \n\nanalysis (both on lithium group). Demographic characteristics between groups \n\nremained similar with these two exclusions. The other four completed all follow ups. \n\nTwo of them stopped the study medication in the end of titration and beginning of \n\nmaintenance phases due to muscular pain (lithium group) and balance worsening \n\n(placebo). One patient on lithium and one on placebo group discontinued treatment \n\ndue to personal reasons, unrelated to AEs.  \n\nTwo additional patients in the lithium group were not included on per-protocol \n\nanalysis. One of them remained without taking or with lithium levels under the target \n\nfor 75 days (22% of maintenance phase) due to leg pain (severe, non-serious and \n\nprobably drug-related AE). The second patient has only tolerated lithium levels of \n\n0.3mEq/L or less, with higher concentrations being associated with tremor (severe, \n\nnon-serious and definitely drug-related AE). Therefore per-protocol analysis was \n\ndone on 54 patients (87% of randomized patients), 25 on lithium and 29 on placebo \n\ntreatment. ITT analysis included 60 patients (97% of randomized patients), 29 on \n\nlithium and 31 on placebo treatment.  \n\n The mean lithium dose was of 990 (600 to 1650) mg/day or 3.3 (2 to 5.5) \n\ntablets/day. The mean placebo dose was of 3.4 (2 to 5) tablets/day. During \n\nmaintenance phase, plasma concentrations of lithium for both groups were measured \n\non average 5.5 \u00b1 0.7 times per patient. The mean lithium concentration was of 0.57 \u00b1 \n\n0.09 (range: 0.3 to 1.4); mean value per patient ranged: 0.3 to 0.68mEq/L) in the \n\nlithium group. No traces of serum lithium levels were found in the placebo group. In \n\none occasion, lithium concentration reached a toxic level (1.4mEq/L) that was time \n\nrelated to the onset of tremor, which subsided three months after dosage correction. \n\nPatient\u2018s adherence was adequate: lithium and placebo groups ingested 89 and 93% \n\nof the estimated number of tablets (p=0.10) \n\nEffectiveness Outcomes \n\n\n\n148 \n \n\nTable 3 details the main results on ITT after 24 and 48 weeks assessments for the \n\nprimary and secondary effectiveness outcomes.  \n\nIn the next section, we will describe the results of the ITT analysis. Per protocol data \n\nwill be mentioned for the primary endpoint and afterwards only when results differ \n\nfrom ITT. For detailed per-protocol analysis results see Supplemental Table 3.  \n\nPrimary Endpoint \n\nNESSCA \n\nAlthough placebo group has worsened more than lithium after 24 and 48 weeks - \n\n0.93 (95% CI -0.12 to 1.98) and 0.35 points (95% CI -1.0 to 1.7), respectively -, these \n\ndifferences were not significant (p=0.222 - Fig 2A). On per-protocol analysis, the \n\noverall 48 weeks differences in NESSCA between groups remained non-significant \n\n(p=0.116). After 24 weeks, there was an increase in NESSCA progression of 0.91 \n\n(95% CI -0.15 to 1.97) and after 48 weeks of 0.72 points (95% CI -0.65 to 2.09) \n\nlarger in placebo than in lithium-treated group. \n\nFutility analysis \n\nThe futility analysis estimated that NESSCA would worsen 0.56 points (95% CI -0.51 \n\nto 1.69) more in the placebo than in the lithium group, a non-statistically significant \n\ndifference, after 72 weeks (p=0.295).  \n\nSecondary Endpoints \n\nSARA and Gait Ataxia Severity \n\nAfter 24 and 48 weeks of treatment, the placebo group worsened 0.26 (95% CI -1.02 \n\nto 1.53) and 0.96 points (95% CI -0.46 to 2.38) more than the lithium group in SARA \n\n(Fig 2B). However, these differences were not statistically significant (p=0.329). \n\nSeverity of gait ataxia progressed significantly less in lithium-treated group in the \n\noverall 48 weeks (p=0.008). After 24 and 48 weeks, the worsening of gait ataxia \n\nseverity was 0.26 (95% CI 0.03 to 0.48) and 0.32 points (95% CI 0.07 to 0.57) larger \n\nin placebo than in lithium group (Fig 2C).  \n\nQuantitative functional tasks (8MW, PATA rate, 9HPT, Click Test) \n\n\n\n149 \n \n\n8MW worsened faster in placebo than in lithium group after 24 (3.62 z scores, 95% \n\nCI -11.4 to 18.66) and 48 weeks of treatment (14.63 z scores, 95% CI -3.09 to \n\n32.36), although not statistically significant (p=0.244, Fig 3A). On per-protocol \n\nanalysis these differences became significant (p=0.026), with a faster progression in \n\nplacebo group after 48 weeks (19.39 z scores, 95% CI 4.37 to 34.41, Supplementary \n\nTable 3). PATA rate progressed differently between groups in the overall 48 weeks \n\n(p=0.002). After 24 (-0.37 z scores, 95% CI -0.65 to -0.08) and 48 weeks (-0.44 z \n\nscores, 95% CI -0.73 to -0.14), the placebo group worsened more than lithium group \n\n(Fig 3B). No significant difference between groups on dominant (9HPT D; p=0.074, \n\nFig 3C) and non-dominant hand 9HPT (9HPT ND; p=0.619) was found. A near \n\nsignificant dominant (p=0.051) and a significant non-dominant hand Click Test (Click \n\nTest ND - p=0.023, Fig 3D) progression was found in the overall 48 weeks between \n\ngroups. Click Test ND seemed to worsen faster in placebo than in lithium group after \n\n24 (0.57, 95% CI -0.03 to 1.17) and 48 weeks (0.38, 95% CI -0.06 to 0.82). On per-\n\nprotocol analysis, the differences in Click Test D (p=0.210) and Click Test ND \n\n(p=0.137) between groups were not significant. \n\nComposite Scores (SCAFI, CCFS) \n\nThe mean SCAFI progression was significantly different between groups in the \n\noverall 48 weeks (p=0.015, Fig 3E). After 24 weeks of treatment there was less \n\nworsening (0.20, 95% CI -0.003 to 0.41) in lithium than in placebo group, which \n\nbecame significant after 48 weeks (0.32, 95% CI 0.06 to 0.57). CCFS progressed \n\ndifferently between groups in the overall 48 weeks (p=0.029, Fig 3F). After 24 weeks \n\nof treatment, there was a mean worsening of 0.03 (95% CI -0.002 to 0.06) units \n\nlarger in placebo than in lithium group that became significant after 48 weeks (95% \n\nCI 0.003 to 0.05). On per-protocol analysis, the difference between groups in CCFS \n\nprogression was not observed (p=0.155). \n\nMood, disability and Quality of Life (BDI, Barthel Index and WHOQOL-bref) \n\nDuring the 48 weeks of follow up, there were no significant differences between \n\ngroups on BDI (p=0.420), Barthel Index (p=0.780) and in the physical (p=0.442), \n\npsychological (p=0.402), social relationships (p=0.209) and environment (p=0.948) \n\ndomains of WHOQOL-bref.  \n\nPatients\u2019 Clinical Global Impression of change (PGI) \n\n\n\n150 \n \n\nAfter completing 48 weeks of treatment, mean PGI scores of lithium (3.59\u00b11.15) were \n\nlower than of placebo-treated patients (4.45\u00b11.26) on both ITT (p=0.007, Fig 2D) and \n\nper-protocol analysis (p=0.042).  \n\nDifferences in the slope of progression from 24 to 48 weeks. \n\nA time-group interaction model showed no differences in the slope of progression \n\nbetween groups from 24 to 48 weeks of treatment, for all variables, except 9HPTND \n\n(p=0.050). These results indicated that the effects (positive, negative or null) were \n\nalready present after 24 weeks of treatment, remaining similar.  \n\nExploratory analysis \n\nIn order to explore the possibility of a heterogenic pattern of response to lithium \n\ntherapy in the different neurological systems, we performed further analysis on \n\nNESSCA and SARA items (Table 4).  \n\nNESSCA was subdivided in the following clinically defined sub scores: cerebellar \n\n(gait ataxia plus limb ataxia); oculomotor (nystagmus plus progressive external \n\nophthalmoplegia); pyramidal (pyramidal findings); extrapyramidal (dystonia, rigidity, \n\nbradykinesia, eyelid retraction plus blepharospasm) and peripheral (fasciculation, \n\nsensory loss plus distal amyotrophies). The cerebellar sub score of NESSCA \n\nworsened more in placebo than in lithium group during the overall 48 weeks on ITT \n\n(p<0.001). After 24 and 48 weeks of treatment, there was a mean progression in \n\ncerebellar NESSCA of 0.81 (95% CI 0.44 to 1.18, p<0.001) and 0.64 points (95% CI \n\n0.23 to 1.05, p=0.002) faster in placebo than in lithium group. Neither other NESSCA \n\nsub scores nor SARA items presented different progressions during the study period, \n\nsee Table 4.  \n\nPlanned analysis of interactions \n\nCAGexp repeats \u2013 The randomization strata of ?74 or >74 CAGexp were analyzed \n\nagainst the primary and secondary effectiveness outcomes.  \n\nCAGexp strata interacted significantly with NESSCA progression between groups \n\n(p=0.007). Patients with ?74 CAGexp (n=18) progressed significantly less in the \n\nlithium group after 24 weeks (-2.87, CI 95% 1.51 to 4.23, p=<0.001), with a trend \n\nafter 48 weeks (-1.87, CI -3.77 to 0.03, p=0.054). There was no difference between \n\n\n\n151 \n \n\ngroups in NESSCA progression in patients with >74 CAGexp (N=42) after 24 \n\n(p=0.894) or 48 weeks (p=0.709). However, no significant interaction of NESSCA sub \n\nscores with CAG strata was found. For instance, cerebellar NESSCA progressed \n\nsignificantly less in lithium group both in patients with ? 74 CAGexp (p<0.001 and \n\np=0.066; after 24 and 48 weeks, respectively) and >74 CAGexp (p=0.016 and \n\np=0.011; after 24 and 48 weeks, respectively). \n\nThere was a trend for the z score of Click Test D to interacted with CAGexp strata \n\n(p=0.053). Patients with ? 74 CAGexp progressed significantly less in the lithium than \n\nin the placebo group after 48 weeks (1.03, CI 95% 0.33 to 1.74, p=0.004). There was \n\nno difference between groups in patients with > 74 CAG exp after 24 (p=0.415) or 48 \n\nweeks (p=0.651). The z score of Click Test ND did not interact with CAGexp strata \n\n(p=0.468). There was a trend for a CCFS interaction with CAGexp (p=0.069). Only \n\npatients with ? 74 CAGexp progressed significantly less in the lithium than in the \n\nplacebo group, with a trend after 24 weeks (0.05, CI 95% -0.006 to 0.12, p=0.076) \n\nthat became significant after 48 weeks of treatment (0.70, CI 95% 0.02 to 0.12, \n\np=0.004).  \n\nThe only result that significantly favored placebo in the study was the interaction of \n\nBarthel index with CAGexp (p=0.013). Patients with ? 74 CAGexp progressed \n\nsignificantly less in the placebo group than the lithium group only after 48 weeks (-\n\n6.68, CI 95% -11.98 to -1.39, p=0.013). \n\nThere was no significant interaction of CAGexp with the progressions of SARA \n\n(p=0.293), gait ataxia severity (p=0.934), 8MW (p=0.184), PATA rate (p=0.808), \n\n9HPTD (p=0.824) and 9HPTND (p=0.684), SCAFI (p=0.345), BDI (p=0.421) and the \n\nphysical (p=0.484), psychological (p=0.816), social relationships (p=0.597) and \n\nenvironment (p=0.668) domains of WHOQOL-bref.  \n\nLithium levels \n\nAverage lithium levels obtained in per-protocol population under lithium therapy were \n\ntested against all outcomes under study. The only associations found were those \n\nwith total NESSCA (R=0.41, p=0.037, Pearson) and its extrapyramidal subscores \n\n(R=0.40, p=0.04) progressions. In other words, the higher the average lithium levels \n\nof a given patient, the faster was the worsening in the extrapyramidal subscore of \n\nNESSCA. \n\n\n\n152 \n \n\nBlinding \n\nEleven months after the study beginning, the research assistant physicians where \n\nasked about their impression of which drug each of their patients was taking. In the \n\nlithium group, 51.7% were judged as taking lithium and 48.3% placebo. In the \n\nplacebo group 32.3% were judged as taking lithium and 67.7% as taking placebo \n\n(p=0.2), indicating that study masking was effective.  \n\nDiscussion \n\nLithium carbonate was safe in patients with MJD/SCA3 but did not substantially \n\nmodify the disease progression as measured by NESSCA. The study was completed \n\nafter 48 weeks of follow up, and it was stopped based on a futility analysis related to \n\nthe study design. This was a single center study in which the maximum capacity of \n\nfollowing patients with the chosen eligibility criteria was close to the number of the \n\nrecruited patients. Considering this, our futility analysis was performed in a time \n\nbased perspective rather than increasing the number of participants. This analysis \n\nconcluded that the study would be underpowered with the current population and \n\ndesign to detect a significant effect in the primary effectiveness endpoint if continued \n\nuntil 72 weeks. However, even being a single center trial, the present study is the \n\nlargest and longest randomized clinical ever performed for MJD/SCA3. \n\nWe have not found a significant effect of lithium treatment in the semiquantitative \n\nscales NESSCA - a multisystem neurological-examination based evaluation - and \n\nSARA - a scale based only on ataxic manifestation. However, both scales depicted a \n\ntrend for an effect favoring lithium. The quantitative ataxia scores of gait (8MW, on \n\nper-protocol analysis), word speed (PATA rate), and non-dominant finger pointing \n\ncoordination (Click Test ND), all had significant slower progressions with lithium \n\ntreatment after 48 weeks. And in consequence, both composite scores of the \n\nquantitative measures, SCAFI (based on 8MW, 9HPT and PATA rate) and CCFS \n\n(based on Click Test D and 9HPTD) also showed a slower progression in the lithium \n\ngroup during the same period. The main advantage of these quantitative \n\nperformance ataxia scales is to reliably detect small clinical changes over time, in a \n\ncontinuous measure, that theoretically provide better sensitivity and responsiveness \n\nto the scale. Lithium-treated patients also reported lower (better) PGI scores than \n\nplacebo indicating that a subjective difference in disease progression between \n\n\n\n153 \n \n\ngroups was felt by patients and that the results obtained with quantitative ataxia \n\nscales may be clinically relevant.  \n\nGait ataxia severity also progressed slowly in lithium treated patients during both 24 \n\nand 48 weeks. In the exploratory analysis of NESSCA, the cerebellar sub score also \n\npresented a slower progression in the lithium group. These results are in accordance \n\nto those obtained with the quantitative ataxia scores, and strongly suggest that \n\nlithium might be effective in cerebellar function. In contrast, lithium had no significant \n\neffect on oculomotor, pyramidal, extrapyramidal and peripheral subscores of \n\nNESSCA.  The lack of effectiveness on these domains might explain the non-\n\nsignificant result in the total scale. Of note, cerebellar NESSCA accounted for 32.4% \n\nand 23.6% of total NESSCA for patients with ?74 and >74 CAGexp, respectively. This \n\ndifference may explain why lithium was effective in total NESSCA only for patients \n\nwith ?74 CAGexp, while in cerebellar NESSCA lithium was effective for both strata. \n\nAfter 48 weeks, the mean progression of NESSCA in the placebo group was 1.45 \n\npoints. While in this period cerebellar NESSCA (range: 0-7, 2 items) progressed 0.74 \n\n(SE 0.13) points, the sum of pyramidal, extrapyramidal and peripheral NESSCA \n\n(range: 0-19, 9 items) only progressed 0.23 (SE 0.47) points in the placebo group. \n\nTherefore, we could not exclude a lithium effect in some of these symptoms since \n\nthey did not progressed significantly during the study. Extracerebellar signs in SCAs \n\ncontribute importantly to patients\u2018 handicap, which was one of the reasons for \n\nchoosing NESSCA as the primary effectiveness endpoint. Recent evidence from the \n\nInventory of Non-Ataxia Signs (INAS) showed that extracerebellar features, and not \n\nnecessarily the scales, present an unsatisfactory responsiveness\n38,39\n\n and therefore \n\nshould be assessed in future clinical trials only as secondary outcomes. Importantly, \n\nhigher lithium concentrations (> than 0.6 mEq/L) were related to a faster progression \n\nin the extrapyramidal subscore of NESSCA which might have contributed to the \n\nnegative result on the total score. These data indicate that lower lithium \n\nconcentrations ranges should be chosen in future studies.   \n\nThe cerebellar function instruments presented similar progression rates in the \n\nplacebo group than the reported natural history of SCAs.\n4,38,40\n\n Negative findings \n\noccurred with Barthel index and all domains of WHOQOL bref. It is worth to mention \n\nthat lithium showed no effect in BDI, what excludes the possibility that motor \n\n\n\n154 \n \n\nimprovements seen in quantitative cerebellar scores could be attributed to an \n\nantidepressant effect.  \n\nA small number of patients were lost during follow-up. The study dropout rate was \n\nlower than previous trials with lithium in neurodegenerative disorders, even with \n\nsimilar serum levels target.\n41\n\n Most patients were considered adherent, which was \n\nconfirmed with frequent lithium serum levels evaluations in both groups and with the \n\ncounting of the number of tablets that were taken. Therefore, most of ITT and per-\n\nprotocol analysis results were similar.  \n\nIn conclusion, this randomised, double-blind, placebo controlled trial demonstrated \n\nsafety of lithium treatment in MJD/SCA3 patients, but failed to show a significant \n\nmodification of disease progression in the primary endpoint NESSCA. Several \n\nsecondary outcomes, all related to ataxic manifestations such as gait ataxia severity, \n\nquantitative tasks and composite scores, presented slower progressions with lithium \n\ntreatment, after 48 weeks. Although a symptomatic effect could not be excluded, \n\nthese results strongly suggest that lithium might be effective against ataxia \n\nprogression in MJD/SCA3. \n\nLithium acts on different neuroprotective pathways that may interfere with polyQ \n\nclass-wide pathogenic routes. Future cellular, animal and clinical studies will play a \n\nsignificant role to uncover these mechanisms. The present results open the \n\nperspectives for an effective treatment for MJD/SCA3 and other polyQ disorders. A \n\nmulticentric, randomized clinical trial is warrant in a near future, aiming to confirm \n\nlithium effectiveness in reducing the progression rate of cerebellar ataxia. \n\nContributors \n\nJAMS and LBJ participated in conception and design of the study. GNS, ADR and \n\nJAMS provided project management. AFSS, KCD, JAMS, RMC, RD, TLM were the \n\nresearch assistant and evaluating physicians. GVF, TCG and MLSP were \n\nresponsible for dispensing medications and provided the molecular diagnoses of \n\npatients. CRMR and LBJ were responsible for the dosage changes in the study \n\ndrugs. LBJ, DOGS and LVCP were responsible for the study financial support. \n\nJAMS, LBJ, VBLT and SC contributed to analysis and interpretation of data, and \n\nwriting of the paper. All authors reviewed the paper. \n\n\n\n155 \n \nAcknowledgments \n\nWe thank the patients who participated in the study and also the ones who were not \n\neligible. We thank HCPA and its Postgraduate Research Group (GPPG) that not only \n\nprovided financial support to the study, but also indirectly turn its realization possible \n\nby constructing the Center for Clinical Research building. We are grateful to \n\nEurofarma for donating lithium carbonate tablets used in this study. We had to thank \n\nspecially to the following workers of HCPA: Andrea Ramos Rambo, Cleber Ferrari, \n\nRodrigo Pires de Medeiros, Suzete Guterres Coelho, Tania Alves Braga, Jo\u00edza Lins \n\nCamargo and Rafael Zimmer. We thank Jos\u00e9 Roberto Goldim for all additional \n\nethical consultations and advices during the study.  This study was supported by \n\nFAPERGS (09/0078-5), CNPq (478888/2010-4), and FIPE-HCPA (09-418). JAMS \n\nand GVF were supported by CAPES. TCG, ADR, DOGS, LVP, MLSP, CRMR and \n\nLBJ were supported by CNPq. \n\nConflicts of interest \n\nWe have no conflicts of interest. \n\n \n\nReferences  \n\n \n\n1.  Kawaguchi Y, Okamoto T, Taniwaki M, et al. CAG expansions in a novel gene \n\nfor Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994;8:221\u2013\n\n228.  \n\n2. Maciel P, Gaspar C, DeStefano AL, et al. Correlation between CAG repeat \n\nlength and clinical features in Machado-Joseph disease. Am J Hum Genet \n\n1995;57:54\u201361.  \n\n3. Jardim LB, Pereira ML, Silveira I, et al. Neurologic findings in Machado-Joseph \n\ndisease: relation with disease duration, subtypes, and (CAG)n. Arch Neurol \n\n2001;58:899\u2013904.  \n\n4. Jardim LB, Hauser L, Kieling C, et al. Progression rate of neurological deficits in \n\na 10-year cohort of SCA3 patients. Cerebellum 2010; 9:419\u2013428.  \n\n5. Prestes PR, Saraiva-Pereira ML, Silveira I, et al. Machado-Joseph disease \n\nenhances genetic fitness: a comparison between affected and unaffected \n\nwomen and between MJD and the general population. Ann Hum Genet 2008; \n\n\n\n156 \n \n\n72:57\u201364.  \n\n6. Sequeiros J, Martins S, Silveira I. Epidemiology and population genetics of \n\ndegenerative ataxias. Handb Clin Neurol 2012;103:227\u2013251.  \n\n7. D\u00fcrr A, Stevanin G, Cancel G, et al. Spinocerebellar ataxia 3 and Machado-\n\nJoseph disease: clinical, molecular, and neuropathological features. Ann Neurol \n\n1996;39:490\u2013499. \n\n8. Costa M do C, Paulson HL. Toward understanding Machado-Joseph disease. \n\nProg Neurobiol 2012;97:239\u2013257.  \n\n9. Kieling C, Prestes PR, Saraiva-Pereira ML, Jardim LB. Survival estimates for \n\npatients with Machado-Joseph disease (SCA3). Clin Genet 2007;72:543\u2013545.  \n\n10. Zesiewicz TA, Greenstein PE, Sullivan KL, et al. A randomized trial of \n\nvarenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. \n\nNeurology 2012;78:545\u2013550. \n\n11. Carmichael J, Sugars KL, Bao YP, Rubinsztein DC. Glycogen synthase kinase-\n\n3beta inhibitors prevent cellular polyglutamine toxicity caused by the \n\nHuntington\u2018s disease mutation. J Biol Chem 2002;277:33791\u2013798.  \n\n12. Wood NI, Morton AJ. Chronic lithium chloride treatment has variable effects on \n\nmotor behaviour and survival of mice transgenic for the Huntington\u2018s disease \n\nmutation. Brain Res Bull 2003;61:375\u2013383.  \n\n13. Berger Z, Ttofi EK, Michel CH, et al. Lithium rescues toxicity of aggregate-prone \n\nproteins in Drosophila by perturbing Wnt pathway. Hum Mol Genet \n\n2005;14:3003\u20133011.  \n\n14. Pouladi MA, Brillaud E, Xie Y, et al. NP03, a novel low-dose lithium formulation, \n\nis neuroprotective in the YAC128 mouse model of Huntington disease. Neurobiol \n\nDis 2012;48:282\u2013289.  \n\n15. Watase K, Gatchel JR, Sun Y, Emamian E, Atkinson R, Richman R, et al. \n\nLithium therapy improves neurological function and hippocampal dendritic \n\narborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med \n\n2007;4:e182.  \n\n16. Wada A. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen \n\nsynthase kinase-3beta, beta-catenin, and neurotrophin cascades. J Pharmacol \n\nSci 2009;110:14\u201328.  \n\n17. Chuang D-M. The antiapoptotic actions of mood stabilizers: molecular \n\nmechanisms and therapeutic potentials. Ann N Y Acad Sci 2005;1053:195\u2013204. \n\n18. Leyhe T, Eschweiler GW, Stransky E, et al. Increase of BDNF serum \n\n\n\n157 \n \n\nconcentration in lithium treated patients with early Alzheimer\u2018s disease. J \n\nAlzheimers Dis 2009;16:649\u201356.  \n\n19. De Sousa RT, Van de Bilt MT, Diniz BS, et al. Lithium increases plasma brain-\n\nderived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. \n\nNeurosci Lett 2011;494:54\u201356. \n\n20. Bijur GN, Jope RS. Opposing actions of phosphatidylinositol 3-kinase and \n\nglycogen synthase kinase-3beta in the regulation of HSF-1 activity. J \n\nNeurochem 2000;75:2401\u20132408.  \n\n21. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic \n\nlateral sclerosis. Proc Natl Acad Sci USA 2008;105:2052\u20132057. \n\n22. McColl G, Killilea DW, Hubbard AE, et al. Pharmacogenetic analysis of lithium-\n\ninduced delayed aging in Caenorhabditis elegans. J Biol Chem 2008;283:350\u2013\n\n357.  \n\n23. Kwon B, Houpt TA. Phospho-acetylation of histone H3 in the amygdala after \n\nacute lithium chloride. Brain Res 2010;1333:36\u201347.  \n\n24. Lopez GJ, McElroy BA, Considine E, et al. Safety and tolerability of lithium \n\ncarbonate in spinocerebellar ataxia   type 1 (SCA1) patients: Lessons from a \n\nfeasibility study. Mov Disord 2010;25:S194\u2013S194. \n\n25. Hering S, Achm\u00fcller C, K\u00f6hler A, et al. Phenotype variability in spinocerebellar \n\nataxia type 2: a longitudinal family survey and a case featuring an unusual \n\nbenign course of disease. Mov Disord 2009;24:774\u2013777.  \n\n26. Adityanjee, Munshi KR, Thampy A. The syndrome of irreversible lithium-\n\neffectuated neurotoxicity. Clin Neuropharmacol 2005;28:38\u201349.  \n\n27. Bauer PO, Kotliarova SE, Matoska V, et al. Fluorescent multiplex PCR--fast \n\nmethod for autosomal dominant spinocerebellar ataxias screening. Genetika \n\n2005;41:830\u2013837.  \n\n28. Kieling C, Rieder CRM, Silva ACF, et al. A neurological examination score for \n\nthe assessment of spinocerebellar ataxia 3 (SCA3). Eur J Neurol 2008;15:371\u2013\n\n376.  \n\n29. Schmitz-H\u00fcbsch T, Du Montcel ST, Baliko L, et al. Scale for the assessment and \n\nrating of ataxia: development of a new clinical scale. Neurology 2006;66:1717\u2013\n\n1720. \n\n30. Saute JAM, Donis KC, Serrano-Munuera C, et al. Ataxia rating scales--\n\npsychometric profiles, natural history and their application in clinical trials. \n\nCerebellum 2012;11:488\u2013504.  \n\n\n\n158 \n \n\n31. Schmitz-H\u00fcbsch T, Giunti P, Stephenson DA, et al. SCA Functional Index: a \n\nuseful compound performance measure for spinocerebellar ataxia. Neurology \n\n2008;71:486\u2013492. \n\n32. Du Montcel ST, Charles P, Ribai P, et al. Composite cerebellar functional \n\nseverity score: validation of a quantitative score of cerebellar impairment. Brain \n\n2008;131:1352\u20131361.  \n\n33. Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. Md State \n\nMed J 1965;14:61\u201365.  \n\n34. Fleck MP, Louzada S, Xavier M, et al. Application of the Portuguese version of \n\nthe abbreviated instrument of quality life WHOQOL-bref. Rev Saude Publica \n\n2000;34:178\u2013183. \n\n35. Gorenstein C, Andrade L. Validation of a Portuguese version of the Beck \n\nDepression Inventory and the State-Trait Anxiety Inventory in Brazilian subjects. \n\nBraz J Med Biol Res 1996;29:453\u2013457.  \n\n36. Guy W. ECDEU Assessment Manual for Psychopharmacology, rev. ed. \n\nRockville (Maryland), National Institute of Mental Health, 1976. \n\n37. Saute JAM, Da Silva ACF, Donis KC, Vedolin L, Saraiva-Pereira ML, Jardim LB. \n\nDepressive mood is associated with ataxic and non-ataxic neurological \n\ndysfunction in SCA3 patients. Cerebellum 2010;9:603\u2013605; author reply 606\u2013\n\n607.  \n\n38. Schmitz-H\u00fcbsch T, Fimmers R, Rakowicz M, et al. Responsiveness of different \n\nrating instruments in spinocerebellar ataxia patients. Neurology 2010;74:678\u2013\n\n84. \n\n39. Jacobi H, Rakowicz M, Rola R, et al. Inventory of Non-Ataxia Signs (INAS): \n\nValidation of a New Clinical Assessment Instrument. Cerebellum 2012 Oct 23. \n\n40. Chan E, Charles P, Ribai P, et al. Quantitative assessment of the evolution of \n\ncerebellar signs in spinocerebellar ataxias. Mov Disord 2011;26:534\u2013538. \n\n41. Aggarwal SP, Zinman L, Simpson E, et al. Safety and efficacy of lithium in \n\ncombination with riluzole for treatment of amyotrophic lateral sclerosis: a \n\nrandomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:481\u2013\n\n488. \n\n \n\n  \n\n\n\n159 \n \nFigures Subtitles \n\nFigure 1 - Trial Flow Diagram \n\nFigure 2 \u2013 Mean progression of semiquantitative SCA scales  \n\nA. Mean progression of NESSCA, ITT. B. Mean progression of NESSCA, per-protocol. C. Mean progression of \n\nSARA, ITT. D. Mean progression of gait ataxia severity, ITT. Bars are SE. ITT= Intention-to-treat. NESSCA= \n\nNeurological Examination Score for the Assessment of Spinocerebellar Ataxia. SARA= Scale for the \n\nAssessment and Rating of Ataxia. \n\nFigure 3 \u2013 Mean progression of individual and composite quantitative ataxia scores \n\nA. Mean progression of 8MW. B. Mean progression of PATA rate. C. Mean progression of 9HPTD. D. Mean \n\nprogression of non-dominant hand Click Test. E. Mean progression of SCAFI. F. Mean progression of CCFS. \n\nBars are SE. 8MW= 8m Walking-time. 9HPTD= Dominant hand 9-Hole Pegboard Test. SCAFI= SCA \n\nFunctional Index. CCFS= Composite Cerebellar Functional Score.  \n\n \n\nTables \n\nTable 1 - Demografics and Baseline Characteristics \n\n \n\nData are mean (SD), median (25\nth\n to 75\n\nth\n percentile) or number (%). CAGn= number of expanded CAG repeats. \n\nNESSCA= Neurological Examination Score for the Assessment of Spinocerebellar Ataxia. SARA= Scale for the \n\nAssessment and Rating of Ataxia. 8MW= 8m Walking-time. 9HPT= 9-Hole Pegboard Test. D= dominant hand. \n\nND=non-dominant hand. SCAFI= SCA Functional Index. CCFS= Composite Cerebellar Functional Score. BDI= \n\nBeck Depression Inventory. All functional scores were shown as z-scores. \n\n \n\nTable 2 \u2013 Adverse events after 48 weeks.  \n\nData are number of events (%). AE = Adverse events \n\n \n\nTable 3 \u2013 Intention-to-treat analysis: lithium carbonate effectiveness in MJD/SCA3  \n\n\n\n160 \n \n1\nOverall 48 weeks difference between groups in GEE model; \n\n2\nEffect related to the difference in progression of \n\nplacebo to lithium groups; \n# \n\nN=51, see methods for explanation.*p<0.05, **p<0.01. All functional scores were \n\nshown as z-scores. NESSCA= Neurological Examination Score for the Assessment of Spinocerebellar Ataxia. \n\nSARA= Scale for the Assessment and Rating of Ataxia. 8MW= 8m Walking-time. 9HPT= 9-Hole Pegboard \n\nTest. D= dominant hand. ND=non-dominant hand. SCAFI= SCA Functional Index. CCFS= Composite \n\nCerebellar Functional Score. BDI= Beck Depression Inventory. \n\n \n\nTable 4 \u2013 NESSCA and SARA exploratory analysis \n\n1\nOverall 48 weeks difference between groups in GEE model on ITT;\n\n 2\n Effect related to the difference in \n\nprogression of placebo to lithium groups. ***p<0.001. NESSCA= Neurological Examination Score for the \n\nAssessment of Spinocerebellar Ataxia. SARA= Scale for the Assessment and Rating of Ataxia. \n\n \n\nSupplemental Material \n\n \n\nSupplemental table 1 \u2013 Other medical treatments \n\nData are the total number of patients taking other medical treatments at baseline visit. \n1\nVitamins, nutritional \n\nsupplements and antioxidants included: coenzyme Q10, isoflavone, omega 3, tryptophan and vitamins C and E. \n\nPPI= Proton-Pump Inhibitors. SNRI= Serotonin\u2013Norepinephrine Reuptake Inhibitors. SSRI= \n\nSelective Serotonin Reuptake Inhibitors.  \n\n \n\nSupplemental Table 2 \u2013 Most frequent adverse events after 48 weeks  \n\nData are number of events (%). AE = Adverse events. ECG = electrocardiogram. TSH= thyroid stimulating \n\nhormone.  \n\n \n\nSupplemental Table 3 \u2013 Per-protocol analysis: lithium carbonate efficacy in MJD/SCA3  \n\n\n\n161 \n \n1\n Overall 48 weeks difference between groups in GEE model; \n\n2\n Effect related to the difference in progression of \n\nplacebo to lithium groups; \n# \n\nN=48, see methods for explanation. *p<0.05, **p<0.01. All functional scores were \n\nshown as z-scores. NESSCA= Neurological Examination Score for the Assessment of Spinocerebellar Ataxia. \n\nSARA= Scale for the Assessment and Rating of Ataxia. 8MW= 8m Walking-time. 9HPT= 9-Hole Pegboard \n\nTest. D= dominant hand. ND=non-dominant hand. SCAFI= SCA Functional Index. CCFS= Composite \n\nCerebellar Functional Score. BDI= Beck Depression Inventory. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  \n\n\n\n162 \n \n\n \nPlacebo (n=31) Lithium (n=31) \n\nWomen 17 (54%) 15 (48%) \n\nAge at Baseline 40.4 (9.2) 40.5 (9.6) \n\nAge at Onset 34.5 (9) 34.5 (8.8) \n\nDuration 6.1 (2.5) 6 (2.6) \n\nCAGn 75.4 (2.8) 75.3 (3.3) \n\nNESSCA 14.7 (4.7) 13.8 (4.7) \n\nSARA 11.4 (3.7) 10.3 (4.3) \n\nGait Ataxia \n\nSeverity \n\n1 3 (10%) 5 (16%) \n\n2 19 (61%) 18 (58%) \n\n3 9 (29%) 8 (26%) \n\n8MW 8.48 (7.0 to 14.2) 7.3 (5.9 to 12.7) \n\nPATA rate 25.6 (5.8) 26.3 (7.3) \n\n9HPT D 17.8 (2.9) 18.9 (6.0) \n\n9HPT ND 20.37 (4.0) 20.7 (6.7) \n\nClick Test D 20.35 (3.8) 20.9 (4.8) \n\nClick Test ND 20.55 (3.6) 21.1(5.7) \n\nSCAFI -0.19 (0.62) -0.02 (1.11) \n\nCCFS 1.07 (0.06) 1.08 (0.08) \n\nBarthel 95 (6.58) 93.4 (9.8) \n\nBDI 13.23 (9.6) 11.4 (8.5) \n\nWHOQOL-bref \n\nPhysical \n50.58 (15.27) 57.6 (17.6) \n\nWHOQOL-bref \n\nPsychological \n60.35 (17.0) 65.7 (15.7) \n\nWHOQOL-bref \n\nSocial \n69.09 (17.10) 70.1 (17.3) \n\nWHOQOL-bref \n\nEnvironment \n60.9 (16.57) 61.6 (13.0) \n\nPhysical Therapy 14 (45%) 14 (45%) \n\nPhonotherapy 6 (19%) 3 (10%) \n\n \n\n \n\nTable 1 - Demografics and Baseline Characteristics \n\nData are mean (SD), median (25\nth\n to 75\n\nth\n percentile) or number (%). CAGn= number of expanded CAG repeats. \n\nNESSCA= Neurological Examination Score for the Assessment of Spinocerebellar Ataxia. SARA= Scale for the \n\nAssessment and Rating of Ataxia. 8MW= 8m Walking-time. 9HPT= 9-Hole Pegboard Test. D= dominant hand. \n\nND=non-dominant hand. SCAFI= SCA Functional Index. CCFS= Composite Cerebellar Functional Score. BDI= \n\nBeck Depression Inventory. All functional scores were shown as z-scores. \n\n \n\n\n\n163 \n \nAE Placebo Lithium Total p \n\nTotal 92 (49.7%) 95 (50.3%) 187 0.884 \n\nMild 59 (50.4%) 58 (49.6%) 117 (62.6%) \n\n0.913 Moderate 28 (47.5%) 31 (52.5%) 59 (31.6%) \n\nSevere 5 (45.5%) 6 (54.5%) 11 (5.9%) \n\nSerious 1 (1.1%) 3 (3.2%) 4 (2.1%) 0.621 \n\n \n\nTable 2 \u2013 Adverse events after 48 weeks  \n\nData are number of events (%). AE = Adverse events \n\n  \n\n\n\n164 \n \n\nN=60 p\n1\n Favoring Effect\n\n2\n 95% CI \n\nNESSCA 0.222 Lithium \n24w 0.93 [-0.12;1.98] \n\n48w 0.35 [-1.0; 1.70] \n\nSARA 0.329 Lithium \n24w 0.26 [-1.02;1.53] \n\n48w 0.96 [-0.46;2.38] \n\nAtaxia Severity 0.008** Lithium \n24w 0.26* [0.03;0.48] \n\n48w 0.32* [0.07;0.57] \n\n8MW\n#\n 0.244 Lithium \n\n24w 3.62 [-11.4;18.66] \n\n48w 14.63 [-3.09;32.36] \n\nPATA rate 0.002** Lithium \n24w -0.37* [-0.65;-0.08] \n\n48w -0.44** [-0.73;-0.14] \n\n9HPT D 0.074 Lithium \n24w 0.31 [-0.06;0.68] \n\n48w 0.34 [-0.07;0.76] \n\n9HPT ND 0.619 \nLithium 24w 0.14 [-0.19;0.48] \n\nPlacebo 48w -0.33 [-0.84;0.18] \n\nClick Test D 0.051 Lithium \n24w 0.42 [-0.08;0.93] \n\n48w 0.38 [-0.006;0.76] \n\nClick Test ND 0.023* Lithium \n24w 0.57 [-0.03;1.17] \n\n48w 0.38 [-0.06;0.82] \n\nSCAFI\n#\n 0.015* Lithium \n\n24w -0.20 [-0.41;0.003] \n\n48w -0.32* [-0.57;-0.06] \n\nCCFS 0.029* Lithium \n24w 0.03 [-0.002;0.06] \n\n48w 0.03* [0.003;0.05] \n\nBarthel 0.780 Lithium \n24w -0.68 [-4.37;3.00] \n\n48w -0.23 [-3.74;3.28] \n\nBDI 0.420 Lithium \n24w 1.58 [-1.50;4.66] \n\n48w 0.39 [-1.87;2.66] \n\nWHOQOL-bref \n\nPhysical \n0.442 Lithium \n\n24w -0.95 [-8.85;6.95] \n\n48w -4.24 [-11.29;2.80] \n\nWHOQOL-bref \n\nPsychological \n0.402 Placebo \n\n24w 0.61 [-6.27;7.49] \n\n48w 3.97 [-1.81;9.76] \n\nWHOQOL-bref \n\nSocial \n0.209 Placebo \n\n24w 5.69 [-2.59;13.97] \n\n48w 3.16 [-5.10;11.43] \n\nWHOQOL-bref \n\nEnvironment \n0.948 \n\nPlacebo 24w 0.57 [-5.44;6.59] \n\nLithium 48w -0.25 [-6.05;5.54] \n\n \n\nTable 3 \u2013 Intention-to-treat analysis: lithium carbonate effectiveness in MJD/SCA3  \n\n1\nOverall 48 weeks difference between groups in GEE model; \n\n2\nEffect related to the difference in progression of \n\nplacebo to lithium groups; \n# \n\nN=51, see methods for explanation.*p<0.05, **p<0.01. All functional scores were \n\nshown as z-scores. NESSCA= Neurological Examination Score for the Assessment of Spinocerebellar Ataxia. \n\nSARA= Scale for the Assessment and Rating of Ataxia. 8MW= 8m Walking-time. 9HPT= 9-Hole Pegboard Test. \n\nD= dominant hand. ND=non-dominant hand. SCAFI= SCA Functional Index. CCFS= Composite Cerebellar \n\nFunctional Score. BDI= Beck Depression Inventory. \n\n\n\n165 \n \n\nVariable p\n1\n Favoring Effect\n\n2\n 95% CI \n\nNESSCA sub scores     \n\nNESSCA cerebellar &lt;0.001*** Lithium \n24w 0.81*** [0.44;1.18] \n\n48w 0.64** [0.23; 1.05] \n\nNESSCA oculomotor 0.685 Lithium \n24w 0.09 [-0.23;0.41] \n\n48w 0.02 [-0.28;0.31] \n\nNESSCA pyramidal 0.788 Placebo \n24w -0.01 [-0.38;0.36] \n\n48w -0.07 [-0.41;0.26] \n\nNESSCA \n\nextrapyramidal \n0.766 \n\nLithium 24w 0.074 [-0.52;0.67] \n\nPlacebo 48w -0.240 [-0.84;0.36] \n\nNESSCA peripheral 0.912 \nPlacebo 24w -0.048 [-0.47;0.37] \n\nLithium 48w 0.005 [-0.53;0.54] \n\nSARA items      \n\nGait 0.176 Lithium \n24w 0.227 [-0.16;0.61] \n\n48w 0.299 [-0.16;0.76] \n\nStance 0.181 Lithium \n24w 0.293 [-0.20;0.78] \n\n48w 0.288 [-0.19;0.77] \n\nSitting 0.756 Lithium \n24w 0.67 [-0.15;0.29] \n\n48w 0.002 [-0.28;0.28] \n\nSpeech 0.913 \nPlacebo 24w -0.112 [-0.47;0.25] \n\nLithium 48w 0.077 [-0.25;0.41] \n\nFinger chase 0.271 Lithium \n24w 0.050 [-0.16;0.26] \n\n48w 0.139 [-0.05;0.33] \n\nNose-finger  0.920 \nPlacebo 24w -0.081 [-0.27;0.11] \n\nLithium 48w 0.098 [-0.10;0.30] \n\nFast alternating \n\nmovements \n0.230 Lithium \n\n24w 0.149 [-0.21;0.51] \n\n48w 0.269 [-0.13;0.67] \n\nHeel-shin  0.869 \nPlacebo 24w -0.006 [-2.43;3.36] \n\nLithium 48w 0.46 [-1.87;2.66] \n\n \n\nTable 4 \u2013 NESSCA and SARA exploratory analysis \n\n1\nOverall 48 weeks difference between groups in GEE model on ITT;\n\n 2\n Effect related to the difference in \n\nprogression of placebo to lithium groups. ***p<0.001. NESSCA= Neurological Examination Score for the \n\nAssessment of Spinocerebellar Ataxia. SARA= Scale for the Assessment and Rating of Ataxia. \n\n \n\n \n\n \n\n\n\n166 \n \n\n \n\n  \n\n\n\n167 \n \n\n\n\n168 \n \n\n \n\n \n\n \n\n  \n\n\n\n169 \n \n\nDrug Class Placebo Lithium \n\nSSRI 8 8 \n\nTricyclic antidepressants 6 4 \n\nHormonal contraceptives 3 4 \n\nBenzodiazepines 2 4 \n\nVitamins, nutritional \n\nsupplements and \n\nantioxidants1 \n\n3 3 \n\nMuscle relaxant / analgesics 3 2 \n\nPPI 1 4 \n\nAnticholinergics 2 1 \n\nBeta-blockers 1 2 \n\nCalcium channel blockers 1 1 \n\n?-agonists 0 1 \n\nLevodopa 1 0 \n\nSNRI 1 0 \n\nStatins 1 0 \n\n \nSupplemental table 1 \u2013 Other medical treatments \n\nData are the total number of patients taking other medical treatments at baseline visit. \n1\nVitamins, nutritional \n\nsupplements and antioxidants included: coenzyme Q10, isoflavone, omega 3, tryptophan and vitamins C and E. \n\nPPI= Proton-Pump Inhibitors. SNRI= Serotonin\u2013Norepinephrine Reuptake Inhibitors. SSRI= \n\nSelective Serotonin Reuptake Inhibitors.  \n\n \n\n  \n\n\n\n170 \n \n\nAE Placebo Lithium Total \n\nMinor ECG \n\nabnormalities \n6 (50%) 6 (50%) 12 \n\nMuscular pain 7 (63.6%) 4 (36.4%) 11 \n\nHeadache 4 (44.4%) 5 (55.6%) 9 \n\nTSH elevation 1 (12.5%) 7 (87.5%) 8 \n\nFalls 2 (25%) 6 (75%) 8 \n\nSomnolence 4 (50%) 4 (50%) 8 \n\nMild transaminases \n\nelevation \n5 (71.4%) 2 (28.6%) 7 \n\nDiarrhea 2 (33.2%) 4 (66.7%) 6 \n\nErectile dysfunction 1 (16.7%) 5 (83.3%) 6 \n\nMicroscopic hematuria 4 (66.7%) 2 (33.3%) 6 \n\nHeart burn 2 (40%) 3 (60%) 5 \n\nInsomnia 3 (60%) 2 (40%) 5 \n\n \n\nSupplemental Table 2 \u2013 Most frequent adverse events after 48 weeks  \n\nData are number of events (%). AE = Adverse events. ECG = electrocardiogram. TSH= thyroid stimulating \n\nhormone.  \n\n \n\n  \n\n\n\n171 \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nSupplemental Table 3 \u2013 Per-protocol analysis: lithium carbonate efficacy in MJD/SCA3  \n\n1\n Overall 48 weeks difference between groups in GEE model; \n\n2\n Effect related to the difference in progression of \n\nplacebo to lithium groups; \n# \n\nN=48, see methods for explanation. *p<0.05, **p<0.01. All functional scores were \n\nshown as z-scores. NESSCA= Neurological Examination Score for the Assessment of Spinocerebellar Ataxia. \n\nSARA= Scale for the Assessment and Rating of Ataxia. 8MW= 8m Walking-time. 9HPT= 9-Hole Pegboard Test. \n\nD= dominant hand. ND=non-dominant hand. SCAFI= SCA Functional Index. CCFS= Composite Cerebellar \n\nFunctional Score. BDI= Beck Depression Inventory. \n\nN=54 p\n1\n Favoring Effect\n\n2\n 95% CI \n\nNESSCA 0.116 Lithium \n24w 0.91 [-0.15;1.97] \n\n48w 0.72 [-0.65;2.09] \n\nSARA 0.557 \nPlacebo 24w -0.10 [-1.33;1.14] \n\nLithium 48w 0.81 [-0.61;2.24] \n\nAtaxia Severity 0.010** Lithium \n24w 0.28* [0.05;0.51] \n\n48w 0.30* [0.03;0.58] \n\n8MW\n#\n 0.026* Lithium \n\n24w 8.49 [-3.41;20.4] \n\n48w 19.39* [4.37;34.41] \n\nPATA rate 0.010** Lithium \n24w -0.28 [-0.58;0.01] \n\n48w -0.44* [-0.74;-0.13] \n\n9HPT D\n#\n 0.117 Lithium \n\n24w 0.36 [-0.02;0.75] \n\n48w 0.24 [-0.19;0.68] \n\n9HPT ND\n#\n 0.184 \n\nLithium 24w 0.01 [-0.33;0.35] \n\nPlacebo 48w -0.49 [-1.02;0.03] \n\nClick Test D 0.210 Lithium \n24w 0.23 [-0.27;0.75] \n\n48w 0.26 [-0.10;0.63] \n\nClick Test ND 0.137 Lithium \n24w 0.45 [-0.18;1.10] \n\n48w 0.17 [-0.23;0.58] \n\nSCAFI 0.015* Lithium \n24w -0.21 [-0.43;0.007] \n\n48w -0.33* [-0.59;-0.07] \n\nCCFS 0.155 Lithium \n24w 0.02 [-0.01;0.05] \n\n48w 0.02 [-0.006;0.01] \n\nBarthel 0.945 Lithium \n24w -0.14 [-4.11;3.84] \n\n48w -0.10 [-3.71;3.50] \n\nBDI 0.827 \nLithium 24w 0.62 [-2.58;3.82] \n\nPlacebo 48w -0.08 [-2.30;2.13] \n\nWHOQOL-bref \n\nPhysical \n0.527 Lithium \n\n24w -0.70 [-8.73;7.33] \n\n48w -3.78 [-11.24;3.68] \n\nWHOQOL-bref \n\nPsychological \n0.271 Placebo \n\n24w 2.08 [-5.32;9.49] \n\n48w 4.50 [-1.97;10.98] \n\nWHOQOL-bref \n\nSocial \n0.110 Placebo \n\n24w 7.98 [-0.74;16.7] \n\n48w 3.56 [-4.83;11.96] \n\nWHOQOL-bref \n\nEnvironment \n0.841 Lithium \n\n24w -0.420 [-6.19;5.35] \n\n48w -0.558 [-6.78;5.67] \n\n\n\n172 \n \n \n\n \n\n6 CONSIDERA\u00c7\u00d5ES FINAIS \n \n\nEste trabalho produziu informa\u00e7\u00f5es originais sobre aspectos nutricionais e \n\nhormonais e sobre a seguran\u00e7a e a efic\u00e1cia do carbonato de l\u00edtio na DMJ/SCA3. \n\nAdemais, trouxe mais compreens\u00e3o sobre quais podem ser os melhores desfechos \n\ncl\u00ednicos (as escalas revisadas) e os melhores delineamentos, em futuros ensaios \n\ncl\u00ednicos para a condi\u00e7\u00e3o. \n\n \u00c9 da natureza da investiga\u00e7\u00e3o cient\u00edfica que uma linha nunca se encerre e \n\nque os seus resultados gerem novas hip\u00f3teses para os passos a seguir. A \n\ndescoberta cient\u00edfica \u00e9 um processo \u2013 e n\u00e3o uma revela\u00e7\u00e3o \u2013 e uma de suas \n\nbelezas \u00e9 justamente o seu car\u00e1ter especulativo em rela\u00e7\u00e3o ao que ainda n\u00e3o se \n\nsabe e que reside, por ora, no futuro. Nossos resultados levantaram diversas \n\nhip\u00f3teses, que por sua vez se imp\u00f5em como novos desafios a serem testados da \n\nmelhor maneira poss\u00edvel. \n\n Nossas conclus\u00f5es, ou evid\u00eancias principais, e sua incompletude, s\u00e3o as \n\nseguintes: \n\n1) Os sintomas depressivos s\u00e3o frequentes em pacientes com DMJ/SCA3 e \n\nest\u00e3o intimamente relacionados tanto com a gravidade das manifesta\u00e7\u00f5es \n\ncerebelares quanto extracerebelares. Estes sintomas representam significativo \n\nimpacto negativo sobre a qualidade de vida dos indiv\u00edduos, e s\u00e3o trat\u00e1veis. A \n\navalia\u00e7\u00e3o dos demais fatores relacionados \u00e0 redu\u00e7\u00e3o da qualidade de vida dos \n\npacientes com DMJ/SCA3 n\u00e3o est\u00e1 bem elucidada, assim como a defini\u00e7\u00e3o dos \n\nmelhores instrumentos para sua avalia\u00e7\u00e3o. A an\u00e1lise de valida\u00e7\u00e3o e responsividade \n\nno presente ECR do question\u00e1rio WHOQOL-bref est\u00e1 em fase de execu\u00e7\u00e3o e ser\u00e1 \n\nrelatada nos pr\u00f3ximos meses.    \n\n2) A DMJ/SCA3 est\u00e1 associada definitivamente \u00e0 perda de peso. Ao contr\u00e1rio \n\ndas previs\u00f5es, este emagrecimento associou-se muito claramente \u00e0 muta\u00e7\u00e3o (ao \n\ntamanho da repeti\u00e7\u00e3o expandida) e n\u00e3o exatamente \u00e0 progress\u00e3o da doen\u00e7a \u2013 \u00e0 \n\ndisfagia e outras incapacidades. Esse resultado sugere que a ATXN3 mutada produz \n\nalgum efeito sist\u00eamico, possivelmente de origem extraneuronal, que provoca \n\nprimariamente o emagrecimento. Uma taxa metab\u00f3lica basal elevada \u00e9 a primeira \n\nexplica\u00e7\u00e3o que se apresenta. Ademais, resta confirmar com mais robustez que a \n\n\n\n173 \n \n\ndisfagia ter\u00e1 de fato um papel irrelevante nesse achado. Um estudo caso-controle \n\nsobre o metabolismo basal e avalia\u00e7\u00e3o de pept\u00eddeos reguladores do apetite em \n\npacientes com in\u00edcio recente dos sintomas e em indiv\u00edduos pr\u00e9-sintom\u00e1ticos; e um \n\noutro que correlacione o grau de disfagia \u2013 medido por seu melhor instrumento, a \n\nvideofluoroscopia da degluti\u00e7\u00e3o \u2013 com o emagrecimento poderiam responder a \n\nessas d\u00favidas. Ambos est\u00e3o sendo planejados e ser\u00e3o realizados na sequ\u00eancia \n\ndesta tese. \n\n3) A expans\u00e3o CAG no ATXN3 est\u00e1 associada a altera\u00e7\u00f5es nos n\u00edveis s\u00e9ricos \n\nda prote\u00edna ligante do IGF-1, a IGFBP-1. Esse dado \u00e9 outra evid\u00eancia de um efeito \n\nsist\u00eamico, extraneuronal, da ATXN3 mutada e coloca a IGFBP-1 como poss\u00edvel \n\nbiomarcador da DMJ/SCA3. Como este efeito \u00e9 mediado e quais s\u00e3o suas \n\nconsequ\u00eancias s\u00e3o as perguntas que levantamos. Um novo estudo, que me\u00e7a a \n\nexpress\u00e3o da IGFBP-1 e a correlacione com a CAG expandida, poder\u00e1 ajudar a \n\nesclarecer se este efeito \u00e9 devido a uma express\u00e3o aumentada ou a uma redu\u00e7\u00e3o \n\nde sua degrada\u00e7\u00e3o. Esse estudo, em consequ\u00eancia desta tese, j\u00e1 est\u00e1 em \n\nandamento. Uma melhor defini\u00e7\u00e3o do papel da IGFBP-1 como biomarcador da \n\ndoen\u00e7a e a avalia\u00e7\u00e3o da relev\u00e2ncia cl\u00ednica deste achado ser\u00e1 realizada no estudo de \n\nbiomarcadores aninhado ao ECR com carbonato de l\u00edtio. \n\n4) A DMJ/SCA3 est\u00e1 associada a um aumento da sensibilidade perif\u00e9rica \u00e0 \n\ninsulina que leva a redu\u00e7\u00e3o de seus n\u00edveis s\u00e9ricos e manuten\u00e7\u00e3o da glicemia.  A \n\nmaior sensibilidade perif\u00e9rica \u00e0 insulina ocorreu em indiv\u00edduos com idades de inicio \n\nmais precoces e de forma independente do tamanho da CAG expandida, seu \n\nprincipal preditor. Apesar de a redu\u00e7\u00e3o da sinaliza\u00e7\u00e3o intracelular de insulina poder \n\nresultar em Diabetes Mellitus, ela tamb\u00e9m pode aumentar a longevidade e atrasar o \n\nprocesso de toxicidade mediada pela agrega\u00e7\u00e3o proteica (Cohen e Dillin, 2009). \n\nEsse cen\u00e1rio \u00e9 o oposto do que encontramos para DMJ/SCA3 e gera hip\u00f3teses \n\niniciais sobre os mecanismos do prov\u00e1vel efeito modificador da doen\u00e7a que \n\ndescrevemos para a insulina. Como e quando estas altera\u00e7\u00f5es iniciam e se existe \n\npotencial terap\u00eautico na modula\u00e7\u00e3o destas vias, s\u00e3o algumas das perguntas a \n\nserem respondidas. Um estudo avaliando o sistema insulina/IGF-1 em est\u00e1gios pr\u00e9-\n\nsintom\u00e1ticos e precoces da doen\u00e7a poder\u00e1 come\u00e7ar a responder \u00e0 quest\u00e3o. Esse \n\nestudo, consequ\u00eancia desta tese, j\u00e1 est\u00e1 em andamento.  \n\n\n\n174 \n \n\n 5) A progress\u00e3o da NESSCA possivelmente n\u00e3o foi capaz de demonstrar a \n\nefetividade do tratamento com carbonato de l\u00edtio em 60 pacientes com DMJ/SCA3. \n\nAinda que v\u00e1rios desfechos secund\u00e1rios tenham apresentado melhora significativa, \n\nn\u00e3o resultam em n\u00edvel de evid\u00eancia suficiente para recomendar o uso deste \n\nmedicamento. Estes resultados indicam a necessidade de um segundo ECR, que \n\nuse outro desfecho prim\u00e1rio e que utilize os dados do ensaio anterior para aprimorar \n\no seu delineamento. Os dados essenciais seriam conhecer a progress\u00e3o do \n\ndesfecho no tempo e ter uma estimativa mais pr\u00f3xima do tamanho do efeito a ser \n\nbuscado. Estudos de hist\u00f3ria natural podem ser uteis neste sentido, contudo os \n\ndados do presente ECR ser\u00e3o certamente de maior valia para o planejamento de \n\nfuturos estudos com l\u00edtio e com outros medicamentos, pois demonstram a evolu\u00e7\u00e3o \n\ndas principais escalas cl\u00ednicas de SCAs j\u00e1 descritas considerando a presen\u00e7a do \n\nefeito placebo e de um maior efeito Hawthorne, relacionado ao acompanhamento \n\ncontrolado de um ensaio cl\u00ednico. Duas classes de desfecho poder\u00e3o ser eleitas: \n\nescalas cl\u00ednicas ou biomarcadores. Para a quest\u00e3o dos biomarcadores, n\u00f3s nos \n\npreparamos e colhemos uma s\u00e9rie deles nos tr\u00eas tempos do ECR \u2013 baseline, 6 e 12 \n\nmeses \u2013 e poderemos ver como eles progrediram. Entre eles, est\u00e3o o IGF-1, \n\nInsulina, IGFBP-1, NSE e BDNF. Esses resultados ser\u00e3o analisados em 2013 e \n\npodem levar \u00e0 sugest\u00e3o de biomarcadores mais sens\u00edveis \u00e0 resposta terap\u00eautica. \n\nPor outro lado, vimos que v\u00e1rios instrumentos de medida da ataxia melhoraram em \n\n12 meses. Seria essa resposta observada esp\u00faria? Um ECR usando uma delas \n\ncomo desfecho prim\u00e1rio poder\u00e1 dar convic\u00e7\u00e3o completa. Ser\u00e1 necess\u00e1rio nos \n\npr\u00f3ximos meses analisar em detalhes os desfechos que utilizamos no ECR \n\napresentado, bem como as subpopula\u00e7\u00f5es em que se sugere um maior benef\u00edcio, a \n\nfim de calcularmos os tamanhos amostrais necess\u00e1rios para cada um dos \n\ninstrumentos. Certamente um n\u00famero ainda maior de pacientes ser\u00e1 necess\u00e1rio \n\npara provar a efetividade do carbonato de l\u00edtio em reduzir a progress\u00e3o da \n\nDMJ/SCA3, havendo a necessidade deste segundo ECR ser multic\u00eantrico, e \u00e9 essa \n\na nossa proposi\u00e7\u00e3o final. \n\n \n\n \n\n \n\n \n\n\n\n175 \n \n\n7 AP\u00caNDICES \n\n7.1 Termos de consentimento livre e esclarecido  \n\n \n\nPROJETO: O PAPEL DO FATOR SEMELHANTE \u00c0 INSULINA TIPO I (IGF-1) NA DOEN\u00c7A DE MACHADO-\n\nJOSEPH \n\nINFORMA\u00c7\u00d5ES AOS INDIV\u00cdDUOS CONVIDADOS A PARTICIPAR DO ESTUDO (CASOS). \n\n \n\n \n\nEsta \u00e9 uma pesquisa que tem por objetivo principal analisar se uma subst\u00e2ncia \n\nnatural e circulante no sangue e nos tecidos das pessoas, um neuroprotetor, conhecido pelo \n\nnome de ?Sistema do Fator de Crescimento semelhante \u00e0 Insulina do Tipo 1 (IGF-1)?,  est\u00e1  \n\nalterado nos pacientes com a Doen\u00e7a de Machado-Joseph. A inten\u00e7\u00e3o \u00e9 a de se \n\ncompreender melhor os mecanismos dessa doen\u00e7a e, talvez, buscar a aquisi\u00e7\u00e3o de \n\nconhecimento que possibilite um futuro tratamento eficaz para os pacientes afetados por \n\nesse problema de sa\u00fade. Ser\u00e3o dosadas v\u00e1rias subst\u00e2ncias no seu sangue ou plasma: os \n\nn\u00edveis s\u00e9ricos de IGF-1, IGFBP-1 e 3, Albumina, Insulina, Colesterol Total, Colesterol HDL, \n\nTriglicer\u00eddeos, Glicose, Creatinina, Bilirrubinas e Tempo de Protrombina. Essas subst\u00e2ncias \n\nser\u00e3o dosadas em dois grupos de pessoas: nos doentes portadores da Doen\u00e7a de \n\nMachado-Joseph e em pessoas sadias, que servir\u00e3o de compara\u00e7\u00e3o. \u00c9 necess\u00e1rio estudar \n\num grupo de pessoas que n\u00e3o possuam a doen\u00e7a para comparar seus resultados com os do \n\ngrupo de pacientes portadores da Doen\u00e7a de Machado-Jospeh.  \n\nVoc\u00ea est\u00e1 sendo convidado a participar dessa pesquisa, por ser portador da Doen\u00e7a \n\nde Machado-Joseph. Sua participa\u00e7\u00e3o, caso estiver de acordo com ela, envolver\u00e1 (1) uma \n\nentrevista cl\u00ednica; (2) o preenchimento de um question\u00e1rio para avaliar se voc\u00ea tem \n\nmanifesta\u00e7\u00f5es depressivas; (3) a realiza\u00e7\u00e3o de exames f\u00edsicos neurol\u00f3gicos padronizados; e \n\n(4) a coleta de duas amostras de sangue (20 mL). Entretanto, tudo isso somente ser\u00e1 feito, \n\ndepois de voc\u00ea autorizar a sua participa\u00e7\u00e3o nesse estudo, entregando um documento \n\nassinado por si ou por seu representante legal. \n\n O sangue coletado ser\u00e1 armazenado, para fins dessa pesquisa. Ele poder\u00e1 ser \n\nutilizado para outros fins somente mediante a sua autoriza\u00e7\u00e3o por escrito, tanto no presente \n\ntermo de consentimento, como em documentos futuros. Solicitaremos sua autoriza\u00e7\u00e3o \n\nexpressa para qualquer nova pesquisa para a qual cogitarmos em aproveitar seu material \n\narmazenado. Por isso, ficaremos com seu endere\u00e7o e telefone.  Novos projetos de pesquisa \n\nque aparecerem no futuro, para os quais eventualmente solicitarmos sua aprova\u00e7\u00e3o para o \n\n\n\n176 \n \naproveitamento do seu material estocado, tamb\u00e9m dever\u00e3o obter aprova\u00e7\u00e3o pr\u00e9via da \n\nComiss\u00e3o de \u00c9tica Local (chamada de GPPG) e da Comiss\u00e3o Nacional de Pesquisa \n\n(chamada de CONEP). \n\nOs riscos envolvidos nessa pesquisa s\u00e3o: mal-estar passageiro ou mancha roxa no \n\nlocal da coleta de sangue e cansa\u00e7o. Seu nome ser\u00e1 mantido em sigilo pelos pesquisadores \n\nenvolvidos no estudo, sendo estes dados utilizados apenas para esta pesquisa.  \n\nOs resultados definitivos n\u00e3o ter\u00e3o prazo para sua libera\u00e7\u00e3o, pois dependem de \n\nan\u00e1lises bioqu\u00edmicas em implementa\u00e7\u00e3o no laborat\u00f3rio. Esses resultados tamb\u00e9m n\u00e3o ter\u00e3o \n\numa interpreta\u00e7\u00e3o direta: ou seja, n\u00e3o ser\u00e3o ?bons? ou ?maus?. Mesmo assim, se voc\u00ea o \n\ndesejar, podemos entreg\u00e1-los assim que ficarem prontos. Se assim o desejar, por favor, \n\nassinale na folha do Termo de Consentimento. \n\nOs resultados dos exames realizados no seu material ficar\u00e3o guardados em bancos \n\nde dados protegidos, aos quais ter\u00e3o acesso somente os pesquisadores envolvidos. \n\nNenhum resultado seu ser\u00e1 divulgado ou liberado para terceiros. S\u00e3o considerados dados \n\nsigilosos, e estar\u00e3o apenas \u00e0 sua disposi\u00e7\u00e3o ou de seu representante legal.  \n\n \n\n \n\nPesquisador Respons\u00e1vel:      Pesquisador Executor: \n\nDr\u00aa Laura Bannach Jardim                                                   Jonas A. M. Saute ou \n\nAndrew Chaves \n\n \n\nEndere\u00e7o e telefone da pesquisadora respons\u00e1vel, Laura Bannach Jardim, \n\nServi\u00e7o de Gen\u00e9tica M\u00e9dica do HCPA \n\nHospital de Cl\u00ednicas de Porto Alegre \n\nRua Ramiro Barcelos 2350 \n\n90035-903 Porto Alegre, RS, Brasil \n\nTel.: (51) 2101-8011 \n\nFax: (51) 2101-8010 \n\n\n\n177 \n \n\nPROJETO: O PAPEL DO FATOR SEMELHANTE \u00c0 INSULINA TIPO I (IGF-1) NA DOEN\u00c7A DE MACHADO-\n\nJOSEPH \n\nINFORMA\u00c7\u00d5ES AOS INDIV\u00cdDUOS CONVIDADOS A PARTICIPAR DO ESTUDO, COMO CONTROLES \n\nSAUD\u00c1VEIS. \n\n \n\n \n\nEsta \u00e9 uma pesquisa que tem por objetivo principal analisar se uma subst\u00e2ncia \n\nnatural e circulante no sangue e nos tecidos das pessoas, um neuroprotetor, conhecido pelo \n\nnome de ?Sistema do Fator de Crescimento semelhante \u00e0 Insulina do Tipo 1 (IGF-1)?,  est\u00e1  \n\nalterada nos pacientes com a Doen\u00e7a de Machado-Joseph. A inten\u00e7\u00e3o \u00e9 a de se \n\ncompreender melhor os mecanismos dessa doen\u00e7a e, talvez, buscar a aquisi\u00e7\u00e3o de \n\nconhecimento que possibilite um futuro tratamento eficaz para os pacientes afetados por \n\nesse problema de sa\u00fade. Ser\u00e3o dosadas v\u00e1rias subst\u00e2ncias no seu sangue ou plasma: os \n\nn\u00edveis s\u00e9ricos de IGF-1, IGFBP-1 e 3, Albumina, Insulina, Colesterol Total, Colesterol HDL, \n\nTriglicer\u00eddeos, Glicose, Creatinina, Bilirrubinas e Tempo de Protrombina. Essas subst\u00e2ncias \n\nser\u00e3o dosadas em dois grupos de pessoas: nos doentes portadores da Doen\u00e7a de \n\nMachado-Joseph e em pessoas sadias, que servir\u00e3o de compara\u00e7\u00e3o. \u00c9 necess\u00e1rio estudar \n\num grupo de pessoas que n\u00e3o possuam a doen\u00e7a para comparar seus resultados com os do \n\ngrupo de pacientes portadores da Doen\u00e7a de Machado-Jospeh.  \n\nVoc\u00ea est\u00e1 sendo convidado a participar dessa pesquisa, por n\u00e3o ter a Doen\u00e7a de \n\nMachado-Joseph e ser um poss\u00edvel ?controle?, ou seja, saud\u00e1vel. Sua participa\u00e7\u00e3o, caso \n\nestiver de acordo com ela, envolver\u00e1 (1) uma entrevista cl\u00ednica; (2) o preenchimento de um \n\nquestion\u00e1rio para avaliar se voc\u00ea tem manifesta\u00e7\u00f5es depressivas; e (3) a coleta de duas \n\namostras de sangue (20 mL). Entretanto, tudo isso somente ser\u00e1 feito, depois de voc\u00ea \n\nautorizar a sua participa\u00e7\u00e3o nesse estudo, entregando um documento assinado por si ou por \n\nseu representante legal. \n\n O sangue coletado ser\u00e1 armazenado, para fins dessa pesquisa. Ele poder\u00e1 ser \n\nutilizado para outros fins somente mediante a sua autoriza\u00e7\u00e3o por escrito, tanto no presente \n\ntermo de consentimento, como em documentos futuros. Solicitaremos sua autoriza\u00e7\u00e3o \n\nexpressa para qualquer nova pesquisa para a qual cogitarmos em aproveitar seu material \n\narmazenado. Por isso, ficaremos com seu endere\u00e7o e telefone.  Novos projetos de pesquisa \n\nque aparecerem no futuro, para os quais eventualmente solicitarmos sua aprova\u00e7\u00e3o para o \n\naproveitamento do seu material estocado, tamb\u00e9m dever\u00e3o obter aprova\u00e7\u00e3o pr\u00e9via da \n\nComiss\u00e3o de \u00c9tica Local (chamada de GPPG) e da Comiss\u00e3o Nacional de Pesquisa \n\n(chamada de CONEP). \n\n\n\n178 \n \n\nOs riscos envolvidos nessa pesquisa s\u00e3o: mal-estar passageiro ou mancha roxa no \n\nlocal da coleta de sangue e cansa\u00e7o. Seu nome ser\u00e1 mantido em sigilo pelos pesquisadores \n\nenvolvidos no estudo, sendo estes dados utilizados apenas para esta pesquisa.  \n\nOs resultados definitivos n\u00e3o ter\u00e3o prazo para sua libera\u00e7\u00e3o, pois dependem de \n\nan\u00e1lises bioqu\u00edmicas em implementa\u00e7\u00e3o no laborat\u00f3rio. Esses resultados tamb\u00e9m n\u00e3o ter\u00e3o \n\numa interpreta\u00e7\u00e3o direta: ou seja, n\u00e3o ser\u00e3o ?bons? ou ?maus?. Mesmo assim, se voc\u00ea o \n\ndesejar, podemos entreg\u00e1-los assim que ficarem prontos. Se assim o desejar, por favor, \n\nassinale na folha do Termo de Consentimento. \n\nOs resultados dos exames realizados no seu material ficar\u00e3o guardados em bancos \n\nde dados protegidos, aos quais ter\u00e3o acesso somente os pesquisadores envolvidos. \n\nNenhum resultado seu ser\u00e1 divulgado ou liberado para terceiros. S\u00e3o considerados dados \n\nsigilosos, e estar\u00e3o apenas \u00e0 sua disposi\u00e7\u00e3o ou de seu representante legal. \n\n \n\n \n\n \n\n \n\n \n\nPesquisador Respons\u00e1vel:      Pesquisador Executor: \n\nDr\u00aa Laura Bannach Jardim                                                    Jonas A. M. Saute ou \n\n                                                                Andrew Chaves \n\n \n\nEndere\u00e7o e telefone da pesquisadora respons\u00e1vel, Laura Bannach Jardim, \n\nServi\u00e7o de Gen\u00e9tica M\u00e9dica do HCPA \n\nHospital de Cl\u00ednicas de Porto Alegre \n\nRua Ramiro Barcelos 2350 \n\n90035-903 Porto Alegre, RS, Brasil \n\nTel.: (51) 2101-8011 \n\nFax: (51) 2101-8010 \n\n \n\n\n\n179 \n \n\n \n\nTERMO DE CONSENTIMENTO LIVRE E ESCLARECIDO \n\nPROJETO: O PAPEL DO FATOR SEMELHANTE \u00c0 INSULINA TIPO I (IGF-1) NA DOEN\u00c7A \n\nDE MACHADO-JOSEPH \n\n(uma c\u00f3pia para o Servi\u00e7o Executor e outra para o indiv\u00edduo) \n\n \n\nRespons\u00e1veis:  Professores Diogo Souza e Laura Bannach Jardim \n\nServi\u00e7o de Gen\u00e9tica M\u00e9dica do Hospital de Cl\u00ednicas de Porto Alegre; e \n\nUniversidade Federal do Rio Grande do Sul. \n\n \n\n1. Voc\u00ea teve acesso \u00e0s informa\u00e7\u00f5es dadas pelo  \n\n laborat\u00f3rio que vai realizar a pesquisa?  \n\n Ficou com essas informa\u00e7\u00f5es?       \n\n          Sim N\u00e3o \n\n \n\n2.   Voc\u00ea p\u00f4de fazer perguntas a respeito do teste?   Sim N\u00e3o \n\n \n\n3. As respostas que lhe deram foram satisfat\u00f3rias?   Sim N\u00e3o \n\n \n\n4. Voc\u00ea entendeu que o resultado ser\u00e1 sigiloso e  \n\n somente entregue a voc\u00ea ou a seu representante   \n\n legal?         Sim N\u00e3o \n\n \n\n5. Voc\u00ea entendeu que n\u00e3o h\u00e1 prazo para a entrega \n\ndos resultados de seus exames, pois os testes  \n\nser\u00e3o feitos como pesquisa? \n\nSim N\u00e3o \n\n  \n\n6.  Voc\u00ea concorda que a sua amostra seja aproveitada \n\n em outras pesquisas, futuras, e para isso seja  \n\n guardada  no laborat\u00f3rio que vai fazer a pesquisa?  Sim N\u00e3o \n\n\n\n180 \n \n  \n\n Quais m\u00e9dicos e estudantes conversaram com voc\u00ea  \n\n sobre esses testes e estudos?       \n\n \u2026\u2026\u2026\u2026. \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 \n\n \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.  \n\n  \n\n7.   Voc\u00ea entendeu que voc\u00ea est\u00e1 livre para sair do estudo \n\n \n\n a qualquer momento?      Sim N\u00e3o \n\n sem precisar dar qualquer explica\u00e7\u00e3o?    Sim N\u00e3o \n\n sem que isso afete o seu atendimento m\u00e9dico aqui?  Sim N\u00e3o \n\n \n\n8.   Voc\u00ea deseja receber os resultados das an\u00e1lises, \n\n          quando ficarem prontos?      Sim N\u00e3o \n\n \n\n9..   Voc\u00ea concorda em participar desse estudo?   Sim N\u00e3o \n\n \n\n \n\nAssinatura \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026        Data \u2026\u2026\u2026\u2026\u2026\u2026. \n\nNome por extenso \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. \n\n    Paciente ou Respons\u00e1vel legal \n\n \n\nEndere\u00e7o: \n\n \n\nTelefone: \n\n \n\nM\u00e9dico \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. \n\n   Assinatura    Nome por extenso \n\n \n\nO m\u00e9dico preenche:    (          ) caso    (        ) controle \n\n\n\n181 \n \n \n\nServi\u00e7o de Gen\u00e9tica M\u00e9dica do HCPA \n\nHospital de Cl\u00ednicas de Porto Alegre \n\nRua Ramiro Barcelos 2350 \n\n90035-903 Porto Alegre, RS, Brasil \n\nTel.: (51) 2101-8011 \n\nFax: (51) 2101-8010 \n\n \n\nData:  \n\n\n\n182 \n \nTERMO DE CONSENTIMENTO \n\nProjeto: Ensaio cl\u00ednico randomizado, duplo-cego, placebo-controlado, para determinar \n\na seguran\u00e7a e a efic\u00e1cia  do tratamento com Carbonato de L\u00edtio em pacientes com a \n\nDoen\u00e7a de Machado-Joseph \n\n \n\nUma c\u00f3pia para o paciente e outra para o pesquisador \n\n \n\nPesquisadora respons\u00e1vel: Profa. Laura Bannach Jardim \n\nHospital de Cl\u00ednicas de Porto Alegre \n\nRua Ramiro Barcelos 2350 \n\n90035-903 Porto Alegre, RS, Brasil \n\nTel.: (51) 3359-8000    \n\nFax: (51) 3359-8001 \n\n \n\nPesquisadores executores:  \n\nM\u00e9dicos: Jonas Alex Morales Saute, Carlos Roberto de Melo Rieder, Thais Lampert Monte e  \nRaphael Machado de Castilhos \n\nEstudantes de medicina: Rafael Faraco e Karina Donis \n\n \n\nTelefones para contato:  \n\n- (51) 3359-8309 (Servi\u00e7o de Gen\u00e9tica M\u00e9dica - HCPA)  \n\n- (51) 3359-8520 (Servi\u00e7o de Neurologia \u2013 HCPA) \n\n \n\nVoc\u00ea est\u00e1 sendo convidado a participar de um estudo que testar\u00e1 a medica\u00e7\u00e3o Cabonato de \n\nL\u00edtio em pacientes com a Doen\u00e7a de Machado-Joseph. Esta medica\u00e7\u00e3o j\u00e1 \u00e9 utilizada h\u00e1 \n\nmuitos anos para outras doen\u00e7as com poucos efeitos adversos. \n\nTemos como objetivo principal avaliar se o Carbonato de L\u00edtio \u00e9 seguro para pacientes com \n\nDoen\u00e7a de Machado-Joseph. Aproveitaremos para tamb\u00e9m analisar se seus efeitos ser\u00e3o \n\neficazes sobre a evolu\u00e7\u00e3o da doen\u00e7a. Para tanto, precisamos comparar os resultados de \n\nquem usa-lo com os resultados de quem n\u00e3o us\u00e1-lo. Por isso, no in\u00edcio do estudo, metade \n\ndos indiv\u00edduos usar\u00e1 a medica\u00e7\u00e3o e a outra metade, usar\u00e1 um placebo. Um placebo \u00e9 um \n\ncomprimido no qual falta o agente farmacol\u00f3gico. Cada paciente que concordar em \n\nparticipar desse estudo poder\u00e1 ser sorteado a entrar em qualquer um dos dois grupos: o do \n\nf\u00e1rmaco ou o do placebo. No entanto, nem voc\u00ea, nem os m\u00e9dicos que lhe atender\u00e3o \n\nsaber\u00e3o em qual grupo voc\u00ea entrou. Ou se voc\u00ea est\u00e1 ou n\u00e3o est\u00e1 tomando a medica\u00e7\u00e3o \n\nverdadeiramente. O sorteio ser\u00e1 realizado por uma pessoa que n\u00e3o ter\u00e1 contato direto com \n\nos doentes que entrarem no estudo. \n\n\n\n183 \n \nA pesquisa sobre a efic\u00e1cia dos rem\u00e9dios precisa ser assim: nem o m\u00e9dico, nem o paciente \n\ndevem saber se ele est\u00e1 recebendo o medicamento ou o placebo. \u00c9 assim que \n\nconseguimos evitar que as nossas emo\u00e7\u00f5es influenciem a nossa leitura dos resultados, nos \n\nexames f\u00edsicos dos pacientes. Tanto m\u00e9dicos como pacientes naturalmente desejam que o \n\nrem\u00e9dio funcione, e podem ver resultados l\u00e1 onde eles talvez sejam apenas ilus\u00f5es. \n\nO estudo ter\u00e1 dura\u00e7\u00e3o de 12 meses, se tudo correr bem. Existe um coordenador do estudo \n\nque fiscalizar\u00e1 tanto se vai haver resultados positivos antes do t\u00e9rmino dos 12 meses, como \n\nse acontecerem eventos indesejados. Em qualquer eventualidade que coloque o grupo de \n\npacientes em risco, o estudo ser\u00e1 interrompido ou modificado, ou mesmo aberto. No caso \n\nde o estudo ser aberto, todos os pacientes receber\u00e3o a prescri\u00e7\u00e3o do rem\u00e9dio ativo. \n\nOs efeitos colaterais poss\u00edveis causados pelo medicamento em estudo s\u00e3o: altera\u00e7\u00f5es na \n\nfun\u00e7\u00e3o da tire\u00f3ide e nos n\u00edveis de glicose e c\u00e1lcio no sangue; aumento de peso, perda de \n\napetite, sede; sonol\u00eancia, altera\u00e7\u00e3o de mem\u00f3ria, tremor, altera\u00e7\u00e3o do equil\u00edbrio, diminui\u00e7\u00e3o \n\nde sensibilidade do tato, disfun\u00e7\u00e3o sexual; arritmias card\u00edacas, incha\u00e7o nas pernas; \n\nn\u00e1useas, v\u00f4mitos, boca seca; queda de cabelos, coceira no corpo, vermelhid\u00e3o na pele; \n\ndores nas articula\u00e7\u00f5es e musculares. Durante o estudo ser\u00e1 coletado sangue para \n\nrealiza\u00e7\u00e3o de exames que avaliam a presen\u00e7a desses efeitos colaterais. Tamb\u00e9m ser\u00e3o \n\nrealizados question\u00e1rios para avaliar a evolu\u00e7\u00e3o da doen\u00e7a.  \n\nO sangue e as informa\u00e7\u00f5es coletadas ser\u00e3o continuadamente monitorizados. Se algum \n\nevento adverso acontecer, seu m\u00e9dico ir\u00e1 contact\u00e1-lo imediatamente. Duas coisas poder\u00e3o \n\nser indicadas, se houver evento adverso: ou a medica\u00e7\u00e3o ser\u00e1 reduzida, ou suspensa.  \n\nVoc\u00ea dever\u00e1 comparecer a muitas consultas, para que essa monitoriza\u00e7\u00e3o seja segura: \n\nser\u00e3o entre 4 e 7 consultas previstas nas primeiras semanas, para acertar a dose do seu \n\nmedicamento. Depois disso, voc\u00ea dever\u00e1 voltar ao Hospital mais quatro vezes, no correr de \n\num ano. Al\u00e9m dessas consultas, vamos combinar telefonemas de quinze em quinze dias \n\npara saber se tudo est\u00e1 correndo bem. \n\nEsses contatos s\u00e3o diferentes do atendimento habitual que voc\u00ea recebe, pois estamos \n\nfazendo um estudo cientifico. Ademais, se eventos indesejados e que tragam risco \u00e0 sua \n\nsa\u00fade acontecerem, somente saberemos se mantivermos esses contatos freq\u00fcentes com \n\nvoc\u00ea.  Se for necess\u00e1rio interromper a administra\u00e7\u00e3o do rem\u00e9dio, ainda assim as consultas \n\nacontecer\u00e3o, para sua seguran\u00e7a. \n\nA participa\u00e7\u00e3o neste estudo \u00e9 volunt\u00e1ria e voc\u00ea est\u00e1 livre para retirar-se dela a qualquer \n\nmomento. \n\nDurante a pesquisa voc\u00ea poder\u00e1 entrar em contados com os pesquisadores atrav\u00e9s destes \n\nn\u00fameros:  \n\n- (51) 3359-8309 (Servi\u00e7o de Gen\u00e9tica M\u00e9dica - HCPA) \n\n- (51) 3359-8520 (Servi\u00e7o de Neurologia \u2013 HCPA) \n\n \n\nA seguir, leia atentamente estas perguntas e responda como voc\u00ea julgar melhor. \n\n1. Voc\u00ea teve acesso \u00e0s informa\u00e7\u00f5es dadas por quem vai realizar a pesquisa?  \n\n\n\n184 \n \n Ficou com essas informa\u00e7\u00f5es?       \n\n          Sim N\u00e3o \n\n \n\n2.   Voc\u00ea p\u00f4de fazer perguntas a respeito da pesquisa?  Sim N\u00e3o \n\n \n\n3. As respostas que lhe deram foram satisfat\u00f3rias?   Sim N\u00e3o \n\n \n\n4. Voc\u00ea entendeu que o resultado ser\u00e1 confidencial e  \n\n somente entregue a voc\u00ea ou a seu representante   \n\n legal?         Sim N\u00e3o \n\n \n\n5. Voc\u00ea entendeu que o objetivo principal deste estudo \n\n \u00e9 definir se o medicamento Carbonato de L\u00edtio \u00e9 seguro?   Sim N\u00e3o  \n\n  \n\n6.  Voc\u00ea entendeu que, nos primeiros seis meses,  \n\n voc\u00ea n\u00e3o saber\u00e1 se estar\u00e1 tomando o medicamento \n\n ou um comprimido neutro, sem efeito (Placebo)? \n\n Voc\u00ea concorda com isso?      Sim N\u00e3o \n\n7. Voc\u00ea entendeu que ao menos 9 consultas ser\u00e3o \n\n agendadas nos primeiros 6 meses, e que a sua \n\n assiduidade ser\u00e1 muito importante?     Sim N\u00e3o \n\n \n\n8. Quais m\u00e9dicos e estudantes conversaram com voc\u00ea  \n\n sobre esses testes e estudos?       \n\n \u2026\u2026\u2026\u2026. \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \u2026 \n\n9.  Voc\u00ea entendeu que voc\u00ea est\u00e1 livre para sair do estudo \n\n a qualquer momento?      Sim N\u00e3o \n\n sem precisar dar qualquer explica\u00e7\u00e3o?    Sim N\u00e3o \n\n sem que isso afete o seu atendimento m\u00e9dico aqui?  Sim N\u00e3o \n\n \n\n\n\n185 \n \n10.   Voc\u00ea entendeu que os organizadores desse estudo  \n\n podem decidir interromper o estudo a qualquer momento, \n\n por raz\u00f5es de seguran\u00e7a?      Sim N\u00e3o \n\n \n\n11.   Voc\u00ea concorda em participar desse estudo?   Sim N\u00e3o \n\n \n\nAssinatura \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026        Data \u2026\u2026\u2026\u2026\u2026\u2026. \n\nNome por extenso \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. \n\n    Paciente ou Respons\u00e1vel legal \n\nEndere\u00e7o: \n\nTelefone: \n\nM\u00e9dico \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. \n\n   Assinatura    Nome por extenso \n\nData:  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  \n\n\n\n186 \n \n\n8 ANEXOS \n\n8.1 Escalas de Ataxias \n\n- NESSCA \n\n- SARA \n\n- Escalas Quantitativas \n\n- Barthel  \n\n- BDI \n\n- WHOQOL-bref \n  \n\n\n\n187 \n \nNESSCA    Nome:                          Data: __ __ / __ __ / __ __ \n\nAvaliador:     (Circular)  Baseline      6 meses    12meses \n\nItem  Proofs  Severity Score \n\nGait ataxia - Walking spontaneously, ten \nsteps, parallel to a wall, and \n\nincluding a half-turn \n\n- Walking on toes, on heels, \n\nand in tandem \n\nAbsent 0 \n\nMinimal: only while walking on toes, heels, or in \n\ntandem \n\n1 \n\nModerate: gait autonomy preserved 2 \n\nInability to walk without help 3 \n\nWheelchair bound or bedridden 4 \n\nLimb ataxia \n\n(bilateral) \n\n- Finger-to-nose test \n\n- Test for dysdiadochokinesia \n\n(fast alternating pronation \n\nand supination of hands, \n\nelbows fixed to his/her sides) \n\n- Rebound test of Gordon-\nHolmes \n\nAbsent 0 \n\nMinimal: one single altered proof 1 \n\nModerate: two altered proofs 2 \n\nImportant: three altered proofs \n\nProofs: (a) dysmetria, (b) fast alternating hand \n\nmovements, and (c) upper limb rebound. Positive \nfindings can be uni or bilateral. \n\n3 \n\n \n\nNistagmus  Absent 0 \n\nOn extreme gaze; or circular, after saccades 1 \n\nPermanent 2 \n\nProgressive \n\nexternal \n\nophthalmoplegia \n\n Absent 0 \n\nSupranuclear: medial longitudinal fasciculus \n\nsyndrome; or limitation in upward gaze or \n\nconvergence \n\n1 \n\nNuclear ophthalmoplegia, with strabismus 2 \n\nPyramidal \n\nfindings  \n\n- Limb reflexes, including \n\npatellar and ankle clonus test  \n\n- Plantar reflex \n\n- Muscle tone examination \n\n- Motor strength proofs: \nextended arms and \n\nMingazzini test ( 60 sec each) \n\nAbsent 0 \n\nFew brisk reflexes 1 \n\nGeneral hyperreflexia; or clonus; or Babinski sign 2 \n\nThree findings: (a) general hyperreflexia, (b) \n\nspasticity, (c) clonus, (d) Babinski sign; (e) paresis \n\n3 \n\nFour or five of the above mentioned signs 4 \n\nDysarthria  Absent 0 \n\nMild: Impaired speech, but easy to understand  1 \n\nModerate: speech understandable, but with \n\ndifficulty  \n\n2 \n\nSevere: speech hardly understandable 3 \n\nAnarthria 4 \n\nDysfagia  Absent 0 \n\nMild 1 \n\nImportant: occuring every day 2 \n\n \n\n \n\nFasciculations  Absent 0 \n\nContraction fasciculation in the face  1 \n\n\n\n188 \n \n\nDiffuse, or in other parts of the body 2 \n\nSensory loss (a) Vibratory sense in the \nfirst toes; normal: >11 sec. \n\n(b) Discrimination between \n\ntactile and algesic stimuli \n\nusing a needle; 10 trials per \nfoot (tpf). \n\n(c) Discrimination between \n\ncold (10\no\nC) and warm (40-\n\n60\no\nC) water; 10 tpf \n\nAbsent 0 \n\nOne altered proof: Reduction in (a) or (b) or (c): \n\ntwo to four mistakes, on average of both feet \n\n1 \n\nTwo altered proofs 2 \n\nTotal loss of vibratory sense in toes; or 5 or more \n\nmistakes in one of discriminating proofs; or three \n\naltered proofs \n\n \n\n3 \n\nDystonia  Absent 0 \n\nMild, triggered by voluntary movements  1 \n\nModerate,  impairing, in some degree, voluntary \n\nmovements (vm) \n\n2 \n\nAlmost constant, severely impairing vm 3 \n\nRigidity  Absent 0 \n\nModerate: does not prevent total, passive \n\nmobilization  \n\n1 \n\nImportant: prevent total, passive mobilization 2 \n\nBradykinesia \n\n \n\n- Patient is asked to perform \n\n10 cycles of repetitive \n\nopposition (extension and \n\nflexion) of the second finger \n\nagainst the thumb \n\nAbsent 0 \n\nSlow movements, with reduction in amplitude 1 \n\nMovements can hardly be done 2 \n\nEyelid \n\nretraction \n\n Absent 0 \n\nPresent 1 \n\nBlepharospasm   Absent  0 \n\nPresent  1 \n\nDistal \n\namyotrophies \n\n- Inspection of the interossei, \n\ntenar and hypotenar muscles \n\nAbsent 0 \n\nPresent  1 \n\nSphincter \n\nfunction \n\n Normal 0 \n\nUrgency 1 \n\nIncontinence 2 \n\nCramps   Absent 0 \n\nPresent  1 \n\nVertigo  Absent 0 \n\nPresent 1 \n\nTotal score   \n\n \n\n \n\n\n\n189 \n \n\nScale for the assessment and rating of ataxia (SARA) \n\nPaciente: \n\nData: __ __ / __ __ / __ __ \n\nAvaliador: \n\nAvalia\u00e7\u00e3o (Circular) Baseline 6 meses 12 meses \n\n1) Gait \n\nProband is asked (1) to walk at a safe distance parallel to a \n\nwall including a half-turn (turn around to face the opposite \n\ndirection of gait) and (2) to walk in tandem (heels to toes) \n\nwithout support.  \n\n \n0 Normal, no difficulties in walking, turning and walking tandem \n\n(up to one misstep allowed) \n\n1 Slight difficulties, only visible when walking 10  consecutive \n\nsteps in tandem \n\n2 Clearly abnormal, tandem walking >10 steps not possible \n\n3 Considerable staggering, difficulties in half-turn, but  without \n\nsupport \n\n4 Marked staggering, intermittent support of the wall required \n\n5 Severe staggering, permanent support of one stick or light \n\nsupport by one arm required \n\n6 Walking > 10 m only with strong support (two special sticks or \n\nstroller or accompanying person)  \n\n7 Walking &lt;10 m only with strong support (two  special sticks or \n\nstroller or accompanying person) \n\n8 Unable to walk, even supported \n\n2) Stance \n\nProband is asked to stand (1) in natural position, (2) with feet \n\ntogether in parallel (big toes touching each other) and (3) in \n\ntandem (both feet on one line, no space between heel and toe). \n\nProband does not wear shoes, eyes are open. For each condition, \n\nthree trials are allowed. Best trial is rated. \n\n \n0 Normal, able to stand in tandem for > 10 s \n\n1 Able to stand with feet together without sway, but not in tandem \n\nfor > 10s \n\n2 Able to stand with feet together for > 10 s, but only with sway \n\n3 Able to stand for > 10 s without support in natural position, but  \n\nnot with feet together \n\n4 Able to stand for >10 s in natural position only with intermittent \n\nsupport \n\n5 Able to stand >10 s in natural position only with constant support \n\nof one arm \n\n6 Unable to stand for >10 s even with constant support  \n\n          of one arm \n\n \n\n \n\n  Score    Score  \n\n3) Sitting \n\nProband is asked to sit on an examination bed without support \n\nof feet, eyes open and arms outstretched to the front. \n\n \n0 Normal, no difficulties sitting >10 sec \n\n1 Slight difficulties, intermittent sway \n\n2 Constant sway, but able to sit > 10 s without support \n\n3 Able to sit for > 10 s only with intermittent support \n\n4 Unable to sit for >10 s without continuous support \n\n \n\n4) Speech disturbance \n\nSpeech is assessed during normal conversation. \n\n \n0 Normal \n\n1 Suggestion of speech disturbance \n\n2 Impaired speech, but easy to understand \n\n3 Occasional words difficult to understand \n\n4 Many words difficult to understand \n\n5 Only single words understandable \n\n6 Speech unintelligible / anarthria \n\n  Score     Score  \n\n\n\n190 \n \n\n \n\nEscore Total:\n\n5) Finger chase  \n\nRated separately for each side \n\nProband sits comfortably. If necessary, support of feet and \n\ntrunk is allowed. Examiner sits in front of proband and \n\nperforms 5 consecutive sudden and fast pointing movements in \n\nunpredictable directions in a frontal plane, at about 50 % of \n\nproband\u00b4s reach. Movements have an amplitude of 30 cm and \n\na frequency of 1 movement every 2 s. Proband is asked to \n\nfollow the movements with his index finger, as fast and \n\nprecisely as possible. Average performance of last 3 movements \n\nis rated.  \n\n \n   0     No dysmetria  \n\n   1     Dysmetria, under/ overshooting target&lt;5 cm \n\n   2     Dysmetria, under/ overshooting target &lt;15 cm  \n\n   3     Dysmetria, under/ overshooting target > 15 cm \n\n   4     Unable to perform 5 pointing movements \n\n \n\n6) Nose-finger test  \n\nRated separately for each side \n\nProband sits comfortably. If necessary, support of feet and \n\ntrunk is allowed. Proband is asked to point repeatedly with his \n\nindex finger from his nose to examiner\u2019s finger which is in \n\nfront of the proband at about 90 % of proband\u2019s reach. \n\nMovements are performed at moderate speed. Average \n\nperformance of movements is rated according to the amplitude \n\nof the kinetic tremor.  \n\n \n\n \n\n \n   0     No tremor  \n\n   1     Tremor with an amplitude &lt;2 cm \n\n   2     Tremor with an amplitude &lt;5 cm  \n\n   3     Tremor with an amplitude > 5 cm  \n\n   4     Unable to perform 5 pointing movements  \n\nScore Right Left Score Right Left \n\nmean of both sides (R+L)/2  mean of both sides (R+L)/2  \n\n7) Fast alternating hand movements  \n\nRated separately for each side  \n\nProband sits comfortably. If necessary, support of feet and \n\ntrunk is allowed. Proband is asked to perform 10 cycles of \n\nrepetitive alternation of pro- and supinations of the hand on \n\nhis/her thigh as fast and as precise as possible. Movement is \n\ndemonstrated by examiner at a speed of approx. 10 cycles \n\nwithin 7 s. Exact times for movement execution have to be \n\ntaken. \n\n \n0 Normal, no irregularities (performs&lt;10s) \n\n1 Slightly irregular (performs&lt;10s) \n\n2 Clearly irregular, single movements difficult to distinguish or \n\nrelevant interruptions, but performs&lt;10s \n\n3 Very irregular, single movements difficult to distinguish or \n\nrelevant interruptions, performs >10s \n\n4 Unable to complete 10 cycles \n\n  \n\n8) Heel-shin slide  \n\nRated separately for each side \n\nProband lies on examination bed, without sight of his legs. \n\nProband is asked to lift one leg, point with the heel to the \n\nopposite knee, slide down along the shin to the ankle, and lay \n\nthe leg back on the examination bed. The task is performed 3 \n\ntimes. Slide-down movements should be performed within 1 s. \n\nIf proband slides down without contact to shin in all three \n\ntrials, rate 4.  \n \n\n0 Normal \n\n1 Slightly abnormal, contact to shin maintained  \n\n2 Clearly abnormal, goes off shin up to 3 times during 3 cycles \n\n3 Severely abnormal, goes off shin 4 or more times during 3  \n\ncycles \n\n4 Unable to perform the task \n\n \n\n      Score Right Left   Score Right Left \n\n  mean of both sides (R+L)/2    mean of both sides (R+L) / 2  \n\n\n\n191 \n \n\nPaciente: \n\nData: __ __ / __ __ / __ __ \n\nAvaliador: \n\nAvalia\u00e7\u00e3o (Circular) Baseline 6 meses 12 meses \n\n \n\nTeste de caminhada de 8 metros (8-MW) \n\nInstru\u00e7\u00f5es: \u00c9 realizada a medida do tempo levado pelo paciente para caminhar 8 metros \n\npodendo utilizar qualquer aparelho (bengala, andador), por\u00e9m sem o auxilio de outra pessoa \n\nou da parede para realizar o teste. \u00c9 dada a instru\u00e7\u00e3o de o mesmo realizar a tarefa o mais \n\nr\u00e1pido poss\u00edvel, mas de forma segura. Ao iniciar o teste o paciente deve estar com os p\u00e9s \n\natr\u00e1s da linha de largada, sendo permitido que o aparelho que o auxilia esteja \u00e0 frente desta \n\nlinha. Realizar o teste 2 vezes e anotar os valores. Se o paciente n\u00e3o conseguir, anotar que \n\nfoi incapaz de realizar o teste. \n\n                                              \n\n8 - MW Tempo (s) \n\nTempo 1 (s):  \n\nTempo 2 (s):  \n\n \n\n \n\n \n\nMedida PATA  \n\n \n\nInstru\u00e7\u00f5es: Contar o qu\u00e3o freq\u00fcente o paciente consegue repetir as s\u00edlabas ?PATA? em 10 \n\nsegundos. Realizar o teste 2 vezes e anotar os valores \n \n \n \n\nPATA rate Tempo (s) \n\nTempo 1 (s):  \n\nTempo 2 (s):  \n\n \n\n  \n\n\n\n192 \n \n\nPaciente: \n\nData: __ __ / __ __ / __ __ \n\nAvaliador: \n\nAvalia\u00e7\u00e3o (Circular) Baseline 6 meses 12 meses \n\n \n\n9-Hole Pegboard Test \n\nInstru\u00e7\u00f5es: O paciente, que est\u00e1 sentado, segura nove cilindros (9mm de diametro e 32mm \n\nde comprimento) em uma da m\u00e3os e os coloca arbitrariamente, um por um, com a m\u00e3o \n\ncontr\u00e1ria em uma prancha de madeira com 9 buracos. O cron\u00f4metro deve ser iniciado \n\nquando o primeiro cilindro \u00e9 colocado corretamente em um buraco e termina quando o \n\n\u00faltimo cilindro tiver sido colocado. O examinador deve segurar firmemente a prancha \n\ndurante o teste. Uma tentativa \u00e9 desempenhada para cada m\u00e3o. Se o paciente deixar cair \n\num cilindro o examinador p\u00e1ra o cron\u00f4metro e o paciente reinicia o teste desde o seu in\u00edcio. \n\n                                              \n\n9-Hole Pegboard Tempo 1 (s)   Tempo 2 (s) \n\nM\u00e3o dominante  \n\nM\u00e3o n\u00e3o-dominante   \n\n \n\n \n\nClick Test \n\nInstru\u00e7\u00f5es: O paciente fica sentado de frente para o examinador com o contador \nposicionado sobre a mesa com os n\u00fameros voltados para o examinador. O paciente deve \nutilizar o seu dedo indicador para pressionar o bot\u00e3o do contador, alternadamente, 10 \nvezes. O tempo inicia quando o primeiro bot\u00e3o for apertado e encerra quando o segundo \ncontador marcar 10. O teste \u00e9 realizado apenas 1x para cada m\u00e3o. \n \n \n\nClick Test Tempo 1 (s)   Tempo 2 (s) \n\nM\u00e3o dominante  \n\nM\u00e3o n\u00e3o-dominante   \n\n \n\n(ATEN\u00c7\u00c3O: Anotar esquerda ou direita para todos e especificar se ambidestro) \n\n\n\n193 \n \n\n\u00cdNDICE DE BARTHEL \n\nPaciente: \n\nData: __ __ / __ __ / __ __ \n\nAvaliador: \n\nAvalia\u00e7\u00e3o (Circular) Baseline 6 meses 12 meses \n\n \n\nComo voc\u00ea realiza as suas refei\u00e7\u00f5es? \n\n(   ) 10 \u2013 Independente. Capaz de comer por si s\u00f3 em tempo razo\u00e1vel. A comida pode ser \n\ncozida ou servida por outra pessoa. \n\n(  ) 5 \u2013 Necessita de ajuda para se cortar a carne, passar a manteiga, por\u00e9m \u00e9 capaz de \n\ncomer sozinho. \n\n(  ) 0 \u2013 Dependente. Necessita ser alimentado por outra pessoa. \n\nComo voc\u00ea toma seu banho? \n\n(  ) 5 - Independente. Capaz de se lavar inteiro, de entrar e sair do banho sem ajuda e de \n\nfaz\u00ea-lo sem que outra pessoa supervisione. \n\n(  ) 0 \u2013 Dependente.Necessita de algum tipo de ajuda ou supervis\u00e3o. \n\nComo voc\u00ea se veste? (parte superior e inferior do corpo) \n\n(  ) 10 - Independente. Capaz de vestir-se e despir-se sem ajuda. \n\n(  ) 5 \u2013 Necessita de ajuda. Realiza todas as atividades pessoais sem ajuda mais da metade \n\ndas tarefas em tempo razo\u00e1vel. \n\n(  ) 0 - Dependente.Necessita de algum tipo de ajudA \n\nComo voc\u00ea realiza seus asseios? \n\n(  ) 5 \u2013 Independente. Realiza todas as atividades pessoais sem  nenhuma ajuda, os \n\ncomponentes necess\u00e1rios podem ser providos por alguma pessoa. \n\n(  ) 0 -  Dependente.Necessita de algum tipo de ajuda. \n\nComo \u00e9 sua evacua\u00e7\u00e3o? \n\n(  ) 10 \u2013 Continente. N\u00e3o apresenta epis\u00f3dios de incontin\u00eancia. \n\n(  ) 5 \u2013 Acidente ocasional. Menos de uma vez por semana necessita de ajuda para colocar \n\nenemas ou suposit\u00f3rios. \n\n(  ) 0 \u2013 Incontinente. Mais de um epis\u00f3dio semanal. \n\n\n\n194 \n \n\nComo \u00e9 sua mic\u00e7\u00e3o. Como voc\u00ea a realiza? \n\n(  ) 10 \u2013 Continente. N\u00e3o apresenta epis\u00f3dios. Capaz de utilizar qualquer dispositivo por si \n\ns\u00f3 (sonda, urinol, garrafa). \n\n(  ) 5 \u2013 Acidente ocasional. Apresenta no m\u00e1ximo um epis\u00f3dio em 24 e requer ajuda para \n\nmanipula\u00e7\u00e3o de sondas ou de outros dispositivos. \n\n(  ) 0 \u2013 Incontinente. Mais de um epis\u00f3dio em 24 horas. \n\nComo voc\u00ea vai ao banheiro? \n\n(  ) 10 \u2013 Independente. Entra e sai sozinho e n\u00e3o necessita de ajuda por parte de outra \n\npessoa. \n\n(  ) 5 \u2013 Necessita de ajuda. Capaz de mover-se com uma pequena ajuda; \u00e9 capaz de usar o \n\nbanheiro. Pode limpar-se sozinho. \n\n(  ) 0 \u2013 Dependente. Incapaz de ter acesso a ele ou de utiliz\u00e1-lo sem ajuda maior \n\nComo voc\u00ea realiza as suas transfer\u00eancia (cama, poltrona, cadeira de rodas)? \n\n(  ) 15 \u2013 Independente. N\u00e3o requer ajuda para sentar-se ou levantar-se de uma cadeira nem \n\npara entrar ou sair da cama. \n\n(  ) 10 \u2013 M\u00ednima ajuda. Incluindo uma supervis\u00e3o ou uma pequena ajuda f\u00edsica. \n\n(  ) 5 \u2013 Grande ajuda. Precisa de uma pessoa forte e treinada. \n\n(  ) 0 \u2013 Dependente necessita um apoio ou ser levantado por duas pessoas. \u00c9 incapaz de \n\npermanecer sentada. \n\nComo voc\u00ea realiza a deambula\u00e7\u00e3o (locomo\u00e7\u00e3o, caminhar) \n\n(  ) 15 \u2013 Independente. Pode andar 50 metros ou seu equivalente em casa sem ajuda ou \n\nsupervis\u00e3o. Pode utilizar qualquer ajuda mec\u00e2nica exceto andador. SE utilizar uma pr\u00f3tese, \n\npode colocar a pr\u00f3tese nela e tirar sozinha. \n\n(  ) 10 - Necessita ajuda. Necessita supervis\u00e3o ou uma pequena ajuda por parte de outra \n\npessoa ou utiliza andador. \n\nComo voc\u00ea realiza a subida e descida de escadas? \n\n(  ) 10 \u2013 Independente. Capaz de subir e descer um piso sem ajuda ou supervis\u00e3o de outra \n\npessoa. \n\n(  ) 5  - Necessita ajuda. Necessita ajuda e supervis\u00e3o. \n\n(  ) 0 \u2013 Dependente. \u00c9 incapaz de subir e descer degraus. \n\nValores: Muito grave:  45 pontos;  Grave: 45 \u2013 49 pontos \n\nModerada: 60-80 pontos;   Leve: 80 \u2013 100 pontos                                                                 \n\nPontua\u00e7\u00e3o total: _______________________ \n\n\n\n195 \n \n\nBECK DEPRESSION INVENTORY \n\nPaciente: \n\nData: __ __ / __ __ / __ __ \n\nAvaliador: \n\nAvalia\u00e7\u00e3o (Circular) Baseline 6 meses 12 meses \n\n \n\nEste question\u00e1rio consiste em 21 grupos de afirma\u00e7\u00f5es. Depois de ler cuidadosamente cada \n\ngrupo, fa\u00e7a um c\u00edrculo em torno do n\u00famero (0, 1, 2 ou 3) diante da afirma\u00e7\u00e3o, em cada \n\ngrupo, que descreve melhor a maneira como voc\u00ea tem se sentido nesta semana, incluindo \n\nhoje. Se v\u00e1rias afirma\u00e7\u00f5es num grupo parecerem se aplicar igualmente bem, fa\u00e7a um \n\nc\u00edrculo em cada uma. Tome o cuidado de ler todas as afirma\u00e7\u00f5es, em cada grupo, antes de \n\nfazer a sua escolha. \n\n1. 0 N\u00e3o me sinto triste. \n\n    1 Eu me sinto triste. \n\n    2 Estou sempre triste e n\u00e3o consigo sair disso. \n\n    3 Estou t\u00e3o triste ou infeliz que n\u00e3o consigo suportar. \n\n2. 0 N\u00e3o estou especialmente desanimado quanto ao futuro. \n\n    1 Eu me sinto desanimado quanto ao futuro. \n\n    2 Acho que nada tenho a esperar. \n\n    3 Acho o futuro sem esperan\u00e7a e tenho a impress\u00e3o de que as coisas n\u00e3o podem \n\nmelhorar. \n\n3. 0 N\u00e3o me sinto um fracasso. \n\n    1 Acho que fracassei mais do que uma pessoa comum. \n\n    2 Quando olho para tr\u00e1s, na minha vida, tudo o que posso ver \u00e9 um monte de fracassos. \n\n    3 Acho que, como pessoa, sou um completo fracasso. \n\n4. 0 Tenho tanto prazer em tudo como antes. \n\n    1 N\u00e3o sinto mais prazer nas coisas como antes. \n\n    2 N\u00e3o encontro um prazer real em mais nada. \n\n    3 Estou insatisfeito ou aborrecido com tudo. \n\n5. 0 N\u00e3o me sinto especialmente culpado. \n\n    1 Eu me sinto culpado \u00e0s vezes. \n\n    2 Eu me sinto culpado na maior parte do tempo. \n\n    3 Eu me sinto sempre culpado. \n\n6. 0 N\u00e3o acho que esteja sendo punido. \n\n    1 Acho que posso ser punido. \n\n    2 Creio que vou ser punido.  \n\n    3 Acho que estou sendo punido. \n\n7. 0 N\u00e3o me sinto decepcionado comigo mesmo. \n\n    1 Estou decepcionado comigo mesmo. \n\n\n\n196 \n \n\n    2 Estou enojado de mim. \n\n    3 Eu me odeio. \n\n8. 0 N\u00e3o me sinto de qualquer modo pior que os outros. \n\n    1 Sou cr\u00edtico em rela\u00e7\u00e3o a mim devido a minhas fraquezas ou meus erros. \n\n    2 Eu me culpo sempre por minhas falhas. \n\n    3 Eu me culpo por tudo de mal que acontece. \n\n9. 0 N\u00e3o tenho quaisquer id\u00e9ias de me matar. \n\n    1 Tenho id\u00e9ias de me matar, mas n\u00e3o as executaria. \n\n    2 Gostaria de me matar. \n\n    3 Eu me mataria se tivesse oportunidade. \n\n10. 0 N\u00e3o choro mais que o habitual. \n\n      1 Choro mais agora do que costumava. \n\n      2 Agora, choro o tempo todo. \n\n      3 Costumava ser capaz de chorar, mas agora n\u00e3o consigo mesmo que o queira. \n\n11. 0 N\u00e3o sou mais irritado agora do que j\u00e1 fui. \n\n      1 Fico molestado ou irritado mais facilmente do que costumava. \n\n      2 Atualmente me sinto irritado o tempo todo. \n\n      3 Absolutamente n\u00e3o me irrito com as coisas que costumavam irritar-me. \n\n12. 0 N\u00e3o perdi o interesse nas outras pessoas. \n\n      1 Interesso-me menos do que costumava pelas outras pessoas. \n\n      2 Perdi a maior parte do meu interesse nas outras pessoas. \n\n      3 Perdi todo o meu interesse nas outras pessoas. \n\n13. 0 Tomo decis\u00f5es mais ou menos t\u00e3o bem como em outra \u00e9poca. \n\n      1 Adio minhas decis\u00f5es mais do que costumava.  \n\n      2 Tenho maior dificuldade em tomar decis\u00f5es do que antes. \n\n      3 N\u00e3o consigo mais tomar decis\u00f5es. \n\n14. 0 N\u00e3o sinto que minha apar\u00eancia seja pior do que costumava ser.  \n\n      1 Preocupo-me por estar parecendo velho ou sem atrativos.  \n\n      2 Sinto que h\u00e1 mudan\u00e7as permanentes em minha apar\u00eancia que me fazem parecer sem \n\natrativos. \n\n      3 Considero-me feio. \n\n15. 0 Posso trabalhar mais ou menos t\u00e3o bem quanto antes. \n\n      1 Preciso de um esfor\u00e7o extra para come\u00e7ar qualquer coisa. \n\n      2 Tenho de me esfor\u00e7ar muito at\u00e9 fazer qualquer coisa. \n\n      3 N\u00e3o consigo fazer nenhum trabalho. \n\n16. 0 Durmo t\u00e3o bem quanto de h\u00e1bito. \n\n      1 N\u00e3o durmo t\u00e3o bem quanto costumava. \n\n      2 Acordo uma ou duas horas mais cedo do que de h\u00e1bito e tenho dificuldade para voltar \n\na dormir. \n\n      3 Acordo v\u00e1rias horas mais cedo do que costumava e tenho dificuldade para voltar a \n\ndormir. \n\n\n\n197 \n \n\n17. 0 N\u00e3o fico mais cansado que de h\u00e1bito. \n\n      1 Fico cansado com mais facilidade do que costumava. \n\n      2 Sinto-me cansado ao fazer quase qualquer coisa. \n\n      3 Estou cansado demais para fazer qualquer coisa. \n\n18. 0 Meu apetite n\u00e3o est\u00e1 pior do que de h\u00e1bito.  \n\n      1 Meu apetite n\u00e3o \u00e9 t\u00e3o bom quanto costumava ser.  \n\n      2 Meu apetite est\u00e1 muito pior agora.  \n\n      3 N\u00e3o tenho mais nenhum apetite. \n\n19. 0 N\u00e3o perdi muito peso, se \u00e9 que perdi algum ultimamente.  \n\n      1 Perdi mais de 2,5 Kg. \n\n      2 Perdi mais de 5,0 Kg. \n\n      3 Perdi mais de 7,5 Kg. \n\nEstou deliberadamente tentando perder peso, comendo menos: SIM ( ) N\u00c3O ( ) \n\n20. 0 N\u00e3o me preocupo mais que o de h\u00e1bito com minha sa\u00fade. \n\n      1 Preocupo-me com problemas f\u00edsicos como dores e afli\u00e7\u00f5es ou perturba\u00e7\u00f5es no \n\nest\u00f4mago ou pris\u00e3o de ventre. \n\n      2 Estou muito preocupado com problemas f\u00edsicos e \u00e9 dif\u00edcil pensar em outra coisa que \n\nn\u00e3o isso. \n\n      3 Estou t\u00e3o preocupado com meus problemas f\u00edsicos que n\u00e3o consigo pensar em outra \n\ncoisa. \n\n21.0 N\u00e3o tenho observado qualquer mudan\u00e7a recente em meu interesse sexual.  \n\n     1 Estou menos interessado por sexo que costumava. \n\n     2 Estou bem menos interessado em sexo atualmente.  \n\n     3 Perdi completamente o interesse por sexo. \n\n \n\nEscore Total:  __ __ \n\n\n\n198 \n \n\nWHOQOL-BREF \n\nPaciente: \n\nData: __ __ / __ __ / __ __ \n\nAvaliador: \n\nAvalia\u00e7\u00e3o (Circular) Baseline 6 meses 12 meses \n\n \n\nInstru\u00e7\u00f5es \n\nEste question\u00e1rio \u00e9 sobre como voc\u00ea se sente a respeito de sua qualidade de vida, sa\u00fade \n\ne outras \u00e1reas de sua vida. Por favor responda a todas as quest\u00f5es. Se voc\u00ea n\u00e3o tem \n\ncerteza sobre que resposta dar em uma quest\u00e3o, por favor, escolha entre as alternativas a \n\nque lhe parece mais apropriada. Esta, muitas vezes, poder\u00e1 ser sua primeira escolha.  \n\nPor favor, tenha em mente seus valores, aspira\u00e7\u00f5es, prazeres e preocupa\u00e7\u00f5es. N\u00f3s \n\nestamos perguntando o que voc\u00ea acha de sua vida, tomando como como refer\u00eancia as \n\nduas \u00faltimas semanas. Por exemplo, pensando nas \u00faltimas duas semanas, uma quest\u00e3o \n\npoderia ser:  \n\n Nada \nMuito  \n\npouco \nm\u00e9dio Muito \n\nCompleta\n\nmente \n\nVoc\u00ea recebe dos outros o apoio de que \n\nnecessita? \n1 2 3 4 5 \n\n \n\nVoc\u00ea deve circular o n\u00famero que melhor corresponde ao quanto voc\u00ea recebe dos  \n\noutros o apoio de que necessita nestas \u00faltimas duas semanas.  \n\nPortanto, voc\u00ea deve circular o n\u00famero 4 se voc\u00ea recebeu \"muito\" apoio como abaixo.  \n\n Nada \nMuito \n\npouco \nm\u00e9dio Muito \n\ncompleta\n\nmente \n\nVoc\u00ea recebe dos outros o apoio de que \n\nnecessita? \n1 2 3  5 \n\nVoc\u00ea deve circular o n\u00famero 1 se voc\u00ea n\u00e3o recebeu \"nada\" de apoio.  \n\n\n\n199 \n \n\nPor favor, leia cada quest\u00e3o, veja o que voc\u00ea acha e circule no n\u00famero e lhe parece a \n\nmelhor resposta.  \n\n  \nmuito \n\nruim \nRuim \n\nNem \n\nruim \n\nnem \n\nboa \n\nboa \nmuito \n\nboa \n\n1 \nComo voc\u00ea avaliaria sua qualidade \n\nde vida?  \n1 2 3 4 5 \n\n \n\n  \n\nMuito \n\ninsa-\n\ntisfeito \n\nInsatis-\n\nfeito \n\nnem \n\nsatisfeito \n\nnem \n\ninsatisfeito \n\nSatis-\n\nfeito \n\nMuito \n\nsatisfeito \n\n2 \nQu\u00e3o satisfeito(a) voc\u00ea \n\nest\u00e1 com a sua sa\u00fade? \n1 2 3 4 5 \n\n \n\nAs quest\u00f5es seguintes s\u00e3o sobre o quanto voc\u00ea \n\ntem sentido algumas coisas nas \u00faltimas duas semanas. \n\n  nada \nmuito \n\npouco \n\nmais ou \n\nmenos \n\nBas-\n\ntante \n\nExtrema-\n\nmente \n\n3 \n\nEm que medida voc\u00ea acha que \n\nsua dor (f\u00edsica) impede voc\u00ea de \n\nfazer o que voc\u00ea precisa? \n\n1 2 3 4 5 \n\n4 \n\nO quanto voc\u00ea precisa de algum \n\ntratamento m\u00e9dico para levar sua \n\nvida di\u00e1ria? \n\n1 2 3 4 5 \n\n5 O quanto voc\u00ea aproveita a vida? 1 2 3 4 5 \n\n6 \nEm que medida voc\u00ea acha que a \n\nsua vida tem sentido? \n1 2 3 4 5 \n\n7 \nO quanto voc\u00ea consegue se \n\nconcentrar? \n1 2 3 4 5 \n\n8 \nQu\u00e3o seguro(a) voc\u00ea se sente \n\nem sua vida di\u00e1ria? \n1 2 3 4 5 \n\n9 \n\nQu\u00e3o saud\u00e1vel \u00e9 o seu ambiente \n\nf\u00edsico (clima, barulho, polui\u00e7\u00e3o, \n\natrativos)? \n\n1 2 3 4 5 \n\n\n\n200 \n \n\n \n\nAs quest\u00f5es seguintes perguntam sobre qu\u00e3o completamente voc\u00ea tem sentido ou \u00e9 \n\ncapaz de fazer certas coisas nestas \u00faltimas duas semanas. \n\n  nada \nmuito \n\npouco \nm\u00e9dio Muito \n\ncompleta\n\nmente \n\n1\n\n0 \n\nVoc\u00ea tem energia suficiente para \n\nseu dia-a- dia? \n1 2 3 4 5 \n\n1\n\n1 \n\nVoc\u00ea \u00e9 capaz de aceitar sua \n\napar\u00eancia f\u00edsica? \n1 2 3 4 5 \n\n1\n\n2 \n\nVoc\u00ea tem dinheiro suficiente para \n\nsatisfazer suas necessidades? \n1 2 3 4 5 \n\n1\n\n3 \n\nQu\u00e3o dispon\u00edveis para voc\u00ea \n\nest\u00e3o as informa\u00e7\u00f5es que precisa \n\nno seu dia-a-dia? \n\n1 2 3 4 5 \n\n1\n\n4 \n\nEm que medida voc\u00ea tem \n\noportunidades de atividade de \n\nlazer? \n\n1 2 3 4 5 \n\n \n\nAs quest\u00f5es seguintes perguntam sobre qu\u00e3o bem ou satisfeito voc\u00ea se sentiu a respeito \n\nde v\u00e1rios aspectos de sua vida nas \u00faltimas duas semanas.  \n\n  \nMuito \n\nruim \nruim \n\nnem \n\nruim \n\nnem \n\nbom \n\nbom \nmuito \n\nbom \n\n1\n\n5 \n\nQu\u00e3o bem voc\u00ea \u00e9 capaz de se \n\nlocomover? \n1 2 3 4 5 \n\n  \n\nMuito \n\ninsati\n\nsfeito \n\nInsati\n\nsfeito \n\nnem \n\nsatisfeit\n\no nem \n\ninsatisf\n\neito \n\nsatisfe\n\nito \n\nMuito \n\nsatisfeito \n\n1\n\n6 \n\nQu\u00e3o satisfeito(a) voc\u00ea est\u00e1 com \n\no seu sono?  \n1 2 3 4 5 \n\n1\n\n7 \n\nQu\u00e3o satisfeito(a) voc\u00ea est\u00e1 com \n\nsua capacidade de desempenhar \n\nas atividades do seu dia-a-dia? \n\n1 2 3 4 5 \n\n\n\n201 \n \n\n1\n\n8 \n\nQu\u00e3o satisfeito(a) voc\u00ea est\u00e1 com \n\nsua capacidade para o trabalho? \n1 2 3 4 5 \n\n1\n\n9 \n\nQu\u00e3o satisfeito(a) voc\u00ea est\u00e1 \n\nconsigo mesmo? \n1 2 3 4 5 \n\n2\n\n0 \n\nQu\u00e3o satisfeito(a) voc\u00ea est\u00e1 com \n\nsuas rela\u00e7\u00f5es pessoais (amigos, \n\nparentes, conhecidos, colegas)? \n\n1 2 3 4 5 \n\n2\n\n1 \n\nQu\u00e3o satisfeito(a) voc\u00ea est\u00e1 com \n\nsua vida sexual? \n1 2 3 4 5 \n\n2\n\n2 \n\nQu\u00e3o satisfeito(a) voc\u00ea est\u00e1 com  \n\no apoio que voc\u00ea recebe de seus \n\namigos? \n\n1 2 3 4 5 \n\n2\n\n3 \n\nQu\u00e3o satisfeito(a) voc\u00ea est\u00e1 com  \n\nas condi\u00e7\u00f5es do local onde \n\nmora? \n\n1 2 3 4 5 \n\n \n\n2\n\n4 \n\n \n\nQu\u00e3o satisfeito(a) voc\u00ea est\u00e1 com \n\no  \n\nseu acesso aos servi\u00e7os de \n\nsa\u00fade? \n\n1 2 3 4 5 \n\n2\n\n5 \n\nQu\u00e3o satisfeito(a) voc\u00ea est\u00e1 com \n\no seu meio de transporte? \n1 2 3 4 5 \n\n \n\nAs quest\u00f5es seguintes referem-se a com que freq\u00fc\u00eancia voc\u00ea sentiu ou experimentou certas \n\ncoisas nas \u00faltimas duas semanas.  \n\n  Nunca \nAlgumas \n\nvezes \n\nfreq\u00fcen\n\ntement\n\ne \n\nMuito \n\nfreq\u00fcen\n\ntemente \n\nsempre \n\n2\n\n6 \n\nCom que freq\u00fc\u00eancia voc\u00ea \n\ntem sentimentos negativos \n\ntais como mau humor, \n\ndesespero, ansiedade, \n\ndepress\u00e3o? \n\n1 2 3 4 5 \n\n \n\nAlgu\u00e9m lhe ajudou a preencher este question\u00e1rio? \n\nQuanto tempo voc\u00ea levou para preencher este question\u00e1rio?  \n\nVoc\u00ea tem algum coment\u00e1rio sobre o question\u00e1rio?  \n\nOBRIGADO PELA SUA \nCOLABORA\u00c7\u00c3O"}]}}}